0001593034-18-000036.txt : 20181108 0001593034-18-000036.hdr.sgml : 20181108 20181108095948 ACCESSION NUMBER: 0001593034-18-000036 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181108 DATE AS OF CHANGE: 20181108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Endo International plc CENTRAL INDEX KEY: 0001593034 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36326 FILM NUMBER: 181168537 BUSINESS ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 353-1-268-2000 MAIL ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Endo International Ltd DATE OF NAME CHANGE: 20131203 FORMER COMPANY: FORMER CONFORMED NAME: Sportwell Ltd DATE OF NAME CHANGE: 20131126 10-Q 1 endp-9302018x10q.htm 10-Q 9.30.2018 ENDP-9.30.2018-10Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________ 
FORM 10-Q
____________________________________________________________________________________________ 
(Mark One)
x    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018

or

o    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
FOR THE TRANSITION PERIOD FROM                          TO
Commission File Number: 001-36326
____________________________________________________________________________________________
ENDO INTERNATIONAL PLC
(Exact name of registrant as specified in its charter)
____________________________________________________________________________________________

Ireland
68-0683755
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
 
 
First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland
Not Applicable
(Address of Principal Executive Offices)
(Zip Code)
011-353-1-268-2000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
The NASDAQ Global Market
Securities registered pursuant to Section 12(g) of the Act:
None
____________________________________________________________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ
No o
 
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes þ
No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
þ
Accelerated filer
o
 
 
 
 
Non-accelerated filer
o  (Do not check if a smaller reporting company)
Smaller reporting company
o
 
 
 
 
Emerging Growth Company
o
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes o
No þ
Indicate the number of shares outstanding of each of the issuer’s classes of ordinary shares, as of the latest practicable date.
Ordinary shares, $0.0001 par value
Number of ordinary shares outstanding as of November 1, 2018:
224,344,760


ENDO INTERNATIONAL PLC
INDEX
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



FORWARD-LOOKING STATEMENTS
Statements contained or incorporated by reference in this document contain information that includes or is based on “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). These statements, including estimates of future revenues, future expenses, future net income and future net income per share, contained in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this document, are subject to risks and uncertainties. Forward-looking statements include the information concerning our possible or assumed results of operations. We have tried, whenever possible, to identify such statements by words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “projected,” “forecast,” “will,” “may” or similar expressions. We have based these forward-looking statements on our current expectations and projections about the growth of our business, our financial performance and the development of our industry. Because these statements reflect our current views concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in Part II, Item 1A of this document and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017, as supplemented and amended by the risk factors previously disclosed by us in Part II, Item 1A under the caption “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018, and as otherwise enumerated herein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained or incorporated by reference in this document.
We do not undertake any obligation to update our forward-looking statements after the date of this document for any reason, even if new information becomes available or other events occur in the future, except as may be required under applicable securities law. You are advised to consult any further disclosures we make on related subjects in our reports filed with the Securities and Exchange Commission (SEC) and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval (SEDAR). Also note that, in Part II, Item 1A of this document and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017, as supplemented and amended by the risk factors previously disclosed by us in Part II, Item 1A under the caption “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018, and as otherwise enumerated herein, we provide a cautionary discussion of the risks, uncertainties and possibly inaccurate assumptions relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We note these factors for investors as permitted by Section 27A of the Securities Act and Section 21E of the Exchange Act. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this to be a complete discussion of all potential risks or uncertainties.

i

PART I. FINANCIAL INFORMATION
Item 1.        Financial Statements
ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share data)
 
September 30, 2018
 
December 31, 2017
ASSETS
 
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
1,118,885

 
$
986,605

Restricted cash and cash equivalents
289,667

 
320,453

Accounts receivable
467,156

 
517,436

Inventories, net
332,787

 
391,437

Prepaid expenses and other current assets
50,697

 
43,098

Income taxes receivable
16,407

 
12,048

Total current assets
$
2,275,599

 
$
2,271,077

MARKETABLE SECURITIES
1,693

 
1,456

PROPERTY, PLANT AND EQUIPMENT, NET
495,546

 
523,971

GOODWILL
4,056,668

 
4,450,082

OTHER INTANGIBLES, NET
3,624,216

 
4,317,684

DEFERRED INCOME TAXES
6

 
11,582

OTHER ASSETS
67,934

 
59,728

TOTAL ASSETS
$
10,521,662

 
$
11,635,580

LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
 
 
 
CURRENT LIABILITIES:
 
 
 
Accounts payable and accrued expenses
$
1,019,004

 
$
1,096,825

Current portion of legal settlement accrual
966,633

 
1,087,793

Current portion of long-term debt
34,150

 
34,205

Income taxes payable
1,681

 
2,086

Total current liabilities
$
2,021,468

 
$
2,220,909

DEFERRED INCOME TAXES
43,630

 
43,131

LONG-TERM DEBT, LESS CURRENT PORTION, NET
8,228,612

 
8,242,032

LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION
35,450

 
210,450

OTHER LIABILITIES
411,961

 
434,178

COMMITMENTS AND CONTINGENCIES (NOTE 14)


 


SHAREHOLDERS' (DEFICIT) EQUITY:
 
 
 
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both September 30, 2018 and December 31, 2017
46

 
48

Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 224,288,553 and 223,331,706 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
22

 
22

Additional paid-in capital
8,830,351

 
8,791,170

Accumulated deficit
(8,833,024
)
 
(8,096,539
)
Accumulated other comprehensive loss
(216,854
)
 
(209,821
)
Total shareholders' (deficit) equity
$
(219,459
)
 
$
484,880

TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
$
10,521,662

 
$
11,635,580

See Notes to Condensed Consolidated Financial Statements.

1

ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
TOTAL REVENUES
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

COSTS AND EXPENSES:
 
 
 
 
 
 
 
Cost of revenues
412,965

 
514,522

 
1,198,468

 
1,722,885

Selling, general and administrative
163,791

 
135,880

 
478,615

 
468,675

Research and development
39,683

 
39,644

 
160,431

 
123,522

Litigation-related and other contingencies, net
(1,750
)
 
(12,352
)
 
15,370

 
(14,016
)
Asset impairment charges
142,217

 
94,924

 
613,400

 
1,023,930

Acquisition-related and integration items
1,288

 
16,641

 
13,284

 
31,711

OPERATING LOSS FROM CONTINUING OPERATIONS
$
(12,728
)
 
$
(2,372
)
 
$
(318,879
)
 
$
(656,489
)
INTEREST EXPENSE, NET
131,847

 
127,521

 
385,896

 
361,267

LOSS ON EXTINGUISHMENT OF DEBT
—

 
—

 
—

 
51,734

OTHER INCOME, NET
(1,507
)
 
(2,097
)
 
(33,216
)
 
(10,843
)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
INCOME TAX EXPENSE (BENEFIT)
3,003

 
(28,109
)
 
24,729

 
(97,517
)
LOSS FROM CONTINUING OPERATIONS
$
(146,071
)

$
(99,687
)

$
(696,288
)
 
$
(961,130
)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)
(27,134
)
 
3,017

 
(43,273
)
 
(705,886
)
NET LOSS
$
(173,205
)
 
$
(96,670
)
 
$
(739,561
)
 
$
(1,667,016
)
NET (LOSS) INCOME PER SHARE—BASIC:
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.45
)
 
$
(3.11
)
 
$
(4.31
)
Discontinued operations
(0.12
)
 
0.02

 
(0.19
)
 
(3.16
)
Basic
$
(0.77
)
 
$
(0.43
)
 
$
(3.30
)
 
$
(7.47
)
NET (LOSS) INCOME PER SHARE—DILUTED:
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.45
)
 
$
(3.11
)
 
$
(4.31
)
Discontinued operations
(0.12
)
 
0.02

 
(0.19
)
 
(3.16
)
Diluted
$
(0.77
)
 
$
(0.43
)
 
$
(3.30
)
 
$
(7.47
)
WEIGHTED AVERAGE SHARES:
 
 
 
 
 
 
 
Basic
224,132

 
223,299

 
223,829

 
223,157

Diluted
224,132

 
223,299

 
223,829

 
223,157

See Notes to Condensed Consolidated Financial Statements.

2

ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
(In thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
NET LOSS
 
 
$
(173,205
)
 
 
 
$
(96,670
)
 
 
 
$
(739,561
)
 
 
 
$
(1,667,016
)
OTHER COMPREHENSIVE INCOME (LOSS):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net unrealized gain on securities, net of tax:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
 
 
$
188

 
 
 
$
—

 
 
 
$
333

 
 
Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
188

 
—

 
—

 
—

 
333

Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation gain (loss) arising during the period
$
4,735

 
 
 
$
9,941

 
 
 
$
(7,033
)
 
 
 
$
35,415

 
 
Less: reclassification adjustments for loss realized in net loss
—

 
4,735

 
29,325

 
39,266

 
—

 
(7,033
)
 
29,325

 
64,740

OTHER COMPREHENSIVE INCOME (LOSS)
 
 
$
4,735

 
 
 
$
39,454

 
 
 
$
(7,033
)
 
 
 
$
65,073

COMPREHENSIVE LOSS
 
 
$
(168,470
)
 
 
 
$
(57,216
)
 
 
 
$
(746,594
)
 
 
 
$
(1,601,943
)
See Notes to Condensed Consolidated Financial Statements.

3

ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
Nine Months Ended September 30,
 
2018
 
2017
OPERATING ACTIVITIES:
 
 
 
Net loss
$
(739,561
)
 
$
(1,667,016
)
Adjustments to reconcile Net loss to Net cash provided by operating activities:





Depreciation and amortization
556,503


742,936

Inventory step-up
261


281

Share-based compensation
43,722


40,252

Amortization of debt issuance costs and discount
15,289


17,698

Deferred income taxes
13,118


(239,174
)
Change in fair value of contingent consideration
11,731


23,574

Loss on extinguishment of debt
—


51,734

Asset impairment charges
613,400


1,023,930

Gain on sale of business and other assets
(29,859
)

(5,074
)
Changes in assets and liabilities which provided (used) cash:





Accounts receivable
31,634


471,448

Inventories
52,499


91,047

Prepaid and other assets
993


11,626

Accounts payable, accrued expenses and other liabilities
(367,979
)
 
(159,245
)
Income taxes payable/receivable
(4,759
)

18,145

Net cash provided by operating activities
$
196,992


$
422,162

INVESTING ACTIVITIES:
 
 
 
Purchases of property, plant and equipment, excluding capitalized interest
(56,544
)
 
(94,102
)
Capitalized interest payments
(2,569
)
 
—

Decrease in notes receivable
—

 
7,000

Proceeds from sale of business and other assets, net
43,753

 
96,066

Other investing activities
1,678

 
—

Net cash (used in) provided by investing activities
$
(13,682
)
 
$
8,964


4

 
Nine Months Ended September 30,
 
2018
 
2017
FINANCING ACTIVITIES:
 
 
 
Proceeds from issuance of notes
—

 
300,000

Proceeds from issuance of term loans
—

 
3,415,000

Principal payments on term loans
(25,614
)
 
(3,722,413
)
Principal payments on other indebtedness
(3,921
)
 
(4,912
)
Deferred financing fees
—

 
(57,358
)
Payments for contingent consideration
(28,664
)
 
(63,712
)
Payments of tax withholding for restricted shares
(5,082
)
 
(1,958
)
Exercise of options
473

 
—

Net cash used in financing activities
$
(62,808
)
 
$
(135,353
)
Effect of foreign exchange rate
(608
)
 
3,983

Movement in cash held for sale
—

 
(1,450
)
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS
$
119,894

 
$
298,306

CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD
1,311,014

 
805,180

CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD
$
1,430,908

 
$
1,103,486

SUPPLEMENTAL INFORMATION:
 
 
 
Cash paid into Qualified Settlement Funds for mesh legal settlements
$
216,770

 
$
623,128

Cash paid out of Qualified Settlement Funds for mesh legal settlements
$
248,485

 
$
545,379

Other cash distributions for mesh legal settlements
$
17,114

 
$
3,625

See Notes to Condensed Consolidated Financial Statements.

5

ENDO INTERNATIONAL PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018
NOTE 1. BASIS OF PRESENTATION
Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs.
Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our,” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries.
The accompanying unaudited Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2018 and the results of our operations and our cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The year-end Condensed Consolidated Balance Sheet data as of December 31, 2017 was derived from audited financial statements.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2017.
Certain prior period amounts have been reclassified to conform to the current period presentation as a result of our fourth-quarter 2017 adoption of Accounting Standards Update (ASU) No. 2016-18 “Statement of Cash Flows (Topic 230) - Restricted Cash” (ASU 2016-18). The table below presents the effects of ASU 2016-18 on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 (in thousands):
 
Prior to Adoption
 
Impact of Adoption
 
Subsequent to Adoption
Net cash provided by operating activities
$
424,062

 
$
(1,900
)
 
$
422,162

Net cash (used in) provided by investing activities
(69,802
)
 
78,766

 
8,964

Net cash used in financing activities
(135,353
)
 
—

 
(135,353
)
Effect of foreign exchange rate
3,686

 
297

 
3,983

Movement in cash held for sale
(1,450
)
 
—

 
(1,450
)
Net change (1)
$
221,143

 
$
77,163

 
$
298,306

Beginning-of-period balance (2)
517,250

 
287,930

 
805,180

End-of-period balance (2)
$
738,393

 
$
365,093

 
$
1,103,486

__________
(1)
This line refers to the “Net increase in cash and cash equivalents” prior to the adoption of ASU 2016-18 and the “Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
(2)
These lines refer to the beginning or end of period amounts of “Cash and cash equivalents” prior to the adoption of ASU 2016-18 and the beginning or end of period amounts of “Cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
Additionally, the information in this Quarterly Report on Form 10-Q has been retrospectively recast to reflect the change in reportable segments referenced in Note 6. Segment Results.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Significant Accounting Policies Updated since December 31, 2017
Significant changes to our significant accounting policies since December 31, 2017 are detailed below. For additional discussion of the Company’s significant accounting policies, see Note 2. Summary of Significant Accounting Policies in the Consolidated Financial Statements, included in Part IV, Item 15 of our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on February 27, 2018.

6

Revenue Recognition. The Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. For further discussion of the impact of adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2018” section below. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.
Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order and invoice the customer upon shipment. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract’s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, distribution service agreement (DSA) and other fees for services, returns and allowances. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within 30 to 90 days of invoicing. Our most significant components of variable consideration are further described below. Our estimates for these components are based on factors such as historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors.
Returns and Allowances. Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified period of time both subsequent to and, in certain cases, prior to the products’ expiration date. Our return policy generally allows customers to receive credit for expired products within six months prior to expiration and within one year after expiration. Our provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and delivery errors.
Rebates. Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:
•
direct rebates;
•
indirect rebates;
•
governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and
•
managed-care rebates.
We establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers which have purchased our products from a wholesaler under a contract with us.
We are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes with respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and group purchasing organizations. For example, we are required to provide a 50% discount on our brand-name drugs to patients who fall within the Medicare Part D coverage gap, also referred to as the donut hole.
We participate in various federal and state government-managed programs whereby discounts and rebates are provided to participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal requirements with public sector (Medicaid) benefit providers after the final dispensing of the product by a pharmacy to a benefit plan participant.
Chargebacks. We market and sell products to both: (i) direct customers including wholesalers, distributors, warehousing pharmacy chains and other direct purchasing groups and (ii) indirect customers including independent pharmacies, non-warehousing chains, managed-care organizations, group purchasing organizations and government entities. We enter into agreements with certain of our indirect customers to establish contract pricing for certain products. These indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler’s invoice price. Such credit is called a chargeback.

7

New Significant Accounting Policies Added since December 31, 2017
Contract Assets and Contract Liabilities. Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time including, for example, the entity’s future performance. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company’s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.
Contract liabilities represent the Company’s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing the corresponding performance obligation, the contract liability amount is reversed and revenue is recognized.
Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in Note 11. Contract Assets and Liabilities.
Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2018
In February 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for most leases. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, “Leases (Topic 842) - Targeted Improvements” (ASU 2018-11), which addresses implementation issues related to the new lease standard. This guidance will be effective for the Company beginning in the first quarter of 2019, with early application permitted. The Company plans to adopt this guidance in the first quarter of 2019 using the modified retrospective approach and will recognize a cumulative-effect adjustment to the opening balance of Accumulated deficit in that period. This guidance includes a number of optional practical expedients that the Company may elect to apply, including an expedient that permits lease agreements that are twelve months or less to be excluded from the balance sheet. The Company is continuing to evaluate the impact that this new guidance will have on its consolidated financial statements, including its disclosures. It is expected that the primary impact upon adoption will be the recognition, on a discounted basis, of the Company’s minimum commitments under noncancelable operating leases as right of use assets and obligations on the consolidated balance sheets. This will result in a significant increase in assets and liabilities on the Company’s consolidated balance sheets. In preparation for the adoption of this guidance, the Company is continuing the process of identifying and validating the Company’s lease information and evaluating the impact that this new guidance will have on its processes and controls.
In February 2018, the FASB issued ASU No. 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02 on the Company’s consolidated results of operations and financial position.
In July 2018, the FASB issued ASU No. 2018-09, “Codification Improvements” (ASU 2018-09). ASU 2018-09 makes changes to a variety of topics to clarify, correct errors in or make minor improvements to the Accounting Standards Codification. Certain of these provisions are effective immediately; however, these provisions did not have a material impact on the Company’s financial statements or disclosures. The remaining provisions are generally effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. The Company is currently evaluating the impact of these remaining provisions of ASU 2018-09 on the Company’s consolidated results of operations and financial position.
In August 2018, the FASB issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company’s disclosures.

8

In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-15 may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-15 on the Company’s consolidated results of operations, financial position and disclosures.
In November 2018, the FASB issued ASU No. 2018-18, “Clarifying the Interaction Between Topic 808 and Topic 606” (ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should generally be applied retrospectively to the date of initial application of Topic 606 (January 1, 2018 for the Company) and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company’s consolidated results of operations, financial position and disclosures.
Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2018
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:
•
ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;
•
ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” (issued in March 2016), which clarified the guidance on reporting revenue as a principal versus agent;
•
ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (issued in April 2016), which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and
•
ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” and ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.
These ASUs have generally been codified in Accounting Standards Codification Topic 606 “Revenue from Contracts with Customers”, and are collectively referred to herein as ASC 606. ASC 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (ASC 605), and requires entities to recognize revenue when control of promised goods or services is transferred to customers at an amount that reflects the consideration to which entities expect to be entitled in exchange for those goods or services.
The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded a net decrease of $3.1 million to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.

9

The current period impact of adoption on our Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets is as follows (in thousands, except per share amounts):
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Statement of Operations:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
 
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
Total revenues
$
745,466

 
$
747,571

 
$
(2,105
)
 
$
2,160,689

 
$
2,160,132

 
$
557

Cost of revenues
$
412,965

 
$
414,430

 
$
(1,465
)
 
$
1,198,468

 
$
1,199,042

 
$
(574
)
Other income, net
$
(1,507
)
 
$
(1,507
)
 
$
—

 
$
(33,216
)
 
$
(32,216
)
 
$
(1,000
)
Loss from continuing operations
$
(146,071
)
 
$
(145,431
)
 
$
(640
)
 
$
(696,288
)
 
$
(698,419
)
 
$
2,131

Net loss
$
(173,205
)
 
$
(172,565
)
 
$
(640
)
 
$
(739,561
)
 
$
(741,692
)
 
$
2,131

Net loss per share—Basic:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total basic
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

Net loss per share—Diluted:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total diluted
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

__________
(1)
Amounts may not add due to rounding.
 
At September 30, 2018
Balance Sheet:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606
Assets:
 
 
 
 
 
Inventories, net
$
332,787

 
$
341,189

 
$
(8,402
)
Prepaid expenses and other current assets
$
50,697

 
$
40,368

 
$
10,329

Other assets
$
67,934

 
$
64,972

 
$
2,962

Liabilities:
 
 
 
 
 
Accounts payable and accrued expenses
$
1,019,004

 
$
1,019,322

 
$
(318
)
Shareholders' (deficit) equity:
 
 
 
 
 
Accumulated deficit
$
(8,833,024
)
 
$
(8,838,231
)
 
$
5,207

In May 2017, the FASB issued ASU No. 2017-09 “Compensation - Stock Compensation” (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date.

10

NOTE 3. DISCONTINUED OPERATIONS AND DIVESTITURES
Astora
The Company’s Astora business ceased business operations on March 31, 2016. The operating results of Astora are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. The following table provides the operating results of Astora for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Litigation-related and other contingencies, net
$
19,000

 
$
—

 
$
19,000

 
$
775,684

Loss from discontinued operations before income taxes
$
(27,134
)
 
$
(8,957
)
 
$
(43,273
)
 
$
(813,442
)
Income tax benefit
$
—

 
$
(11,974
)
 
$
—

 
$
(107,556
)
Discontinued operations, net of tax
$
(27,134
)
 
$
3,017

 
$
(43,273
)
 
$
(705,886
)
Amounts reported in the table above as Litigation-related and other contingencies, net relate to charges for vaginal-mesh-related matters. Loss from discontinued operations before income taxes also includes mesh-related legal defense costs and certain other items.
The cash flows from discontinued operating activities related to Astora included the impact of net losses of $43.3 million and $705.9 million for the nine months ended September 30, 2018 and 2017, respectively, and the impact of cash activity related to vaginal mesh cases. There was no net cash used in discontinued investing activities related to Astora during the nine months ended September 30, 2018 or 2017. There was no depreciation or amortization during the nine months ended September 30, 2018 or 2017 related to Astora.
Refer to Note 14. Commitments and Contingencies for amounts and additional information relating to vaginal mesh-related matters.
Litha
During the fourth quarter of 2016, the Company initiated a process to sell its Litha Healthcare Group Limited and related Sub-Sahara African business assets (Litha) and, on February 27, 2017, the Company entered into a definitive agreement to sell Litha to Acino Pharma AG (Acino). The sale closed on July 3, 2017 and the Company received net cash proceeds of approximately $94.2 million, after giving effect to cash and net working capital purchase price adjustments, as well as a short-term receivable of $4.4 million, which was subsequently collected in October 2017. No additional gain or loss was recognized upon sale. However, in December 2017, Acino became obligated to pay $10.1 million of additional consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on the sale of Litha for this amount. The gain was recorded in Other income, net in the Condensed Consolidated Statements of Operations. Litha was part of the Company’s International Pharmaceuticals segment. Litha does not meet the requirements for treatment as a discontinued operation.
Somar
On June 30, 2017, the Company entered into a definitive agreement to sell Grupo Farmacéutico Somar, S.A.P.I. de C.V. (Somar) and all of the securities thereof, to AI Global Investments (Netherlands) PCC Limited acting for and on behalf of the Soar Cell (the Purchaser). The sale closed on October 25, 2017 and the Purchaser paid an aggregate purchase price of approximately $124 million in cash, after giving effect to estimated cash, debt and net working capital purchase price adjustments. The Company recognized a $1.3 million loss upon sale. Somar was part of the Company’s International Pharmaceuticals segment. Somar does not meet the requirements for treatment as a discontinued operation.
NOTE 4. RESTRUCTURING
January 2017 Restructuring Initiative
On January 26, 2017, the Company announced a restructuring initiative implemented as part of its ongoing organizational review (the January 2017 Restructuring Initiative). This restructuring was intended to further integrate, streamline and optimize the Company’s operations by aligning certain corporate and research and development (R&D) functions with its recently restructured U.S. generics and U.S. branded business units in order to create efficiencies and cost savings. As part of this restructuring, the Company undertook certain cost reduction initiatives, including a reduction of approximately 90 positions of its workforce, primarily related to corporate and branded R&D functions in Malvern, Pennsylvania and Chestnut Ridge, New York, a streamlining of general and administrative expenses, an optimization of commercial spend and a refocusing of research and development efforts.

11

The Company did not incur any pre-tax charges during the three and nine months ended September 30, 2018 as a result of the January 2017 Restructuring Initiative. During the nine months ended September 30, 2017, the Company incurred total pre-tax charges of approximately $15.1 million related to employee separation and other benefit-related costs. Of the total charges incurred, $6.9 million was included in the U.S. Branded - Specialty & Established Pharmaceuticals segment, $4.9 million was included in Corporate unallocated costs and $3.3 million was included in the U.S. Generic Pharmaceuticals segment. These charges were included in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. There were no charges related to this restructuring initiative for the three months ended September 30, 2017. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments were made by the end of 2017 and substantially all of the actions associated with this restructuring were completed by the end of April 2017.
2017 U.S. Generic Pharmaceuticals Restructuring Initiative
On July 21, 2017, the Company announced that after completing a comprehensive review of its manufacturing network, the Company would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative). The closure of the facilities was completed in June 2018. Employee separation, retention and certain other employee benefit-related costs are expensed ratably over the requisite service period. Other costs including, but not limited to, contract termination fees and product technology transfer costs, are expensed as incurred.
As a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $4.8 million and $59.6 million during the three and nine months ended September 30, 2018, respectively. During the three months ended September 30, 2018, the expenses consisted of employee separation and other benefit-related costs of $2.1 million and certain other charges of $2.7 million. During the nine months ended September 30, 2018, the expenses consisted of charges relating to accelerated depreciation of $35.2 million, employee separation, retention and other benefit-related costs of $9.8 million, asset impairment charges of $2.6 million and certain other charges of $12.0 million.
During the three and nine months ended September 30, 2017, the Company incurred pre-tax charges of $94.2 million and $203.7 million, respectively, related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. The amounts incurred during the three months ended September 30, 2017 included accelerated depreciation charges of $59.8 million, employee separation, retention and other benefit-related costs of $19.5 million, certain property, plant and equipment impairment charges of $14.2 million and certain other charges of $0.6 million. The amounts incurred during the nine months ended September 30, 2017 included accelerated depreciation charges of $59.8 million, employee separation, retention and other benefit-related costs of $19.5 million, certain intangible asset and property, plant and equipment impairment charges of $103.7 million, charges to increase excess inventory reserves of $7.9 million and certain other charges of $12.7 million. In the third quarter of 2017, the Company recorded a correcting entry to increase Property, plant and equipment impairment charges resulting from certain assets that should have been impaired during the second quarter of 2017. The pre-tax impact for the three months ended September 30, 2017 includes a correcting adjustment of $14.2 million, which had a corresponding decrease to Property, plant and equipment, net. The Company determined that the impact to the prior period and the current period are not material to the quarterly periods presented and have no impact on 2017 full year results.
These charges are included in the U.S. Generic Pharmaceuticals segment. Accelerated depreciation and employee separation, retention and other benefit-related costs are included in Cost of revenues. Certain other charges are included in both Cost of revenues and Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments are expected to be made by the end of the third quarter in 2019.
The liability related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this liability during the nine months ended September 30, 2018 were as follows (in thousands):
 
Employee Separation and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2018
$
22,975

 
$
1,610

 
$
24,585

Expenses
9,779

 
9,341

 
19,120

Cash distributions
(22,518
)
 
(10,951
)
 
(33,469
)
Liability balance as of September 30, 2018
$
10,236

 
$
—

 
$
10,236

January 2018 Restructuring Initiative
In January 2018, the Company initiated a restructuring initiative that included a reorganization of its U.S. Generic Pharmaceuticals segment’s research and development network, a further simplification of the Company’s manufacturing networks and a company-wide unification of certain corporate functions (the January 2018 Restructuring Initiative).

12

As a result of the January 2018 Restructuring Initiative, the Company incurred pre-tax charges of $23.8 million during the nine months ended September 30, 2018. The expenses consisted primarily of employee separation, retention and other benefit-related costs of $22.1 million and certain other charges of $1.7 million. Of the total charges incurred, $10.8 million are included in the U.S. Generic Pharmaceuticals segment, $5.2 million are included in Corporate unallocated costs, $4.0 million are included in the U.S. Branded - Sterile Injectables segment, $3.1 million are included in the International Pharmaceuticals segment and $0.7 million are included in the U.S. Branded - Specialty & Established Pharmaceuticals segment. The Company did not incur material charges related to this restructuring initiative during the three months ended September 30, 2018.
Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and administrative and Research and development expenses in the Condensed Consolidated Statements of Operations. Certain other charges are primarily included in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments are expected to be made by the end of the second quarter in 2019.
The liability related to the January 2018 Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this liability during the nine months ended September 30, 2018 were as follows (in thousands):
 
Employee Separation and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2018
$
—

 
$
650

 
$
650

Expenses
22,087

 
1,705

 
23,792

Cash distributions
(18,439
)
 
(1,949
)
 
(20,388
)
Liability balance as of September 30, 2018
$
3,648

 
$
406

 
$
4,054

NOTE 5. ACQUISITIONS
On April 26, 2018, the Company entered into a Membership Interest and Asset Purchase Agreement (the Somerset Purchase Agreement) with Mendham Holdings, LLC (the Seller) and certain other Seller related parties in connection with the acquisition of all of the limited liability company membership interests (the LLC Interests) of Somerset Therapeutics, LLC (Somerset) and certain of Somerset’s assets, including intellectual property, product Abbreviated New Drug Applications (ANDAs) and inventory (the Somerset Assets). Somerset is a specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. market. The Somerset acquisition is contingent upon the closing of the acquisition of the Indian-based Wintac business (as defined below).
Pursuant to the terms of the Somerset Purchase Agreement, the Company will acquire 100% of the LLC Interests of Somerset and the Somerset Assets for an aggregate cash purchase price of approximately $160 million, subject to customary adjustments for cash, net working capital and indebtedness as described in the Somerset Purchase Agreement. The Somerset Purchase Agreement contains certain customary representations, warranties and covenants and provides for indemnification rights of the parties in respect of inaccuracies or breaches of certain representations, warranties and covenants, subject to the limitations set forth in the Somerset Purchase Agreement.
The Somerset acquisition is expected to close in the first quarter of 2019, subject to satisfaction of customary closing conditions, including required regulatory approvals and the closing of the acquisition of the Wintac business. In connection with the Somerset acquisition, the Company’s Indian subsidiary has entered into separate agreements to acquire the entire business of Somerset’s Indian-based contract development and manufacturing affiliate, Wintac Limited (Wintac), including certain real property in Bangalore, India and the manufacturing plants thereon and to assume certain debt of Wintac for the expected aggregate amount of the rupee equivalent of approximately $30 million, subject to customary adjustments for net working capital.
NOTE 6. SEGMENT RESULTS
As of January 1, 2018, we made changes to our reportable segments. Following these changes, the four reportable business segments in which we operate are: (1) U.S. Branded - Specialty & Established Pharmaceuticals, (2) U.S. Branded - Sterile Injectables, (3) U.S. Generic Pharmaceuticals and (4) International Pharmaceuticals. Previously, we had three reportable segments: (1) U.S. Generic Pharmaceuticals, (2) U.S. Branded Pharmaceuticals and (3) International Pharmaceuticals. The updates to our reportable segments were made based on first quarter 2018 changes to the way we manage and evaluate our business.

13

Our new U.S. Branded - Sterile Injectables segment consists of our sterile injectables product portfolio, which was previously part of our former U.S. Generic Pharmaceuticals segment. Our new U.S. Generic Pharmaceuticals segment represents the remainder of our former U.S. Generic Pharmaceuticals segment. Additionally, our former U.S. Branded Pharmaceuticals segment has been renamed “U.S. Branded - Specialty & Established Pharmaceuticals.”
Our segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
We evaluate segment performance based on each segment’s adjusted income from continuing operations before income tax, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items.
Certain of the corporate expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate items.
U.S. Branded - Specialty & Established Pharmaceuticals
Our U.S. Branded - Specialty & Established Pharmaceuticals segment includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products in this segment include XIAFLEX®, SUPPRELIN® LA, TESTOPEL®, NASCOBAL® Nasal Spray, AVEED®, PERCOCET®, VOLTAREN® Gel, LIDODERM®, EDEX®, TESTIM® and FORTESTA® Gel, among others.
U.S. Branded - Sterile Injectables
Our U.S. Branded - Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT®, ADRENALIN® and APLISOL®, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others.
U.S. Generic Pharmaceuticals
Our U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.
International Pharmaceuticals
Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs Inc. (Paladin). This segment’s key products serve growing therapeutic areas, including attention deficit hyperactivity disorder (ADHD), pain, women’s health and oncology. This segment also included: (i) our South African Litha business, which was sold in July 2017, and (ii) our Latin American Somar business, which was sold in October 2017.

14

The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net revenues from external customers:
 
 
 
 
 
 
 
U.S. Branded - Specialty & Established Pharmaceuticals
$
220,100

 
$
233,803

 
$
632,972

 
$
729,150

U.S. Branded - Sterile Injectables
237,150

 
201,905

 
670,847

 
554,365

U.S. Generic Pharmaceuticals
257,969

 
294,749

 
748,445

 
1,227,584

International Pharmaceuticals (1)
30,247

 
56,430

 
108,425

 
189,119

Total net revenues from external customers
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

Adjusted income from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded - Specialty & Established Pharmaceuticals
$
84,891


$
123,754


$
262,454


$
380,841

U.S. Branded - Sterile Injectables
170,329


150,531


513,082


417,060

U.S. Generic Pharmaceuticals
82,555


86,236


247,137


415,172

International Pharmaceuticals
13,377


17,434


45,594


47,128

Total segment adjusted income from continuing operations before income tax
$
351,152


$
377,955


$
1,068,267


$
1,260,201

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.
There were no material revenues from external customers attributed to an individual country outside of the United States during any of the periods presented. There were no material tangible long-lived assets in an individual country other than the United States as of September 30, 2018 or December 31, 2017.
The table below provides reconciliations of our consolidated Loss from continuing operations before income tax, which is determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), to our total segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Total consolidated loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Interest expense, net
131,847

 
127,521

 
385,896

 
361,267

Corporate unallocated costs (1)
49,187

 
33,035

 
144,693

 
114,655

Amortization of intangible assets
161,275

 
161,413

 
471,662

 
615,490

Inventory step-up
71

 
66

 
261

 
281

Upfront and milestone payments to partners
4,731

 
775

 
43,027

 
6,952

Separation benefits and other cost reduction initiatives (2)
4,001

 
80,693

 
82,141

 
127,977

Certain litigation-related and other contingencies, net (3)
(1,750
)
 
(12,352
)
 
15,370

 
(14,016
)
Asset impairment charges (4)
142,217

 
94,924

 
613,400

 
1,023,930

Acquisition-related and integration items (5)
1,288

 
16,641

 
13,284

 
31,711

Loss on extinguishment of debt
—

 
—

 
—

 
51,734

Foreign currency impact related to the remeasurement of intercompany debt instruments
1,528

 
3,005

 
(1,560
)
 
(2,922
)
Other, net (6)
(175
)
 
30

 
(28,348
)
 
1,789

Total segment adjusted income from continuing operations before income tax
$
351,152

 
$
377,955

 
$
1,068,267

 
$
1,260,201

__________
(1)
Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.

15

(2)
Amounts for the three and nine months ended September 30, 2018 relate to employee separation costs of $2.1 million and $32.7 million, respectively, charges to increase excess inventory reserves of $0.2 million and $2.8 million, respectively, and other charges of $1.7 million and $11.4 million, respectively, each of which related primarily to our restructuring initiatives. Also included in the amount for the nine months ended September 30, 2018 is accelerated depreciation of $35.2 million, which related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. During the three and nine months ended September 30, 2017, amounts primarily relate to employee separation costs of $19.8 million and $41.3 million, accelerated depreciation of $59.8 million and $60.2 million, other charges of $1.1 million and $18.5 million, respectively, and charges to increase excess inventory reserves of $7.9 million during the nine months ended September 30, 2017. These charges were related primarily to the 2017 U.S. Generics Pharmaceuticals restructuring initiative. See Note 4. Restructuring for discussion of our material restructuring initiatives.
(3)
Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.
(4)
Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 7. Fair Value Measurements.
(5)
Amounts during the three and nine months ended September 30, 2018 are primarily related to charges due to changes in the fair value of contingent consideration of $0.8 million and $11.7 million, respectively. Amounts during the three and nine months ended September 30, 2017 include charges due to changes in the fair value of contingent consideration of $15.4 million and $23.6 million, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.
(6)
Amounts during the three and nine months ended September 30, 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 17. Other income, net.
Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.
The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.

Three Months Ended September 30,

Nine Months Ended September 30,

2018

2017

2018

2017
U.S. Branded - Specialty & Established Pharmaceuticals:
 
 
 
 
 
 
 
Specialty Products:
 
 
 
 
 
 
 
XIAFLEX®
$
64,214

 
$
52,511

 
$
184,855

 
$
152,113

SUPPRELIN® LA
20,408

 
20,638

 
60,948

 
63,468

Other Specialty (1)
43,576

 
40,634

 
114,202

 
113,407

Total Specialty Products
$
128,198

 
$
113,783

 
$
360,005

 
$
328,988

Established Products:
 
 
 
 
 
 
 
PERCOCET®
$
30,730

 
$
31,349

 
$
93,539

 
$
93,183

VOLTAREN® Gel
15,057

 
19,102

 
44,185

 
53,646

OPANA® ER
—

 
14,756

 
—

 
82,056

Other Established (2)
46,115

 
54,813

 
135,243

 
171,277

Total Established Products
$
91,902

 
$
120,020

 
$
272,967

 
$
400,162

Total U.S. Branded - Specialty & Established Pharmaceuticals (3)
$
220,100

 
$
233,803

 
$
632,972

 
$
729,150

U.S. Branded - Sterile Injectables:
 
 
 
 
 
 
 
VASOSTRICT®
$
112,333


$
105,741


$
332,387


$
300,649

ADRENALIN®
35,460


25,335


101,858


50,464

Ertapenem for injection
25,798

 
—

 
25,798

 
—

Other Sterile Injectables (4)
63,559


70,829


210,804


203,252

Total U.S. Branded - Sterile Injectables (3)
$
237,150


$
201,905


$
670,847


$
554,365

Total U.S. Generic Pharmaceuticals (5)
$
257,969

 
$
294,749

 
$
748,445

 
$
1,227,584

Total International Pharmaceuticals (6)
$
30,247

 
$
56,430

 
$
108,425

 
$
189,119

Total Revenues
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

__________
(1)
Products included within Other Specialty include TESTOPEL®, NASCOBAL® Nasal Spray and AVEED®.
(2)
Products included within Other Established include, but are not limited to, LIDODERM®, EDEX®, TESTIM® and FORTESTA® Gel, including the authorized generics.
(3)
Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $25 million during any quarterly period in 2018 or 2017.
(4)
Products included within Other Sterile Injectables include, but are not limited to, APLISOL® and ephedrine sulfate injection.

16

(5)
The U.S. Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the nine months ended September 30, 2017, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up 9% of consolidated total revenue. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.
(6)
The International Pharmaceuticals segment, which accounted for 4% and 5% of consolidated total revenues during the three and nine months ended September 30, 2018, respectively, and 7% of consolidated total revenues during both the three and nine months ended September 30, 2017, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs, Inc. (Paladin). This segment also included: (i) our South African business, which was sold in July 2017 and consisted of Litha and certain assets acquired from Aspen Holdings in October 2015 and (ii) our Latin American business consisting of Somar, which was sold in October 2017.
NOTE 7. FAIR VALUE MEASUREMENTS
Financial Instruments
The financial instruments recorded in our Condensed Consolidated Balance Sheets include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.
At September 30, 2018 and December 31, 2017, the Company had combined restricted cash and cash equivalents of $312.0 million and $324.4 million, respectively, of which $289.7 million and $320.5 million, respectively, are classified as current assets and reported in our Condensed Consolidated Balance Sheets as Restricted cash and cash equivalents. The remaining amounts, which are classified as non-current assets, are reported in our Condensed Consolidated Balance Sheets as Other assets. Approximately $283.8 million and $313.8 million of our restricted cash and cash equivalents are held in qualified settlement funds (QSFs) for mesh-related matters at September 30, 2018 and December 31, 2017, respectively. The remaining amount of restricted cash and cash equivalents at September 30, 2018 primarily relates to other litigation-related matters. See Note 14. Commitments and Contingencies for further information.
Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
•
Level 1—Quoted prices in active markets for identical assets or liabilities.
•
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Marketable Securities
Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in our Condensed Consolidated Balance Sheets at September 30, 2018 and December 31, 2017.
Acquisition-Related Contingent Consideration
The fair value of contingent consideration liabilities is determined using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.

17

Recurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2018 and December 31, 2017 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
September 30, 2018
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
691,579

 
$
—

 
$
—

 
$
691,579

Equity securities
1,693

 
—

 
—

 
1,693

Total
$
693,272

 
$
—

 
$
—

 
$
693,272

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
42,261

 
$
42,261

Acquisition-related contingent consideration—long-term
—

 
—

 
86,209

 
86,209

Total
$
—

 
$
—

 
$
128,470

 
$
128,470

 
Fair Value Measurements at Reporting Date using:
December 31, 2017
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
439,831

 
$
—

 
$
—

 
$
439,831

Time deposits
—

 
303,410

 
—

 
303,410

Equity securities
1,456

 
—

 
—

 
1,456

Total
$
441,287

 
$
303,410

 
$
—

 
$
744,697

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
70,543

 
$
70,543

Acquisition-related contingent consideration—long-term
—

 
—

 
119,899

 
119,899

Total
$
—

 
$
—

 
$
190,442

 
$
190,442

At September 30, 2018 and December 31, 2017, money market funds include $57.0 million and $35.6 million, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See Note 14. Commitments and Contingencies for further discussion of our product liability cases. The differences between the amortized cost and fair value of our money market funds and equity securities were not material, individually or in the aggregate, at September 30, 2018 or December 31, 2017, nor were any of the related gross unrealized gains or losses.
Fair Value Measurements Using Significant Unobservable Inputs
The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Beginning of period
$
152,098

 
$
210,460

 
$
190,442

 
$
262,113

Amounts settled
(24,564
)
 
(31,617
)
 
(73,298
)
 
(91,927
)
Changes in fair value recorded in earnings
769

 
15,440

 
11,731

 
23,574

Effect of currency translation
167

 
504

 
(405
)
 
1,027

End of period
$
128,470

 
$
194,787

 
$
128,470

 
$
194,787


18

At September 30, 2018, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from approximately 10% to 22% (weighted average rate of approximately 14.1%). Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Condensed Consolidated Statements of Operations as Acquisition-related and integration items, and amounts recorded for the short-term and long-term portions of acquisition-related contingent consideration are included in Accounts payable and accrued expenses and Other liabilities, respectively, in our Condensed Consolidated Balance Sheets.
The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2018 by acquisition (in thousands):
 
Balance as of December 31, 2017
 
Fair Value Adjustments and Accretion
 
Payments and Other
 
Balance as of September 30, 2018
Auxilium acquisition
$
13,061

 
$
(263
)
 
$
(1,844
)
 
$
10,954

Lehigh Valley Technologies, Inc. acquisitions
63,001

 
11,169

 
(39,469
)
 
34,701

VOLTAREN® Gel acquisition
98,124

 
3,839

 
(30,923
)
 
71,040

Other
16,256

 
(3,014
)
 
(1,467
)
 
11,775

Total
$
190,442

 
$
11,731

 
$
(73,703
)
 
$
128,470

Nonrecurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2018 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
 
Total Expense for the Nine Months Ended September 30, 2018
 
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Assets:
 
 
 
 
 
 
 
Intangible assets, excluding goodwill (Note 9)
$
—

 
$
—

 
$
239,857

 
$
(217,576
)
Certain property, plant and equipment (1)
—

 
—

 
—

 
(4,824
)
Total
$
—

 
$
—

 
$
239,857

 
$
(222,400
)
__________
(1)
Amount includes $2.6 million related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring.
Additionally, the Company recorded aggregate goodwill impairment charges during the nine months ended September 30, 2018 of $391.0 million. Refer to Note 9. Goodwill and Other Intangibles for further description, including the valuation methodologies utilized.
NOTE 8. INVENTORIES
Inventories consist of the following at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
Raw materials (1)
$
119,627

 
$
124,685

Work-in-process (1)
83,665

 
109,897

Finished goods (1)
129,495

 
156,855

Total
$
332,787

 
$
391,437

__________
(1) The components of inventory shown in the table above are net of allowance for obsolescence.
Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX® inventory, is classified as long-term inventory and is not included in the table above. At September 30, 2018 and December 31, 2017, $13.3 million and $17.1 million, respectively, of long-term inventory was included in Other assets in the Condensed Consolidated Balance Sheets. As of September 30, 2018 and December 31, 2017, the Company’s Condensed Consolidated Balance Sheets included approximately $13.6 million and $5.9 million, respectively, of capitalized pre-launch inventories related to generic products that were not yet available to be sold.

19

NOTE 9. GOODWILL AND OTHER INTANGIBLES
Goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2018 were as follows (in thousands):
 
U.S. Branded - Specialty & Established Pharmaceuticals
 
U.S. Branded - Sterile Injectables
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2017
$
828,818

 
$
—

 
$
3,531,301

 
$
89,963

 
$
4,450,082

Allocation to current segments (1)
—

 
2,731,193

 
(2,731,193
)
 
—

 
—

Effect of currency translation
—

 
—

 
—

 
(2,414
)
 
(2,414
)
Goodwill impairment charges
—

 
—

 
(391,000
)
 
—

 
(391,000
)
Goodwill as of September 30, 2018
$
828,818

 
$
2,731,193

 
$
409,108

 
$
87,549

 
$
4,056,668

__________
(1)
This allocation relates to the change in segments described in Note 6. Segment Results. The amount of goodwill initially attributed to the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals segments was determined using a relative fair value methodology in accordance with U.S. GAAP.
The carrying amounts of goodwill at September 30, 2018 and December 31, 2017 are net of the following accumulated impairments (in thousands):

U.S. Branded - Specialty & Established Pharmaceuticals
 
U.S. Branded - Sterile Injectables
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2017
$
855,810

 
$
—

 
$
2,342,549

 
$
463,545

 
$
3,661,904

Accumulated impairment losses as of September 30, 2018
$
855,810

 
$
—

 
$
2,733,549

 
$
451,209

 
$
4,040,568


20

Other Intangible Assets
Changes in the amount of other intangible assets for the nine months ended September 30, 2018 are set forth in the table below (in thousands).
Cost basis:
Balance as of December 31, 2017
 
Acquisitions
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2018
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
347,200

 
$
—

 
$
(87,900
)
 
$
(165,400
)
 
$
—

 
$
93,900

Total indefinite-lived intangibles
$
347,200

 
$
—

 
$
(87,900
)
 
$
(165,400
)
 
$
—

 
$
93,900

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
457,402

 
$
—

 
$
—

 
$
—

 
$
—

 
$
457,402

Tradenames
6,409

 
—

 
—

 
—

 
—

 
6,409

Developed technology (weighted average life of 11 years)
6,187,764

 
—

 
(129,676
)
 
154,753

 
(7,447
)
 
6,205,394

Total finite-lived intangibles (weighted average life of 11 years)
$
6,651,575

 
$
—

 
$
(129,676
)
 
$
154,753

 
$
(7,447
)
 
$
6,669,205

Total other intangibles
$
6,998,775

 
$
—

 
$
(217,576
)
 
$
(10,647
)
 
$
(7,447
)
 
$
6,763,105

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2017
 
Amortization
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2018
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(370,221
)
 
$
(21,262
)
 
$
—

 
$
—

 
$
—

 
$
(391,483
)
Tradenames
(6,409
)
 
—

 
—

 
—

 
—

 
(6,409
)
Developed technology
(2,304,461
)
 
(450,400
)
 
—

 
10,647

 
3,217

 
(2,740,997
)
Total other intangibles
$
(2,681,091
)
 
$
(471,662
)
 
$
—

 
$
10,647

 
$
3,217

 
$
(3,138,889
)
Net other intangibles
$
4,317,684

 
 
 
 
 
 
 
 
 
$
3,624,216

__________
(1)
Other adjustments relate to reclassification adjustments of $165.4 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the nine months ended September 30, 2018 and the removal of certain fully amortized intangible assets.
Amortization expense for the three and nine months ended September 30, 2018 totaled $161.3 million and $471.7 million, respectively. Amortization expense for the three and nine months ended September 30, 2017 totaled $161.4 million and $615.5 million, respectively. Amortization expense is included in Cost of revenues in the Condensed Consolidated Statements of Operations. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2017 is as follows (in thousands):
2018
$
622,384

2019
$
552,516

2020
$
481,300

2021
$
447,157

2022
$
420,786

Impairments
Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.

21

As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach. The discounted cash flow models are dependent upon our estimates of future cash flows and other factors. These estimates of future cash flows involve assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, tax rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows are based on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Condensed Consolidated Statements of Operations.
During the three and nine months ended September 30, 2018 and 2017, the Company incurred the following goodwill and other intangible asset impairment charges:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Goodwill impairment charges
$
—

 
$
—

 
$
391,000

 
$
288,745

Other intangible asset impairment charges
$
140,609

 
$
78,300

 
$
217,576

 
$
674,177

A summary of significant goodwill and other intangible asset impairment tests and related charges is included below. Other intangible asset impairment charges that are not included in the below narrative totaled $140.6 million and $78.3 million during the three months ended September 30, 2018 and 2017, respectively, and $217.6 million and $461.1 million during the nine months ended September 30, 2018 and 2017, respectively. These charges relate primarily to certain in-process research and development and/or developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.
Our first quarter 2018 change in segments described in Note 6. Segment Results resulted in changes to our reporting units for goodwill impairment testing purposes, including the creation of a new U.S. Branded - Sterile Injectables reporting unit, which was previously part of our Generics reporting unit. As a result of these changes, under U.S. GAAP, we tested the goodwill of the former Generics reporting unit immediately before the segment realignment and the goodwill of both the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals reporting units immediately after the segment realignment. These goodwill tests were performed using an income approach that utilizes a discounted cash flow model. The results of these goodwill impairment tests were as follows:
•
The former Generics reporting unit’s estimated fair value (determined using a discount rate of 9.5%) exceeded its carrying amount, resulting in no related goodwill impairment charge.
•
The new U.S. Branded - Sterile Injectables reporting unit’s estimated fair value (determined using a discount rate of 9.5%) exceeded its carrying amount, resulting in no related goodwill impairment charge.
•
The new U.S. Generic Pharmaceuticals reporting unit’s carrying amount exceeded its estimated fair value (determined using a discount rate of 9.5%), resulting in a pre-tax non-cash goodwill impairment charge of $391.0 million.
In March 2017, we announced that the Food and Drug Administration’s (FDA) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA® ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA’s request that we voluntarily withdraw OPANA® ER from the market, and in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA® ER from the market. As a result of our decision, the Company determined that the carrying amount of its OPANA® ER intangible asset was no longer recoverable, resulting in a pre-tax, non-cash impairment charge of $20.6 million in the second quarter of 2017, representing the remaining carrying amount.
As a result of the withdrawal of OPANA® ER from the market and the continued erosion of our U.S. Branded Pharmaceuticals segment’s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during the second quarter of 2017. We recorded a pre-tax, non-cash goodwill impairment charge of $180.4 million during the three months ended June 30, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Branded reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Branded goodwill impairment test was 9.5%.

22

As further described in Note 4. Restructuring, the Company announced the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative in July 2017, which includes the discontinuation of certain commercial products. As a result, the Company assessed the recoverability of the impacted products, resulting in pre-tax, non-cash intangible asset impairment charges of approximately $57.5 million during the second quarter of 2017. The Company also initiated an interim goodwill impairment analysis of its Generics reporting unit during the second quarter of 2017 as a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative and determined that the estimated fair value of the Generics reporting unit exceeded its carrying amount. Accordingly, no related goodwill impairment was recorded. The Company estimated the fair value of the Generics reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Generics goodwill impairment test was 9.0%.
Pursuant to an existing agreement with a wholly owned subsidiary of Novartis AG (Novartis), Paladin licensed the Canadian rights to commercialize serelaxin, an investigational drug for the treatment of acute heart failure (AHF). In March 2017, Novartis announced that a Phase 3 study of serelaxin in patients with AHF failed to meet its primary endpoints. As a result, we concluded that the full carrying amount of our serelaxin in-process research and development intangible asset was impaired, resulting in a $45.5 million pre-tax non-cash impairment charge for the three months ended March 31, 2017. In addition and as a result of the serelaxin impairment, we assessed the recoverability of our Paladin goodwill balance and determined that the estimated fair value of the Paladin reporting unit was below its carrying amount. We recorded a pre-tax, non-cash goodwill impairment charge of $82.6 million during the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Paladin reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Paladin goodwill impairment test was 10.0%.
As further discussed in Note 3. Discontinued Operations and Divestitures, we entered into a definitive agreement to sell Somar on June 30, 2017, which resulted in Somar’s assets and liabilities being classified as held for sale. The initiation of held-for-sale accounting, together with the agreed upon sale price, triggered an impairment review. Accordingly, we performed an impairment analysis using a market approach and determined that impairment charges were required. We recorded pre-tax, non-cash impairment charges of $25.7 million and $89.5 million related to Somar’s goodwill and other intangible assets, respectively, during the second quarter of 2017, each of which represented the remaining carrying amounts of the corresponding assets.
NOTE 10. LICENSE AND COLLABORATION AGREEMENTS
Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products.
Generally, under these agreements: (i) we are required to make upfront payments and other payments upon successful completion of regulatory or sales milestones, (ii) we are required to pay royalties on sales of the products arising from these agreements and (iii) termination is permitted with no significant continuing obligation.
During the second quarter of 2018, we entered into a development, license and commercialization agreement with a third party pharmaceutical company related to five sterile injectable product candidates. Pursuant to this agreement, the third party will generally be responsible, at its expense, to develop and seek regulatory approval for these product candidates, and the Company will generally be responsible, at its expense, to launch and distribute any products that are approved. The Company will have exclusive license rights to all of these products launched in the U.S. and a first right of refusal for the Canadian territory. Upon entering into this agreement, the Company became obligated to make an upfront payment, which was recorded as Research and development expense in the Condensed Consolidated Statements of Operations during the three months ended June 30, 2018. The Company could become obligated to make additional payments based on certain potential future milestones being achieved.
There have been no other significant changes to our license, collaboration and discovery agreements since our Annual Report on Form 10-K for the year ended December 31, 2017.
NOTE 11. CONTRACT ASSETS AND LIABILITIES
Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At September 30, 2018, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within one week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.
Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.

23

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):
 
September 30, 2018
 
January 1, 2018
 
$ Change
 
% Change
Contract assets, net (1)
$
13,291

 
$
11,287

 
$
2,004

 
18
 %
Contract liabilities, net (2)
$
19,635

 
$
20,954

 
$
(1,319
)
 
(6
)%
__________
(1)
At September 30, 2018 and January 1, 2018, approximately $10.3 million and $8.2 million, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other assets. The net increase in contract assets during the nine months ended September 30, 2018 was primarily due to certain sales activity during the period, partially offset by reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company’s rights to consideration for the sale of certain goods.
(2)
At September 30, 2018 and January 1, 2018, approximately $1.7 million and $1.9 million, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other liabilities. During the nine months ended September 30, 2018, the Company recognized revenue of $1.3 million that was included in the contract liability balance at January 1, 2018, resulting in a corresponding decrease in contract liabilities.
During the nine months ended September 30, 2018, we recognized revenue of $4.6 million relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.
NOTE 12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses include the following at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
Trade accounts payable
$
106,321

 
$
85,348

Returns and allowances
250,637

 
291,034

Rebates
152,297

 
168,333

Chargebacks
2,022

 
14,604

Accrued interest
64,647

 
130,257

Accrued payroll and related benefits
84,240

 
113,908

Accrued royalties and other distribution partner payables
103,673

 
63,114

Acquisition-related contingent consideration—short-term
42,261

 
70,543

Other
212,906

 
159,684

Total
$
1,019,004


$
1,096,825


24

NOTE 13. DEBT
The following table presents information about the Company’s total indebtedness at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
 
Effective Interest Rate
 
Principal Amount
 
Carrying Amount
 
Effective Interest Rate
 
Principal Amount
 
Carrying Amount
7.25% Senior Notes due 2022
7.91
%
 
$
400,000

 
$
392,439

 
7.91
%
 
$
400,000

 
$
390,974

5.75% Senior Notes due 2022
6.04
%
 
700,000

 
694,053

 
6.04
%
 
700,000

 
692,855

5.375% Senior Notes due 2023
5.62
%
 
750,000

 
743,083

 
5.62
%
 
750,000

 
742,048

6.00% Senior Notes due 2023
6.28
%
 
1,635,000

 
1,615,955

 
6.28
%
 
1,635,000

 
1,613,446

5.875% Senior Secured Notes due 2024
6.14
%
 
300,000

 
295,922

 
6.14
%
 
300,000

 
295,513

6.00% Senior Notes due 2025
6.27
%
 
1,200,000

 
1,182,859

 
6.27
%
 
1,200,000

 
1,181,243

Term Loan B Facility Due 2024
5.46
%
 
3,372,313

 
3,338,451

 
5.46
%
 
3,397,925

 
3,360,103

Other debt
 
 
—

 
—

 
1.50
%
 
55

 
55

Total long-term debt, net
 
 
$
8,357,313

 
$
8,262,762

 
 
 
$
8,382,980

 
$
8,276,237

Less current portion, net
 
 
34,150

 
34,150

 
 
 
34,205

 
34,205

Total long-term debt, less current portion, net
 
 
$
8,323,163

 
$
8,228,612

 
 
 
$
8,348,775

 
$
8,242,032

The senior unsecured notes are unsecured and effectively subordinated in right of priority to our credit agreement (the 2017 Credit Agreement) and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto.
The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $7.9 billion and $7.5 billion at September 30, 2018 and December 31, 2017, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.
Credit Facility
We have $997.2 million of remaining credit available through our revolving credit facility as of September 30, 2018. As of September 30, 2018, we were in compliance with all covenants contained in our credit agreement.
NOTE 14. COMMITMENTS AND CONTINGENCIES
Legal Proceedings and Investigations
We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief, and an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the aggregate, we will disclose such matters.
We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies could be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

25

As of September 30, 2018, our accrual for loss contingencies totaled $1,002.1 million, of which $845.6 million relates to our liability accrual for vaginal mesh cases and other mesh-related matters. During the fourth quarter of 2017, the Company recorded a total increase to its liability accrual of approximately $200 million related to testosterone-related product liability matters and LIDODERM®-related antitrust matters. The accrual for LIDODERM®-related matters includes an estimated loss for, among other matters, settlement of all remaining claims filed against EPI in multidistrict litigation (MDL) No. 2521, which is further discussed below under the heading “Other Antitrust Matters.” The testosterone-related accrual includes an estimated loss for, among other matters, all testosterone-related product liability cases filed in MDL No. 2545 and in other courts. These cases are further discussed below under the heading “Product Liability and Related Matters.” Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.
Product Liability and Related Matters
We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries. These and other related matters are described below in more detail.
Vaginal Mesh. Since 2008, we and certain of our subsidiaries, including American Medical Systems Holdings, Inc. (subsequently converted to Astora Women’s Health Holding LLC and merged into Astora Women’s Health LLC and referred to herein as AMS) and/or Astora, have been named as defendants in multiple lawsuits in various state and federal courts in the U.S. (including a federal MDL pending in the U.S. District Court for the Southern District of West Virginia (MDL No. 2325)), and in Canada and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). In January 2018, a representative proceeding (class action) was filed in the Federal Court of Australia against American Medical Systems, LLC. In the various class action and individual complaints, plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.
We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately 71,000 filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries.
All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation requirements regarding the claims represented by each law firm party to the MSA. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents.
Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant is required to represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlements.
In June 2017, the MDL court entered a case management order which, among other things, requires plaintiffs in newly-filed MDL cases to provide expert disclosures on specific causation within one hundred twenty (120) days of filing a claim (the Order). Under the Order, a plaintiff's failure to meet the foregoing deadline may be grounds for the entry of judgment against such plaintiff. In July 2017, a similar order was entered in Minnesota state court. In June 2018, at the request of the MDL court, the Judicial Panel on Multidistrict Litigation entered a minute order suspending the transfer of cases into the MDL. Subsequently, the MDL court issued a pretrial order discontinuing the direct filing of claims in MDL No. 2325. The MDL court also issued similar orders in other MDLs involving claims against other mesh manufacturers.
Although the Company believes it has appropriately estimated the probable total amount of loss associated with all matters as of the date of this report, fact and expert discovery is ongoing in certain cases that have not settled, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

26

The following table presents the changes in the QSFs and mesh liability accrual balance during the nine months ended September 30, 2018 (in thousands):
 
Qualified Settlement Funds
 
Mesh Liability Accrual
Balance as of January 1, 2018
$
313,814

 
$
1,087,172

Additional charges
—

 
19,000

Cash contributions to Qualified Settlement Funds
216,770

 
—

Cash distributions to settle disputes from Qualified Settlement Funds
(248,485
)
 
(248,485
)
Cash distributions to settle disputes
—

 
(17,114
)
Other (1)
1,653

 
5,038

Balance as of September 30, 2018
$
283,752

 
$
845,611

__________
(1)
Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. The $5.0 million in the table above also includes a second quarter 2018 reclassification adjustment of $4.4 million for accrued interest amounts previously recorded in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets.
As of September 30, 2018, $820.2 million of the mesh liability accrual amount shown above is classified in the Current portion of the legal settlement accrual in the Condensed Consolidated Balance Sheets, with the remainder classified as Long-term legal settlement accrual, less current portion. Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Condensed Consolidated Statements of Operations.
To date, the Company has made total mesh liability payments of approximately $3.1 billion, $283.8 million of which remains in the QSFs as of September 30, 2018. We expect to fund into the QSFs the remaining payments under all settlement agreements during the remainder of 2018 and 2019. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.
We were contacted in October 2012 regarding a civil investigation initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are cooperating with these investigations.
We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.
Testosterone. Various manufacturers of prescription medications containing testosterone, including our subsidiaries Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), have been named as defendants in multiple lawsuits alleging personal injury resulting from the use of such medications, including FORTESTA® Gel, DELATESTRYL®, TESTIM®, TESTOPEL®, AVEED® and STRIANT®. Plaintiffs in these suits generally allege various personal injuries, including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and seek compensatory and/or punitive damages, where available.
As of November 1, 2018, we were aware of approximately 1,205 testosterone cases (some of which may have been filed on behalf of multiple plaintiffs) pending against one or more of our subsidiaries in federal or state court. Many of these cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2545). In November 2015, the MDL court entered an order granting defendants’ motion to dismiss claims involving certain testosterone products that were approved pursuant to ANDAs, including TESTOPEL®. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the MDL court granted plaintiffs’ motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing. An MDL trial against Auxilium involving TESTIM® took place in November 2017 and resulted in a defense verdict. A trial against Auxilium involving TESTIM® was scheduled for January 2018 in the Philadelphia Court of Common Pleas (PCCP) but resolved prior to trial.
In June 2018, counsel for plaintiffs, on the one hand, and Auxilium and EPI, on the other, executed an MSA allowing for the resolution of all known testosterone replacement therapy product liability claims against our subsidiaries. The MSA was solely by way of compromise and settlement and was not in any way an admission of fault by us or any of our subsidiaries.

27

The MSA is subject to a process that includes guidelines and procedures for administering the settlement and the release of funds. Among other things, the MSA provides for the creation of a QSF into which the settlement funds will be deposited, establishes participation requirements, and allows for a reduction of the total settlement payment in the event the participation threshold is not met. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use and injury as determined by a third-party special master, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.
Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related product liability matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.
The MDL also includes a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers that claim to have paid for certain testosterone products. After a series of motions to dismiss, plaintiff filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act (RICO) and negligent misrepresentation based on defendants’ marketing of certain testosterone products. The court denied a motion to dismiss this complaint in August 2016. In July 2018, the court denied plaintiff’s motion for class certification. In October 2018, defendants moved for summary judgment. This lawsuit is not part of the settlement described above.
We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.
Unapproved Drug Litigation
In September 2013, the state of Louisiana filed a petition for damages against certain of our subsidiaries, including EPI, and more than 50 other pharmaceutical companies in Louisiana state court (19th Judicial District) alleging that the defendants or their subsidiaries marketed products that were not approved by the FDA and seeking damages, fines, penalties, attorneys’ fees and costs under various causes of action. In October 2015, the district court entered judgment for defendants on their exception for no right of action. The state appealed, and in October 2016 the Louisiana First Circuit Court of Appeals reversed the dismissal as to the state’s Medicaid Assistance Program Integrity Law (MAPIL) and Louisiana Unfair Trade Practices Act (LUTPA) claims but affirmed the dismissal as to the state’s other claims. The state’s petition for rehearing was denied in December 2016. Both sides applied to the Louisiana Supreme Court for a writ of certiorari to review the First Circuit’s decision. Those writs were denied in March 2017. In May 2017, defendants filed exceptions for no cause of action in the district court. In August 2017, the court sustained defendants’ exception as to the MAPIL claim but overruled defendants’ exception as to the LUTPA claim. The state then filed a motion seeking reconsideration with respect to the MAPIL claim, and defendants filed a motion for clarification with respect to the court’s ruling on the LUTPA claim. In October 2017, the court denied the state’s motion and entered final judgment against the state with respect to the MAPIL claim. The court also granted defendants’ motion for clarification and dismissed the state’s LUTPA claim insofar as it sought civil penalties for alleged violations occurring before June 2, 2006. In October 2017, defendants applied for a supervisory writ of certiorari to the Louisiana First Circuit Court of Appeals on the district court’s August 2017 order overruling defendants’ exception on the state’s LUTPA claim. The First Circuit Court of Appeals denied defendants’ writ application in July 2018. In August 2018, the defendants filed an application for a supervisory writ of certiorari to the Louisiana Supreme Court. That writ application is fully briefed.
In March 2017, the state of Mississippi filed a complaint against our subsidiary EPI in Mississippi state court (Hinds County Chancery Court) alleging that EPI marketed products that were not approved by the FDA and seeking damages, penalties, attorneys’ fees, costs and other relief under various causes of action. In April 2017, EPI removed the case to the U.S. District Court for the Southern District of Mississippi. In May 2017, the state moved to remand the case to state court, and that motion was granted in October 2017. In November 2017, EPI filed a motion to dismiss the state’s complaint on various grounds. In January 2018, the state filed a motion for leave to amend its complaint. In February 2018, following an unopposed motion by the state, the court consolidated the state’s case against EPI with five substantially similar cases brought by the state against other defendants. The consolidation is solely for purposes of coordinated pretrial proceedings and discovery, not for trial. In March 2018, the court signed an agreed order dismissing EPI and granting the state leave to file a first amended complaint. The first amended complaint names our subsidiary Generics International (US), Inc. (Generics) as the defendant. In April 2018, Generics moved to dismiss on various grounds. The case is currently stayed by agreement of the parties.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

28

Opioid-Related Matters
Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against certain of our subsidiaries, including Endo Health Solutions Inc. (EHSI), EPI, Par Pharmaceutical, Inc. (PPI), Par Pharmaceutical Companies, Inc. (Par), Vintage Pharmaceuticals, LLC and/or Generics Bidco I, LLC and, in some instances, the Company, as well as various other manufacturers, distributors and/or others, asserting claims relating to defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of November 1, 2018, the cases of which we were aware include, but are not limited to, approximately 11 cases filed by or on behalf of states; approximately 1,505 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 112 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers; and approximately 48 cases filed by individuals. Certain of the cases have been filed as putative class actions. In addition to the litigation in the U.S., in September 2018, an action against Paladin Labs, EPI, the Company and various other manufacturers and distributors was commenced in British Columbia on behalf of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids.
Many of the U.S. cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). In March 2018, the U.S. Department of Justice (DOJ) filed a statement of interest in the case, and in April 2018 it filed a motion to participate in settlement discussions and as a friend of the court, which the MDL court has granted. The MDL court has issued a series of case management orders permitting motions to dismiss addressing threshold legal issues in certain cases, setting a trial date in September 2019 for three cases originally filed in the Northern District of Ohio, allowing certain discovery and establishing certain other deadlines and procedures, among other things.
Other cases remain pending in various state courts. In some jurisdictions, such as Connecticut, Illinois, New York, Pennsylvania and Texas, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. The state cases are generally at the pleading and/or discovery stage.
The complaints in the cases assert a variety of claims including, but not limited to, claims for alleged violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability statutes and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:
In September 2017, the Department of Justice for the state of Oregon and the Office of the Attorney General for the Commonwealth of Massachusetts issued CIDs to EHSI and EPI on behalf of a multistate group which we understand currently includes approximately 30 states. Our subsidiaries are cooperating with this investigation. Certain states participating in the multistate investigation had issued their own CIDs, subpoenas or requests for information to the Company prior to their participation in the multistate investigation.
Other states are conducting their own investigations outside of the multistate group. These states include New Hampshire (subpoenas received by EPI in August 2015 and December 2017); New Jersey (subpoena received by EPI in March 2017); Washington (CID received by the Company, EHSI and EPI in August 2017); Montana (CID received by EHSI and EPI in January 2018); Alaska (CID received by EPI in February 2018); and South Carolina (CID received by EHSI and EPI in February 2018). We are cooperating with these investigations.
In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida in connection with an investigation being conducted by the U.S. Attorney’s Office for the Southern District of Florida in conjunction with the U.S. Food and Drug Administration. The subpoena seeks information related to OPANA® ER and other oxymorphone products. EPI is cooperating with the investigation.
Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

29

Generic Drug Pricing Matters
In December 2014, we received a grand jury subpoena from the Antitrust Division of the DOJ issued by the U.S. District Court for the Eastern District of Pennsylvania to Par Pharmaceuticals. The subpoena requested documents and information focused primarily on product and pricing information relating to Par’s authorized generic version of Lanoxin (digoxin) oral tablets and Par’s generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.
In December 2015, EPI received interrogatories and a subpoena from the Connecticut Attorney General’s Office requesting documents and information regarding pricing of certain of generic products, including doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride. EPI is cooperating with this investigation.
In May 2018, we and our subsidiary Par each received a CID from the U.S. Department of Justice in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.
Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Certain cases alleging price-fixing and other anticompetitive conduct with respect to various generic pharmaceutical products have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania under the caption In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724). Among the lawsuits consolidated and/or coordinated in the MDL, the earliest lawsuits naming the Company and/or its subsidiaries were filed in November 2016 and related to digoxin and doxycycline.
The private plaintiffs in the MDL include alleged direct purchasers, end-payers and indirect purchaser resellers who purport to represent not only themselves but also all others similarly situated. At the MDL court’s direction, in August 2017, each group of private plaintiffs (direct purchasers, end-payers and indirect purchaser resellers) filed separate consolidated amended class action complaints as to each of 18 products, except with respect to one product (propranolol) direct purchaser plaintiffs stated their intention to proceed on a consolidated amended complaint filed in the U.S. District Court for the Southern District of New York prior to MDL transfer (the Southern District of New York had denied a motion to dismiss this complaint). Each of the consolidated amended complaints filed in August 2017 relates to one product, and our subsidiary PPI was named as a defendant in complaints relating to the following six products: digoxin, doxycycline hyclate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. The MDL court divided the various cases into three separate product-based tranches for certain administrative and scheduling purposes, including briefing on motions to dismiss, and allowed certain targeted discovery. As to the six products in the first tranche (including digoxin, doxycycline hyclate and divalproex ER), defendants filed motions to dismiss in October 2017. In October 2018, the MDL court denied portions of these motions and has yet to rule on other aspects.
In December 2016, the Attorney General for the state of Connecticut, leading a coalition of 20 state attorneys general, filed a complaint in the U.S. District Court for the District of Connecticut alleging price-fixing and other anticompetitive conduct with respect to doxycycline hyclate delayed release and glyburide against certain manufacturers of those products. The Company and its subsidiaries were not named in that complaint, or in an amended complaint filed on behalf of 40 states in March 2017, or in a separate lawsuit filed by four more states and the District of Columbia in the same court in July 2017. In August 2017, the state cases were transferred to MDL No. 2724. In October 2017, the state plaintiffs filed a motion for leave to (1) consolidate their two cases, (2) add Alaska and the Commonwealth of Puerto Rico as plaintiffs and (3) assert additional claims against existing and new defendants. In June 2018, the MDL court granted this motion, and the state plaintiffs filed their amended complaint. The amended complaint adds new allegations and claims against 14 new defendants, including our subsidiary Par, relating to 13 additional products. The amended complaint alleges anticompetitive conduct by our subsidiary with respect to doxycycline monohydrate. It also alleges that all defendants engaged in an overarching conspiracy to restrain trade across the generic pharmaceutical industry and seeks to hold all defendants, including our subsidiary, jointly and severally liable for harm caused by alleged anticompetitive activity concerning each of the 15 drugs at issue. The amended complaint seeks declaratory and injunctive relief, disgorgement and other equitable relief, compensatory and treble damages, civil penalties, costs and attorneys’ fees.
In January 2018, The Kroger Co., Albertsons Companies, LLC, and H.E. Butt Grocery Company LP filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against PPI, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to 30 separate generic pharmaceutical products, including seven products allegedly manufactured by PPI: digoxin, doxycycline hyclate, doxycycline monohydrate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. This lawsuit has been assigned to the MDL court. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all 30 products, as well as product-specific conspiracies relating to each individual product, in violation of federal antitrust law. The complaint seeks monetary damages, including treble damages, attorneys’ fees and injunctive relief.

30

In June 2018, direct purchaser, end-payer and indirect purchaser reseller plaintiffs filed additional class action complaints in the U.S. District Court for the Eastern District of Pennsylvania, alleging anticompetitive conduct relating to approximately 15 generic pharmaceuticals (generally those that were the subject of the state plaintiffs’ amended complaint). These lawsuits have also been assigned to the MDL court. The end payer and indirect purchaser reseller complaints name our subsidiaries PPI, Generics Bidco I, LLC and DAVA Pharmaceuticals, LLC, as well as other companies, as defendants. The direct purchaser complaint names our subsidiary Par and other companies as defendants. As to our subsidiaries, these complaints allege anticompetitive conduct with respect to doxycycline hyclate, doxycycline monohydrate, nystatin cream and/or zoledronic acid. These complaints also seek to hold all defendants jointly and severally liable for alleged anticompetitive conduct relating to all products identified in the complaints on the basis of an “overarching conspiracy” theory similar to that asserted by the state plaintiffs.
In August 2018, Humana Inc. filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against the Company, PPI and Par, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to approximately 16 generic pharmaceutical products, including amitriptyline, baclofen, digoxin, divalproex, doxycycline (both doxycycline hyclate and doxycycline monohydrate) and propranolol. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all 16 products, as well as product-specific conspiracies relating to each individual product. The complaint asserts claims under state and federal law and seeks monetary damages, including treble damages, attorneys’ fees and equitable relief. The lawsuit has been assigned to the MDL court.
In September 2018, Marion Diagnostic Center, LLC and Marion HealthCare, LLC filed a class action complaint in the U.S. District Court for the Eastern District of Pennsylvania against Par, as well as other manufacturers and one distributor of generic pharmaceuticals, McKesson Corporation (McKesson), on behalf of all direct purchasers of all generic drugs from McKesson. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing and market allocation with respect to all generic drugs sold by McKesson, seeking to hold all defendants jointly and severally liable. The complaint asserts claims under state and federal law and seeks monetary damages, including treble damages, attorneys’ fees and equitable relief.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Other Antitrust Matters
Beginning in November 2013, multiple direct and indirect purchasers of LIDODERM® filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. (collectively, Teikoku), and Actavis plc and certain of its subsidiaries (collectively, Actavis, which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries from Allergan plc). Plaintiffs generally alleged that EPI, Teikoku and Actavis entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ‘529 patent) and other patents. Some complaints also alleged that Teikoku wrongfully listed the ‘529 patent in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) as related to LIDODERM®, that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies’ efforts to obtain FDA approval of their versions of LIDODERM®. The complaints asserted claims under Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), and/or various state antitrust and consumer protection statutes, as well as common law claims, and generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. The cases were consolidated and/or coordinated in April 2014 in a federal MDL in the U.S. District Court for the Northern District of California (MDL No. 2521). The MDL court certified classes of direct and indirect purchasers in February 2017. In June 2017, defendants moved for summary judgment on all claims, and plaintiffs also moved for partial summary judgment on certain elements of their claims. In November 2017, the court granted defendants’ motion in part, ruling in defendants’ favor on the issues of infringement and derivation and also limiting the time period at issue. Defendants’ motions for summary judgment were denied in all other respects. The court also granted plaintiffs’ motions for summary judgment on the issues of agreement and relevant market. EPI settled with certain opt-out retailer plaintiffs in October 2017. EPI reached agreements to settle with the class plaintiffs in March 2018. In connection with the settlements, several indirect purchasers which previously had opted out were permitted to rejoin the class. The class settlement agreements provide for aggregate payments of approximately $100 million. In September 2018, the court approved the class settlement agreements and entered judgment dismissing the class cases with prejudice.

31

Beginning in June 2014, multiple direct and indirect purchasers of OPANA® ER filed cases against our subsidiaries EHSI and EPI and other pharmaceutical companies, including Impax Laboratories Inc. (Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. All cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2580). Plaintiffs generally allege that an agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA® ER and EPI’s introduction of reformulated OPANA® ER violated antitrust laws. The complaints assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In February 2016, the MDL court issued orders (i) denying defendants’ motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants’ motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants’ motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the MDL court’s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers also filed amended complaints. The court has dismissed the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. The cases are currently in discovery. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.
Beginning in February 2009, the FTC and certain private plaintiffs, including distributors and retailers, filed suit against our subsidiary Par Pharmaceutical Companies, Inc. (since June 2016, Endo Generics Holdings, Inc., and referred to in this Commitments and Contingencies note as EGHI) and others alleging violations of antitrust law arising out of EGHI’s settlement of certain patent litigation concerning the generic version of AndroGel®. Generally, the complaints seek damages, treble damages, equitable relief and attorneys’ fees and costs. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia (MDL No. 2084). In September 2012, the MDL court granted summary judgment to defendants on plaintiffs’ claims of sham litigation. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. Claims by certain alleged direct purchasers or their assignees are still pending. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, the court rejected two of direct purchasers’ three causation theories, rejected damages claims related to AndroGel® 1.62% and granted in part a motion seeking to exclude part of plaintiffs’ proposed manufacturing expert’s opinions. The motions were denied in all other respects, and the court denied a motion for reconsideration, or in the alternative leave to file an interlocutory appeal, in October 2018. In July 2018, the district court denied certain plaintiffs’ motion for certification of a direct purchaser class. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.
Beginning in February 2018, several alleged indirect purchasers filed proposed class actions against our subsidiary PPI and others alleging a conspiracy to delay generic competition and monopolize the market for Zetia® (ezetimibe) and its generic equivalents. The complaints generally asserted claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek injunctive relief, damages, treble damages, attorneys’ fees and costs. In June 2018, the cases were consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Virginia (MDL No. 2836). In September 2018, plaintiffs voluntarily dismissed without prejudice all claims against PPI.
Beginning in May 2018, multiple alleged direct and indirect purchasers filed complaints in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as others, alleging a conspiracy to delay generic competition and monopolize the market for Exforge® (amlodipine/valsartan) and its generic equivalents. Some cases were filed on behalf of putative classes of direct and indirect purchasers; another was filed on behalf of individual retailers. The plaintiffs generally assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek damages, treble damages, equitable relief and attorneys’ fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs did the same in November 2018. PPI filed a partial motion to dismiss certain claims in September 2018. We intend to vigorously defend these matters and to explore other options as appropriate in our best interests.
In November 2014, EPI received a CID from Florida’s Office of the Attorney General seeking documents and other information concerning EPI’s agreement with Actavis settling the LIDODERM® patent litigation, as well as information concerning marketing and sales of LIDODERM®. EPI received similar CIDs from South Carolina’s Office of the Attorney General in February 2016 and from Alaska’s Office of the Attorney General in February 2015. The Alaska CID was also directed to EHSI and included requests for documents and information concerning agreements with Actavis and Impax settling the OPANA® ER patent litigation. We are cooperating with these investigations.
In February 2015, EGHI and affiliates received a CID from the Office of the Attorney General for the state of Alaska seeking production of certain documents and information regarding EGHI’s settlement of the AndroGel® patent litigation as well as documents produced in the aforementioned litigation filed by the FTC. We are cooperating with this investigation.

32

Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.
Securities Litigation
In May 2016, a putative class action entitled Craig Friedman v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the court appointed Steamfitters’ Industry Pension Fund and Steamfitters’ Industry Security Benefit Fund as lead plaintiffs in the action. In October 2016, plaintiffs filed a second amended complaint that, among other things, added Paul Campanelli as a defendant, and we filed a motion to dismiss. In response, and without resolving the motion, the court permitted lead plaintiffs to file a third amended complaint. The amended complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company’s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par Pharmaceutical Holdings, Inc. and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney’s Office for the Southern District of New York regarding contracts with pharmacy benefit managers concerning FROVA®. Lead plaintiffs sought class certification, damages in an unspecified amount and attorneys’ fees and costs. We filed a motion to dismiss the third amended complaint in December 2016. In January 2018, the court granted our motion and dismissed the case with prejudice. In February 2018, lead plaintiffs filed a motion for relief from the judgment and leave to file a fourth amended complaint; the court denied this motion in April 2018. Lead plaintiffs appealed to the U.S. Court of Appeals for the Second Circuit; that appeal is still pending.
In February 2017, a putative class action entitled Public Employees’ Retirement System of Mississippi v. Endo International plc was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering, on behalf of itself and all similarly situated purchasers. The lawsuit alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against Endo, certain of its current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo’s generics business. In March 2017, defendants removed the case to the U.S. District Court for the Eastern District of Pennsylvania. In August 2017, the court remanded the case back to the Chester County Court of Common Pleas. In October 2017, plaintiff filed an amended complaint. In December 2017, defendants filed preliminary objections to the amended complaint. The court denied those preliminary objections in April 2018. The case is currently in discovery. Plaintiff filed its motion for class certification in July 2018.
In April 2017, a putative class action entitled Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo’s securities between January 11 and May 5, 2016. The statement of claim generally seeks class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act. The statement of claim alleges negligent misrepresentations concerning the Company’s revenues, profit margins and earnings per share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company’s U.S. generic pharmaceuticals business.
In August 2017, a putative class action entitled Bier v. Endo International plc, et al. was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The original complaint alleged violations of Section 10(b) and 20(a) of the Exchange Act against Endo and four current and former directors and officers, based on the Company’s decision to remove reformulated OPANA® ER from the market. In December 2017, the court appointed SEB Investment Management AB lead plaintiff in the action. In February 2018, the lead plaintiff filed an amended complaint, which added claims alleging violations of Sections 11 and 15 of the Securities Act in connection with the June 2015 offering. The amended complaint named the Company, EHSI and 20 current and former directors, officers and employees of Endo as defendants. In April 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.
In November 2017, a putative class action entitled Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay, and Paul V. Campanelli was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park Employees’ Annuity and Benefit Fund of Chicago lead plaintiff in the action. In August 2018, the lead plaintiff filed an amended complaint. In September 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.

33

VASOSTRICT® Related Matters
In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its affiliate Par Sterile Products, LLC (PSP) in the U.S. District Court for the District of New Jersey alleging that Par and its affiliate engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par’s VASOSTRICT® (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that Par and its affiliate entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that, as a result, Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages, attorneys’ fees and costs, and injunctive relief. In September 2016, Par and its affiliate filed a motion to dismiss, which the district court denied in February 2017. The case is currently in discovery.
In August 2017, our subsidiaries PPI and PSP filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa Pharma, Inc. (QuVa), Stuart Hinchen, Peter Jenkins, and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT®, a vasopressin-based cardiopulmonary drug. In October 2017, defendants answered the complaint and QuVa asserted counterclaims against PPI and PSP alleging unfair competition under New Jersey common law and seeking declaratory judgment of non-infringement as to five U.S. Patents assigned to PPI that are listed in FDA’s Orange Book for VASOSTRICT®. The counterclaims seek actual, exemplary and punitive damages, injunctive relief and other relief. We filed a motion to dismiss the unfair competition counterclaim in November 2017. This motion is still pending. Also in November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In January 2018, we filed a first amended complaint adding five former employees of PSP as defendants and numerous causes of action against some or all of those former employees, including misappropriation under the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as breach of contract, breach of the duty of loyalty and breach of the duty of confidence. In March 2018, the court granted in part our motion for preliminary injunction and enjoined QuVa from marketing and releasing its planned vasopressin product through the conclusion of trial. We subsequently deposited a bond to the court’s interest-bearing account to secure the preliminary injunction. Defendants have filed a motion asking the court to reconsider the bond amount, which remains pending. Also in March 2018, QuVa and seven of the individual defendants filed a motion to dismiss the New Jersey common law claims, four of the individual defendants filed a motion to dismiss for lack of personal jurisdiction and one of the individuals filed a motion to dismiss the breach of contract claim. In April 2018, another individual defendant filed a motion to dismiss asserting numerous arguments, including lack of personal jurisdiction, improper venue and choice of law. These motions are still pending. Full discovery began in May 2018, but the court has not yet set a trial date. Also in May 2018, defendants filed a notice of appeal to the Third Circuit Court of Appeal indicating intent to appeal the court’s preliminary injunction, and in October 2018, defendants filed their opening appellate brief.
In October 2017, Endo Par Innovation Company, LLC (EPIC) and PSP filed a complaint in the United States District Court for the District of Columbia challenging the legality of the FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (January 2017) with respect to the listing of vasopressin in Category 1 of the Interim Policy. The complaint contends that the Interim Policy is unlawful because it is inconsistent with the Federal Food, Drug, and Cosmetic Act, including, but not limited to, Section 503B of that Act. The complaint seeks (i) a declaration that FDA’s Interim Policy and its listing of vasopressin in Category 1 of the Interim Policy are unlawful, and (ii) an order enjoining and vacating the Interim Policy and FDA’s listing of vasopressin in Category 1 of the Interim Policy. In January 2018, EPIC and PSP agreed to a temporary 60-day stay of the litigation in light of the FDA’s announcement that forthcoming guidance would address the concerns set forth in the Company’s complaint. In March 2018, the FDA released new draft guidance for industry entitled “Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” Shortly thereafter, the parties agreed to extend the temporary stay for an additional 180 days. In August 2018, before the 180-day stay period expired, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC announced they had commenced bulk compounding of vasopressin, and moved to intervene in EPIC and PSP’s case against the FDA. Later that month, EPIC and PSP invoked their ability to terminate the stay and filed a Motion for Preliminary Injunction. Before responding to the Motion for Preliminary Injunction, the FDA issued a notice containing a proposed finding that there is no clinical need to bulk compound vasopressin under Section 503B in August 2018. In September 2018, the FDA advised EPIC and PSP that it would agree to use its best efforts to finalize the vasopressin clinical need rulemaking by December 31, 2018, if the case were again stayed. As a result of the preliminary finding and the FDA’s commitment to use best efforts to finalize the rulemaking by December 31, 2018, EPIC and PSP agreed to again stay the case until December 31, 2018. In a related action, in August 2018, Athenex filed a declaratory judgment action in the U.S. District Court for the Western District of New York, a case styled Athenex v. Par, alleging non-infringement and/or invalidity of the patents the Company has listed in the Orange Book in view of VASOSTRICT®. The Company also moved to dismiss Athenex’s case on multiple grounds in October 2018.

34

In April 2018, PSP and PPI received a notice letter from Eagle Pharmaceuticals, Inc. (Eagle) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT® (vasopressin IV solution (infusion)) 20 units/ml. In May 2018, PSP and PPI received a second notice letter from Eagle advising of the same filing, but adding an additional patent. The Paragraph IV Notices refer to U.S. Patent Nos. 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; and 9,937,223, which variously cover either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage form to increase blood pressure in humans. In May 2018, PPI, PSP and EPIC filed a lawsuit against Eagle in the United States District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In August 2018, Eagle filed an answer and a counterclaim for non-infringement and invalidity of asserted patents.
In September 2018, PSP and PPI received a notice letter from Sandoz Inc. (Sandoz) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT® (vasopressin IV solution (infusion)) 200 units/10 ml. In October 2018, PPI, PSP and EPIC filed a lawsuit against Sandoz in the United States District Court for the District of New Jersey within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In October 2018, PSP and PPI received an additional notice letter from Sandoz advising of the filing by such company of an ANDA for a generic version of the 20 units/1 ml presentation for VASOSTRICT®. The 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme with respect to the additional notice letter has not yet expired. The Company continues to vigorously defend its intellectual property.
The Company’s legal reserves include, among other things, an estimated accrual for certain VASOSTRICT®-related matters. We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional accruals that could be required.
Paragraph IV Certifications on OPANA® ER
In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA® ER and a highly pure version of the API of OPANA® ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal and Sandoz Inc. based on their ANDAs filed against both the INTAC® technology and non-INTAC® technology versions of OPANA® ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the ‘737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the ‘779 patent. In July 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the ‘779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029. A trial for infringement of the ‘799 patent by Actavis was held in February 2017 in the same court (U.S. District Court for the District of Delaware) in front of the same judge. In August 2017, the District Court issued an Opinion holding that Actavis infringed the claims of U.S. Patent No. 8,871,779, and that Actavis had failed to show that U.S. Patent No. 8,871,779 was invalid. Teva, Amneal and Actavis have appealed these holdings. We have appealed the holding that the ‘737 patent is invalid. A hearing on that appeal has been set for December 2018.
We will continue to vigorously defend or prosecute the foregoing matter as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests in defense of our intellectual property, including enforcement of the product’s intellectual property rights and approved labeling. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Other Proceedings and Investigations
Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

35

NOTE 15. OTHER COMPREHENSIVE INCOME (LOSS)
Set forth below are the tax effects allocated to each component of Other comprehensive income (loss) for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
2018
 
2017
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
Net unrealized gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
$
—

 
$
—

 
$
295

 
$
(107
)
 
$
188

Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
—

 
—

 
—

Net unrealized gains on securities
$
—

 
$
—

 
$
—

 
$
295

 
$
(107
)
 
$
188

Net unrealized gain on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation gain arising during the period
4,735

 
—

 
4,735

 
9,941

 
—

 
9,941

Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
29,325

 
—

 
29,325

Foreign currency translation gain
$
4,735

 
$
—

 
$
4,735

 
$
39,266

 
$
—

 
$
39,266

Other comprehensive income
$
4,735

 
$
—

 
$
4,735

 
$
39,561

 
$
(107
)
 
$
39,454

 
Nine Months Ended September 30,
 
2018
 
2017
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
Net unrealized gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
$
—

 
$
—

 
$
522

 
$
(189
)
 
$
333

Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
—

 
—

 
—

Net unrealized gains on securities
$
—

 
$
—

 
$
—

 
$
522

 
$
(189
)
 
$
333

Net unrealized (loss) gain on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation (loss) gain arising during the period
(7,033
)
 
—

 
(7,033
)
 
35,415

 
—

 
35,415

Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
29,325

 
—

 
29,325

Foreign currency translation (loss) gain
$
(7,033
)
 
$
—

 
$
(7,033
)
 
$
64,740

 
$
—

 
$
64,740

Other comprehensive (loss) income
$
(7,033
)
 
$
—

 
$
(7,033
)
 
$
65,262

 
$
(189
)
 
$
65,073

Reclassification adjustments out of Other comprehensive income related to foreign currency translation were recorded upon the liquidation of Litha in the third quarter of 2017.
Substantially all of the Company’s Accumulated other comprehensive loss at September 30, 2018 and December 31, 2017 consists of Foreign currency translation loss.

36

NOTE 16. SHAREHOLDERS' (DEFICIT) EQUITY
Changes in Shareholders' (Deficit) Equity
The following table displays a reconciliation of our beginning and ending balances in Total shareholders' equity (deficit) for the nine months ended September 30, 2018 (in thousands):
 
Total Shareholders' Equity (Deficit)
Shareholders' equity at January 1, 2018, prior to the adoption of ASC 606
$
484,880

Effect of adopting ASC 606 (1)
3,076

Shareholders' equity at January 1, 2018
$
487,956

Net loss
(739,561
)
Other comprehensive loss
(7,033
)
Compensation related to share-based awards
43,722

Tax withholding for restricted shares
(5,082
)
Exercise of options
473

Other
66

Shareholders' deficit at September 30, 2018
$
(219,459
)
__________
(1)
Refer to Note 2. Summary of Significant Accounting Policies for further description of ASC 606.
Share-Based Compensation
During the second quarter of 2018, the Company’s shareholders approved an amendment to the Endo International plc Amended and Restated 2015 Stock Incentive Plan (the Plan). The Plan was amended and restated to increase the number of the Company’s ordinary shares that may be issued with respect to awards under the Plan by 5.0 million ordinary shares and to make certain other changes to the Plan’s terms.
The Company recognized share-based compensation expense of $13.7 million and $13.2 million during the three months ended September 30, 2018 and 2017, respectively, and $43.7 million and $40.3 million during the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, the total remaining unrecognized compensation cost related to non-vested share-based compensation awards amounted to $45.6 million.
During the third quarter of 2017, the Company issued approximately 1.0 million stock options and 0.1 million restricted stock units that were initially subject to shareholder approval and were subsequently approved by shareholders on June 7, 2018 at the Company’s Annual General Meeting of Shareholders. The options have an exercise price equal to the closing share price on their issuance date in August 2017.
There are 0.5 million performance share units outstanding as of September 30, 2018, representing target amounts, for which a grant date has not been established. No fair value has been ascribed to these awards as no grant date has been established. Accordingly, they are not reflected in the remaining unrecognized compensation cost above or the weighted average remaining requisite service period below.
Beginning in 2017, long-term cash incentive (LTCI) awards were provided to certain employees. LTCI awards were designed to vest ratably, in equal amounts, over a three-year service period. Upon vesting, each vested LTCI unit would be settled in cash in an amount equal to the price of Endo’s ordinary shares on the vest date. As of September 30, 2018, approximately 3.0 million unvested LTCI awards were outstanding with a weighted average remaining requisite service period of 2.3 years. A corresponding liability of $14.9 million was recorded as of September 30, 2018 in Accounts payable and accrued expenses and Other liabilities in the Company’s Condensed Consolidated Balance Sheets. On October 1, 2018, the Compensation Committee of the Company’s Board of Directors authorized the Company to settle each of the outstanding unvested LTCI awards in shares, rather than cash, upon vesting in accordance with the original vesting terms of the awards. With the authorization of the Compensation Committee, management’s intent to settle the awards in shares rather than cash is a modification that changes the awards’ classification from liability to equity, effective October 1, 2018. The accounting for the modification will occur in the fourth quarter of 2018. As of September 30, 2018, the LTCI awards are not reflected in the remaining unrecognized compensation cost above or the weighted average remaining requisite service period below.
As of September 30, 2018, the weighted average remaining requisite service period for non-vested stock options was 1.8 years and for non-vested restricted stock units was 2.0 years.

37

NOTE 17. OTHER INCOME, NET
The components of Other income, net for the three and nine months ended September 30, 2018 and 2017 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net gain on sale of business and other assets
$
(2,866
)
 
$
(2,763
)
 
$
(29,859
)
 
$
(5,074
)
Foreign currency loss (gain), net
1,354

 
2,549

 
(734
)

(4,305
)
Net loss (gain) from our investments in the equity of other companies
842

 
(1,075
)
 
3,163


(1,163
)
Other miscellaneous, net
(837
)
 
(808
)
 
(5,786
)

(301
)
Other income, net
$
(1,507
)
 
$
(2,097
)
 
$
(33,216
)

$
(10,843
)
Net gain on sale of business and other assets primarily relates to proceeds received from the sale of various ANDAs during the three and nine months ended September 30, 2018. Foreign currency loss (gain), net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. Net loss (gain) from our investments in the equity of other companies includes the income statement impacts of our investments in the equity of other companies, including those accounted for under the equity method and those classified as marketable securities.
NOTE 18. INCOME TAXES
The following table displays our Loss from continuing operations before income tax, Income tax expense (benefit) and Effective tax rate for the three and nine months ended September 30, 2018 and 2017 (dollars in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Income tax expense (benefit)
$
3,003

 
$
(28,109
)
 
$
24,729

 
$
(97,517
)
Effective tax rate
(2.1
)%
 
22.0
%
 
(3.7
)%
 
9.2
%
The income tax expense for the three months ended September 30, 2018 primarily relates to the geographic mix of pre-tax earnings. As of September 30, 2018, we had valuation allowances established against our deferred tax assets in most jurisdictions in which we operate, with the exception of Canada and India. The income tax benefit for the comparable 2017 period primarily relates to the geographic mix of pre-tax earnings and a discrete tax benefit primarily associated with the filing of the Company’s 2016 U.S. federal income tax return and an intangible asset impairment.
The income tax expense for the nine months ended September 30, 2018 primarily relates to the geographic mix of pre-tax earnings and discrete tax expense incurred in connection with an intercompany asset restructuring. The income tax benefit for the comparable 2017 period relates primarily to the geographic mix of pre-tax earnings and the discrete tax benefits associated with goodwill and intangible asset impairments and the favorable return to provision adjustments resulting from the filing of the Company’s 2016 U.S. federal income tax return.
During the year ended December 31, 2017, we recorded a benefit of $36.2 million as our estimate of the impact of the TCJA. This benefit, which is primarily related to the remeasurement of deferred tax liabilities related to tax deductible goodwill, was recorded in our Consolidated Statements of Operations as Income tax benefit during the three months ended December 31, 2017.
We recorded the aforementioned net benefit based on currently available information and interpretations of the TCJA. In accordance with authoritative guidance issued by the SEC, the income tax effect for certain aspects of the TCJA may represent provisional amounts for which our accounting is incomplete but a reasonable estimate could be determined. We consider amounts related to the various transition rules and interpretations of the TCJA to be provisional. Accordingly, we will continue to evaluate the impacts of the TCJA, including administrative and regulatory guidance as it becomes available. The measurement and existence of current and non-current income tax payables and/or the remeasurement of deferred tax assets and liabilities may change upon finalization of our analysis, which is expected to occur no later than one year from December 22, 2017, the date of the TCJA’s enactment. Any adjustment to a provisional amount identified during the one-year measurement period will be recorded as an income tax expense or benefit in the period the adjustment is determined.
During the nine months ended September 30, 2018, we did not record any adjustments to the provisional amounts recognized in 2017. We will continue to monitor for any significant impact on the Company’s consolidated financial statements with respect to the TCJA as more refined information and further guidance become available.

38

NOTE 19. NET LOSS PER SHARE
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations
$
(146,071
)
 
$
(99,687
)
 
$
(696,288
)
 
$
(961,130
)
(Loss) income from discontinued operations, net of tax
(27,134
)
 
3,017

 
(43,273
)
 
(705,886
)
Net loss
$
(173,205
)
 
$
(96,670
)
 
$
(739,561
)
 
$
(1,667,016
)
Denominator:
 
 
 
 
 
 
 
For basic per share data—weighted average shares
224,132

 
223,299

 
223,829

 
223,157

Dilutive effect of ordinary share equivalents
—

 
—

 
—

 
—

For diluted per share data—weighted average shares
224,132

 
223,299

 
223,829

 
223,157

Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period.
Stock options and awards that have been issued but for which a grant date has not yet been established, such as the performance share units discussed in Note 16. Shareholders' (Deficit) Equity, are not considered in the calculation of basic or diluted weighted average shares.
All potentially dilutive items were excluded from the diluted share calculation for the three and nine months ended September 30, 2018 and 2017 because their effect would have been anti-dilutive, as the Company was in a loss position.
Item 2.        Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations describes the principal factors affecting the results of operations, liquidity and capital resources and critical accounting estimates of Endo International plc. This discussion should be read in conjunction with the accompanying quarterly unaudited Condensed Consolidated Financial Statements and our Annual Report on Form 10-K for the year ended December 31, 2017 (Annual Report). Our Annual Report includes additional information about our significant accounting policies, practices and the transactions that underlie our financial results, as well as a detailed discussion of the most significant risks and uncertainties associated with our financial and operating results. Except for the historical information contained in this report, including the following discussion, this report contains forward-looking statements that involve risks and uncertainties. See "Forward-Looking Statements" beginning on page i of this report.
Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries.
RESULTS OF OPERATIONS
Our quarterly results have fluctuated in the past, and may continue to fluctuate. These fluctuations are primarily due to (1) the timing of new product launches, (2) purchasing patterns of our customers, (3) market acceptance of our products, (4) the impact of competitive products and products we recently acquired, (5) pricing of our products, (6) the timing of mergers, acquisitions, divestitures and other related activity and (7) other actions taken by the Company which may impact the availability of our products. These fluctuations are also attributable to charges incurred for compensation related to share-based payments, amortization of intangible assets, asset impairment charges, litigation-related charges, restructuring charges and certain upfront, milestone and other payments made or accrued pursuant to acquisition or licensing agreements. Additionally, the Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. Refer to Note 2. Summary of Significant Accounting Policies of the Condensed Consolidated Financial Statements included in Part I, Item 1 for additional information, including the impact of adoption on 2018 results.

39

Consolidated Results Review
The following table displays our revenue, gross margin, gross margin percentage and other pre-tax expense or income for the three and nine months ended September 30, 2018 and 2017 (dollars in thousands):
 
Three Months Ended September 30,
 
% Change
 
Nine Months Ended September 30,
 
% Change
 
2018
 
2017
 
2018 vs. 2017
 
2018
 
2017
 
2018 vs. 2017
Total revenues
$
745,466

 
$
786,887

 
(5
)%
 
$
2,160,689

 
$
2,700,218

 
(20
)%
Cost of revenues
412,965

 
514,522

 
(20
)%
 
1,198,468

 
1,722,885

 
(30
)%
Gross margin
$
332,501

 
$
272,365

 
22
 %
 
$
962,221

 
$
977,333

 
(2
)%
Gross margin percentage
44.6
%
 
34.6
%
 
 
 
44.5
%
 
36.2
%
 
 
Selling, general and administrative
$
163,791

 
$
135,880

 
21
 %
 
$
478,615

 
$
468,675

 
2
 %
Research and development
39,683

 
39,644

 
—
 %
 
160,431

 
123,522

 
30
 %
Litigation-related and other contingencies, net
(1,750
)
 
(12,352
)
 
(86
)%
 
15,370

 
(14,016
)
 
NM

Asset impairment charges
142,217

 
94,924

 
50
 %
 
613,400

 
1,023,930

 
(40
)%
Acquisition-related and integration items
1,288

 
16,641

 
(92
)%
 
13,284

 
31,711

 
(58
)%
Interest expense, net
131,847

 
127,521

 
3
 %
 
385,896

 
361,267

 
7
 %
Loss on extinguishment of debt
—

 
—

 
NM

 
—

 
51,734

 
(100
)%
Other income, net
(1,507
)
 
(2,097
)
 
(28
)%
 
$
(33,216
)
 
(10,843
)
 
NM

Loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
12
 %
 
$
(671,559
)
 
$
(1,058,647
)
 
(37
)%
__________
NM indicates that the percentage change is not meaningful or is greater than 100%.
Total Revenues. The decreases for both the three and nine months ended September 30, 2018 are primarily due to competitive pressure on commoditized generic products, generic product rationalization initiatives, actions taken with respect to OPANA® ER that are further described below, generic competition on our U.S. Branded - Specialty & Established Pharmaceuticals segment’s Established Products portfolio, our July 3, 2017 divestiture of Litha and our October 25, 2017 divestiture of Somar. Also contributing to the decrease for the nine months ended September 30, 2018 was the impact of the second quarter 2017 loss of marketing exclusivity for both ezetimibe tablets and quetiapine ER tablets. These declines were partially offset by continued strong performance from our U.S. Branded - Sterile Injectables segment, including VASOSTRICT®, ADRENALIN® and other products, and our U.S. Branded - Specialty & Established Pharmaceuticals segment’s Specialty Products portfolio, which includes XIAFLEX®.
In March 2017, we announced that the Food and Drug Administration’s (FDA) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA® ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA’s request that we voluntarily withdraw OPANA® ER from the market, and in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA® ER from the market. During the second quarter of 2017, we began to work with the FDA to coordinate an orderly withdrawal of the product from the market. By September 1, 2017, we ceased shipments of OPANA® ER to customers and we expect the New Drug Application will be withdrawn. These actions had an adverse effect on the revenues and results of operations of our U.S. Branded - Specialty & Established Pharmaceuticals segment during the three and nine months ended September 30, 2018 compared to the prior year periods.

40

Cost of revenues and gross margin percentage. During the three and nine months ended September 30, 2018 and 2017, we incurred certain charges that impact the comparability of total Cost of revenues, including those related to amortization expense and separation benefits and other cost reduction initiatives, including restructurings. The following table summarizes such amounts (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Amortization of intangible assets (1)
$
161,275

 
$
161,413

 
$
471,662

 
$
615,490

Separation benefits and other cost reduction initiatives (2)
$
3,833

 
$
78,680

 
$
60,254

 
$
93,266

__________
(1)
Amortization expense fluctuates based on changes in the total amount of amortizable intangible assets and the rate of amortization in effect for each intangible asset, both of which can vary based on factors such as the amount and timing of acquisitions, dispositions, asset impairment charges, transfers between indefinite- and finite-lived intangibles assets, changes in foreign currency rates and changes in the composition of our intangible assets impacting the weighted average useful lives and amortization methodologies being utilized. The decrease during the nine months ended September 30, 2018 was primarily driven by the impact of 2017 amortization expense for both ezetimibe tablets and quetiapine ER tablets, which were fully amortized prior to January 1, 2018, and asset impairment charges. This decrease was partially offset by the impact of certain in-process research and development assets put into service.
(2)
Amounts primarily relate to certain accelerated depreciation charges, employee separation costs, charges to increase excess inventory reserves related to restructurings and other cost reduction and restructuring charges. See Note 4. Restructuring of the Condensed Consolidated Financial Statements included in Part I, Item 1 for discussion of our material restructuring initiatives.
The previously described decreases in total revenues, the decreases to amortization expense and decreased restructuring charges were the primary factors leading to the overall period-over-period decreases in Cost of revenues for the three and nine months ended September 30, 2018. Restructuring costs incurred during the periods presented primarily relate to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative and the January 2018 Restructuring Initiative. Our material restructuring initiatives are described more fully in Note 4. Restructuring of the Condensed Consolidated Financial Statements included in Part I, Item 1.
The increases in gross margin percentage for both the three and nine months ended September 30, 2018 were primarily attributable to the gross margin effects of the net Cost of revenues decreases included in the table above and the favorable margin impact of product rationalization efforts. Additionally, changes in the mix of total revenues, including a shift from generic to branded products, contributed to the overall increases in gross margin percentage.
Selling, general and administrative expenses. The increases for both the three and nine months ended September 30, 2018 were primarily a result of increased legal costs related to certain litigation matters and higher long-term cash incentive compensation expenses as a result of recent increases in our share price. Our material legal proceedings and other contingent matters are described in more detail in Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1. The increase during the nine months ended September 30, 2018 was partially offset by cost reductions that were implemented throughout 2017 and 2018, including the impact of those related to various restructuring initiatives. Our material restructuring initiatives are described more fully in Note 4. Restructuring of the Condensed Consolidated Financial Statements included in Part I, Item 1.
Research and development expenses. During the first quarter of 2018, we initiated two Phase 3 trials for the treatment of cellulite in the buttocks, as well as the January 2018 Restructuring Initiative, which included a reorganization of our U.S. Generic Pharmaceuticals segment’s research and development network. The January 2018 Restructuring Initiative is described more fully in Note 4. Restructuring of the Condensed Consolidated Financial Statements included in Part I, Item 1. During the second quarter of 2018, we entered into a development, license and commercialization agreement related to five sterile injectable product candidates, at which time we became obligated to make an upfront payment, which was recorded as Research and development expense in the Condensed Consolidated Statements of Operations. This agreement is described more fully in Note 10. License and Collaboration Agreements of the Condensed Consolidated Financial Statements included in Part I, Item 1.
The increase for the nine months ended September 30, 2018 was primarily a result of increased costs related to our cellulite treatment development program and the upfront payment discussed above. This increase was partially offset by cost savings related to the January 2018 Restructuring Initiative and other cost reduction initiatives.
In November 2018, we announced positive results from the two Phase 3 trials for the treatment of cellulite in the buttocks, where treated subjects showed highly statistically significant levels of improvement in the appearance of cellulite at day 71 as measured by the trials’ primary endpoint. In addition, the RELEASE-1 trial passed 8 out of 8 key secondary endpoints and the RELEASE-2 trial passed 7 out of 8 key secondary endpoints. Finally, CCH was well-tolerated in the actively-treated subjects with most adverse events being mild to moderate in severity and primarily limited to the local injection area.
We expect to continue to incur expenses in 2018 related to the cellulite treatment development program. We also expect our U.S. Generic Pharmaceuticals R&D costs to continue to decline compared to 2017 as a result of decreases in costs associated with offshoring certain of our R&D activities to India and prioritizing assets within our portfolio. There can be no assurance that we will achieve these results.

41

Litigation-related and other contingencies, net. Included within Litigation-related and other contingencies, net are changes to our accruals for litigation-related settlement charges, reimbursements and certain settlements proceeds related to suits filed by our subsidiaries. Our material legal proceedings and other contingent matters are described in more detail in Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1.
Asset impairment charges. The following table presents the components of our total Asset impairment charges for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Goodwill impairment charges
$
—

 
$
—

 
$
391,000

 
$
288,745

Other intangible asset impairment charges
140,609

 
78,300

 
217,576

 
674,177

Property, plant and equipment impairment charges
1,608

 
16,624

 
4,824

 
61,008

Total asset impairment charges
$
142,217

 
$
94,924

 
$
613,400

 
$
1,023,930

The factors leading to our material goodwill and intangible asset impairment tests, as well as the results of these tests, are further described in Note 9. Goodwill and Other Intangibles of the Condensed Consolidated Financial Statements included in Part I, Item 1. A discussion of critical accounting estimates made in connection with certain of our impairment tests is included below under the caption “CRITICAL ACCOUNTING ESTIMATES.”
Acquisition-related and integration items. The following table presents the components of our total Acquisition-related and integration items for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net expense from changes in the fair value of acquisition-related contingent consideration
$
769

 
$
15,440

 
$
11,731

 
$
23,574

Other
519

 
1,201

 
1,553

 
8,137

Acquisition-related and integration items
$
1,288

 
$
16,641

 
$
13,284

 
$
31,711

Net expense from changes in the fair value of acquisition-related contingent consideration resulted from changes in market conditions impacting the commercial potential of the underlying products. See Note 7. Fair Value Measurements of the Condensed Consolidated Financial Statements included in Part I, Item 1 for further discussion of our acquisition-related contingent consideration.
The decreases in other Acquisition-related and integration items during both the three and nine months ended September 30, 2018 were primarily attributable to costs incurred in 2017 associated with prior acquisitions compared to lower costs in 2018, which related primarily to the pending acquisitions of Somerset and Wintac, which are further discussed in Note 5. Acquisitions of the Condensed Consolidated Financial Statements included in Part I, Item 1.
Interest expense, net. The components of Interest expense, net for the three and nine months ended September 30, 2018 and 2017 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Interest expense
$
134,829

 
$
128,672

 
$
395,681

 
$
365,479

Interest income
(2,982
)
 
(1,151
)
 
(9,785
)
 
(4,212
)
Interest expense, net
$
131,847

 
$
127,521

 
$
385,896

 
$
361,267

The increases in interest expense for both the three and nine months ended September 30, 2018 were primarily attributable to increased interest rates, including the effects of both increases in LIBOR, which impact our variable-rate debt, and the refinancing that occurred on April 27, 2017. Interest income varies primarily based on the amounts of our investments in money market funds and time deposits, as well as changes in the corresponding interest rates.
Loss on extinguishment of debt. Loss on extinguishment of debt totaled $51.7 million for the nine months ended September 30, 2017, with no such amounts recorded in any of the other periods presented. The amount during the nine months ended September 30, 2017 related to certain previously unamortized debt issuance costs that were charged to expense in connection with the refinancing that occurred on April 27, 2017.

42

Other income, net. The components of Other income, net for the three and nine months ended September 30, 2018 and 2017 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net gain on sale of business and other assets
$
(2,866
)
 
$
(2,763
)
 
$
(29,859
)
 
$
(5,074
)
Foreign currency loss (gain), net
1,354

 
2,549

 
(734
)
 
(4,305
)
Net loss (gain) from our investments in the equity of other companies
842

 
(1,075
)
 
3,163

 
(1,163
)
Other miscellaneous, net
(837
)
 
(808
)
 
(5,786
)
 
(301
)
Other income, net
$
(1,507
)
 
$
(2,097
)
 
$
(33,216
)
 
$
(10,843
)
Net gain on sale of business and other assets primarily relates to proceeds received from the sale of various ANDAs during the three and nine months ended September 30, 2018. Foreign currency loss (gain), net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. Net loss (gain) from our investments in the equity of other companies includes the income statement impacts of our investments in the equity of other companies, including those accounted for under the equity method and those classified as marketable securities.
Income tax expense (benefit). The following table displays our Loss from continuing operations before income tax, Income tax expense (benefit) and Effective tax rate for the three and nine months ended September 30, 2018 and 2017 (dollars in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Income tax expense (benefit)
$
3,003

 
$
(28,109
)
 
$
24,729

 
$
(97,517
)
Effective tax rate
(2.1
)%
 
22.0
%
 
(3.7
)%
 
9.2
%
Our tax rate is affected by recurring items, such as tax rates in non-U.S. jurisdictions as compared to the notional U.S. federal statutory tax rate, and the relative amount of income or loss in those various jurisdictions. It is also impacted by certain items that may occur in any given period, but are not consistent from period to period.
The income tax expense for the three months ended September 30, 2018 primarily relates to the geographic mix of pre-tax earnings. The income tax benefit for the comparable 2017 period primarily relates to the geographic mix of pre-tax earnings and a discrete tax benefit primarily associated with the filing of the Company’s 2016 U.S. federal income tax return and an intangible asset impairment.
The income tax expense for the nine months ended September 30, 2018 primarily relates to the geographic mix of pre-tax earnings and discrete tax expense incurred in connection with an intercompany asset restructuring. The income tax benefit for the comparable 2017 period relates primarily to the geographic mix of pre-tax earnings and the discrete tax benefits associated with goodwill and intangible asset impairments and the favorable return to provision adjustments resulting from the filing of the Company’s 2016 U.S. federal income tax return.
Although the TCJA reduced the notional U.S. federal statutory tax rate, because the Company has valuation allowances established against its U.S. federal deferred tax assets, as of September 30, 2018, we do not expect a significant reduction in our future tax expense. Moreover, we have valuation allowances established against our deferred tax assets in most other jurisdictions in which we operate, with the exception of Canada and India. Accordingly, it would be unlikely for future pre-tax losses to create a tax benefit that would be more likely than not to be realized.
In addition, the Internal Revenue Service (IRS) presently is examining certain of our subsidiaries’ United States income tax returns for fiscal years ending between December 31, 2011 and December 31, 2015 and, in connection with those examinations, is reviewing our tax positions related to, among other things, certain intercompany arrangements, including the level of profit earned by our United States subsidiaries pursuant to such arrangements, and a worthless stock deduction directly attributable to product liability losses. The IRS may examine our tax returns for other fiscal years. Such examinations may lead to proposed or actual adjustments to our taxes that may be material, individually or in the aggregate. An adverse outcome of these tax examinations could have a material adverse effect on our business, financial position, results of operations and growth prospects. See the risk factor “We may not be able to successfully maintain our low tax rates or other tax positions, which could adversely affect our businesses and financial condition, results of operations and growth prospects” in Part II, Item 1A of this document for more information.
For additional information on our income taxes, see Note 18. Income Taxes of the Condensed Consolidated Financial Statements included in Part I, Item 1.

43

Discontinued operations, net of tax. The operating results of our Astora business are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. The results of our discontinued operations, net of tax, totaled $27.1 million and $43.3 million of loss during the three and nine months ended September 30, 2018, respectively, compared to $3.0 million of income and $705.9 million of loss, respectively, in the comparable 2017 periods.
The primary driver of the period-over-period changes for both the three and nine months ended September 30, 2018 was the after-tax impact of charges related to mesh litigation. Mesh-related charges during the three and nine months ended September 30, 2018 totaled $19.0 million. This compares to $775.5 million during the nine months ended September 30, 2017, with no comparable charges taken during the three months ended September 30, 2017. Additionally, following the settlement strategy we pursued in 2017, there were decreases in mesh-related legal defense costs during both the three and nine months ended September 30, 2018. For additional discussion of mesh-related matters, refer to Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1.
2018 Outlook
We estimate that our 2018 total revenues will be between $2.87 billion and $2.92 billion. This estimate reflects an anticipated decline in our U.S. Generic Pharmaceuticals segment driven by the expiration of the marketing exclusivity periods for both ezetimibe tablets and quetiapine ER tablets in the second quarter of 2017, the impact of product rationalization initiatives resulting from the 2016 and 2017 U.S. Generic Pharmaceuticals segment restructuring initiatives and continued competitive pressure on commoditized generic products; a decline in our U.S. Branded - Specialty & Established Pharmaceuticals segment resulting from the continued decline in the Established Products portfolio partly driven by the ceasing of shipments of OPANA® ER by September 1, 2017, partially offset by growth in the Specialty Products portfolio primarily driven by XIAFLEX®; a decline in the International Pharmaceuticals segment primarily due to the divestitures of Litha and Somar; partially offset by growth in the U.S. Branded - Sterile Injectables segment. The Company anticipates continued margin improvement in 2018 compared to 2017 driven by cost efficiencies associated with our U.S. Generic Pharmaceuticals segment restructuring initiatives, a continued shift in product mix to higher margin products and targeted cost reductions in selling, general and administrative expenses. We will continue to invest in XIAFLEX® and other core products to position the Company for long-term success. There can be no assurance that we will achieve these results.
Business Segment Results Review
The four reportable business segments in which we operate are: (1) U.S. Branded - Specialty & Established Pharmaceuticals (2) U.S. Branded - Sterile Injectables, (3) U.S. Generic Pharmaceuticals and (4) International Pharmaceuticals. Our segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
We evaluate segment performance based on each segment’s adjusted income from continuing operations before income tax, a financial measure not determined in accordance with U.S. GAAP, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items.
Certain of the corporate expenses incurred by us are not attributable to any specific segment. Accordingly, these costs are not allocated to any of our segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of our segments. Our consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of our segments less these unallocated corporate items.
We refer to adjusted income from continuing operations before income tax in making operating decisions because we believe it provides meaningful supplemental information regarding our operational performance. For instance, we believe that this measure facilitates internal comparisons to our historical operating results and comparisons to competitors’ results. We believe this measure is useful to investors in allowing for greater transparency related to supplemental information used in our financial and operational decision-making. In addition, we have historically reported similar financial measures to our investors and believe that the inclusion of comparative numbers provides consistency in our current financial reporting. Further, we believe that adjusted income from continuing operations before income tax may be useful to investors as we are aware that certain of our significant shareholders utilize adjusted income from continuing operations before income tax to evaluate our financial performance. Finally, adjusted income from continuing operations before income tax is utilized in the calculation of adjusted diluted income per share, which is used by the Compensation Committee of Endo’s Board of Directors in assessing the performance and compensation of substantially all of our employees, including our executive officers.

44

There are limitations to using financial measures such as adjusted income from continuing operations before income tax. Other companies in our industry may define adjusted income from continuing operations before income tax differently than we do. As a result, it may be difficult to use adjusted income from continuing operations before income tax or similarly named adjusted financial measures that other companies may use to compare the performance of those companies to our performance. Because of these limitations, adjusted income from continuing operations before income tax is not intended to represent cash flow from operations as defined by U.S. GAAP and should not be used as alternatives to net income as indicators of operating performance or to cash flows as measures of liquidity. We compensate for these limitations by providing reconciliations of our total segment adjusted income from continuing operations before income tax to our consolidated Loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP and included in our Condensed Consolidated Statements of Operations.
Revenues. The following table displays our revenue by reportable segment for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
% Change
 
Nine Months Ended September 30,
 
% Change
 
2018
 
2017
 
2018 vs. 2017
 
2018
 
2017
 
2018 vs. 2017
U.S. Branded - Specialty & Established Pharmaceuticals
$
220,100

 
$
233,803

 
(6
)%
 
$
632,972

 
$
729,150

 
(13
)%
U.S. Branded - Sterile Injectables
237,150

 
201,905

 
17
 %
 
670,847

 
554,365

 
21
 %
U.S. Generic Pharmaceuticals
257,969

 
294,749

 
(12
)%
 
748,445

 
1,227,584

 
(39
)%
International Pharmaceuticals (1)
30,247

 
56,430

 
(46
)%
 
108,425

 
189,119

 
(43
)%
Total net revenues from external customers
$
745,466

 
$
786,887

 
(5
)%
 
$
2,160,689

 
$
2,700,218

 
(20
)%
__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America, respectively.
U.S. Branded - Specialty & Established Pharmaceuticals. The following table displays the significant components of our U.S. Branded - Specialty & Established Pharmaceuticals revenues from external customers for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
% Change
 
Nine Months Ended September 30,
 
% Change
 
2018
 
2017
 
2018 vs. 2017
 
2018
 
2017
 
2018 vs. 2017
Specialty Products:
 
 
 
 
 
 
 
 
 
 
 
XIAFLEX®
$
64,214


$
52,511

 
22
 %
 
$
184,855


$
152,113

 
22
 %
SUPPRELIN® LA
20,408


20,638

 
(1
)%
 
60,948


63,468

 
(4
)%
Other Specialty (1)
43,576


40,634

 
7
 %
 
114,202


113,407

 
1
 %
Total Specialty Products
$
128,198


$
113,783

 
13
 %
 
$
360,005


$
328,988

 
9
 %
Established Products:





 
 
 





 
 
PERCOCET®
$
30,730

 
$
31,349

 
(2
)%
 
$
93,539

 
$
93,183

 
—
 %
VOLTAREN® Gel
15,057

 
19,102

 
(21
)%
 
44,185

 
53,646

 
(18
)%
OPANA® ER
—

 
14,756

 
(100
)%
 
—

 
82,056

 
(100
)%
Other Established (2)
46,115

 
54,813

 
(16
)%
 
135,243

 
171,277

 
(21
)%
Total Established Products
$
91,902


$
120,020

 
(23
)%
 
$
272,967


$
400,162

 
(32
)%
Total U.S. Branded - Specialty & Established Pharmaceuticals (3)
$
220,100


$
233,803

 
(6
)%
 
$
632,972


$
729,150

 
(13
)%
__________
(1)
Products included within Other Specialty include TESTOPEL®, NASCOBAL® Nasal Spray and AVEED®.
(2)
Products included within Other Established include, but are not limited to, LIDODERM®, EDEX®, TESTIM® and FORTESTA® Gel, including the authorized generics.
(3)
Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $25 million during any quarterly period in 2018 or 2017.
Specialty Products
The increases in net sales of XIAFLEX® for both the three and nine months ended September 30, 2018 were primarily attributable to demand growth driven by the continued investment and promotional efforts behind XIAFLEX®.
The decreases in net sales of SUPPRELIN® LA for both the three and nine months ended September 30, 2018 were primarily attributable to decreases in volume.

45

The increases in net sales of Other Specialty Products for both the three and nine months ended September 30, 2018 were primarily attributable to increased sales of NASCOBAL® Nasal Spray and AVEED®, partially offset by lower sales of TESTOPEL®. When compared to 2017, this product portfolio generally benefited from increased volumes, offset by decreases in price.
Established Products
The decrease in net sales of PERCOCET® for the three months ended September 30, 2018 was primarily attributable to volume decreases, partially offset by price increases.
The decreases in net sales of VOLTAREN® Gel for both the three and nine months ended September 30, 2018 were primarily attributable to volume and price decreases as a result of ongoing competitive pressure from generic competition. To the extent additional competitors are able to launch generic versions of VOLTAREN® Gel, our revenues could decline further.
The decreases in net sales of OPANA® ER for both the three and nine months ended September 30, 2018 relate to our cessation of shipments of OPANA® ER to customers by September 1, 2017, as further described above.
Net sales of Other Established Products for both the three and nine months ended September 30, 2018 were negatively impacted primarily by volume decreases resulting from generic competition.
U.S. Branded - Sterile Injectables. The following table displays the significant components of our U.S. Branded - Sterile Injectables revenues from external customers for the three and nine months ended September 30, 2018 and 2017 (dollars in thousands):
 
Three Months Ended September 30,
 
% Change
 
Nine Months Ended September 30,
 
% Change
 
2018
 
2017
 
2018 vs. 2017
 
2018
 
2017
 
2018 vs. 2017
VASOSTRICT®
$
112,333

 
$
105,741

 
6
 %
 
$
332,387

 
$
300,649

 
11
%
ADRENALIN®
35,460

 
25,335

 
40
 %
 
101,858

 
50,464

 
NM

Ertapenem for injection
25,798

 
—

 
NM

 
25,798

 
—

 
NM

Other Sterile Injectables (1)
63,559

 
70,829

 
(10
)%
 
210,804

 
203,252

 
4
%
Total U.S. Branded - Sterile Injectables (2)
$
237,150

 
$
201,905

 
17
 %
 
$
670,847

 
$
554,365

 
21
%
__________
NM indicates that the percentage change is not meaningful or is greater than 100%.
(1)
Products included within Other Sterile Injectables include, but are not limited to, APLISOL® and ephedrine sulfate injection.
(2)
Individual products presented above represent the top two performing products within the U.S. Branded - Sterile Injectables segment and/or any product having revenues in excess of $25 million during any quarterly period in 2018 or 2017.
Net sales of VASOSTRICT® and ADRENALIN® increased during both the three and nine months ended September 30, 2018 due to increases in both price and volume. Sales of ADRENALIN® also benefited from the market withdrawal of competing unapproved sources beginning in May of 2017. VASOSTRICT® is currently the first and only vasopressin injection with an NDA approved by the FDA. We have been issued six patents relating to VASOSTRICT® by the U.S. Patent and Trademark Office (PTO). These patents are listed in the Orange Book. The FDA requires any applicant seeking FDA approval for vasopressin prior to patent expiry and relying on VASOSTRICT® as the Reference Listed Drug to notify us of filing before the FDA will issue an approval.
We are aware of certain competitive actions taken by other pharmaceutical companies related to VASOSTRICT®, which include the filing of ANDAs for generic versions of VASOSTRICT® and the commencement of bulk compounding of vasopressin, the active ingredient of VASOSTRICT®. These matters are further discussed in Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1 under the heading “VASOSTRICT® Related Matters.” We have taken and plan to continue to take action in our best interest to protect our rights with respect to VASOSTRICT®. The introduction of any compounded or generic of versions of VASOSTRICT® could result in reductions to our market share, profitability and cash flows.
Ertapenem for injection, the authorized generic of Invanz®, launched during the third quarter of 2018 and had no sales in 2017.
The decrease in Other Sterile Injectables for the three months ended September 30, 2018 was primarily driven by generic competition on certain products within this category. During the nine months ended September 30, 2018, Other Sterile Injectables benefited from increased net sales from a number of products, including the impacts of new product launches, increased market share and certain price increases.

46

U.S. Generic Pharmaceuticals. Continued competitive pressure on commoditized generic products and the impact of product rationalization initiatives resulting from prior restructurings resulted in revenue decreases for both the three and nine months ended September 30, 2018. Additionally, included within this segment’s revenues for the nine months ended September 30, 2017 are ezetimibe tablets and quetiapine ER tablets, both of which are first-to-file products launched in the fourth quarter of 2016. Combined net sales for these two products for the nine months ended September 30, 2017 were $253.3 million. The marketing exclusivity periods for both ezetimibe tablets and quetiapine ER tablets expired in the second quarter of 2017. As a result, combined revenues for these products declined significantly during the second quarter of 2017 and beyond. Partially offsetting the decreases for both the three and nine months ended September 30, 2018 was the impact of certain recent product launches including, among others, colchicine tablets, the authorized generic of Colcrys®, which launched in July 2018.
International Pharmaceuticals. The decreases in revenue for the International Pharmaceuticals segment for both the three and nine months ended September 30, 2018 were primarily attributable to the combined impact of our divestitures of Litha in July 2017 and Somar in October 2017. Additionally, certain other products within this segment decreased during the three months ended September 30, 2018 and increased during the nine months ended September 30, 2018. For additional detail regarding the divestitures of Litha and Somar refer to Note 3. Discontinued Operations and Divestitures of the Condensed Consolidated Financial Statements included in Part I, Item 1.
Adjusted income from continuing operations before income tax. The following table displays our Adjusted income from continuing operations before income tax by reportable segment for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
% Change
 
Nine Months Ended September 30,
 
% Change
 
2018
 
2017
 
2018 vs. 2017
 
2018
 
2017
 
2018 vs. 2017
U.S. Branded - Specialty & Established Pharmaceuticals
$
84,891

 
$
123,754

 
(31
)%
 
$
262,454

 
$
380,841

 
(31
)%
U.S. Branded - Sterile Injectables
170,329

 
150,531

 
13
 %
 
513,082

 
417,060

 
23
 %
U.S. Generic Pharmaceuticals
82,555

 
86,236

 
(4
)%
 
247,137

 
415,172

 
(40
)%
International Pharmaceuticals
13,377

 
17,434

 
(23
)%
 
45,594

 
47,128

 
(3
)%
Total segment adjusted income from continuing operations before income tax
$
351,152

 
$
377,955

 
(7
)%
 
$
1,068,267

 
$
1,260,201

 
(15
)%
U.S. Branded - Specialty & Established Pharmaceuticals. Amounts were negatively impacted during both the three and nine months ended September 30, 2018 as a result of decreased revenues and gross margins related to generic competition and the cessation of shipments of OPANA® ER by September 1, 2017. Additionally, R&D expenses increased as a result of our cellulite treatment development program and legal costs related to certain litigation matters also increased. Our material legal proceedings and other contingent matters are described in more detail in Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1.
U.S. Branded - Sterile Injectables. The increases for both the three and nine months ended September 30, 2018 were primarily driven by increased revenues and gross margins resulting from strong performance of a variety of products in this segment as described above.
U.S. Generic Pharmaceuticals. The decreases for both the three and nine months ended September 30, 2018 were primarily attributable to decreased revenues as described above and the resulting reduction to gross margin. Partially offsetting the decreases were cost reductions, including the impact of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative and the January 2018 Restructuring Initiative, which are described more fully in Note 4. Restructuring of the Condensed Consolidated Financial Statements included in Part I, Item 1.
International Pharmaceuticals. The decreases for both the three and nine months ended September 30, 2018 were primarily attributable to the combined impact of the July 3, 2017 divestiture of Litha and October 25, 2017 divestiture of Somar. Also contributing to respective changes were the gross margin effects of the revenue results of certain other International Pharmaceuticals products, as described above.

47

The table below provides reconciliations of our consolidated Loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our total segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Total consolidated loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Interest expense, net
131,847

 
127,521

 
385,896

 
361,267

Corporate unallocated costs (1)
49,187

 
33,035

 
144,693

 
114,655

Amortization of intangible assets
161,275

 
161,413

 
471,662

 
615,490

Inventory step-up
71

 
66

 
261

 
281

Upfront and milestone payments to partners
4,731

 
775

 
43,027

 
6,952

Separation benefits and other cost reduction initiatives (2)
4,001

 
80,693

 
82,141

 
127,977

Certain litigation-related and other contingencies, net (3)
(1,750
)
 
(12,352
)
 
15,370

 
(14,016
)
Asset impairment charges (4)
142,217

 
94,924

 
613,400

 
1,023,930

Acquisition-related and integration items (5)
1,288

 
16,641

 
13,284

 
31,711

Loss on extinguishment of debt
—


—


—


51,734

Foreign currency impact related to the remeasurement of intercompany debt instruments
1,528

 
3,005

 
(1,560
)
 
(2,922
)
Other, net (6)
(175
)
 
30

 
(28,348
)
 
1,789

Total segment adjusted income from continuing operations before income tax
$
351,152

 
$
377,955

 
$
1,068,267

 
$
1,260,201

__________
(1)
Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Amounts for the three and nine months ended September 30, 2018 relate to employee separation costs of $2.1 million and $32.7 million, respectively, charges to increase excess inventory reserves of $0.2 million and $2.8 million, respectively, and other charges of $1.7 million and $11.4 million, respectively, each of which related primarily to our restructuring initiatives. Also included in the amount for the nine months ended September 30, 2018 is accelerated depreciation of $35.2 million, which related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. During the three and nine months ended September 30, 2017, amounts primarily relate to employee separation costs of $19.8 million and $41.3 million, accelerated depreciation of $59.8 million and $60.2 million, other charges of $1.1 million and $18.5 million, respectively, and charges to increase excess inventory reserves of $7.9 million during the nine months ended September 30, 2017. These charges were related primarily to the 2017 U.S. Generics Pharmaceuticals restructuring initiative. See Note 4. Restructuring of the Condensed Consolidated Financial Statements included in Part I, Item 1 for discussion of our material restructuring initiatives.
(3)
Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.
(4)
Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 7. Fair Value Measurements.
(5)
Amounts during the three and nine months ended September 30, 2018 are primarily related to charges due to changes in the fair value of contingent consideration of $0.8 million and $11.7 million, respectively. Amounts during the three and nine months ended September 30, 2017 include charges due to changes in the fair value of contingent consideration of $15.4 million and $23.6 million, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.
(6)
Amounts during the three and nine months ended September 30, 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 17. Other income, net.
LIQUIDITY AND CAPITAL RESOURCES
Our principal source of liquidity is cash generated from operations. Our principal liquidity requirements are primarily for working capital for operations, licenses, milestone payments, capital expenditures, acquisitions, contingent liabilities, vaginal mesh liability payments and debt service payments. The Company’s working capital was $254.1 million at September 30, 2018 compared to working capital of $50.2 million at December 31, 2017. The amounts at September 30, 2018 and December 31, 2017 include restricted cash and cash equivalents of $283.8 million and $313.8 million, respectively, held in Qualified Settlement Funds (QSFs) for mesh-related matters. Although these amounts in QSFs are included in working capital, they are required to be used for mesh product liability settlement agreements that are expected to be paid to qualified claimants within the next twelve months.

48

Cash and cash equivalents, which primarily consisted of bank deposits, time deposits and money market accounts, totaled $1,118.9 million at September 30, 2018 compared to $986.6 million at December 31, 2017. We expect cash generated from operations together with our cash, cash equivalents, restricted cash, restricted cash equivalents and the revolving credit facilities to be sufficient to cover our principal liquidity requirements over the next year. However, on a longer term basis, we may not be able to accurately predict the effect of certain developments on our sales and gross margins, such as the degree of market acceptance, patent protection and exclusivity of our products, pricing pressures (including those due to the impact of competition), the effectiveness of our sales and marketing efforts and the outcome of our current efforts to develop, receive approval for and successfully launch our product candidates. We may also face unexpected expenses in connection with our business operations, including expenses related to our ongoing and future legal proceedings and governmental investigations and other contingent liabilities. Furthermore, we may not be successful in implementing, or may face unexpected changes or expenses in connection with our strategic direction, including the potential for opportunistic corporate development transactions. Any of the above could adversely affect our future cash flows.
We may need to obtain additional funding to repay our outstanding indebtedness, for our future operational needs or for future transactions. We have historically had broad access to financial markets that provide liquidity; however, we cannot be certain that funding will be available on terms acceptable to us, or at all. Any issuances of equity securities or convertible securities could have a dilutive effect on the ownership interest of our current shareholders and may adversely impact net income per share in future periods. An acquisition may be accretive or dilutive and, by its nature, involves numerous risks and uncertainties. As a result of acquisition efforts, if any, we are likely to experience significant charges to earnings for merger and related expenses (whether or not the acquisitions are consummated) that may include transaction costs, closure costs or costs of restructuring activities.
Borrowings. At September 30, 2018, under the 2017 Credit Agreement, the Company had outstanding borrowings with an aggregate principal amount of $3,372.3 million and additional availability of approximately $997.2 million under its revolving credit facility.
The 2017 Credit Agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility. The negative covenants include, among other things, limitations on asset sales, mergers and acquisitions, indebtedness, liens, dividends and other restrictive payments, investments and transactions with the Company’s affiliates. As of September 30, 2018, we were in compliance with all such covenants.
At September 30, 2018, the Company’s indebtedness also includes senior notes with aggregate principal amounts totaling $5.0 billion. These notes mature between 2022 and 2025, subject to earlier repurchase or redemption in accordance with the terms of the respective indentures. Interest rates on these notes range from 5.375% to 7.25%. Other than the 5.875% Senior Secured Notes due 2024, these notes are senior unsecured obligations of the Company’s subsidiaries party to the applicable indenture governing such notes. These notes are issued by certain of our subsidiaries and are guaranteed on a senior unsecured basis by the subsidiaries of Endo International plc that also guarantee our 2017 Credit Agreement, except for a de minimis amount of the 7.25% Senior Notes due 2022, which are issued by Endo Health Solutions Inc. and guaranteed on a senior unsecured basis by the guarantors named in the Fifth Supplemental Indenture relating to such notes. The 5.875% Senior Secured Notes due 2024 are senior secured obligations of Endo International plc and its subsidiaries that are party to the indenture governing such notes. These notes are issued by certain of our subsidiaries and are guaranteed on a senior secured basis by Endo International plc and its subsidiaries that also guarantee our 2017 Credit Agreement.
The indentures governing our various senior notes contain affirmative and negative covenants that the Company believes to be usual and customary for similar indentures. The negative covenants, among other things, restrict the Company’s ability, and the ability of its restricted subsidiaries, to incur certain additional indebtedness and issue preferred stock, make certain investments and restricted payments, sell certain assets, enter into sale and leaseback transactions, agree to payment restrictions on the ability of restricted subsidiaries to make certain payments to Endo International plc or any of its restricted subsidiaries, create certain liens, merge, consolidate or sell all or substantially all of the Company’s assets or enter into certain transactions with affiliates. As of September 30, 2018, we were in compliance with all covenants.
The obligations of the borrowers under the 2017 Credit Agreement are guaranteed by the Company and the subsidiaries of the Company (with certain customary exceptions) (the Guarantors and, together with the Borrowers, the Loan Parties). The obligations (i) under the 2017 Credit Agreement and related loan documents and (ii) the indenture governing the 5.875% Senior Secured Notes due 2024 and related documents are secured on a pari passu basis by a perfected first priority (subject to permitted liens) lien on substantially all of the assets of the Loan Parties (subject to customary exceptions).
Credit ratings. The Company’s corporate credit ratings assigned by Moody’s Investors Service and Standard & Poor’s are B2 with a negative outlook and B with a stable outlook, respectively.

49

Working capital. The components of our working capital and our liquidity at September 30, 2018 and December 31, 2017 are below (dollars in thousands):
 
September 30, 2018
 
December 31, 2017
Total current assets
$
2,275,599

 
$
2,271,077

Less: total current liabilities
(2,021,468
)
 
(2,220,909
)
Working capital
$
254,131

 
$
50,168

Current ratio
1.1:1

 
1.0:1

Net working capital increased by $204.0 million from December 31, 2017 to September 30, 2018. This increase reflects the favorable impact to net current assets resulting from operations during the nine months ended September 30, 2018, partially offset by certain items including, but not limited to, the working capital effect of net decreases in long-term litigation-related liabilities of $175.0 million, purchases of property, plant and equipment, excluding capitalized interest, of $56.5 million and net decreases in the aggregate principal amount of noncurrent debt of $25.7 million.
The following table summarizes our Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017 (in thousands):
 
2018
 
2017
Net cash flow provided by (used in):
 
 
 
Operating activities
$
196,992

 
$
422,162

Investing activities
(13,682
)
 
8,964

Financing activities
(62,808
)
 
(135,353
)
Effect of foreign exchange rate
(608
)
 
3,983

Movement in cash held for sale
—

 
(1,450
)
Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents
$
119,894

 
$
298,306

Operating activities. Net cash provided by operating activities represents the cash receipts and cash disbursements from all of our activities other than investing activities and financing activities. Changes in cash from operating activities reflect, among other things, the timing of cash collections from customers, payments to suppliers, managed care organizations, government agencies, collaborative partners and employees, as well as tax payments and refunds in the ordinary course of business.
The $225.2 million decrease in Net cash provided by operating activities for the nine months ended September 30, 2018 compared to the prior year period was primarily the result of the timing of cash collections and cash payments related to our operations. In particular, net sales of ezetimibe tablets and quetiapine ER tablets, which were launched in the fourth quarter of 2016 and for which the marketing exclusivity periods expired in the second quarter of 2017, generated significant cash receipts during the nine months ended September 30, 2017 that did not reoccur during the same period in 2018. Additionally, cash paid for interest for the nine months ended September 30, 2018 increased from the prior year period as a result of the April 2017 refinancing and changes in interest rates. These decreases were partially offset by a decline in cash outlays for mesh settlements, which decreased $283.4 million during the nine months September 30, 2018 from the prior year period.
Investing activities. The $22.6 million change in Net cash (used in) provided by investing activities for the nine months ended September 30, 2018 compared to the prior year period reflects a decrease in net proceeds from the sales of businesses and other assets of $52.3 million. Amounts during the nine months ended September 30, 2018 primarily relate to proceeds from the sales of various ANDAs, as well as additional proceeds received in 2018 from our 2017 sale of Litha. Amounts during the comparable prior year period primarily relate to our sales of Litha and our Charlotte, North Carolina manufacturing facilities. Also contributing to the change in Net cash (used in) provided by investing activities was a decrease in proceeds from notes receivable of $7.0 million during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. These items were partially offset by a decrease in purchases of property, plant and equipment, excluding capitalized interest of $37.6 million.
Financing activities. The $72.5 million decrease in Net cash used in financing activities for the nine months ended September 30, 2018 compared to the prior year period reflects a decrease in principal payments on term loans of $3,696.8 million, a decrease in deferred financing fees of $57.4 million and a decrease in payments for contingent consideration of $35.0 million, partially offset by a decrease in proceeds from issuance of term loans of $3,415.0 million and a decrease in proceeds from issuance of notes of $300.0 million.
Contractual Obligations. As of September 30, 2018, there were no material changes in our contractual obligations from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on February 27, 2018.

50

Fluctuations. Our quarterly results have fluctuated in the past and may continue to fluctuate. These fluctuations may be due to the timing of new product launches, purchasing patterns of our customers, market acceptance of our products, the impact of competitive products and pricing, certain actions taken by us which may impact the availability of our products, asset impairment charges, litigation-related charges, restructuring costs, including separation benefits, business combination transaction costs, upfront, milestone and certain other payments made or accrued pursuant to licensing agreements and changes in the fair value of financial instruments and contingent assets and liabilities recorded as part of business combinations. Further, a substantial portion of our total revenues are through three wholesale drug distributors who in turn supply our products to pharmacies, hospitals and physicians. Accordingly, we are potentially subject to a concentration of credit risk with respect to our trade receivables.
Inflation. We do not believe that inflation had a material adverse effect on our financial statements for the periods presented.
Off-balance sheet arrangements. We have no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.
CRITICAL ACCOUNTING ESTIMATES
Significant changes to our critical accounting estimates since December 31, 2017 are detailed below. For additional discussion of the Company’s critical accounting estimates, see “Critical Accounting Estimates” in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on February 27, 2018.
Revenue recognition
The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. For further discussion of the impact of adoption, refer to Note 2. Summary of Significant Accounting Policies of the Condensed Consolidated Financial Statements included in Part I, Item 1. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.
Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract’s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, distribution service agreement and other fees for services, returns and allowances. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. The variable component of the transaction price is estimated based on historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved.
We believe that speculative buying of product, particularly in anticipation of possible price increases, has been the historical practice of certain of our customers. The timing of purchasing decisions made by wholesaler and large retail chain customers can materially affect the level of our sales in any particular period. Accordingly, our sales may not correlate to the number of prescriptions written for our products based on external third-party data.
We have entered into distribution service agreements with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations.
Goodwill and indefinite-lived intangible assets
As further described in Note 9. Goodwill and Other Intangibles of the Condensed Consolidated Financial Statements included in Part I, Item 1, as a result of the first quarter 2018 change in reportable segments and resulting goodwill impairment tests performed during the three months ended March 31, 2018, we recorded a pre-tax, non-cash goodwill impairment charge relating to our new U.S. Generic Pharmaceuticals reporting unit of $391.0 million. A 50 basis point increase in the assumed discount rate used in the impairment test would have increased this goodwill impairment charge by approximately $60 million. Additionally, with respect to the first quarter 2018 goodwill impairment tests performed related to our former Generics and new U.S. Branded - Sterile Injectables reporting units, which did not result in impairment charges, a 50 basis point increase in the assumed discount rates would not have changed the results of these tests.

51

We have not made any substantial changes to our methodology used in our impairment tests since our previous assessment. Determination of the fair value of a reporting unit is a matter of judgment and involves the use of estimates and assumptions, which are based on management’s best estimates at the time. The use of different assumptions would increase or decrease our estimated discounted future cash flows and the resulting estimated fair value of our reporting units, and could result in the fair value of a reporting unit being less than its carrying amount in the impairment test. Any resulting non-cash impairment charges could be material.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies in the Condensed Consolidated Financial Statements in Part I, Item 1.
Item 3.        Quantitative and Qualitative Disclosures About Market Risk
Market risk is the potential loss arising from adverse changes in the financial markets, including interest rates and foreign currency exchange rates.
Interest Rate Risk
Our exposure to interest rate risk relates primarily to our variable rate indebtedness associated with our term loan and revolving credit facilities. At September 30, 2018, our variable-rate debt borrowings related to our term loan facilities and had an aggregate principal amount of $3.4 billion. Borrowings under our credit facilities bear interest at a LIBOR-based variable rate. A hypothetical 1% increase in the applicable rate over the floor would result in $33.7 million in incremental annual interest expense related to our variable-rate debt borrowings.
To the extent that we utilize amounts under our revolving credit facilities or take on additional variable rate indebtedness, we will be exposed to additional interest rate risk.
As of September 30, 2018 and December 31, 2017, we had no other assets or liabilities with significant interest rate sensitivity.
Foreign Currency Exchange Risk
We operate and transact business in various foreign countries and are therefore subject to risks associated with foreign currency exchange rate fluctuations. The Company manages this foreign currency risk, in part, through operational means including managing foreign currency revenues in relation to same currency costs as well as managing foreign currency assets in relation to same currency liabilities. The Company is also exposed to the potential earnings effects from intercompany foreign currency assets and liabilities that arise from normal trade receivables and payables and other intercompany loans. Additionally, certain of the Company’s subsidiaries maintain their books of record in currencies other than their respective functional currencies. These subsidiaries’ financial statements are remeasured into their respective functional currencies using current or historic exchange rates. Such remeasurement adjustments could have an adverse effect on the Company’s results of operations.
All assets and liabilities of our international subsidiaries, which maintain their financial statements in local currency, are translated to U.S. dollars at period-end exchange rates. Translation adjustments arising from the use of differing exchange rates are included in Accumulated other comprehensive loss in shareholders' (deficit) equity. Gains and losses on foreign currency transactions and short-term intercompany receivables from foreign subsidiaries are included in Other income, net in the Condensed Consolidated Statements of Operations. Refer to Note 17. Other income, net in Part I, Item 1 for the amount of Foreign currency loss (gain), net.
Based on the Company’s significant foreign currency denominated intercompany loans existing at September 30, 2018, we estimate that a 10% change in the underlying currencies of our foreign currency denominated intercompany loans, relative to the U.S. Dollar, could result in approximately $4.5 million in incremental foreign currency losses.
Item 4.        Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as of September 30, 2018. Based on that evaluation, the Company’s Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2018.
Changes in Internal Control over Financial Reporting
There have been no changes in the Company’s internal control over financial reporting during the fiscal quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

52

PART II. OTHER INFORMATION
Item 1.        Legal Proceedings
The disclosures under Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1 are incorporated into this Part II, Item 1 by reference.
Item 1A.    Risk Factors
For a discussion of our risk factors, see the information in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, and the information in Part II, Item 1A under the caption “Risk Factors” of our Quarterly Report on Form 10-Q for the three months ended March 31, 2018. There have been no material changes in our risk factors from those described in our Annual Report or our Quarterly Reports, except as set forth below.
If we fail to successfully identify and develop additional generic pharmaceutical products, obtain exclusive marketing rights for our generic products or fail to introduce these generic products on a timely basis, our revenues, gross margin and operating results may decline.
We may not be successful in our efforts to continue to create a pipeline of product candidates or develop commercially successful products. Identifying, developing and obtaining regulatory approval and commercializing additional product candidates is prone to risks of failure inherent in drug development. For example, our research programs may initially show promise in identifying potential additional product candidates, yet fail to yield results for a number of reasons, including, among others, that the research methodology used may not be successful. No assurance can be given that we will be able to successfully identify additional product candidates, advance any of these additional product candidates through the development process or successfully commercialize any such additional product candidates. If we are unable to successfully identify, develop and commercialize additional product candidates, our revenues and operating results may decline significantly and our prospects and business may be materially adversely affected.
Even if we are able to identify and develop additional product candidates, we may fail to obtain exclusive marketing rights for such product candidates or fail to introduce such product candidates on a timely basis. Subject to certain exceptions and limitations, the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act (FFDCA) provide for a period of 180 days of marketing exclusivity for a generic version of a previously approved drug for any applicant that is the first to file an ANDA containing a certification of invalidity, non-infringement or unenforceability related to a patent listed with respect to the corresponding brand-name drug (commonly referred to as a Paragraph IV certification). Our revenues have historically included and may from time to time continue to include sales of generic drugs with limited competition resulting from this 180-day marketing exclusivity period or other factors, and the amounts of such revenues may be material. ANDAs that contain Paragraph IV certifications challenging patents, however, generally become the subject of patent litigation that can be both lengthy and costly. There is no certainty that we will prevail in any such litigation, that we will be the first-to-file and be granted the 180-day marketing exclusivity period, or, if we are granted the 180-day marketing exclusivity period, that we will not forfeit such period. Even where we are awarded marketing exclusivity, we may be required to share our exclusivity period with other ANDA applicants who submit Paragraph IV certifications. In addition, brand-name pharmaceutical companies often authorize a generic version of the corresponding brand-name drug to be sold during any period of marketing exclusivity that is awarded. Authorized generics are not prohibited from sale during the 180-day marketing exclusivity period. Furthermore, timely commencement of the litigation by the patent owner imposes an automatic stay of ANDA approval by the FDA for 30 months, unless the case is decided in the ANDA applicant’s favor during that period. Finally, if the court decision is adverse to the ANDA applicant, the ANDA approval will be delayed until the challenged patent expires, and the applicant will not be granted 180 days of marketing exclusivity.
The future profitability of our U.S. Generic Pharmaceuticals segment depends, to a significant extent, upon our ability to introduce, on a timely basis, new generic products that are either the first-to-market (or among the first-to-market) or that otherwise can gain significant market share during the 180-day marketing period as permitted by the Hatch-Waxman Act. Our ability to timely bring our products to market is dependent upon, among other things, the timing of regulatory approval of our products, which to a large extent is outside of our control, as well as the timing of competing products. Our revenues and future profitability are dependent, in large part, upon our ability or the ability of our development partners to file, timely and effectively, ANDAs with the FDA or similar filings with other regulatory agencies, or to enter into contractual relationships with other parties that have obtained marketing exclusivity. No assurances can be given that we will be able to develop and introduce commercially successful products in the future within the time constraints necessary to be successful. If we or our development partners are unable to continue to timely and effectively file ANDAs with the FDA or similar filings with other regulatory agencies, or to partner with other parties that have obtained marketing exclusivity, our revenues and operating results may decline significantly and our prospects and business may be materially adversely affected.

53

We have been, continue to be and may be the subject of product liability claims, other significant litigation matters, government investigations or product recalls for which we may be unable to obtain or maintain insurance adequate to cover potential liabilities.
Our business exposes us to significant potential risk from product liability claims, other significant litigation matters, government investigations or product recalls, including, but not limited to, such matters associated with the testing, manufacturing, marketing and sale of our products. We have been, continue to be and may be subject to various product liability cases, other significant litigations and government investigations. For example, we, along with other manufacturers of prescription opioid medications, are the subject of lawsuits and have received subpoenas and other requests for information from various state and local government agencies regarding the sales and marketing of opioid medications. In addition to direct expenditures for damages, settlement and defense costs, there is a possibility of adverse publicity, loss of revenues and disruption of business as a result of product liability claims or other litigation matters. Some plaintiffs have received substantial damage awards in some jurisdictions against pharmaceutical and/or medical device companies based upon claims for injuries allegedly caused by the use of their products. Any failure to effectively identify, analyze, report and protect adverse event data, and/or fully comply with relevant laws, rules and regulations around adverse event reporting could expose the Company to penalties, fines and reputational damage. In addition, in the age of social media, plaintiffs’ attorneys have a wide variety of tools to advertise their services and solicit new clients for litigation, including using judgments obtained in litigation against other pharmaceutical companies as an advertising tool. For these or other reasons, any significant product liability or mass tort litigation in which we are a defendant could have a larger number of plaintiffs than such actions have seen historically and we could also see an increase in number of cases filed against us because of the increasing use of widespread and media-varied advertising. Furthermore, a ruling against other pharmaceutical companies in product liability or mass tort litigation in which we are not a defendant could have a negative impact on pending litigation where we are a defendant. In addition, it may be necessary for us to voluntarily or mandatorily recall or withdraw products that do not meet approved specifications or which subsequent data demonstrate may be unsafe or ineffective or misused. Any such recall or withdrawal could result in adverse publicity, costs connected to the recall and loss of revenue. Adverse publicity could also result in an increased number of additional product liability claims, whether or not these claims have a basis in scientific fact. See the risk factor “Public concern around the abuse of opioids, including law enforcement concerns over diversion and marketing of opioids, and regulatory efforts to combat abuse, could result in costs to our business” for more information. If we are found liable on a product liability claim or series of claims, including those described below, or in connection with other litigation matters, including those related to sales, marketing or pricing practices, government investigations or product recalls, or if we incur significant expenses in defense thereof, defaults could occur and be declared under our debt agreements, we could suffer substantial costs, reputational damage and/or restrictions on our product use, and we could incur losses, any of which could materially and adversely impact our business, financial condition, results of operations and cash flows and/or the price of our ordinary shares.
Our pharmaceutical and medical device products may cause, or may appear to cause, serious adverse side effects or potentially dangerous drug interactions if misused, improperly prescribed or subject to faulty surgical technique. For example, we and/or certain of our subsidiaries have been named as defendants in multiple lawsuits in various federal and state courts alleging personal injury resulting from use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence. For more information regarding this litigation, see Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1.
We may be unable to obtain or maintain product liability insurance in the future on acceptable terms or with adequate coverage against potential liabilities or other losses such as the cost of a recall if any claim is brought against us, regardless of the success or failure of the claim. For example, we generally no longer have product liability insurance to cover the claims in connection with the mesh-related litigation described above. Additionally, we may be limited by the surviving insurance policies of our acquired subsidiaries, which may not be adequate to cover against potential liabilities or other losses. The failure to generate sufficient cash flow or to obtain other financing could affect our ability to pay the amounts due under those liabilities not covered by insurance. See Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1 for further discussion of our product liability claims.
If generic manufacturers use litigation and regulatory means to obtain approval for generic versions of our branded drugs, our sales may suffer.
Under the Hatch-Waxman Act, the U.S. Food and Drug Administration (FDA) can approve an Abbreviated New Drug Application (ANDA) for a generic bioequivalent version of a previously approved drug, without requiring the ANDA applicant to undertake the full clinical testing necessary to obtain approval to market a new drug. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its generic product is bioequivalent to the branded product.

54

Various generic manufacturers have filed ANDAs seeking FDA approval for generic versions of certain of our key pharmaceutical products, including but not limited to LIDODERM®, VASOSTRICT® and AVEED®. In connection with such filings, these manufacturers have challenged the validity and/or enforceability of one or more of the underlying patents protecting our products. In the case of LIDODERM®, we no longer have patent protection in the markets where we sell these products. Our revenues from LIDODERM® have been negatively affected by Actavis’s September 2013 launch and Mylan’s August 2015 launch of their lidocaine patch 5%, generic versions of LIDODERM®, and we anticipate that these revenues could decrease further should one or more additional generic versions launch. We also believe it is likely that generic manufacturers may file ANDAs in the future seeking FDA approval or may use other means to seek FDA approval for generic versions of other of our key pharmaceutical products.
With respect to AVEED®, VASOSTRICT® and other branded pharmaceutical products, it has been and continues to be our practice to vigorously defend and pursue all available legal and regulatory avenues in defense of the intellectual property rights protecting our products. Despite our efforts to defend our products, litigation is inherently uncertain, and we cannot predict the timing or outcome of our efforts. If we are not successful in defending our intellectual property rights or opt to settle, or if a product’s marketing exclusivity rights expire or become otherwise unenforceable, our competitors could ultimately launch generic versions of our products, which would likely cause sales and revenues of the affected products to decline rapidly and materially, could require us to write off a portion or all of the intangible assets associated with the affected product and could have a material adverse effect on our business, results of operations, financial condition and cash flows as well as our share price. In the case of VASOSTRICT®, PSP and PPI received a notice letter from Eagle Pharmaceuticals, Inc. (Eagle) in April 2018 advising of the filing by such company of an ANDA for a generic version of VASOSTRICT® (vasopressin IV solution (infusion)). The Paragraph IV Notice refers to patents the Company has listed in the Orange Book covering either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage form to increase blood pressure in humans. In May 2018, PPI, PSP and EPIC filed a lawsuit against Eagle in the United States District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. We intend to vigorously defend VASOSTRICT®’s intellectual property rights and to pursue all available legal, business and regulatory avenues in defense of VASOSTRICT®, including enforcement of the product’s intellectual property rights. However, there can be no assurance that our defense will be successful. If a generic version of VASOSTRICT® were introduced to the market before 2020, our revenues from VASOSTRICT® would decrease significantly and, depending on the timing of such introduction and its effect on VASOSTRICT® pricing, could have a material adverse effect on our business, results of operations, financial condition and cash flows as well as our share price.
For a description of the material related legal proceedings, see Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1. As a result, there are currently ongoing legal proceedings brought by us and/or our subsidiaries, and in certain cases our third party partners, against manufacturers seeking FDA approval for generic versions of our products.
Our ability to protect and maintain our proprietary and licensed third party technology, which is vital to our business, is uncertain.
Our success, competitive position and future income will depend in part on our ability to obtain and protect patent rights relating to our current and future technologies, processes and products. Our policy is to seek patent protection for technologies, processes and products we own and to enforce the intellectual property rights we own and license. The patent applications we submit and have submitted may not result in patents being issued. If an invention qualifies as a joint invention, the joint inventor may have intellectual property rights in the invention, which it might not protect. A third party may infringe upon, design around or develop uses not covered by any patent issued or licensed to us and our patents may not otherwise be commercially viable. In this regard, the patent position of pharmaceutical compounds and compositions is particularly uncertain. Even issued patents may later be modified or revoked by the PTO, by analogous foreign offices or in legal proceedings. Laws relating to such rights may in the future also be changed or withdrawn. Upon the expiration or loss of necessary intellectual property protection for a product, others may manufacture and distribute such patented product, which will result in the loss of a significant portion of our sales of that product.
In addition, our success, particularly in our branded businesses, depends in part on the ability of our partners and suppliers to obtain, maintain and enforce patents, and protect trademarks, trade secrets, know-how and other intellectual property and proprietary information. Our ability to commercialize any branded product successfully will largely depend upon our and/or our partners’ or suppliers’ ability to obtain and maintain patents and trademarks of sufficient scope to lawfully prevent third-parties from developing and/or marketing infringing products.

55

The degree of protection any patents will afford is uncertain, including whether the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all the countries where we conduct business. The issuance of a patent is not conclusive as to its claim scope, validity or enforceability. These patent rights may be challenged, revoked, invalidated, infringed or circumvented by third parties. The patent positions of pharmaceutical companies, including us, are generally uncertain and involve complex legal and factual questions. There is no assurance that any of our patent claims in our pending non-provisional and provisional patent applications relating to our technologies, processes or products will issue or if issued, that any of our existing and future patent claims will be held valid and enforceable against third-party infringement or that our products will not infringe any third-party patent or intellectual property. Moreover, any patent claims relating to our technologies, processes and products may not be sufficiently broad to protect our technologies, processes and products. In addition, issued patent claims may be challenged, potentially invalidated or potentially circumvented. Our patent claims may not afford us protection against competitors with similar technology or permit the commercialization of our products without infringing third-party patents or other intellectual property rights. It is possible that we could incur significant costs and management distraction if we are required to initiate litigation against others to protect or enforce our intellectual property rights. Such patent disputes may be lengthy and a potential violator of our patents may bring a potentially infringing product to market during the dispute, subjecting us to competition and damages due to infringement of the competitor product. No assurance can be given that if challenged, our patents would be declared by the PTO, comparable foreign patent offices or a court to be valid or enforceable or that even if found valid and enforceable, a competitor’s technology or product would be found by a court to infringe our patents.
Furthermore, our products may infringe on the patents or other intellectual property rights held by third parties. It is also possible that third parties will obtain patent or other proprietary rights that might be necessary or useful for the development, manufacture or sale of our products. If we infringe on the intellectual property rights of others, we could lose our right to develop, manufacture or sell products or we could be required to pay monetary damages or royalties to license proprietary rights from third parties and we may not be able to obtain such licenses on commercially reasonable terms or at all. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products.
The Company also relies on trade secrets and other unpatented proprietary information, which it generally seeks to protect by confidentiality and nondisclosure agreements with its employees, consultants, advisors and partners. These agreements may not effectively prevent disclosure of confidential information and may not provide the Company with an adequate remedy in the event of unauthorized disclosure. For example, in August 2017, we filed a complaint against QuVa Pharma, Inc. and certain individual defendants in the U.S. District Court for the District of New Jersey alleging misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT®, a vasopressin-based cardiopulmonary drug. For more information regarding this litigation, see Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1. In addition, we may also not be able to discover or determine the extent of any unauthorized use of our proprietary rights, and we may not be able to prevent third parties from misappropriating or infringing upon our proprietary rights. In addition, if the Company’s employees, scientific consultants or partners develop inventions or processes that may be applicable to the Company’s products under development, such inventions and processes will not necessarily become the Company’s property, but may remain the property of those persons or their employers.
If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our intellectual property rights, our results of operations, financial condition and cash flows could be materially adversely affected.

56

The availability of third party reimbursement for our products is uncertain, and thus we may find it difficult to maintain current price levels. Additionally, the market may not accept those products for which third party reimbursement is not adequately provided.
Our ability to commercialize our products depends, in part, on the extent to which reimbursement for the costs of these products is available from government healthcare programs, such as Medicaid and Medicare, private health insurers and others. We cannot be certain that, over time, third party reimbursements for our products will be adequate for us to maintain price levels sufficient for realization of an appropriate return on our investment. Government payers, private insurers and other third party payers are increasingly attempting to contain healthcare costs by: (i) limiting both coverage and the level of reimbursement (including adjusting co-pays) for products approved for marketing by the FDA, (ii) refusing, in some cases, to provide any coverage for uses of approved products for indications for which the FDA has not granted marketing approval and (iii) requiring or encouraging, through more favorable reimbursement levels or otherwise, the substitution of generic alternatives to branded products. The Trump Administration also has been targeting drug prices in ways that could affect reimbursement for our products. For example, beginning in January 2019, Medicare Advantage Plans will be permitted to apply “step therapy” to products covered under Part B, which could impact our ability to negotiate for favorable product access in this sector. Additionally, in October 2018, President Trump announced a new initiative to contain drug costs. In particular, the Centers for Medicare and Medicaid Services (CMS) issued an Advance Notice of Proposed Rulemaking for the Medicare Program that would reduce Part B drug spending and reimbursement in part based on the prices that manufacturers charge to customers in foreign countries. This proposal targets physician-administered drugs, and it is therefore possible that any final rule could adversely affect reimbursement for certain products that we sell, and we cannot anticipate the adverse impact on our business.
We are dependent on third parties to supply all raw materials used in our products and to provide services for certain core aspects of our business. Any interruption or failure by these suppliers, distributors and collaboration partners to meet their obligations pursuant to various agreements with us could have a material adverse effect on our business, results of operations, financial condition and cash flows.
We rely on third parties to supply all raw materials used in our products. In addition, we rely on third party suppliers, distributors and collaboration partners to provide services for certain core aspects of our business, including manufacturing, warehousing, distribution, customer service support, medical affairs services, clinical studies, sales and other technical and financial services. All third party suppliers and contractors are subject to FDA, and very often DEA, requirements. Our business and financial viability are dependent on the continued supply of goods and services by these third party suppliers, the regulatory compliance of these third parties and on the strength, validity and terms of our various contracts with these third party manufacturers, distributors and collaboration partners. Any interruption or failure by our suppliers, distributors and collaboration partners to meet their obligations pursuant to various agreements with us on schedule or in accordance with our expectations, which could be the result of one or many factors outside of our control, could delay or prevent the development, approval, manufacture or commercialization of our products, result in non-compliance with applicable laws and regulations, disrupt our operations or cause reputational harm to our company, any or all of which could have a material adverse effect on our business, financial condition, results of operations and cash flows. We may also be unsuccessful in resolving any underlying issues with such suppliers, distributors and partners or replacing them within a reasonable time and on commercially reasonable terms.
All APIs imported into the European Union (EU) must be certified as complying with the good manufacturing practice standards established by the EU, as stipulated by the International Conference for Harmonization. These regulations place the certification requirement on the regulatory bodies of the exporting countries. Accordingly, the national regulatory authorities of each exporting country must: (i) ensure that all manufacturing plants within their borders that export API into the EU comply with EU manufacturing standards and (ii) for each API exported, present a written document confirming that the exporting plant conforms to EU manufacturing standards. The imposition of this responsibility on the governments of the nations exporting API may cause a shortage of API necessary to manufacture our products, as certain governments may not be willing or able to comply with the regulation in a timely fashion, or at all. A shortage in API may cause us to cease manufacturing of certain products or to incur costs and delays to qualify other suppliers to substitute for those API manufacturers unable to export. This could adversely affect the Company and could have a material adverse effect on our business, results of operations, financial condition and cash flow.
We are dependent upon third parties to provide us with various estimates as a basis for our financial reporting. While we undertake certain procedures to review the reasonableness of this information, we cannot obtain absolute assurance over the accounting methods and controls over the information provided to us by third parties. As a result, we are at risk of them providing us with erroneous data which could have a material adverse impact on our business and or reporting.

57

If our manufacturing facilities are unable to manufacture our products or the manufacturing process is interrupted due to failure to comply with regulations or for other reasons, it could have a material adverse impact on our business.
If any of our or our third party manufacturing facilities fail to comply with regulatory requirements or encounter other manufacturing difficulties, it could adversely affect our ability to supply products. All facilities and manufacturing processes used for the manufacture of pharmaceutical products are subject to inspection by regulatory agencies at any time and must be operated in conformity with cGMP and, in the case of controlled substances, DEA regulations. Compliance with the FDA’s cGMP and DEA requirements applies to both drug products seeking regulatory approval and to approved drug products. In complying with cGMP requirements, pharmaceutical manufacturing facilities must continually expend significant time, money and effort in production, record-keeping and quality assurance and control so that their products meet applicable specifications and other requirements for product safety, efficacy and quality. Failure to comply with applicable legal requirements subjects our or our third party manufacturing facilities to possible legal or regulatory action, including shutdown, which may adversely affect our ability to supply the product. Additionally, our or our third party manufacturing facilities may face other significant disruptions due to labor strikes, failure to reach acceptable agreement with labor and unions, infringement of intellectual property rights, vandalism, natural disaster, storm or other environmental damage, civil or political unrest, export or import restrictions or other events. Were we not able to manufacture products at our or our third party manufacturing facilities because of regulatory, business or any other reasons, the manufacture and marketing of these products would be interrupted. This could have a material adverse impact on our business, results of operation, financial condition, cash flows and competitive position.
For example, our Horsham, Pennsylvania facility and the facilities of the manufacturer that has been qualified as an alternate manufacturer for CCH, which we sell under the trademark XIAFLEX® (such manufacturer, the Alternate Manufacturer and such facility, the Alternate Facility), are subject to such regulatory requirements and oversight. If we or the Alternate Manufacturer fail to comply with cGMP requirements, we may not be permitted to sell our products or may be limited in the jurisdictions in which we are permitted to sell them. Further, if an inspection by regulatory authorities indicates that there are deficiencies, including non-compliance with regulatory requirements, we could be required to take remedial actions, stop production or close our Horsham facility or the Alternate Facility, which would disrupt the manufacturing processes, limit the supply of CCH and delay clinical trials and subsequent licensure and/or limit the sale of commercial supplies. In addition, future noncompliance with any applicable regulatory requirements may result in refusal by regulatory authorities to allow use of CCH in clinical trials, refusal of the government to allow distribution of CCH within the U.S. or other jurisdictions, criminal prosecution, fines, recall or seizure of products, total or partial suspension of production, prohibitions or limitations on the commercial sale of products, refusal to allow the entering into of federal and state supply contracts and follow-on civil litigation.
We purchase certain API and other materials used in our manufacturing operations from foreign and domestic suppliers. The price of API and other materials is subject to volatility. There is no guarantee that we will always have timely, sufficient or affordable access to critical raw materials or supplies from third parties. An increase in the price, or an interruption in the supply, of any API or raw material, could cause our business, financial condition, results of operations, cash flows and/or ordinary share price to be materially adversely affected.
We are subject to health information privacy and data protection laws that include penalties for noncompliance.
We are subject to a number of privacy and data protection laws and regulations globally. The legislative and regulatory landscape for privacy and data security continues to evolve. There has been increased attention to privacy and data security issues in both developed and emerging markets with the potential to affect directly our business. This includes federal and state laws and regulations in the U.S. as well as in Europe and other markets. There has also been increased enforcement activity in the U.S. particularly related to data security breaches. A violation of these laws or regulations by us or our third party vendors could subject us to penalties, fines, liability and/or possible exclusion from Medicare or Medicaid. Such sanctions could materially and adversely affect our business, results of operations, financial condition and cash flows.
Our international operations could expose us to various risks, including risks related to fluctuations in foreign currency exchange rates.
In 2017, 7% of our total revenues were from customers outside the U.S. Some of these sales were to governmental entities and other organizations with extended payment terms. A number of factors, including differing economic conditions, changes in political climate, differing tax regimes, changes in product pricing, changes in diplomatic and trade relationships and political or economic instability in the countries where we do business, could affect payment and credit terms and our ability to collect foreign receivables. A substantial slowdown of the global economy, or major national economies, could negatively affect growth in the markets in which we operate. Such a slowdown could result in national governments making significant cuts to their public spending, including national healthcare budgets, or reducing the level of reimbursement they are willing and able to provide to us for our products and, as a result, adversely affect our revenues, financial condition or results of operations. We have little influence over these factors and changes could have a material adverse impact on our business. In particular, the risk of a debt default by one or more European countries and related European or national financial restructuring efforts may cause volatility in the value of the euro. In addition, foreign sales are influenced by fluctuations in currency exchange rates, primarily the Canadian dollar, euro and British pound.

58

The effective rate of taxation upon our results of operations is dependent on multi-national tax considerations.
We earn a portion of our income outside the U.S. That portion of our earnings is taxed at the more favorable rates applicable to the activities undertaken by our subsidiaries outside of the U.S. Our effective income tax rate in the future could be adversely affected by a number of factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, the outcome of income tax audits and the repatriation of earnings from our subsidiaries for which we have not provided for taxes. Cash repatriations are subject to restrictions in certain jurisdictions and may be subject to withholding and other taxes. We are subject to the examination of our tax returns and tax arrangements by the IRS and other tax and governmental authorities, such as described in the risk factor “We may not be able to successfully maintain our low tax rates or other tax positions, which could adversely affect our businesses and financial condition, results of operations and growth prospects.” We regularly assess all of these matters to determine the adequacy of our tax provisions, which are subject to significant discretion. Although we believe our tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from our historical income tax provisions and accruals. The results of audits and disputes could have a material adverse effect on our financial statements for the period or periods for which the applicable final determinations are made.
Future changes in tax laws and rates, including further administrative or regulatory guidance related to the TCJA, could also affect recorded deferred tax assets and liabilities. Our estimate of the impact of the TCJA has been recorded on a provisional basis based on currently available information and interpretations of the TCJA. Any adjustments to this estimate will be recorded as an income tax expense or benefit in the period the adjustment is determined. Additionally, EU Member States that we operate in and/or have subsidiaries in have begun promulgating draft tax legislation in response to initiatives by the Economic and Financial Affairs Council of the EU. We are currently evaluating the potential impact of such legislation, which could have a material impact on the Company.
We may not be able to successfully maintain our low tax rates or other tax positions, which could adversely affect our businesses and financial condition, results of operations and growth prospects.
We are incorporated in Ireland and also maintain subsidiaries in, amongst other jurisdictions, the United States, Canada, India, Bermuda, the United Kingdom and Luxembourg. The IRS and other taxing authorities continue to challenge our tax positions. In addition, the IRS presently is examining certain of our subsidiaries’ United States income tax returns for fiscal years ending between December 31, 2011 and December 31, 2015 and, in connection with those examinations, is reviewing our tax positions related to, among other things, certain intercompany arrangements, including the level of profit earned by our United States subsidiaries pursuant to such arrangements, and a worthless stock deduction directly attributable to product liability losses. The IRS may examine our tax returns for other fiscal years. Such examinations may lead to proposed or actual adjustments to our taxes that may be material, individually or in the aggregate.
Responding to or defending any challenge or proposed adjustment to our tax positions is expensive, consumes time and other resources and diverts management’s attention. We cannot predict whether taxing authorities will conduct an audit challenging any of our other tax positions, the cost involved in responding to and defending any such audit and resulting litigation, or the outcome. If we are unsuccessful in any of these matters, we may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future or repay certain tax refunds, any of which could require us to reduce our operating expenses, decrease efforts in support of our products or seek to raise additional funds, all of which could have a material adverse effect on our business, financial position, results of operations and growth prospects.
Our failure to comply with various laws protecting the confidentiality of certain patient health information could result in penalties and reputational damage.
Certain countries in which we operate have, or are developing, laws protecting the confidentiality of individually identifiable personal information, including patient health information. EU member states and other jurisdictions have adopted data protection laws and regulations applicable to such information, which impose significant compliance obligations.
For example, the EU General Data Protection Regulation (GDPR), which replaced the pre-existing EU Data Protection Directive and became enforceable as of May 25, 2018, imposes strict restrictions on our authority to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. The GDPR also grants individuals whose personal data (which is very broadly defined) is collected or otherwise processed the right to access the data, request its deletion and control its use and disclosure. The GDPR also requires notification of a breach in the security of such data to be provided within 72 hours of discovering the breach. Although the GDPR itself is self-executing across all EU member states, data protection authorities from different EU member states may interpret and apply the regulation somewhat differently, which adds to the complexity of processing personal data in the EU. To date, there has been scant interpretation of the regulation by any of the different data protection authorities and little time for enforcement, which makes predicting future enforcement very difficult. That uncertainty contributes to liability exposure risk.

59

As did the pre-existing Data Protection Directive, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the European Commission to provide an adequate level of data protection, and transfers of personal data to such countries may be made only in certain circumstances, such as where the transfer is necessary for important reasons of public interest or the individual to whom the personal data relates has given his or her explicit consent to the transfer after being informed of the risks involved. We have policies and practices that we believe make us compliant with applicable privacy regulations. Nevertheless, any failure to comply with the rules arising from the EU GDPR or privacy laws in other countries in which we operate, could lead to government enforcement actions and significant sanctions or penalties against us, adversely impact our results of operations and subject us to negative publicity. Such liabilities could materially affect our operations.
Our business and financial condition may be adversely affected by legislation.
In April 2018, New York enacted a statute called the Opioid Stewardship Act (the Stewardship Act), which, among other things, requires certain sellers and distributors of certain opioids in the state of New York (the Contributing Parties) to make payments to a newly created Opioid Stewardship Fund (the Fund). The Contributing Parties will be required to pay a total of up to $100 million annually into the Fund, with each Contributing Party’s share based on the total amount of morphine milligram equivalents of certain opioids sold or distributed by the Contributing Party in the state of New York during the preceding calendar year, subject to potential adjustments by the New York State Department of Health. Failure of a Contributing Party to make required reports or pay its ratable share, or a Contributing Party passing on the cost of its ratable share to a purchaser, may subject the Contributing Party to penalties. While the effect of this legislation remains uncertain, it is likely that we may be deemed to be a Contributing Party and even if we are not considered to be a Contributing Party, or such a determination is never made, other entities may attempt to seek reimbursement from Endo for payments made related to products manufactured by Endo and distributed in New York. Furthermore, the application of the Stewardship Act may require additional regulatory guidance, which could be substantially delayed, increasing the uncertainty as to the ultimate effect of the Stewardship Act on us. If we are ultimately deemed to be a Contributing Party, compliance with the requirements of the Stewardship Act, or similar requirements that could be enacted by other jurisdictions, could have an adverse effect on our business, results of operations, financial condition and cash flows.
Additionally, in October 2018, the United States Congress enacted the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (H.R. 6). Intended to achieve sweeping reform to combat the opioid epidemic, H.R. 6, among other provisions, amends related laws administered by the FDA, Drug Enforcement Administration (DEA) and CMS. Among other things, the law: amends requirements related to the FDA’s authority to include packaging requirements in risk evaluation and mitigation strategy (REMS) requirements; increases civil and criminal penalties for drug manufacturers and distributors for failing to maintain effective controls against diversion of opioids or for failing to report suspicious opioid orders; requires the DEA to estimate the amount of opioid diversion when establishing manufacturing and procurement quotas; and authorizes the Department of Health and Human Services to implement a demonstration program which would award grants to hospitals and emergency departments to develop, implement, enhance or study alternative pain management protocols and treatments that limit the use and prescription of opioids in emergency departments. While the effect of this legislation is still uncertain, it is likely that our products will be affected by enforcement of the legislation, including through related policies and implementing regulations. It is possible that these changes in law could have an adverse effect on our business, results of operations, financial condition and cash flow.
Also in October 2018, the Canadian province of British Columbia enacted a statute called the Opioid Damages and Health Care Costs Recovery Act, which allows the British Columbia government to file a direct action against opioid manufacturers and wholesalers to recover the health care costs it has incurred, and will incur, resulting from an “opioid-related wrong.” The statute defines “opioid-related wrong” to include any breach of a common law, equitable, or statutory duty or obligation owed to persons in British Columbia who have been or might be exposed to an opioid product. The statute, among other effects, erases limitation periods, reverses certain burdens of proof as to causation, allows the use of population-based evidence and restricts discovery of some relevant documents. It is possible that this statute, or similar statutes enacted by other jurisdictions, and resultant litigation, could have an adverse effect on our business, results of operations, financial condition and cash flow.
In Canada, the prices of patented drug products are subject to regulation by the Patented Medicine Prices Review Board (PMPRB). Under the Canadian Patent Act and Patented Medicines Regulations, patentees of inventions that pertain to drug products sold in Canada are periodically required to file price and sales information about their patented drug products with the PMPRB. The PMPRB reviews this information on an ongoing basis to ensure that the prices charged by pharmaceutical companies for patented drugs are not excessive and comply with the pricing guidelines established by the PMPRB. There is risk that we could fail to comply with the PMPRB’s current guidelines, such as upon the launch of a new product in Canada for which the PMPRB has not yet assessed pricing, or that the guidelines could change, such that the current price of our drug products will be considered excessive under the updated guidelines. The Canadian government has published proposed amendments to the Patented Medicines Regulations and, if these amendments are passed and come into force, the PMPRB guidelines will be updated to account for new price regulatory factors. Failure by us to comply with the current or future guidelines could ultimately result in us reducing the prices of the drug products we sell in Canada and/or making a payment to the Canadian government to offset revenues deemed by the PMPRB to be excessive, which could ultimately reduce the revenues and cash flows of our International Pharmaceuticals segment and could have an adverse effect on our business, results of operations, financial condition, cash flow and reputation.

60

Public concern around the abuse of opioids, including law enforcement concerns over diversion and marketing of opioids, and regulatory efforts to combat abuse, could result in costs to our business.
Media stories regarding prescription drug abuse and the diversion of opioids and other controlled substances are commonplace. Aggressive enforcement and unfavorable publicity regarding, for example, the use or misuse of opioid drugs; the limitations of abuse-deterrent formulations; the ability of drug abusers to discover previously unknown ways to abuse our products; public inquiries and investigations into prescription drug abuse; litigation; or regulatory activity regarding sales, marketing, distribution or storage of opioids could have a material adverse effect on our reputation and impact on the results of litigation.
Opioid manufacturers have been the subject of significant current civil and criminal investigatory and enforcement action. In addition, numerous governmental and private persons and entities are pursuing civil litigation against opioid manufacturers and distributors, invoking current laws and regulations relating to opioids and/or other prescription medicines, as well as novel uses of other laws that seek to hold accountable opioid manufacturers for opioid misuse. See Note 14. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1 for more information.
Regulatory actions at the federal, state and local level may seek to limit or restrict the manufacturing, distribution or sale of opioids, both directly and indirectly, and/or to impose novel policy or regulatory mechanisms regarding the manufacturing, distribution or sales of opioids. For example, in April 2018, New York enacted the Stewardship Act. See the risk factor “Our business and financial condition may be adversely affected by legislation” for more information. Many state legislatures are considering various bills intended to reduce opioid abuse such as by, for example, establishing prescription drug monitoring programs and mandating prescriber education.
Finally, various government entities, including Congress, state legislatures or other policy-making bodies may hold hearings, conduct investigations and/or issue reports calling attention to the opioid crisis, and may mention or criticize the role of manufacturers, including us, in the opioid crisis. Similarly, press organizations have and likely will continue to report on these issues, and such reporting may result in adverse publicity for manufacturers, including us.
Item 2.        Unregistered Sales of Equity Securities and Use of Proceeds
There were no purchases or sales of equity securities by the Company during the three months ended September 30, 2018.
Item 3.        Defaults Upon Senior Securities
None.
Item 4.        Mine Safety Disclosures
Not applicable.
Item 5.        Other Information
None.

61

Item 6.        Exhibits
 
 
Incorporated by Reference from:
Number
Description
File Number
Filing Type
Filing Date
10.1
Not applicable; filed herewith
10.2
Not applicable; filed herewith
10.3
Not applicable; filed herewith
31.1
Not applicable; filed herewith
31.2
Not applicable; filed herewith
32.1
Not applicable; furnished herewith
32.2
Not applicable; furnished herewith
101
The following materials from Endo International plc’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Loss, (iv) the Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements
Not applicable; submitted herewith

62

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
ENDO INTERNATIONAL PLC
 
(Registrant)
 
 
 
/s/ PAUL V. CAMPANELLI
Name:
Paul V. Campanelli
Title:
President and Chief Executive Officer
 
(Principal Executive Officer)
 
 
 
/s/ BLAISE COLEMAN
Name:
Blaise Coleman
Title:
Executive Vice President, Chief Financial Officer
 
(Principal Financial Officer)
Date: November 8, 2018

63
 EX-10.1 2 ex101formofstockoptionawar.htm EXHIBIT 10.1 FORM OF STOCK AWARD AGREEMENT Ex 10.1 Form of Stock Option Award Agreement
Exhibit 10.1

Grant No.
ENDO INTERNATIONAL PLC
STOCK OPTION AGREEMENT
UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN
This Stock Option Agreement (this “Option Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the optionee named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
Name of Participant:
 
Number of Shares Subject to Option:
 
Exercise Price Per Share:
 
Date of Grant:
 
Expiration Date:
The 10th anniversary of the Date of Grant
Vesting Dates:
Option vests ratably over the first, second, third [and fourth] anniversaries of the Date of Grant
Classification of Option:
Non-Qualified Stock Option
1.    Number of Shares. The Company hereby grants to the Participant an option (the “Option”) to purchase the total number of shares of Company Stock set forth above as Shares Subject to Option (the “Option Shares”) at the Exercise Price Per Share set forth above (the “Exercise Price”), subject to all of the terms and conditions of this Option Agreement and the Plan.
2.    Incorporation of Plan. The Plan is hereby incorporated by reference and made a part hereof, and the Option and this Option Agreement shall be subject to all terms and conditions of the Plan. In the event of any conflict between the provisions of this Option Agreement and the provisions of the Plan, the provisions of the Plan shall govern, except as expressly provided by Paragraph 7 of this Option Agreement.
3.    Option Term. The term of the Option and of this Option Agreement (the “Option Term”) shall commence on the Date of Grant set forth above and, unless previously terminated

1

pursuant to Paragraph 4 of this Option Agreement, shall terminate upon the Expiration Date set forth above. As of the Expiration Date, all rights of the Participant hereunder shall terminate.
4.    Termination of Service.
(a)
Termination of Service for Cause. Upon the Participant’s termination of service with the Company and its Subsidiaries by the Company or its Subsidiary for Cause, the portion of outstanding Options that are exercisable as of the date of such termination of service shall remain exercisable for thirty (30) days from and including the date of termination of service (and shall thereafter terminate). Any portion of outstanding Options that are not exercisable as of the date of such termination of service shall terminate upon the date of termination of service.
(b)
Termination of Service on Account of Death. Upon the Participant’s termination of service with the Company and its Subsidiaries on account of death, all of the Participant’s unvested Options shall immediately vest and become exercisable. The Options shall remain exercisable for one (1) year from and including the date of the Participant’s death (and shall thereafter terminate).
(c)
Termination of Service on Account of Disability or Voluntary Retirement with Consent of Company. If the Participant voluntarily Retires with the consent of the Company or if the Participant’s service with the Company and its Subsidiaries terminates due to Disability, the Participant’s unvested Options as of the date of such termination shall continue to vest in accordance with the original vesting schedule set forth above. The Options shall remain exercisable for a period of one (1) year from and including the later to occur of (i) the date such entire Option becomes exercisable in accordance with the vesting schedule and (ii) the date of termination of service (and shall thereafter terminate).
(d)
Termination of Service by the Company without Cause or by the Participant for Good Reason. Upon termination of the Participant’s service with the Company and its Subsidiaries by the Company or its Subsidiaries without Cause, the portion of outstanding Options that are exercisable as of the date of such termination of service shall remain exercisable for one (1) year from and including the date of termination of service (and shall thereafter terminate). Any portion of outstanding Options that are not exercisable as of the date of such termination of service shall terminate upon the date of termination of service. If a Participant is a party to an employment agreement with the Company or a Subsidiary and such employment agreement provides for benefits on a termination of employment for “Good Reason,” (x) a termination of the Participant’s employment for Good Reason shall

2

constitute a termination without Cause for purposes of Paragraphs 4 and 6 of this Option Agreement and (y) Good Reason will also include the Participant’s termination of employment within ninety (90) days following the expiration of the employment term of the Participant’s employment agreement under circumstances that would have constituted Good Reason had such termination occurred during the employment term.
(e)
Termination of Service for any Other Reason. Upon the Participant’s termination of service with the Company and its Subsidiaries for any reason other than the reasons enumerated in Subparagraphs (a) through (d) above, the portion of outstanding Options that are exercisable as of the date of such termination of service shall remain exercisable for ninety (90) days from and including the date of termination of service (and shall thereafter terminate). Any portion of outstanding Options that are not exercisable as of the date of such termination of service shall terminate upon the date of termination of services.
5.    Vesting. Except as provided in Paragraph 4 above, the Option shall become exercisable with respect to the number of Option Shares specified on the Exercisability Dates set forth above. Once exercisable, the Option shall continue to be exercisable at any time or times prior to the Expiration Date, subject to the provisions hereof and of the Plan. No Option may be exercised after the Expiration Date.
6.    Change in Control. In the event of a Change in Control:
(a)
if the Option is assumed or substituted (within the meaning of the Plan) in connection with such Change in Control, and the Participant incurs a termination of service with the Company and its Subsidiaries by the Company or its Subsidiary without Cause during the 24-month period following such Change in Control, then the Option shall vest and become fully exercisable on the date of such termination of services and shall remain exercisable for one (1) year from and including the date of such termination of services (and shall thereafter terminate).
(b)
if the Option is not assumed or substituted in connection with such Change in Control, then the Option shall immediately vest and become fully exercisable on the occurrence of the Change in Control.
7.    Change in Control Definition. Notwithstanding anything to the contrary in the Plan, for purposes of this Option Agreement, “Change in Control” means and shall be deemed to have occurred upon the first of the following events to occur:

3

(a)
Any “Person” (as defined below) is or becomes the “beneficial owner” (“Beneficial Owner”) within the meaning set forth in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its “Affiliates” (as defined in Rule 12b-2 promulgated under Section 12 of the Exchange Act)) representing 30% or more of the combined voting power of the Company’s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (A) of Subparagraph (c) below; or
(b)
The following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the date hereof, constitute the Board of Directors and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board of Directors or nomination for election by the Company’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date hereof or whose appointment, election or nomination for election was previously so approved or recommended; or
(c)
There is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation or other entity, other than (A) a merger or consolidation which results in (i) the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, at least 60% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation and (ii) the individuals who comprise the Board of Directors immediately prior thereto constituting immediately thereafter at least a majority of the board of directors of the Company, the entity surviving such merger or consolidation or, if the Company or the entity surviving such merger is then a subsidiary, the ultimate parent thereof, or (B) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of

4

the Company (not including in the securities Beneficially Owned by such Person any securities acquired directly from the Company or its Affiliates) representing 30% or more of the combined voting power of the Company’s then outstanding securities; or
(d)
The shareholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets (it being conclusively presumed that any sale or disposition is a sale or disposition by the Company of all or substantially all of its assets if the consummation of the sale or disposition is contingent upon approval by the Company’s shareholders unless the Board of Directors expressly determines in writing that such approval is required solely by reason of any relationship between the Company and any other Person or an Affiliate of the Company and any other Person), other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity (A) at least 60% of the combined voting power of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale or disposition and (B) the majority of whose board of directors immediately following such sale or disposition consists of individuals who comprise the Board of Directors immediately prior thereto.
For purposes hereof, “Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 15(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.
Notwithstanding the foregoing, (i) a “Change in Control” shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of Company Stock immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions and (ii) to the extent required to avoid the imposition of taxes or penalties under Section 409A of the Code with respect to any Award that constitutes a deferral of compensation subject to Section

5

409A of the Code, no such Award shall become payable as a result of the occurrence of a Change in Control unless such Change in Control also constitutes a change in the ownership or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company under Section 409A of the Code.
For the avoidance of doubt, any one or more of the events described in subparagraphs (a) through (d) may be effected pursuant to (A) a takeover under Irish takeover rules; (B) a compromise or arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of the Republic of Ireland or (C) Chapter 2 of Part 9 of the Companies Act 2014 of the Republic of Ireland.
8.    Authority of the Committee. The Committee shall have full authority to interpret and construe the terms of the Plan and this Option Agreement. The determination of the Committee as to any such matter of interpretation or construction shall be final, binding and conclusive.
9.    Governing Law. This Option Agreement shall be governed by, interpreted under, and construed and enforced in accordance with the internal laws, and not the laws pertaining to conflicts or choices of laws, of the State of Delaware applicable to agreements made and to be performed wholly within the State of Delaware.
10.    Binding on Successors. The terms of this Option Agreement shall be binding upon the Participant and upon the Participant’s heirs, executors, administrators, personal representatives, transferees, assignees and successors in interest, and upon the Company and its successors and assignees, subject to the terms of the Plan.
11.    No Assignment. Notwithstanding anything to the contrary in this Option Agreement, neither this Option Agreement nor any rights granted herein shall be assignable by the Participant.
12.    Necessary Acts. The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Option Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws and applicable Irish law.
13.    Entire Option Agreement. This Option Agreement and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof.
14.    Headings. Headings are used solely for the convenience of the parties and shall not be deemed to be a limitation upon or descriptive of the contents of any such Paragraph.

6

15.    Counterparts. This Option Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.
16.    Notices. All notices and other communications under this Option Agreement shall be in writing and shall be given by first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three days after mailing to the respective parties named below:
If to Company:
Endo International plc
c/o Endo Health Solutions Inc.
1400 Atwater Drive
Malvern, PA 19355
Attention: Treasurer
If to the Participant:
At the address on file with the Company.
Either party hereto may change such party’s address for notices by notice duly given pursuant hereto.
17.    Amendment. No amendment or modification hereof shall be valid unless it shall be in writing and signed by all the parties hereto.
18.    Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Option Agreement. The Participant has read and understands the terms and provisions thereof, and accepts the Option subject to all the terms and conditions of the Plan and this Option Agreement.
19.    No Compensation for Loss of Rights. The Participant hereby acknowledges that under no circumstances will s/he, on ceasing to be an employee or director of the Company and its Subsidiaries, be entitled to any compensation for any loss of any right or benefit or prospective right or benefit under the Plan that s/he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever.
20.    Severability. All the terms and provisions of this Option Agreement are distinct and severable, and if any term or provision is held unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it shall to that extent be

7

deemed not to form part of this Option Agreement, and the enforceability, legality and validity of the remainder of this Option Agreement will not be affected; if any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, the provision shall apply with whatever modification is necessary to make it valid, enforceable and legal.
21.    Data Protection. The Participant hereby acknowledges and consents to the Company and any Subsidiary sharing and exchanging his/her information held in order to administer and operate the Plan (including personal details, data relating to participation, salary, taxation and employment and sensitive personal data, e.g. data relating to physical or mental health, criminal conviction or the alleged commission of offences) (the “Information”) and providing the Company and/or the Subsidiary’s agents and/or third parties with the Information for the administration and operation of the Plan and the Participant further accepts that this may involve the Information being sent to a country outside the country in which the Participant provides services including to a country which may not have the same level of data protection laws as his/her home country. The Participant acknowledges that s/he has the right to request a list of the names and addresses of any potential recipients of the Information and to review and correct the Information by contacting his/her local human resources representative. The Participant acknowledges that the collection, processing and transfer of the Information is important to Plan administration and that failure to consent to same may prohibit participation in the Plan.
22.    Additional Matters. This Option Agreement is intended to comply with the applicable laws of any country or jurisdiction where Options are granted under the Plan, and all provisions hereof shall be construed in a manner to so comply. The following provisions apply to Participants providing services in the country noted:
Canada:
Section 4 above shall be amended to add the following language at the end thereof as a new sub-section (f):
(f)    The Participant’s date of termination of employment shall be the Participant’s last day of active employment with the Company and its Subsidiaries and shall not include any period of statutory, contractual or common law reasonable notice or any period of deemed employment or salary continuance.
A new Section 23 shall be added as follows:
23.    Tax Withholding. Section 12(b) of the Plan shall not apply. The Company shall be entitled to receive either a cash payment by or on behalf of the Participant or a sufficient amount

8

of the proceeds from the sale of Company Stock to be acquired pursuant to this Option Agreement by the Participant’s delivery to the Company of an assignment of such proceeds and an authorization to the broker or selling agent to pay that amount to the Company and to effect such sale at the time of exercise or other delivery of shares of Company Stock for any sums required by federal, state or local law to be withheld or to satisfy any applicable payroll deductions with respect to the vesting of, lapse of restrictions on, or payment of any Option.
India:
As used herein, “Participant” shall have the meaning set forth in the Plan, except the term shall not include consultants of any Subsidiary in India.
Section 4(b) above shall be modified to read as follows:
Termination of Service on Account of Death. Upon the Participant’s termination of service on account of death, all of the Participant’s unvested Options shall immediately vest and become exercisable by his legal heirs or nominees. The Options shall remain exercisable for one (1) year from and including the date of the Participant’s death (and shall thereafter terminate).
Section 4(c) above shall be deleted in its entirety and replaced with the following language:
Termination of Service on Account of Disability or Voluntary Retirement with Consent of Company. If the Participant voluntarily Retires with the consent of the Company or if the Participant’s service terminates due to Disability, the Participant’s unvested Options as of the date of such termination shall vest on the date of Disability or the date of termination of service due to voluntary retirement, as the case may be. The Options so vested shall remain exercisable for a period of one (1) year from and including the date such Option becomes vested, and shall thereafter terminate.
Section 10 above shall be amended to delete the term “transferee”.
Section 11 above shall be deleted in its entirety and replaced with the following language:
No Assignment. Notwithstanding anything to the contrary in this Option Agreement, but subject to the assignment of the Option upon death of the Participant, neither this Option Agreement nor any rights granted herein shall be assignable by the Participant.
Section 12 above shall be deleted in its entirety and replaced with the following language:
Necessary Acts. The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of

9

this Option Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws and applicable Indian law. The rights and interests of the Participant under the Option Agreement shall be subject to compliance under the Foreign Exchange Management Act, 1999 and the related rules thereto.
Ireland:
Section 4(c) above shall be deleted in its entirety and replaced with the following language:
Termination of Service on Account of Disability. If the Participant’s service terminates due to Disability, the Participant’s unvested Options as of the date of such termination shall continue to vest in accordance with the original vesting schedule set forth above. The Options shall remain exercisable for a period of one (1) year from and including the later of (i) the date such entire Option becomes exercisable in accordance with the vesting schedule and (ii) the date of termination of service (and shall thereafter terminate).
Section 10 above shall be amended to delete the words “transferees, assignees” therefrom.
Section 11 above shall be deleted in its entirety and replaced with the following language:
No Assignment or Transfer. Notwithstanding anything to the contrary in this Option Agreement, neither this Option Agreement nor any rights granted herein shall be assignable by the Participant. Neither this Option Agreement nor any rights granted herein shall be transferable by the Participant in any circumstances, except on the death of the Participant.
Luxembourg:
Section 4(c) above shall be amended to add the following language at the end thereof:
As used herein, “Disability” shall mean either (i) the Participant’s inability to, solely because of injury or physical or mental illness, perform the material duties of his or her regular occupation in a situation where the Participant receives paid sickness, incapacity or invalidity benefits from any of the Luxembourg competent authorities for a period that lasts or can reasonably be expected to last for a continuous period of 6 months, or (ii) the Participant’s reclassement by the competent commission following an irrevocable decision from said commission.
Section 4(d) above shall be amended to delete the following sentence therefrom:
If a Participant is a party to an employment agreement with the Company or a Subsidiary and such employment agreement provides for benefits on a termination of employment for “Good Reason,” (x) a termination of the Participant’s employment for Good Reason

10

shall constitute a termination without Cause for purposes of Paragraphs 4 and 6 of this Option Agreement and (y) Good Reason will also include the Participant’s termination of employment within ninety (90) days following the expiration of the employment term of the Participant’s employment agreement under circumstances that would have constituted Good Reason had such termination occurred during the employment term.
Section 4 above shall be amended to add the following language at the end thereof as a new sub-section (f):
It is understood that the Participant’s termination of service for any reason shall take place in accordance with applicable Luxembourg employment law rules.
Section 10 above shall be amended to delete the word “transferees” therefrom.
Section 11 above shall be deleted in its entirety and replaced with the following language:
No Assignment or Transfer. Notwithstanding anything to the contrary in this Option Agreement, neither this Option Agreement nor any rights granted herein shall be assignable by the Participant. Neither this Option Agreement nor any rights granted herein shall be transferable by the Participant in any circumstances, except on the death of the Participant.
Section 21 above shall be amended to add the following language at the end thereof:
, it being understood that for the purposes hereunder any Information on the Participant shall be processed in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, as well as any applicable local laws.
United Kingdom:
As used herein, “Cause” shall have the meaning set forth in the Plan and, with respect to any Participant who is a party to an employment agreement with the Company, the definition of “Cause” shall include any circumstances in which the Company may terminate the Participant’s employment agreement without notice in accordance with its terms.
As used herein, “Disability” shall mean the Participant’s inability to, solely because of injury or physical or mental illness: (i) perform the material duties of his or her regular occupation and (ii) earn 80% or more of his or her base salary or wages in respect of his or her regular occupation, for a period that lasts or can reasonably be expected to last for a continuous period of 12 months.
Section 4(c) above shall be deleted in its entirety and replaced with the following language:

11

Termination of Service on Account of Disability. If the Participant’s service terminates due to Disability, the Participant’s unvested Options as of the date of such termination shall continue to vest in accordance with the original vesting schedule set forth above. The Options shall remain exercisable for a period of one (1) year from and including the later of (i) the date such entire Option becomes exercisable in accordance with the vesting schedule and (ii) the date of termination of service (and shall thereafter terminate).
The following additional section shall be inserted:
Tax Liabilities. The Participant irrevocably agrees (A) to pay, or enter into arrangements to the satisfaction of the Company to pay, to the Company, the Participant’s employer or former employer (as appropriate) the amount of any Tax Liability, (B) that the Company, the Participant’s employer or former employer (as appropriate) may, if it so elects by written notice to the Participant, recover the whole or any part of any Employer NICs from the Participant, (C) that the Participant shall, promptly upon being requested to do so by the Company, the Participant’s employer or former employer (as appropriate), elect (using a form approved by HM Revenue & Customs) that the whole or any part of the liability for Employer NICs shall be transferred to the Participant; (D) to enter into a joint election, under section 431(1) or 431(2) of the Income Tax (Earnings & Pensions) Act 2003 (“ITEPA”), in respect of the Company Stock to be acquired on exercise of the Participant’s Option, if required to do so by the Company, the Participant’s employer or former employer, before, on or within 14 days after any date of exercise of the Option. For the purposes of this section the following capitalized terms shall have the meanings set out below:
“Employer NICs”: any secondary class 1 (employer) national insurance contributions that the Company or any employer (or former employer) of the Participant is liable to pay as a result of any Taxable Event (or which that person would be liable to pay in the absence of an election of the type referred to in (C) above) and that may be lawfully recovered from the Participant.
“Taxable Event”: any event or circumstance that gives rise to a liability for the Participant to pay income tax and national insurance contributions or either of them in respect of: (a) the Option, including its exercise, its assignment or surrender for consideration, or the receipt of any benefit in connection with it; (b) any shares (or other securities or assets): (i) earmarked or held to satisfy the Option; (ii) acquired on exercise of the Option; (iii) acquired as a result of holding the Option; or (iv) acquired in consideration of the Option’s assignment or surrender; (c) any securities (or other assets) acquired or earmarked as a result of holding shares (or other securities or assets) mentioned in (b); or

12

(d) any amount due in respect of assets within (a) to (c) above and not made good by the Participant within the time limit specified in section 222 ITEPA.
“Tax Liability”: the total of (a) any income tax and primary class 1 (employee) national insurance contributions that any employer (or former employer) of the Participant is liable to account for (or reasonably believes it is liable to account for) as a result of any Taxable Event; and (b) any Employer NICs that any employer (or former employer) of the Participant is liable to pay (or reasonably believes it is liable to pay) as a result of any Taxable Event and that can be recovered lawfully from the Participant.
Section 19 above shall be deleted in its entirety and replaced with the following language:
Nothing contained in the Plan or this Option Agreement shall form part of the Participant’s contract of employment. The Participant hereby acknowledges that under no circumstances will s/he, on ceasing to be an employee or director of or otherwise engaged by the Company or any of its Subsidiaries for any reason (including as a result of a repudiatory breach of contract by the Company or any of its Subsidiaries), be entitled to any compensation for any loss of any right or benefit or prospective right or benefit under the Plan that s/he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever. By signing this Option Agreement the Participant shall be deemed irrevocably to have waived any such entitlement.

13

IN WITNESS WHEREOF, the parties hereto have executed this Option Agreement as of the date set forth above.
ENDO INTERNATIONAL PLC
By:         
Name: Paul V. Campanelli
Title: President & Chief Executive Officer
PARTICIPANT
Signature:         
Print Name:     





14
 EX-10.2 3 ex102formofstockawardagree.htm EXHIBIT 10.2 FORM OF STOCK AWARD AGREEMENT Ex 10.2 Form of Stock Award Agreement
Exhibit 10.2

Grant No.
ENDO INTERNATIONAL PLC
STOCK AWARD AGREEMENT
UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN
This Stock Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
Name of Participant:
 
Number of Stock Awards:
 
Date of Grant:
 
Vesting Dates:
Stock Awards vest ratably over the first, second, third [and fourth] anniversaries of the Date of Grant
1.Grant of Stock Awards. The Company hereby grants to the Participant the total number of restricted stock units set forth above (the “Stock Awards”), subject to all of the terms and conditions of this Award Agreement and the Plan.
2.    Form of Payment and Vesting. The Stock Award granted hereunder shall vest on the vesting dates set forth above, provided that the Participant is employed by the Company or one of its Subsidiaries on the applicable vesting date (except as set forth in Paragraph 4 of this Agreement). The Participant shall be entitled to receive one share of Company Stock in respect of each vested Stock Award as soon as practicable following the applicable vesting date, but no later than the later to occur of (a) the end of the calendar year in which the applicable vesting date occurs and (b) the fifteenth day of the third calendar month following the applicable vesting date.
3.    Restrictions. The Stock Awards granted hereunder may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of or encumbered, and shall be subject to a risk of forfeiture until any requirements or restrictions contained in this Award Agreement or in the Plan have been otherwise satisfied, terminated or expressly waived by the Company in writing.
4.    Termination of Service; Disability.

1

(a)
Termination of Service for Cause. Upon the Participant’s termination of service with the Company and its Subsidiaries for Cause all of the Participant’s unvested Stock Awards shall be forfeited as of such date.
(b)
Termination of Service on Account of Death. Upon termination of the Participant’s service with the Company and its Subsidiaries on account of death, all of the Participant’s unvested Stock Awards shall immediately vest.
(c)
Termination of Service on Account of Voluntary Retirement with Consent of Company. If the Participant voluntarily Retires with the consent of the Company, all of the Participant’s unvested Stock Awards as of the date of termination shall continue to vest in accordance with the original vesting schedule set forth in Paragraph 2 of this Award Agreement.
(d)
Disability. If the Participant incurs a Disability that also constitutes a “disability” within the meaning of Section 409A, all of the Participant’s unvested Stock Awards as of the date of such Disability shall continue to vest in accordance with the original vesting schedule set forth in Paragraph 2 of this Award Agreement regardless of any subsequent termination of service.
(e)
Termination of Service by the Company without Cause or by the Participant for Good Reason. Upon termination of the Participant’s service with the Company and its Subsidiaries by the Company or its Subsidiaries without Cause, Stock Awards that are unvested as of date of termination shall be forfeited. If a Participant is a party to an employment agreement with the Company or a Subsidiary and such employment agreement provides for benefits on a termination of employment for “Good Reason,” (x) a termination of the Participant’s employment for Good Reason shall constitute a termination without Cause for purposes of Paragraphs 4 and 5 of this Award Agreement and (y) Good Reason will also include the Participant’s termination of employment within ninety (90) days following the expiration of the employment term of the Participant’s employment agreement under circumstances that would have constituted Good Reason had such termination occurred during the employment term.
(f)
Termination of Service for any Other Reason. Unless otherwise provided in an individual agreement with the Participant, if the Participant has a termination of service for any reason other than the reasons enumerated in Subparagraphs (a) through (e) above, Stock Awards that are unvested as of date of termination of services shall be forfeited.

2

5.    Change in Control. In the event of a Change in Control:
(a)
if the Stock Awards are assumed or substituted (within the meaning of the Plan) in connection with such Change in Control, and the Participant incurs a termination of service with the Company and its Subsidiaries by the Company or its Subsidiary without Cause during the 24-month period following such Change in Control, then the Stock Awards shall vest on the date of such termination of services.
(b)
if the Stock Awards are not assumed or substituted in connection with such Change in Control, then the Stock Awards shall immediately vest upon the occurrence of the Change in Control.
6.    Change in Control Definition. Notwithstanding anything to the contrary in the Plan, for purposes of this Award Agreement, “Change in Control” means and shall be deemed to have occurred upon the first of the following events to occur:
(a)
Any “Person” (as defined below) is or becomes the “beneficial owner” (“Beneficial Owner”) within the meaning set forth in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its “Affiliates” (as defined in Rule 12b-2 promulgated under Section 12 of the Exchange Act)) representing 30% or more of the combined voting power of the Company’s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (A) of Subparagraph (c) below; or
(b)
The following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the date hereof, constitute the Board of Directors and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board of Directors or nomination for election by the Company’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date hereof or whose appointment, election or nomination for election was previously so approved or recommended; or

3

(c)
There is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation or other entity, other than (A) a merger or consolidation which results in (i) the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, at least 60% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation and (ii) the individuals who comprise the Board of Directors immediately prior thereto constituting immediately thereafter at least a majority of the board of directors of the Company, the entity surviving such merger or consolidation or, if the Company or the entity surviving such merger is then a subsidiary, the ultimate parent thereof, or (B) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities Beneficially Owned by such Person any securities acquired directly from the Company or its Affiliates) representing 30% or more of the combined voting power of the Company’s then outstanding securities; or
(d)
The shareholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets (it being conclusively presumed that any sale or disposition is a sale or disposition by the Company of all or substantially all of its assets if the consummation of the sale or disposition is contingent upon approval by the Company’s shareholders unless the Board of Directors expressly determines in writing that such approval is required solely by reason of any relationship between the Company and any other Person or an Affiliate of the Company and any other Person), other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity (A) at least 60% of the combined voting power of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale or disposition and (B) the majority of whose board of directors immediately following such sale or disposition consists of individuals who comprise the Board of Directors immediately prior thereto.

4

For purposes hereof, “Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 15(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.
Notwithstanding the foregoing, (i) a “Change in Control” shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of Company Stock immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions and (ii) to the extent required to avoid the imposition of taxes or penalties under Section 409A of the Code with respect to any Award that constitutes a deferral of compensation subject to Section 409A of the Code, no such Award shall become payable as a result of the occurrence of a Change in Control unless such Change in Control also constitutes a change in the ownership or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company under Section 409A of the Code.
For the avoidance of doubt, any one or more of the events described in subparagraphs (a) through (d) may be effected pursuant to (A) a takeover under Irish takeover rules; (B) a compromise or arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of the Republic of Ireland or (C) Chapter 2 of Part 9 of the Companies Act 2014 of the Republic of Ireland.
7.    No Shareholder Rights Prior to Vesting. The Participant shall not have any rights of a shareholder (including the right to distributions or dividends) with respect to the Stock Award until shares of Company Stock are issued pursuant to the terms of this Award Agreement.
8.    Stock Award (RSU) Agreement Subject to Plan. This Award Agreement is made pursuant to all of the provisions of the Plan, which is incorporated herein by reference, and is intended, and shall be interpreted in a manner, to comply therewith. In the event of any conflict between the provisions of this Award Agreement and the provisions of the Plan, the provisions of the Plan shall govern, except as expressly provided by Paragraph 6 of this Award Agreement.
9.    No Rights to Continuation of Service. Nothing in the Plan or this Award Agreement shall confer upon the Participant any right to continue in the employ of the Company or any Subsidiary thereof or shall interfere with or restrict the right of the Company or its

5

shareholders (or of a Subsidiary or its shareholders, as the case may be) to terminate the Participant’s service any time for any reason whatsoever, with or without Cause.
10.    Tax Withholding. The Company shall be entitled to require a cash payment by or on behalf of the Participant and/or to deduct from any Stock Awards granted hereunder or other compensation payable to the Participant any sums required by federal, state or local tax law to be withheld or to satisfy any applicable payroll deductions with respect to the vesting of, lapse of restrictions on, or payment of any Stock Award, up to the maximum statutory tax rates. A Participant who is an officer or director subject to the provisions of Section 16 of the Exchange Act as of the date of the withholding requirement may satisfy the foregoing requirement by electing to have the Company withhold from delivery shares of Company Stock in accordance with Section 12(b) of the Plan.
11.    Section 409A Compliance. The Stock Award is intended to comply with Code Section 409A to the extent subject thereto and shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Date of Grant. Notwithstanding any provision in the Plan or Award Agreement to the contrary, no payment or distribution under this Award Agreement that constitutes an item of deferred compensation under Code Section 409A and becomes payable by reason of the Participant’s termination of service with the Company and its Subsidiaries will be made to the Participant until the Participant’s termination of service constitutes a “separation from service” (as defined in Code Section 409A). For purposes of this Award Agreement, each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Code Section 409A. If a participant is a “specified employee” (as defined in Code Section 409A), then to the extent necessary to avoid the imposition of taxes under Code Section 409A, such Participant shall not be entitled to any payments upon a termination of his or her service until the earlier of: (i) the expiration of the six (6)-month period measured from the date of such Participant’s “separation from service” and (ii) the date of such Participant’s death. Upon the expiration of the applicable waiting period set forth in the preceding sentence, all payments and benefits deferred pursuant to this Paragraph 11 (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such deferral) shall be paid to such Participant in a lump sum as soon as practicable, but in no event later than sixty (60) calendar days, following such expired period, and any remaining payments due under this Award Agreement will be paid in accordance with the normal payment dates specified for them herein.
12.    Governing Law. This Award Agreement shall be governed by, interpreted under, and construed and enforced in accordance with the internal laws, and not the laws pertaining to conflicts or choices of laws, of the State of Delaware applicable to agreements made and to be performed wholly within the State of Delaware.

6

13.    Binding on Successors. The terms of this Award Agreement shall be binding upon the Participant and upon the Participant’s heirs, executors, administrators, personal representatives, transferees, assignees and successors in interest, and upon the Company and its successors and assignees, subject to the terms of the Plan.
14.    No Assignment. Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant.
15.    Necessary Acts. The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Award Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws and applicable Irish law.
16.    Entire Stock Award (RSU) Agreement. This Award Agreement and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof.
17.    Headings. Headings are used solely for the convenience of the parties and shall not be deemed to be a limitation upon or descriptive of the contents of any such Paragraph.
18.    Counterparts. This Award Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.
19.    Notices. All notices and other communications under this Award Agreement shall be in writing and shall be given by first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three days after mailing to the respective parties named below:
If to Company:
Endo International plc
c/o Endo Health Solutions Inc.
1400 Atwater Drive
Malvern, PA 19355
Attention: Treasurer
If to the Participant:
At the address on file with the Company.

7

Either party hereto may change such party’s address for notices by notice duly given pursuant hereto.
20.    Amendment. No amendment or modification hereof shall be valid unless it shall be in writing and signed by all parties hereto.
21.    Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Award Agreement. The Participant has read and understands the terms and provisions thereof, and accepts the Stock Awards subject to all the terms and conditions of the Plan and this Award Agreement.
22.    No Compensation for Loss of Rights. The Participant hereby acknowledges that under no circumstances will s/he, on ceasing to be an employee or director of the Company and its Subsidiaries, be entitled to any compensation for any loss of any right or benefit or prospective right or benefit under the Plan that s/he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever.
23.    Severability. All the terms and provisions of this Award Agreement are distinct and severable, and if any term or provision is held unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it shall to that extent be deemed not to form part of this Award Agreement, and the enforceability, legality and validity of the remainder of this Award Agreement will not be affected; if any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, the provision shall apply with whatever modification is necessary to make it valid, enforceable and legal.
24.    Data Protection. The Participant hereby acknowledges and consents to the Company and any Subsidiary sharing and exchanging his/her information held in order to administer and operate the Plan (including personal details, data relating to participation, salary, taxation and employment and sensitive personal data, e.g. data relating to physical or mental health, criminal conviction or the alleged commission of offences) (the “Information”) and providing the Company and/or the Subsidiary’s agents and/or third parties with the Information for the administration and operation of the Plan and the Participant further accepts that this may involve the Information being sent to a country outside the country in which the Participant provides services including to a country which may not have the same level of data protection laws as his/her home country. The Participant acknowledges that s/he has the right to request a list of the names and addresses of any potential recipients of the Information and to review and correct the Information by contacting his/her local human resources representative. The Participant acknowledges that the collection, processing and transfer of the Information is

8

important to Plan administration and that failure to consent to same may prohibit participation in the Plan.
25.    Additional Matters. This Award Agreement is intended to comply with the applicable laws of any country or jurisdiction where the Stock Awards are granted under the Plan, and all provisions hereof shall be construed in a manner to so comply. The following provisions apply to Participants providing services in the country noted:
Canada:
Section 4 above shall be amended to add the following language at the end thereof as a new subsection (g):
(g)    The Participant’s date of termination of service shall be the Participant’s last day of active service with the Company and its Subsidiaries and shall not include any period of statutory, contractual or common law reasonable notice or any period of deemed employment or salary continuance.
Section 10 above shall be deleted in its entirety and replaced with the following language:
10.    Tax Withholding. The Company shall be entitled to receive either a cash payment by or on behalf of the Participant or a sufficient amount of the proceeds from the sale of Company Stock to be acquired pursuant to this Award Agreement by the Participant’s delivery to the Company of an assignment of such proceeds and an authorization to the broker or selling agent to pay that amount to the Company and to effect such sale at the time of exercise or other delivery of shares of Company Stock for any sums required by federal, state or local tax law to be withheld or to satisfy any applicable payroll deductions with respect to the vesting of, lapse of restrictions on, or payment of any Stock Award.
India:
As used herein, “Participant” shall have the meaning set forth in the Plan, except the term shall not include consultants of any Subsidiary in India.
Section 4(b) shall deleted in its entirety and replaced with the following language:
Termination of Service on Account of Death. Upon termination of the Participant’s service on account of death, all of the Participant’s unvested Stock Awards shall immediately vest in his legal heirs or nominees.
Section 4(c) shall be deleted in its entirety and replaced with the following language:

9

Termination of Service on Account of Voluntary Retirement with Consent of Company. If the Participant voluntarily Retires with the consent of the Company, all of the Participant’s unvested Stock Awards shall vest on the date of termination of service.
Section 4(d) shall be deleted in its entirety and replaced with the following language:
Disability. If the Participant incurs a Disability that also constitutes a “disability” within the meaning of Section 409A, all of the Participant’s unvested Stock Awards as of the date of such Disability shall continue to vest in accordance with the original vesting schedule set forth in Paragraph 2 of this Award Agreement regardless of any subsequent termination of service, provided such Disability does not result in termination of service. In the event of termination of service, the unvested Stock Award shall vest in him on the date of termination.
Section 10 shall be deleted in its entirety and replaced with the following language:
Tax Withholding. The Subsidiary under whose payroll the Participant is registered shall have the right to deduct or withhold from the Stock Award or payroll of the Participant an amount sufficient to satisfy income taxes required by law to be withheld with respect to the vesting of, lapse of restrictions on, or payment of any Stock Award or to satisfy any applicable payroll deductions. The obligations of the Company under this Award Agreement will be conditioned on such arrangement and the Company or such Subsidiary will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the Participant. A Participant who is an officer or director subject to the provisions of Section 16 of the Exchange Act as of the date of the withholding requirement may satisfy the foregoing requirement by electing to have the Subsidiary under whose payroll the Participant is registered withhold from delivery shares of Company Stock in accordance with Section 12(b) of the Plan.
Section 13 shall be amended to delete the term “transferees”.
Section 14 shall be deleted in its entirety and replaced with the following language:
No Assignment. Notwithstanding anything to the contrary in this Award Agreement, but subject to the assignment of the Stock Award upon death of the Participant, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant.
Section 15 shall be deleted in its entirety and replaced with the following language:
Necessary Acts. The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of

10

this Award Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws and applicable Indian law. The rights and interests of the Participant under the Award Agreement shall be subject to compliance under the Foreign Exchange Management Act, 1999 and the related rules thereto.
Ireland:
Section 4(c) above shall be deleted and be of no force and effect.
Section 13 above shall be amended to delete the words “transferees, assignees” therefrom.
Section 14 above shall be deleted in its entirety and replaced with the following language:
No Assignment or Transfer. Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant. Neither this Award Agreement nor any rights granted herein shall be transferable by the Participant in any circumstances, except on the death of the Participant.
Luxembourg:
Section 4(c) above shall be deleted in its entirety and replaced with the following language:
Termination of Service on Account of Retirement. If the Participant voluntarily retires according to Luxembourg employment law, all of the Participant’s then unvested Stock Awards shall vest on the Participant’s termination date.
Section 4(d) above shall be amended to (i) delete the phrase “that also constitutes a ‘disability’ within the meaning of Section 409A of the Code” therefrom and (ii) add the following language at the end thereof:
As used herein, “Disability” shall mean either (i) the Participant’s inability to, solely because of injury or physical or mental illness, perform the material duties of his or her regular occupation in a situation where the Participant receives paid sickness, incapacity or invalidity benefits from any of the Luxembourg competent authorities for a period that lasts or can reasonably be expected to last for a continuous period of 6 months, or (ii) the Participant’s reclassement by the competent commission following an irrevocable decision from said commission.
Section 4 above shall be amended to add the following language at the end thereof as a new sub-section (g):
It is understood that the Participant’s termination of service for any reason shall take place in accordance with applicable Luxembourg employment law rules.

11

Section 10 above shall be amended to add the following language at the end thereof:
For Participants subject to Luxembourg employment law, the Company shall comply with Circular L.I.R. n°104/2 dated 29 November 2017 and issued by the Luxembourg Tax Administration to the extent subject thereto and shall be interpreted in accordance with its provisions and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Date of Grant.
Section 13 above shall be amended to delete the word “transferees” therefrom.
Section 14 above shall be deleted in its entirety and replaced with the following language:
No Assignment or Transfer. Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant. Neither this Award Agreement nor any rights granted herein shall be transferable by the Participant in any circumstances, except on the death of the Participant.
Section 24 above shall be amended to add the following language at the end thereof:
, it being understood that for the purposes hereunder any Information on the Participant shall be processed in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, as well as any applicable local laws.
United Kingdom:
As used herein, “Cause” shall have the meaning set forth in the Plan and, with respect to any Participant who is a party to an employment agreement with the Company, the definition of “Cause” shall include any circumstances in which the Company may terminate the Participant’s employment agreement without notice in accordance with its terms.
As used herein, “Disability” shall mean the Participant’s inability to, solely because of injury or physical or mental illness: (i) perform the material duties of his or her regular occupation and (ii) earn 80% or more of his or her base salary or wages in respect of his or her regular occupation, for a period that lasts or can reasonably be expected to last for a continuous period of 12 months.
Section 4(c) above shall be deleted and be of no force and effect.
Section 10 above shall be deleted in its entirety and replaced with the following:

12

Tax Liabilities. The Participant irrevocably agrees (A) to pay, or enter into arrangements to the satisfaction of the Company to pay, to the Company, the Participant’s employer or former employer (as appropriate) the amount of any Tax Liability, (B) that the Company, the Participant’s employer or former employer (as appropriate) may, if it so elects by written notice to the Participant, recover the whole or any part of any Employer NICs from the Participant, (C) that the Participant shall, promptly upon being requested to do so by the Company, the Participant’s employer or former employer (as appropriate), elect (using a form approved by HM Revenue & Customs) that the whole or any part of the liability for Employer NICs shall be transferred to the Participant; (D) to enter into a joint election, under section 431(1) or 431(2) of the Income Tax (Earnings & Pensions) Act 2003 (“ITEPA”), in respect of the Company Stock delivered pursuant to a Stock Award, if required to do so by the Company, the Participant’s employer or former employer, before, on or within 14 days after any date of delivery of such Company Stock. For the purposes of this section the following capitalized terms shall have the meanings set out below:
“Employer NICs”: any secondary class 1 (employer) national insurance contributions that the Company or any employer (or former employer) of the Participant is liable to pay as a result of any Taxable Event (or which that person would be liable to pay in the absence of an election of the type referred to in (C) above) and that may be lawfully recovered from the Participant.
“Taxable Event”: any event or circumstance that gives rise to a liability for the Participant to pay income tax and national insurance contributions or either of them in respect of: (a) the Stock Award, including its assignment or surrender for consideration, or the receipt of any benefit in connection with it; (b) any shares (or other securities or assets): (i) earmarked or held to satisfy the Stock Award; (ii) acquired pursuant to the Stock Award; or (iv) acquired in consideration of the assignment or surrender of the Stock Award; (c) any securities (or other assets) acquired or earmarked as a result of holding shares (or other securities or assets) mentioned in (b); or (d) any amount due in respect of assets within (a) to (c) above and not made good by the Participant within the time limit specified in section 222 ITEPA.
“Tax Liability”: the total of (a) any income tax and primary class 1 (employee) national insurance contributions that any employer (or former employer) of the Participant is liable to account for (or reasonably believes it is liable to account for) as a result of any Taxable Event; and (b) any Employer NICs that any employer (or former employer) of the Participant is liable to pay (or reasonably believes it is liable to pay) as a result of any Taxable Event and that can be recovered lawfully from the Participant.
Section 22 shall be replaced by the following provision:

13

Nothing contained in the Plan or this Stock Award shall form part of the Participant’s contract of employment. The Participant hereby acknowledges that under no circumstances will s/he, on ceasing to be an employee or director of or otherwise engaged by the Company or any of its Subsidiaries for any reason (including as a result of a repudiatory breach of contract by the Company or any of its Subsidiaries), be entitled to any compensation for any loss of any right or benefit or prospective right or benefit under the Plan that s/he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever. By signing this Stock Award the Participant shall be deemed irrevocably to have waived any such entitlement.

14

IN WITNESS WHEREOF, the parties hereto have executed this Award Agreement as of the date set forth above.
ENDO INTERNATIONAL PLC
By:         
Name: Paul V. Campanelli
Title: President & Chief Executive Officer
PARTICIPANT
Signature:         
Print Name:     


15
 EX-10.3 4 ex103formofperformanceawar.htm EXHIBIT 10.3 FORM OF PERFORMANCE AWARD AGREEMENT Ex 10.3 Form of Performance Award Agreement
Exhibit 10.3

Grant No.
ENDO INTERNATIONAL PLC
PERFORMANCE AWARD AGREEMENT
UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN
This Performance Award Agreement (this “Award Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
Name of Participant:
 
Total Target Performance Award (Total Number of Restricted Stock Units Underlying the Target Performance Award):
 
Date of Grant:
 
Performance Period for the TSR Performance Award:
The period beginning on the Date of Grant and ending on the third anniversary of the Date of Grant.
Performance Period for the FCF Performance Award:
Each of three successive annual periods, the first of which begins on the first day of the Company’s fiscal year that includes the Date of Grant.

1.     Grant of Performance Awards. The Company hereby grants to the Participant the total number of restricted stock units set forth above, fifty percent (50%) of which shall be subject to Total Shareholder Return performance targets (the “TSR Performance Award”) and the other fifty percent (50%) of which shall be subject to Free Cash Flow performance targets (the “FCF Performance Award,” and together with the TSR Performance Award, the “Performance Award”). The Performance Award shall be subject to all of the terms and conditions of this Award Agreement and the Plan.
2.     Form of Payment and Vesting.
(a)    The TSR Performance Award shall vest on the last day of the TSR Performance Period (the “TSR Vesting Date”) in a number of shares of Company Stock equal to the multiple of the TSR Performance Award achieved, as determined by the Committee (or its designee) in accordance with the performance conditions set forth in Exhibit A hereto (“Exhibit A”), provided that the Participant is providing service to the Company or one of its Subsidiaries on the TSR Vesting Date (other than as is provided by Paragraph 4 of this Award Agreement).

1


Any shares of Company Stock earned in accordance with the prior sentence shall be delivered to the Participant as soon as practicable following the TSR Vesting Date, but no later than the later to occur of (i) the end of the calendar year in which the TSR Vesting Date occurs and (ii) the fifteenth day of the third calendar month following the TSR Vesting Date. Any portion of the TSR Performance Award that could have been earned in accordance with the provisions of Exhibit A that is not earned as of the TSR Vesting Date, as determined by the Committee (or its designee), shall be immediately forfeited.
(b)    During each FCF Performance Period, one third (1/3rd) of the number of restricted stock units underlying the target FCF Performance Award shall be eligible to be earned based on achievement of the performance conditions set forth in Exhibit B hereto (as may be supplemented from time to time) (“Exhibit B”). The FCF Performance Award shall vest on the third anniversary of the Date of Grant of the FCF Performance Award (the “FCF Vesting Date”) in a number of shares of Company Stock equal to the sum of the number of shares of Company Stock so earned for each of the three FCF Performance Periods, as determined by the Committee (or its designee), provided that the Participant is providing service to the Company or one of its Subsidiaries on the FCF Vesting Date (other than as is provided by Paragraph 4 of this Award Agreement). Any shares of Company Stock earned and vested in accordance with the foregoing shall be delivered to the Participant as soon as practicable following the FCF Vesting Date, but no later than the fifteenth day of the third calendar month following the calendar year in which the FCF Vesting Date occurs. For each FCF Performance Period, any portion of the FCF Performance Award that could have been earned in accordance with the provisions of Exhibit B that is not earned as of the last day of the applicable FCF Performance Period, as determined by the Committee (or its designee), shall be immediately forfeited.
3.     Restrictions. The Performance Award granted hereunder may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of or encumbered, and shall be subject to a risk of forfeiture until any requirements or restrictions contained in this Award Agreement or in the Plan have been otherwise satisfied, terminated or expressly waived by the Company in writing.
4.     Termination of Service; Disability.
(a)    Termination of Service for Cause. Upon the Participant’s termination of service with the Company and its Subsidiaries for Cause prior to the TSR Vesting Date or the FCF Vesting Date, the unvested portion, if any, of the Participant’s Performance Award shall be forfeited as of the date of such termination of service.
(b)    Termination of Service on Account of Death. Upon termination of the Participant’s service with the Company and its Subsidiaries on account of death prior to the TSR Vesting Date or the FCF Vesting Date, the unvested portion, if any, of the Participant’s Performance Award shall vest as of the date of such termination of service at target levels (as set forth on Exhibit A and Exhibit B, as applicable). The vested Performance Award (determined in accordance with the foregoing and including any portion of the FCF Performance Award that was earned prior to the Participant’s death in accordance with Exhibit B for any completed FCF Performance Period) shall be settled in shares of Company Stock for the benefit of the

2


Participant’s estate no later than the later to occur of (i) the end of the calendar year in which the Participant’s death occurs or (ii) the fifteenth day of the third calendar month following the Participant’s death.
(c)    Termination of Service on Account of Voluntary Retirement with Consent of Company. If the Participant voluntarily Retires with the consent of the Company prior to the TSR Vesting Date or the FCF Vesting Date, the Participant’s Performance Award shall continue to be eligible to vest in accordance with the performance-based vesting conditions set forth on Exhibit A and Exhibit B, as applicable, regardless of such termination of service.
(d)    Disability. If the Participant incurs a Disability that also constitutes a “disability” within the meaning of Section 409A of the Code prior to the TSR Vesting Date or the FCF Vesting Date, the Participant’s Performance Award shall continue to be eligible to vest in accordance with the performance-based vesting conditions set forth on Exhibit A and Exhibit B, as applicable, regardless of any subsequent termination of service.
(e)    Termination of Service by the Company without Cause or by the Participant for Good Reason.
(i)    Upon termination of the Participant’s service with the Company and its Subsidiaries by the Company or its Subsidiaries without Cause prior to the TSR Vesting Date, a portion of the Participant’s TSR Performance Award shall vest based upon achievement of the TSR Performance Criteria (as defined in Exhibit A) measured as of the date of the Participant’s termination of service, multiplied by a fraction, the numerator of which is the number of full months of the Participant’s service during the TSR Performance Period and the denominator of which is the total number of months in the TSR Performance Period. The vested portion of the TSR Performance Award shall be settled in shares of Company Stock as soon as practicable following the Participant’s termination of service, but no later than the later to occur of (A) the end of the calendar year in which such termination occurs or (B) the fifteenth day of the third calendar month following such termination. Notwithstanding the foregoing, the Committee (or such individual or individuals authorized by the Committee) may exercise discretion to determine payout achievement. Any portion of the TSR Performance Award that could have been earned in accordance with the provisions of this Section 4(e)(i) that is not earned as of the date of the Participant’s termination of service shall be immediately forfeited on the date of the Participant’s termination of service.
(ii)    Upon termination of the Participant’s service with the Company and its Subsidiaries by the Company or its Subsidiaries without Cause prior to the FCF Vesting Date but after the Company’s first approval of estimated Free Cash Flow for the FCF Performance Period in which such termination of service occurs, the Participant’s FCF Performance Award in respect of such FCF Performance Period shall vest based upon achievement of the most recently approved estimate of Free Cash Flow for the applicable FCF Performance Period, multiplied by a fraction, the numerator of which is the number of full months of Participant’s service during the current FCF Performance Period and the denominator of which is twelve (12). If such termination occurs prior to the FCF Vesting Date and prior to the Company’s first approval of estimated Free Cash Flow for the FCF Performance Period in which

3


such termination of service occurs, then the Participant shall not vest in any portion of the FCF Performance Award in respect of the FCF Performance Period in which such termination of service occurs. The vested portion of the FCF Performance Award determined in accordance with the foregoing (plus any portion of the Participant’s FCF Performance Award for which the FCF Performance Criteria (as defined in Exhibit B) has been achieved in respect of any previously completed FCF Performance Period) shall be settled in shares of Company Stock immediately following such termination. Notwithstanding the foregoing the Committee (or such individual or individuals authorized by the Committee) may exercise discretion to determine payout achievement. Any portion of the FCF Performance Award that could have been earned in accordance with the provisions of this Section 4(e)(ii) that is not earned as of the date of the Participant’s termination of service shall be immediately forfeited on the date of the Participant’s termination of service.
(iii)    If a Participant is a party to an employment agreement with the Company or a Subsidiary and such employment agreement provides for benefits on a termination of employment for “Good Reason,” (x) a termination of the Participant’s employment for Good Reason shall constitute a termination without Cause for purposes of Sections 4 and 5 and (y) Good Reason will also include the Participant’s termination of employment within ninety (90) days following the expiration of the employment term of the Participant’s employment agreement under circumstances that would have constituted Good Reason had such termination occurred during the employment term.
(f)    Termination of Service for any Other Reason. Unless otherwise provided in an individual agreement with the Participant, if the Participant has a termination of service with the Company and its Subsidiaries prior to the TSR Vesting Date or the FCF Vesting Date for any reason other than the reasons enumerated in Subparagraphs (a) through (e) above, the Participant’s Performance Award as of the date of termination of service shall be forfeited.
5.     Change in Control. Notwithstanding anything to the contrary in the Plan, in the event of a Change in Control prior to the TSR Vesting Date or the FCF Vesting Date, as applicable, the provisions of this Section 5 shall apply.
(a)    if the entire Performance Award is assumed or substituted (within the meaning of the Plan) in connection with such Change in Control, and the Participant incurs a termination of service from the Company and its Subsidiaries by the Company or its Subsidiary without Cause during the 24-month period following such Change in Control, then the restrictions, deferral limitations, payment conditions, and forfeiture conditions applicable to any portion of the Performance Award shall lapse and:
(i)    the TSR Performance Award shall be settled in shares of Company Stock as soon as practicable following the Participant’s termination of service, but no later than the later to occur of the end of the calendar year in which such termination occurs or the fifteenth day of the third calendar month following such termination, based on the greater of (y) actual achievement of TSR Performance Criteria or (z) target achievement of the TSR Performance Criteria, in either case measured as of the date of such termination, and

4


(ii)    the FCF Performance Award shall be settled as soon as practicable following the Participant’s termination of service, but no later than the later to occur of the end of the calendar year in which such termination occurs or the fifteenth day of the third calendar month following such termination, with the number of shares equal to the sum of (y) the number of shares of Company Stock underlying any portion of the Participant’s FCF Performance Award for which the FCF Performance Criteria has been achieved in respect of any previously completed FCF Performance Period and (z) the number of shares of Company Stock subject to any portion of the FCF Performance Award for any FCF Performance Period not completed multiplied by one (1) or, if greater, a multiple determined based upon achievement of the most recently approved estimate of Free Cash Flow.
(b)    if any portion of the Performance Award is not assumed or substituted in connection with such Change in Control, then the restrictions, deferral limitations, payment conditions, and forfeiture conditions applicable to any portion of the Performance Award shall lapse and:
(i)    the TSR Performance Award shall be settled in shares of Company Stock immediately prior to the Change in Control based on the greater of (1) actual achievement of TSR Performance Criteria or (2) target achievement of the TSR Performance Criteria, in either case measured as of the date of the Change in Control, and
(ii)    the FCF Performance Award shall be settled immediately prior to the Change in Control, with the number of shares equal to the sum of (y) the number of shares of Company Stock underlying any portion of the Participant’s FCF Performance Award for which the FCF Performance Criteria has been achieved in respect of any previously completed FCF Performance Period and (z) the number of shares of Company Stock subject to any portion of the FCF Performance Award for any FCF Performance Period not completed multiplied by one (1) or, if greater, a multiple determined based upon achievement of the most recently approved estimate of Free Cash Flow.
(c)    Any portion of the Performance Award that could have been earned in accordance with Section 5(a) or Section 5(b) that is not earned shall be immediately forfeited on the date of termination of service or the date the Change in Control occurs, as applicable.
6.     Change in Control Definition. Notwithstanding anything to the contrary in the Plan, for purposes of this Award Agreement, “Change in Control” means and shall be deemed to have occurred upon the first of the following events to occur:
(a)    Any “Person” (as defined below) is or becomes the “beneficial owner” (“Beneficial Owner”) within the meaning set forth in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its “Affiliates” (as defined in Rule 12b-2 promulgated under Section 12 of the Exchange Act)) representing 30% or more of the combined voting power of the Company’s then outstanding securities, excluding any Person who becomes such a

5


Beneficial Owner in connection with a transaction described in clause (A) of Subparagraph (c) below; or
(b)    The following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the date hereof, constitute the Board of Directors and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board of Directors or nomination for election by the Company’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date hereof or whose appointment, election or nomination for election was previously so approved or recommended; or
(c)    There is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation or other entity, other than (A) a merger or consolidation which results in (i) the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, at least 60% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation and (ii) the individuals who comprise the Board of Directors immediately prior thereto constituting immediately thereafter at least a majority of the board of directors of the Company, the entity surviving such merger or consolidation or, if the Company or the entity surviving such merger is then a subsidiary, the ultimate parent thereof, or (B) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities Beneficially Owned by such Person any securities acquired directly from the Company or its Affiliates) representing 30% or more of the combined voting power of the Company’s then outstanding securities; or
(d)    The shareholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets (it being conclusively presumed that any sale or disposition is a sale or disposition by the Company of all or substantially all of its assets if the consummation of the sale or disposition is contingent upon approval by the Company’s shareholders unless the Board of Directors expressly determines in writing that such approval is required solely by reason of any relationship between the Company and any other Person or an Affiliate of the Company and any other Person), other than a sale or disposition by the Company of all or substantially all of the Company’s assets to an entity (A) at least 60% of the combined voting power of the voting securities of which are owned by shareholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale or disposition and (B) the majority of whose board of

6


directors immediately following such sale or disposition consists of individuals who comprise the Board of Directors immediately prior thereto.
For purposes hereof, “Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 15(d) thereof, except that such term shall not include (i) the Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.
Notwithstanding the foregoing, (i) a “Change in Control” shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of Company Stock immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions and (ii) to the extent required to avoid the imposition of taxes or penalties under Section 409A of the Code with respect to any Award that constitutes a deferral of compensation subject to Section 409A of the Code, no such Award shall become payable as a result of the occurrence of a Change in Control unless such Change in Control also constitutes a change in the ownership or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company under Section 409A of the Code.
For the avoidance of doubt, any one or more of the events described in subparagraphs (a) through (d) may be effected pursuant to (A) a takeover under Irish takeover rules; (B) a compromise or arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of the Republic of Ireland or (C) Chapter 2 of Part 9 of the Companies Act 2014 of the Republic of Ireland.
7.     No Shareholder Rights Prior to Delivery. The Participant shall not have any rights of a shareholder (including the right to distributions or dividends) with respect to the Performance Award until shares of Company Stock are issued pursuant to the terms of this Award Agreement.
8.     Performance Award Agreement Subject to Plan. This Award Agreement is made pursuant to all of the provisions of the Plan, which is incorporated herein by reference, and is intended, and shall be interpreted, in a manner to comply therewith. In the event of any conflict between the provisions of this Award Agreement and the provisions of the Plan, the provisions of the Plan shall govern, except as expressly provided by Sections 5 and 6 of this Award Agreement.
9.     No Rights to Continuation of Service. Nothing in the Plan or this Award Agreement shall confer upon the Participant any right to continue in the employ of the Company or any Subsidiary thereof or shall interfere with or restrict the right of the Company or its

7


shareholders (or of a Subsidiary or its shareholders, as the case may be) to terminate the Participant’s service at any time for any reason whatsoever, with or without Cause.
10.    Tax Withholding. The Company shall be entitled to require a cash payment by or on behalf of the Participant and/or to deduct from the Performance Award granted hereunder or other compensation payable to the Participant any sums required by federal, state or local tax law to be withheld or to satisfy any applicable payroll deductions with respect to the vesting of, lapse of restrictions on, or payment of the Performance Award, up to the maximum statutory tax rates. A Participant who is an officer or director subject to the provisions of Section 16 of the Exchange Act as of the date of the withholding requirement may satisfy the foregoing requirement by electing to have the Company withhold from delivery shares of Company Stock in accordance with Section 12(b) of the Plan.
11.    Section 409A Compliance. The Performance Award is intended to comply with Code Section 409A to the extent subject thereto and shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Date of Grant. Notwithstanding any provision in the Plan or Award Agreement to the contrary, no payment or distribution under this Award Agreement that constitutes an item of deferred compensation under Code Section 409A and becomes payable by reason of the Participant’s termination of service with the Company and its Subsidiaries will be made to the Participant until the Participant’s termination of service constitutes a “separation from service” (as defined in Code Section 409A). For purposes of this Award Agreement, each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Code Section 409A. If a participant is a “specified employee” (as defined in Code Section 409A), then to the extent necessary to avoid the imposition of taxes under Code Section 409A, such Participant shall not be entitled to any payments upon a termination of his or her service until the earlier of: (i) the expiration of the six (6)-month period measured from the date of such Participant’s “separation from service” and (ii) the date of such Participant’s death. Upon the expiration of the applicable waiting period set forth in the preceding sentence, all payments and benefits deferred pursuant to this Paragraph 11 (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such deferral) shall be paid to such Participant in a lump sum as soon as practicable, but in no event later than sixty (60) calendar days, following such expired period, and any remaining payments due under this Award Agreement will be paid in accordance with the normal payment dates specified for them herein.
12.    Governing Law. This Award Agreement shall be governed by, interpreted under, and construed and enforced in accordance with the internal laws, and not the laws pertaining to conflicts or choice of laws, of the State of Delaware applicable to agreements made and to be performed wholly within the State of Delaware.
13.    Binding on Successors. The terms of this Award Agreement shall be binding upon the Participant and upon the Participant’s heirs, executors, administrators, personal representatives, transferees, assignees and successors in interest, and upon the Company and its successors and assignees, subject to the terms of the Plan.

8


14.    No Assignment. Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant.
15.    Necessary Acts. The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Award Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws and applicable Irish law.
16.    Entire Performance Award Agreement. This Award Agreement (including Exhibits A and B and Annex A) and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof.
17.    Headings. Headings are used solely for the convenience of the parties and shall not be deemed to be a limitation upon or descriptive of the contents of any such Paragraph.
18.    Counterparts. This Award Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.
19.    Notices. All notices and other communications under this Award Agreement shall be in writing and shall be given by first class mail, certified or registered with return receipt requested, and shall be deemed to have been duly given three days after mailing to the respective parties named below:
If to Company:
Endo International plc
c/o Endo Health Solutions Inc.
1400 Atwater Drive
Malvern, PA 19355
Attention: Treasurer
If to the Participant:
At the address on file with the Company.
Either party hereto may change such party’s address for notices by notice duly given pursuant hereto.
20.    Amendment. No amendment or modification hereof shall be valid unless it shall be in writing and signed by all parties hereto.
21.    Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Award Agreement. The Participant has read and understands the terms and provisions thereof, and accepts the Performance Award subject to all the terms and conditions of the Plan and this Award Agreement.

9


22.    No Compensation for Loss of Rights. The Participant hereby acknowledges that under no circumstances will s/he, on ceasing to be an employee or director of the Company and its Subsidiaries, be entitled to any compensation for any loss of any right or benefit or prospective right or benefit under the Plan that s/he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever.
23.    Severability. All the terms and provisions of this Award Agreement are distinct and severable, and if any term or provision is held unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it shall to that extent be deemed not to form part of this Award Agreement, and the enforceability, legality and validity of the remainder of this Award Agreement will not be affected; if any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, the provision shall apply with whatever modification is necessary to make it valid, enforceable and legal.
24.    Data Protection. The Participant hereby acknowledges and consents to the Company and any Subsidiary sharing and exchanging his/her information held in order to administer and operate the Plan (including personal details, data relating to participation, salary, taxation and employment and sensitive personal data, e.g. data relating to physical or mental health, criminal conviction or the alleged commission of offences) (the “Information”) and providing the Company and/or the Subsidiary’s agents and/or third parties with the Information for the administration and operation of the Plan and the Participant further accepts that this may involve the Information being sent to a country outside the country in which the Participant provides service including to a country which may not have the same level of data protection laws as his/her home country. The Participant acknowledges that s/he has the right to request a list of the names and addresses of any potential recipients of the Information and to review and correct the Information by contacting his/her local human resources representative. The Participant acknowledges that the collection, processing and transfer of the Information is important to Plan administration and that failure to consent to same may prohibit participation in the Plan.
25.    Additional Matters. This Award Agreement is intended to comply with the applicable laws of any country or jurisdiction where the Performance Award is granted under the Plan, and all provisions hereof shall be construed in a manner to so comply. The following provisions apply to Participants providing service in the country noted:
Canada:
Section 4 above shall be amended to add the following language at the end thereof as a new sub-section (g):
(g) The Participant’s date of termination of service shall be the Participant’s last day of active service with the Company and its Subsidiaries and shall not include any period of statutory, contractual or common law reasonable notice or any period of deemed employment or salary continuance.

10


Section 10 above shall be deleted in its entirety and replaced with the following language:
The Company shall be entitled to receive either a cash payment by or on behalf of the Participant or a sufficient amount of the proceeds from the sale of Company Stock to be acquired pursuant to this Award Agreement by the Participant’s delivery to the Company of an assignment of such proceeds and an authorization to the broker or selling agent to pay that amount to the Company and to effect such sale at the time of exercise or other delivery of shares of Company Stock for any sums required by federal, state or local tax law to be withheld or to satisfy any applicable payroll deductions with respect to the vesting of, lapse of restrictions on, or payment of any Performance Award.
India:
As used herein, “Participant” shall have the meaning set forth in the Plan, except the term shall not include consultants of any Subsidiary in India.
Section 4(b) shall be deleted in its entirety and replaced with the following language:
Termination of Service on Account of Death. Upon termination of the Participant’s service on account of death prior to the either the TSR Vesting Date or the FCF Vesting Date, the Participant’s Performance Award shall immediately vest in his legal heirs or nominees, subject to fulfilment of the performance conditions specified in Exhibits A and B and shall be settled in shares of Company Stock for the benefit of the Participant’s estate no later than the later of the end of the calendar year in which the Participant’s death occurs or the fifteenth day of the third calendar month following the Participant’s death.
Section 4(c) shall be deleted in its entirety and replaced with the following language:
Termination of Service on Account of Voluntary Retirement with Consent of Company. If the Participant voluntarily Retires with the consent of the Company, the unvested portion, if any, of the Participant’s Performance Award as of the date of termination shall stand vested on the date of termination of service, subject to the fulfilment of the performance conditions specified in Exhibits A and B.
Section 4(d) shall be deleted in its entirety and replaced with the following language:
Disability. If the Participant incurs a Disability that also constitutes a “disability” within the meaning of Section 409A, the unvested portion, if any, of the Participant’s Performance Award as of the date of such Disability shall continue to be eligible to vest in accordance with the performance-based vesting conditions set forth on Exhibits A and B regardless of any subsequent termination of service, provided such Disability does not result in termination of service. In the event of termination of service, the unvested portion, if any, of the Performance Award shall vest in him on the date of termination.

11


Section 10 shall be deleted in its entirety and replaced with the following language:
Tax Withholding. The Subsidiary under whose payroll the Participant is registered shall have the right to deduct or withhold from the Performance Award or payroll of the Participant an amount sufficient to satisfy income taxes required by law to be withheld with respect to the vesting of, lapse of restrictions on, or payment of the Performance Award or to satisfy any applicable payroll deductions. The obligations of the Company under this Award Agreement will be conditioned on such arrangement and the Company or such Subsidiary will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the Participant. A Participant who is an officer or director subject to the provisions of Section 16 of the Exchange Act as of the date of the withholding requirement may satisfy the foregoing requirement by electing to have the Subsidiary under whose payroll the Participant is registered withhold from delivery shares of Company Stock in accordance with Section 12(b) of the Plan.
Section 13 shall be amended to delete the term “transferees”.
Section 14 shall be deleted in its entirety and replaced with the following language:
No Assignment. Notwithstanding anything to the contrary in this Award Agreement, but subject to the assignment of the Performance Award upon death of the Participant, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant.
Section 15 shall be deleted in its entirety and replaced with the following language:
Necessary Acts. The Participant hereby agrees to perform all acts, and to execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Award Agreement, including but not limited to all acts and documents related to compliance with federal and/or state securities and/or tax laws and applicable Indian law. The rights and interests of the Participant under the Award Agreement shall be subject to compliance under the Foreign Exchange Management Act, 1999 and the related rules thereto.
Ireland:
Section 4(c) above shall be deleted and be of no force and effect.
Section 13 above shall be amended to delete the words “transferees, assignees” therefrom.
Section 14 above shall be deleted in its entirety and replaced with the following language:
No Assignment or Transfer. Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant. Neither this Award Agreement nor any

12


rights granted herein shall be transferable by the Participant in any circumstances, except on the death of the Participant.
Luxembourg:
Section 4(c) above shall be deleted in its entirety and replaced with the following language:
Termination of Service on Account of Retirement. If the Participant voluntarily retires according to Luxembourg employment law prior to the TSR Vesting Date or the FCF Vesting Date, any unvested portion of the Participant’s Performance Award as of the Participant’s termination date shall vest on that date and be eligible to be settled subject to the satisfaction of the performance conditions specified in Exhibits A and B, determined at a time and manner as is determined for employees generally, disregarding such termination of service.
Section 4(d) above shall be amended to (i) delete the phrase “that also constitutes a ‘disability’ within the meaning of Section 409A of the Code” therefrom and (ii) add the following language at the end thereof:
As used herein, “Disability” shall mean either (i) the Participant’s inability to, solely because of injury or physical or mental illness, perform the material duties of his or her regular occupation in a situation where the Participant receives paid sickness, incapacity or invalidity benefits from any of the Luxembourg competent authorities for a period that lasts or can reasonably be expected to last for a continuous period of 6 months, or (ii) the Participant’s reclassement by the competent commission following an irrevocable decision from said commission.
Section 4(e)(iii) above shall be deleted in its entirety and be of no force and effect.
Section 4 above shall be amended to add the following language at the end thereof as a new sub-section (g):
It is understood that the Participant’s termination of service for any reason shall take place in accordance with applicable Luxembourg employment law rules.
Section 10 above shall be amended to add the following language at the end thereof:
For Participants subject to Luxembourg employment law, the Company shall comply with Circular L.I.R. n°104/2 dated 29 November 2017 and issued by the Luxembourg Tax Administration to the extent subject thereto and shall be interpreted in accordance with its provisions and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Date of Grant.
Section 13 above shall be amended to delete the word “transferees” therefrom.
Section 14 above shall be deleted in its entirety and replaced with the following language:

13


No Assignment or Transfer. Notwithstanding anything to the contrary in this Award Agreement, neither this Award Agreement nor any rights granted herein shall be assignable by the Participant. Neither this Award Agreement nor any rights granted herein shall be transferable by the Participant in any circumstances, except on the death of the Participant.
Section 24 above shall be amended to add the following language at the end thereof:
, it being understood that for the purposes hereunder any Information on the Participant shall be processed in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, as well as any applicable local laws.
United Kingdom:
As used herein, “Cause” shall have the meaning set forth in the Plan and, with respect to any Participant who is a party to an employment agreement with the Company, the definition of “Cause” shall include any circumstances in which the Company may terminate the Participant’s employment agreement without notice in accordance with its terms.
As used herein, “Disability” shall mean the Participant’s inability to, solely because of injury or physical or mental illness: (i) perform the material duties of his or her regular occupation and (ii) earn 80% or more of his or her base salary or wages in respect of his or her regular occupation, for a period that lasts or can reasonably be expected to last for a continuous period of 12 months.
Section 4(c) above shall be deleted and be of no force and effect.
Section 10 above shall be deleted in its entirety and replaced with the following:
Tax Liabilities. The Participant irrevocably agrees (A) to pay, or enter into arrangements to the satisfaction of the Company to pay, to the Company, the Participant’s employer or former employer (as appropriate) the amount of any Tax Liability, (B) that the Company, the Participant’s employer or former employer (as appropriate) may, if it so elects by written notice to the Participant, recover the whole or any part of any Employer NICs from the Participant, (C) that the Participant shall, promptly upon being requested to do so by the Company, the Participant’s employer or former employer (as appropriate), elect (using a form approved by HM Revenue & Customs) that the whole or any part of the liability for Employer NICs shall be transferred to the Participant; (D) to enter into a joint election, under section 431(1) or 431(2) of the Income Tax (Earnings & Pensions) Act 2003 (“ITEPA”), in respect of the Company Stock delivered pursuant to a Performance Award, if required to do so by the Company, the Participant’s employer or former employer, before, on or within 14 days after any date of delivery of such Company Stock. For the purposes of this section the following capitalized terms shall have the meanings set out below:

14


“Employer NICs”: any secondary class 1 (employer) national insurance contributions that the Company or any employer (or former employer) of the Participant is liable to pay as a result of any Taxable Event (or which that person would be liable to pay in the absence of an election of the type referred to in (C) above) and that may be lawfully recovered from the Participant.
“Taxable Event”: any event or circumstance that gives rise to a liability for the Participant to pay income tax and national insurance contributions or either of them in respect of: (a) the Performance Award, including its assignment or surrender for consideration, or the receipt of any benefit in connection with it; (b) any shares (or other securities or assets): (i) earmarked or held to satisfy the Performance Award; (ii) acquired pursuant to the Performance Award; or (iv) acquired in consideration of the assignment or surrender of the Performance Award; (c) any securities (or other assets) acquired or earmarked as a result of holding shares (or other securities or assets) mentioned in (b); or (d) any amount due in respect of assets within (a) to (c) above and not made good by the Participant within the time limit specified in section 222 ITEPA.
“Tax Liability”: the total of (a) any income tax and primary class 1 (employee) national insurance contributions that any employer (or former employer) of the Participant is liable to account for (or reasonably believes it is liable to account for) as a result of any Taxable Event; and (b) any Employer NICs that any employer (or former employer) of the Participant is liable to pay (or reasonably believes it is liable to pay) as a result of any Taxable Event and that can be recovered lawfully from the Participant.
Section 22 shall be replaced by the following provision:
Nothing contained in the Plan or this Performance Award shall form part of the Participant’s contract of employment. The Participant hereby acknowledges that under no circumstances will s/he, on ceasing to be an employee or director of or otherwise engaged by the Company or any of its Subsidiaries for any reason (including as a result of a repudiatory breach of contract by the Company or any of its Subsidiaries), be entitled to any compensation for any loss of any right or benefit or prospective right or benefit under the Plan that s/he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever. By signing this Performance Award the Participant shall be deemed irrevocably to have waived any such entitlement.


15


IN WITNESS WHEREOF, the parties hereto have executed this Award Agreement as of the date set forth above.

ENDO INTERNATIONAL PLC
By:         
Name: Paul V. Campanelli
Title: President & Chief Executive Officer
PARTICIPANT
Signature:         
Print Name:     


16


EXHIBIT A
(I)    TSR Performance Criteria.
The Participant will be entitled to receive a number of shares of Company Stock as of the TSR Vesting Date, equal to a multiple of the TSR Target Performance Award achieved based on achievement of targets relating to Relative TSR (the “TSR Performance Criteria”) as described below for the TSR Performance Period:
Relative TSR
Multiple Applicable to TSR Target Performance Award
Equal to or above 90th percentile
2
Equal to or above 80th percentile but below 90th percentile
1.61 - 1.80
Equal to or above 70th percentile but below 80th percentile
1.41 - 1.60
Equal to or above 60th percentile but below 70th percentile
1.21 - 1.40
Equal to or above 50th percentile but below 60th percentile
1.00 - 1.20
Equal to or above 40th percentile but below 50th percentile
0.5
Below 40th percentile
0
In the event that Relative TSR over the TSR Performance Period is negative, the multiple applicable to the TSR Target Performance Award shall not exceed 1.
If Relative TSR is equal to or above the 50th percentile but below the 90th percentile, the Participant will vest in a number of shares of Company Stock that is the mathematical linear interpolation between the number of shares of Company Stock that would vest at the defined ends of the applicable spectrum. No such interpolation shall occur in the event that Relative TSR is below the 50th percentile or equal to or above the 90th percentile.
The determination of Relative TSR will be made in the sole discretion of the Committee, after the end of the TSR Performance Period once the applicable year-end audit is available. The Committee has discretion to accelerate the vesting of all or a portion of the Participant’s TSR Performance Award based upon the overall performance of the Company and/or the Participant or based upon any change in business conditions.
(II)    Definitions.
For purposes of this Exhibit A, the following terms have the meanings set forth below:
“Comparator Group” shall mean the companies listed on Annex A, attached hereto. Each such company shall be included in the Comparator Group only if the company is publicly-traded at both the beginning and end of the TSR Performance Period.
“Per Share Price” shall mean the average of the closing prices of common shares for the applicable company during the thirty (30) consecutive trading days ending on the day immediately preceding the applicable measurement date.

1


“Relative TSR” shall mean the percentile ranking of the Company’s Total Shareholder Return as compared to the Total Shareholder Return of each company in the Comparator Group.
“Total Shareholder Return” shall mean the appreciation of the Per Share Price during the TSR Performance Period, plus any dividends paid on the applicable company’s common stock during such TSR Performance Period.

2


ANNEX A
Comparator Group
1.    AbbVie Inc. (ABBV)
2.    Abbott Laboratories (ABT)
3.    Akorn, Inc. (AKRX)
4.    Alexion Pharmaceuticals Inc. (ALXN)
5.    Alkermes plc (ALKS)
6.    Allergan plc (AGN)
7.    AMAG Pharmaceuticals Inc. (AMAG)
8.    Amgen Inc. (AMGN)
9.    AstraZeneca PLC (AZN)
10.    Biogen Inc. (BIIB)
11.    BioMarin Pharmaceutical Inc. (BMRN)
12.    Bristol-Myers Squibb Company (BMY)
13.    Celgene Corporation (CELG)
14.    Dr. Reddy’s Laboratories Ltd. (RDY)
15.    Eli Lilly and Company (LLY)
16.    Gilead Sciences Inc. (GILD)
17.    GlaxoSmithKline plc (GSK)
18.    Horizon Pharma Public Limited Company (HZNP)
19.    Impax Labs Inc. (IPXL)
20.    Incyte Corporation (INCY)
21.    Jazz Pharmaceuticals Public Limited Company (JAZZ)
22.    Johnson & Johnson (JNJ)
23.    Lannett Company (LCI)
24.    Mallinckrodt Public Limited Company (MNK)
25.    Merck & Co. Inc. (MRK)
26.    Mylan N.V. (MYL)
27.    Novartis AG (NVS)
28.    Novo Nordisk A/S (NVO)
29.    Perrigo Company Public Limited Company (PRGO)
30.    Pfizer Inc. (PFE)
31.    Qiagen NV (QGEN)
32.    Regeneron Pharmaceuticals Inc. (REGN)
33.    Roche Holding AG (RHHBY)
34.    Sanofi (SNY)
35.    Shire plc (SHPG)
36.    Taro Pharmaceutical Industries Ltd. (TARO)
37.    Teva Pharmaceutical Industries Limited (TEVA)
38.    United Therapeutics Corporation (UTHR)
39.    Valeant Pharmaceuticals International, Inc. (VRX)
40.    Vertex Pharmaceuticals Inc. (VRTX)
41.    Zoetis Inc. (ZTS)

3


EXHIBIT B
The following exhibit contains the FCF Performance Criteria in respect of 2018, which is the first FCF Performance Period for the 2018 FCF Performance Award.
The FCF Performance Criteria (including any changes thereto) in respect of future FCF Performance Periods for the 2018 FCF Performance Award shall be communicated to the Participant no later than March 31st of the relevant FCF Performance Period.

(I)    FCF Performance Criteria.
The Participant will be eligible to earn a number of shares of Company Stock equal to one third (1/3rd) of the number of restricted stock units underlying the target FCF Performance Award multiplied by the multiple applicable to the FCF Performance Award for the FCF Performance Period, which will be based on achievement of a Target relating to Free Cash Flow (the “FCF Performance Criteria”) and determined in accordance with the below:
Free Cash Flow*
Multiple Applicable to FCF Performance Award for the FCF Performance Period
Equal to or greater than 110% of Target
2
Equal to or greater than 107.5% of Target but less than 110% of Target
1.75
Equal to or greater than 105% of Target but less than 107.5% of Target
1.5
Equal to or greater than 102.5% of Target but less than 105% of Target
1.25
Equal to or greater than 100% of Target but less than 102.5% of Target
1
Equal to or greater than 97.5% of Target but less than 100% of Target
0.75
Equal to or greater than 95% of Target but less than 97.5% of Target
0.5
Less than 95% of Target
0
*Free Cash Flow for each FCF Performance Period associated with the 2018 FCF Performance Award must equal or exceed the following minimum Free Cash Flow: 50% of actual annual adjusted net income for the relevant FCF Performance Period.
If Free Cash Flow is equal to or greater than 95% of Target but below 110% of Target, the Participant will earn a number of shares of Company Stock that is the mathematical linear interpolation between the number of shares of Company Stock that would be earned at the defined ends of the applicable spectrum. No such interpolation shall occur in the event that Free Cash Flow is less than 95% of Target or equal to or greater than 110% of Target.
The determination of Free Cash Flow will be made in the sole discretion of the Committee, after the end of the applicable FCF Performance Period once the applicable year-end audit is available. The Committee may adjust the FCF Performance Award in a manner approved by the Committee at the time of the grant of the FCF Performance Award. The Committee has discretion to increase the portion of the Participant’s FCF Performance Award earned based upon the overall performance of the Company and/or the Participant or based upon any change in business conditions.

1

(II)     Definitions.
For purposes of this Exhibit B, the following terms have the meanings set forth below:
“Adjusted Cash Flow from Operations” shall mean cash from operations less the following expenses: mesh and other legal settlements; unused financing fees; separation, restructuring, transaction and integration payments; and one-time significant tax refunds or payments.
“Capital Expenditures” shall mean the Company’s purchases of property, plant and equipment (including capitalized software costs).
“Free Cash Flow” shall mean Adjusted Cash Flow from Operations less Capital Expenditures.
“Target” shall mean [ ].





2
 EX-31.1 5 ex3119302018ceo302cert.htm EXHIBIT 31.1 CEO 302 CERT Ex 31.1 9.30.2018 CEO 302 Cert
Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Paul V. Campanelli, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Endo International plc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
/S/ PAUL V. CAMPANELLI
Paul V. Campanelli
President and Chief Executive Officer
(Principal Executive Officer)
 
 
Date:
November 8, 2018



 EX-31.2 6 ex3129302018cfo302cert.htm EXHIBIT 31.2 CFO 302 CERT Ex 31.2 9.30.2018 CFO 302 Cert
Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Blaise Coleman, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Endo International plc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
/S/ BLAISE COLEMAN
Blaise Coleman
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
 
 
Date:
November 8, 2018


 EX-32.1 7 ex3219302018ceo906cert.htm EXHIBIT 32.1 CEO 906 CERT Ex 32.1 9.30.2018 CEO 906 Cert
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Paul V. Campanelli, as President and Chief Executive Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2018 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ PAUL V. CAMPANELLI
Name:
 
Paul V. Campanelli
Title:
 
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 8, 2018
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-32.2 8 ex3229302018cfo906cert.htm EXHIBIT 32.2 CFO 906 CERT Ex 32.2 9.30.2018 CFO 906 Cert
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Blaise Coleman, as Chief Financial Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2018 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ BLAISE COLEMAN
Name:
 
Blaise Coleman
Title:
 
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
Date: November 8, 2018
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 9 endp-20180930.xml XBRL INSTANCE DOCUMENT 0001593034 2018-01-01 2018-09-30 0001593034 2018-11-01 0001593034 2017-12-31 0001593034 2018-09-30 0001593034 2018-07-01 2018-09-30 0001593034 2017-07-01 2017-09-30 0001593034 2017-01-01 2017-09-30 0001593034 2016-12-31 0001593034 2017-09-30 0001593034 us-gaap:AccountingStandardsUpdate201618Member us-gaap:RestatementAdjustmentMember 2017-09-30 0001593034 us-gaap:ScenarioPreviouslyReportedMember 2017-01-01 2017-09-30 0001593034 us-gaap:AccountingStandardsUpdate201618Member us-gaap:RestatementAdjustmentMember 2017-01-01 2017-09-30 0001593034 us-gaap:AccountingStandardsUpdate201618Member us-gaap:RestatementAdjustmentMember 2016-12-31 0001593034 us-gaap:ScenarioPreviouslyReportedMember 2016-12-31 0001593034 us-gaap:ScenarioPreviouslyReportedMember 2017-09-30 0001593034 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2017-12-31 0001593034 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-30 0001593034 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-30 0001593034 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0001593034 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0001593034 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0001593034 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001593034 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember endp:LithaHealthcareGroupLimitedMember 2017-07-03 2017-07-03 0001593034 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember endp:SomarMember 2017-10-25 0001593034 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember endp:AstoraMember 2017-01-01 2017-09-30 0001593034 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember endp:SomarMember 2017-10-25 2017-10-25 0001593034 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember endp:LithaHealthcareGroupLimitedMember 2017-12-01 2017-12-31 0001593034 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember endp:AstoraMember 2018-01-01 2018-09-30 0001593034 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember endp:LithaHealthcareGroupLimitedMember 2017-10-01 2017-10-31 0001593034 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember endp:AstoraMember 2018-07-01 2018-09-30 0001593034 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember endp:AstoraMember 2017-07-01 2017-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2017Member 2018-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-01-01 2018-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2017Member 2018-01-01 2018-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-01-01 2018-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-12-31 0001593034 endp:USGenericPharmaceuticalsRestructuring2017Member 2017-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:January2018RestructuringMember 2017-12-31 0001593034 endp:January2018RestructuringMember 2017-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:January2018RestructuringMember 2018-01-01 2018-09-30 0001593034 us-gaap:OtherRestructuringMember endp:January2018RestructuringMember 2017-12-31 0001593034 us-gaap:OtherRestructuringMember endp:January2018RestructuringMember 2018-09-30 0001593034 endp:January2018RestructuringMember 2018-09-30 0001593034 us-gaap:OtherRestructuringMember endp:January2018RestructuringMember 2018-01-01 2018-09-30 0001593034 endp:January2018RestructuringMember 2018-01-01 2018-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:January2018RestructuringMember 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:January2018RestructuringMember endp:BrandedSterileInjectablesMember 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:January2018RestructuringMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:PropertyPlantandEquipmentImpairmentChargesMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-01-01 2017-09-30 0001593034 us-gaap:OtherRestructuringMember endp:January2017RestructuringMember 2017-01-01 2017-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:January2017RestructuringMember endp:GenericPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:January2017RestructuringMember 2018-01-01 2018-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-07-01 2017-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-07-01 2017-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:January2018RestructuringMember endp:GenericPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:January2018RestructuringMember endp:InternationalPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:January2017RestructuringMember endp:BrandedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:AcceleratedDepreciationMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-07-01 2017-09-30 0001593034 endp:January2017RestructuringMember 2018-07-01 2018-09-30 0001593034 endp:AcceleratedDepreciationMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-01-01 2017-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:January2017RestructuringMember endp:BrandedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-07-01 2018-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-07-01 2018-09-30 0001593034 endp:January2018RestructuringMember endp:GenericPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:AcceleratedDepreciationMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-01-01 2018-09-30 0001593034 endp:January2017RestructuringMember 2017-01-26 2017-01-26 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-01-01 2017-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2017Member endp:GenericPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 us-gaap:InventoryValuationReserveMember endp:January2017RestructuringMember 2017-01-01 2017-09-30 0001593034 endp:PropertyPlantandEquipmentImpairmentChargesMember endp:USGenericPharmaceuticalsRestructuring2017Member 2017-07-01 2017-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:January2018RestructuringMember 2018-01-01 2018-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember endp:January2018RestructuringMember 2018-01-01 2018-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2017Member endp:GenericPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:January2017RestructuringMember 2017-07-01 2017-09-30 0001593034 endp:AssetImpairmentChargesMember endp:USGenericPharmaceuticalsRestructuring2017Member 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember endp:January2017RestructuringMember endp:BrandedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember endp:January2017RestructuringMember 2017-01-01 2017-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:January2018RestructuringMember 2018-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:January2017RestructuringMember 2018-01-01 2018-09-30 0001593034 endp:EmployeeSeparationRetentionandOtherBenefitRelatedCostsMember endp:January2017RestructuringMember 2018-09-30 0001593034 endp:SomersetTherapeuticsLLCMember us-gaap:ScenarioForecastMember 2018-12-31 0001593034 endp:SomersetTherapeuticsLLCMember us-gaap:ScenarioForecastMember 2018-10-01 2018-12-31 0001593034 endp:GenericPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:BrandedSterileInjectablesMember 2018-07-01 2018-09-30 0001593034 endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:BrandedSterileInjectablesMember 2017-01-01 2017-09-30 0001593034 endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:BrandedSterileInjectablesMember 2018-01-01 2018-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:BrandedSterileInjectablesMember 2017-07-01 2017-09-30 0001593034 endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:GenericPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:GenericPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:GenericPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:EstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:XiaflexMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:OtherSterileInjectablesMember endp:BrandedSterileInjectablesMember 2018-07-01 2018-09-30 0001593034 endp:EstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:ErtapenemForInjectionMember endp:BrandedSterileInjectablesMember 2017-07-01 2017-09-30 0001593034 endp:ErtapenemForInjectionMember endp:BrandedSterileInjectablesMember 2018-01-01 2018-09-30 0001593034 endp:PERCOCETMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:EstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:OtherSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:VoltarenGelMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:AdrenalinMember endp:BrandedSterileInjectablesMember 2017-07-01 2017-09-30 0001593034 endp:SUPPRELINLAMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:VasostrictMember endp:BrandedSterileInjectablesMember 2017-01-01 2017-09-30 0001593034 endp:TotalSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:ErtapenemForInjectionMember endp:BrandedSterileInjectablesMember 2018-07-01 2018-09-30 0001593034 endp:AdrenalinMember endp:BrandedSterileInjectablesMember 2017-01-01 2017-09-30 0001593034 endp:PERCOCETMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:OtherEstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:OpanaMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:OtherEstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:TotalSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:OtherSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:XiaflexMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:OpanaMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:VasostrictMember endp:BrandedSterileInjectablesMember 2018-07-01 2018-09-30 0001593034 endp:XiaflexMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:SUPPRELINLAMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:EstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:TotalSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:VoltarenGelMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:PERCOCETMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:OtherSterileInjectablesMember endp:BrandedSterileInjectablesMember 2017-01-01 2017-09-30 0001593034 endp:OtherEstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:OtherSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:XiaflexMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:TotalSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:AdrenalinMember endp:BrandedSterileInjectablesMember 2018-01-01 2018-09-30 0001593034 endp:VoltarenGelMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:PERCOCETMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:OtherSterileInjectablesMember endp:BrandedSterileInjectablesMember 2018-01-01 2018-09-30 0001593034 endp:OtherSpecialtyProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:SUPPRELINLAMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:VasostrictMember endp:BrandedSterileInjectablesMember 2018-01-01 2018-09-30 0001593034 endp:VasostrictMember endp:BrandedSterileInjectablesMember 2017-07-01 2017-09-30 0001593034 endp:SUPPRELINLAMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:VoltarenGelMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-07-01 2018-09-30 0001593034 endp:AdrenalinMember endp:BrandedSterileInjectablesMember 2018-07-01 2018-09-30 0001593034 endp:OtherEstablishedProductsMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:OpanaMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:OtherSterileInjectablesMember endp:BrandedSterileInjectablesMember 2017-07-01 2017-09-30 0001593034 endp:OpanaMember endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-01-01 2018-09-30 0001593034 endp:ErtapenemForInjectionMember endp:BrandedSterileInjectablesMember 2017-01-01 2017-09-30 0001593034 us-gaap:OtherRestructuringMember 2017-01-01 2017-09-30 0001593034 us-gaap:ProductConcentrationRiskMember endp:GenericPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 endp:InventoryWriteOffsMember 2018-07-01 2018-09-30 0001593034 endp:InventoryWriteOffsMember 2018-01-01 2018-09-30 0001593034 2017-12-31 2017-12-31 0001593034 endp:InventoryWriteOffsMember 2017-01-01 2017-09-30 0001593034 us-gaap:OtherRestructuringMember 2018-07-01 2018-09-30 0001593034 us-gaap:OtherRestructuringMember 2018-01-01 2018-09-30 0001593034 us-gaap:OtherRestructuringMember 2017-07-01 2017-09-30 0001593034 us-gaap:ProductConcentrationRiskMember endp:EzetimibeandQuetiapineERTabletsMember endp:GenericPharmaceuticalsMember 2017-01-01 2017-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2018-07-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember 2017-07-01 2017-09-30 0001593034 us-gaap:OperatingSegmentsMember 2017-01-01 2017-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2017-07-01 2017-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001593034 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2017-07-01 2017-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2017-06-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2017-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2017-01-01 2017-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2018-01-01 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2016-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2018-06-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2018-07-01 2018-09-30 0001593034 endp:RestrictedCashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2017-12-31 0001593034 us-gaap:MaximumMember 2018-01-01 2018-09-30 0001593034 us-gaap:WeightedAverageMember 2018-01-01 2018-09-30 0001593034 endp:VaginalMeshCasesMember 2017-12-31 0001593034 endp:VaginalMeshCasesMember 2018-09-30 0001593034 us-gaap:MinimumMember 2018-01-01 2018-09-30 0001593034 endp:RestrictedCashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2018-09-30 0001593034 us-gaap:MoneyMarketFundsMember 2017-12-31 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:BankTimeDepositsMember 2017-12-31 0001593034 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember 2017-12-31 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:BankTimeDepositsMember 2017-12-31 0001593034 us-gaap:EquitySecuritiesMember 2017-12-31 0001593034 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2017-12-31 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember 2017-12-31 0001593034 us-gaap:BankTimeDepositsMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2017-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2018-09-30 0001593034 endp:IntangibleAssetsMember us-gaap:FairValueMeasurementsNonrecurringMember 2018-01-01 2018-09-30 0001593034 us-gaap:PropertyPlantAndEquipmentMember us-gaap:FairValueMeasurementsNonrecurringMember 2018-01-01 2018-09-30 0001593034 us-gaap:FairValueMeasurementsNonrecurringMember 2018-01-01 2018-09-30 0001593034 us-gaap:MoneyMarketFundsMember 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001593034 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001593034 us-gaap:EquitySecuritiesMember 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001593034 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2018-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2018-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2017-12-31 0001593034 endp:LehighValleyTechnologiesInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2018-09-30 0001593034 endp:OtherAcquisitionsMember endp:AcquisitionRelatedContingentConsiderationMember 2018-01-01 2018-09-30 0001593034 endp:VoltarenGelMember endp:AcquisitionRelatedContingentConsiderationMember 2017-12-31 0001593034 endp:OtherAcquisitionsMember endp:AcquisitionRelatedContingentConsiderationMember 2018-09-30 0001593034 endp:VoltarenGelMember endp:AcquisitionRelatedContingentConsiderationMember 2018-01-01 2018-09-30 0001593034 endp:VoltarenGelMember endp:AcquisitionRelatedContingentConsiderationMember 2018-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2018-01-01 2018-09-30 0001593034 endp:LehighValleyTechnologiesInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2017-12-31 0001593034 endp:OtherAcquisitionsMember endp:AcquisitionRelatedContingentConsiderationMember 2017-12-31 0001593034 endp:LehighValleyTechnologiesInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2018-01-01 2018-09-30 0001593034 endp:GenericPharmaceuticalsMember 2017-12-31 0001593034 endp:BrandedSterileInjectablesMember 2017-12-31 0001593034 endp:BrandedSterileInjectablesMember 2018-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2018-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2017-12-31 0001593034 endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2017-12-31 0001593034 endp:BrandedSpecialtyandEstablishedPharmaceuticalsMember 2018-09-30 0001593034 endp:GenericPharmaceuticalsMember 2018-09-30 0001593034 endp:SerelaxinInProcessResearchandDevelopmentIntangibleAssetsMember 2017-01-01 2017-03-31 0001593034 endp:PaladinLabsInc.Member 2017-01-01 2017-03-31 0001593034 endp:InProcessResearchandDevelopmentOrDevelopedTechnologyMember 2017-07-01 2017-09-30 0001593034 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember endp:SomarMember 2017-07-01 2017-09-30 0001593034 endp:FormerU.S.GenericPharmaceuticalsMember 2018-01-01 2018-03-31 0001593034 endp:GenericPharmaceuticalsMember 2018-01-01 2018-03-31 0001593034 us-gaap:DevelopedTechnologyRightsMember 2017-07-01 2017-09-30 0001593034 us-gaap:DevelopedTechnologyRightsMember endp:GenericPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:BrandedSterileInjectablesMember 2018-01-01 2018-03-31 0001593034 endp:InProcessResearchandDevelopmentOrDevelopedTechnologyMember 2017-01-01 2017-09-30 0001593034 us-gaap:InProcessResearchAndDevelopmentMember 2018-01-01 2018-09-30 0001593034 endp:InProcessResearchandDevelopmentOrDevelopedTechnologyMember 2018-01-01 2018-09-30 0001593034 us-gaap:DevelopedTechnologyRightsMember endp:BrandedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:BrandedPharmaceuticalsMember 2017-07-01 2017-09-30 0001593034 endp:InProcessResearchandDevelopmentOrDevelopedTechnologyMember 2018-07-01 2018-09-30 0001593034 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0001593034 us-gaap:TradeNamesMember 2018-01-01 2018-09-30 0001593034 us-gaap:LicensingAgreementsMember 2018-01-01 2018-09-30 0001593034 us-gaap:InProcessResearchAndDevelopmentMember 2018-09-30 0001593034 us-gaap:LicensingAgreementsMember 2018-09-30 0001593034 us-gaap:TradeNamesMember 2017-12-31 0001593034 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-09-30 0001593034 us-gaap:TradeNamesMember 2018-09-30 0001593034 us-gaap:InProcessResearchAndDevelopmentMember 2017-12-31 0001593034 us-gaap:DevelopedTechnologyRightsMember 2018-09-30 0001593034 us-gaap:LicensingAgreementsMember 2017-12-31 0001593034 endp:FormerU.S.GenericPharmaceuticalsMember 2017-12-31 0001593034 us-gaap:DevelopedTechnologyRightsMember us-gaap:WeightedAverageMember 2018-01-01 2018-09-30 0001593034 us-gaap:LicensingAgreementsMember us-gaap:WeightedAverageMember 2018-01-01 2018-09-30 0001593034 2018-01-01 0001593034 us-gaap:RevolvingCreditFacilityMember 2018-09-30 0001593034 endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember 2017-12-31 0001593034 endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember 2017-12-31 0001593034 endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember 2017-12-31 0001593034 endp:A6.00SeniorNotesDue2025Member 2017-12-31 0001593034 endp:FivePointEightSevenFivePercentSeniorSecuredNotesDueTwentyTwentyFourMember 2018-09-30 0001593034 endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember 2018-09-30 0001593034 endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember 2018-09-30 0001593034 endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember 2018-09-30 0001593034 endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember 2017-12-31 0001593034 endp:TermLoanBFacilityDueTwoThousandTwentyFourMember 2017-12-31 0001593034 endp:OtherDebtMember 2018-09-30 0001593034 endp:TermLoanBFacilityDueTwoThousandTwentyFourMember 2018-09-30 0001593034 endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember 2018-09-30 0001593034 endp:FivePointEightSevenFivePercentSeniorSecuredNotesDueTwentyTwentyFourMember 2017-12-31 0001593034 endp:A6.00SeniorNotesDue2025Member 2018-09-30 0001593034 endp:OtherDebtMember 2017-12-31 0001593034 endp:VaginalMeshCasesMember 2018-01-01 2018-09-30 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2017-12-31 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2018-01-01 2018-09-30 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2018-09-30 0001593034 endp:ParPharmaceuticalInc.Member endp:Tranche1Member endp:PricingMattersCasesMember 2017-10-01 2017-10-31 0001593034 endp:TestosteroneCasesMember us-gaap:SubsequentEventMember 2018-11-01 0001593034 endp:ParPharmaceuticalInc.Member endp:PricingMattersCasesMember 2017-08-01 2017-08-31 0001593034 endp:OpioidRelatedMattersMember us-gaap:SubsequentEventMember 2018-11-01 0001593034 endp:ParPharmaceuticalInc.Member endp:VASOSTRICTRelatedMattersMember 2018-05-01 2018-05-31 0001593034 endp:ParPharmaceuticalInc.Member endp:PricingMattersCasesMember 2018-01-01 2018-01-31 0001593034 endp:AndroGel1.62Member 2018-06-01 2018-06-30 0001593034 endp:UnapprovedDrugLitigationMember 2013-09-01 2013-09-30 0001593034 endp:PricingMattersCasesMember 2017-10-01 2017-10-31 0001593034 endp:EndoPharmaceuticalsInc.andParPharmaceuticalsInc.Member endp:PricingMattersCasesMember 2018-08-01 2018-08-31 0001593034 endp:ParPharmaceuticalInc.Member endp:VASOSTRICTRelatedMattersMember us-gaap:SubsequentEventMember 2018-10-01 2018-10-31 0001593034 endp:PricingMattersCasesMember 2018-06-01 2018-06-30 0001593034 endp:ParPharmaceuticalInc.Member endp:VASOSTRICTRelatedMattersMember 2018-03-01 2018-03-31 0001593034 endp:AmericanMedicalSystemsMember endp:VaginalMeshCasesMember 2018-09-30 0001593034 endp:AmericanMedicalSystemsMember endp:VaginalMeshCasesMember 2018-01-01 2018-09-30 0001593034 endp:OpioidRelatedMattersMember 2018-04-01 2018-04-30 0001593034 endp:PricingMattersCasesMember 2016-12-01 2016-12-31 0001593034 endp:ParPharmaceuticalInc.Member endp:VASOSTRICTRelatedMattersMember 2018-08-01 2018-08-31 0001593034 endp:EndoPharmaceuticalsInc.andParPharmaceuticalsInc.Member endp:PricingMattersCasesMember 2018-09-01 2018-09-30 0001593034 endp:ParPharmaceuticalInc.Member endp:VASOSTRICTRelatedMattersMember 2018-01-01 2018-01-31 0001593034 endp:Bierv.EndoInternationalplcetal.Member endp:CurrentandFormerDirectorsandOfficersMember 2017-08-01 2017-08-31 0001593034 endp:PricingMattersCasesMember 2017-03-31 0001593034 endp:UnapprovedDrugLitigationMember 2018-02-01 2018-02-28 0001593034 endp:ParPharmaceuticalInc.Member endp:PricingMattersCasesMember 2017-10-01 2017-10-31 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2018-04-01 2018-06-30 0001593034 endp:PricingMattersCasesMember 2017-07-31 0001593034 endp:LidodermMember 2018-09-30 0001593034 endp:Bierv.EndoInternationalplcetal.Member endp:CurrentandFormerDirectorsandOfficersMember 2018-02-01 2018-02-28 0001593034 endp:ParPharmaceuticalInc.Member endp:VASOSTRICTRelatedMattersMember 2017-10-01 2017-10-31 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-07-01 2017-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2018-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-01-01 2017-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-09-30 0001593034 endp:LongtermCashIncentiveMember 2018-09-30 0001593034 endp:PerformanceStockUnitsMember us-gaap:ScenarioPlanMember 2018-09-30 0001593034 us-gaap:ScenarioPlanMember 2017-07-01 2017-09-30 0001593034 endp:LongtermCashIncentiveMember 2018-01-01 2018-09-30 0001593034 endp:PerformanceStockUnitsMember us-gaap:ScenarioPlanMember 2018-01-01 2018-09-30 0001593034 endp:NonVestedStockOptionsMember 2018-01-01 2018-09-30 0001593034 endp:NonVestedRestrictedStockMember 2018-01-01 2018-09-30 0001593034 endp:NonVestedRestrictedStockMember us-gaap:ScenarioPlanMember 2017-07-01 2017-09-30 0001593034 2017-01-01 2017-12-31 xbrli:shares xbrli:pure endp:position iso4217:USD iso4217:USD xbrli:shares endp:Reportable_Business_Segments endp:state endp:patent utreg:D endp:state_attorney_general endp:tranche endp:company endp:distributor endp:product endp:case endp:employee endp:defendant endp:product_candidates endp:claim endp:theory false --12-31 Q3 2018 2018-09-30 10-Q 0001593034 224344760 Large Accelerated Filer Endo International plc ENDP 14604000 2022000 168333000 152297000 291034000 250637000 63114000 103673000 377955000 123754000 150531000 86236000 17434000 1260201000 380841000 417060000 415172000 47128000 351152000 84891000 170329000 82555000 13377000 1068267000 262454000 513082000 247137000 45594000 2004000 0.18 -1319000 -0.06 80693000 127977000 4001000 82141000 8348775000 8323163000 0.5 0 -775684000 -19000000 -19000000 4400000 36200000 0.01 0.01 4000000 4000000 4000000 4000000 48000 46000 1844000 39469000 1467000 30923000 73703000 -263000 11169000 -3014000 3839000 11731000 -154753000 -154753000 0 0 10647000 10647000 0 0 3217000 3217000 0 0 0 0 2731193000 -2731193000 0 0 0 0 0 165400000 165400000 0 0 0 239857000 -7447000 10647000 5900000 13600000 66000 281000 281000 71000 261000 261000 4400000 0 17114000 248485000 3 40 4 11 180 180 P45D P45D 50 4 5 48 112 7 1 4 7 2 5 1 1 6 13 15 30 18 16 3 P30M P30M 60 3 2 5 3625000 17114000 3415000000 0 25000000 25000000 33035000 114655000 49187000 144693000 35600000 313814000 313800000 57000000 283800000 283752000 623128000 216770000 216770000 0 1653000 5038000 5000000 545379000 248485000 248485000 100000 500000 1000000 20 775000 6952000 4731000 43027000 1096825000 1019004000 -318000 1019322000 85348000 106321000 517436000 467156000 113908000 84240000 2086000 1681000 -209821000 -216854000 8791170000 8830351000 -3005000 2922000 -1528000 1560000 5082000 473000 43722000 17698000 15289000 161400000 161413000 615500000 615490000 161300000 161275000 471662000 471700000 471662000 450400000 21262000 0 94924000 94924000 1023930000 1023930000 142217000 142217000 613400000 613400000 217576000 4824000 222400000 11635580000 10521662000 2271077000 2275599000 0 0 239857000 744697000 441287000 0 1456000 439831000 303410000 303410000 0 0 0 0 0 0 303410000 1456000 439831000 693272000 693272000 1693000 691579000 0 0 0 0 0 0 1693000 691579000 1 16641000 16641000 31711000 31711000 1288000 1288000 13284000 13284000 160000000 15400000 23600000 23574000 800000 11700000 11731000 70543000 42261000 30000000 986605000 1118885000 805180000 287930000 517250000 1103486000 365093000 738393000 1311014000 1430908000 298306000 77163000 221143000 119894000 0 0 0.0001 0.0001 1000000000 1000000000 223331706 224288553 223331706 224288553 22000 22000 -57216000 -1601943000 -168470000 -746594000 0.07 0.09 0.05 0.07 0.04 0.05 13291000 11287000 10300000 8200000 19635000 20954000 1700000 1900000 -1300000 -4600000 514522000 1722885000 412965000 -1465000 414430000 1198468000 -574000 1199042000 3076000 -3100000 8382980000 1200000000 300000000 700000000 750000000 55000 400000000 1635000000 3397925000 8357313000 1200000000 300000000 700000000 750000000 0 400000000 1635000000 3372313000 0.0627 0.0614 0.0604 0.0562 0.0150 0.0791 0.0628 0.0546 0.0627 0.0614 0.0604 0.0562 0.0791 0.0628 0.0546 0.0600 0.05875 0.0575 0.05375 0.0725 0.06 14900000 11582000 6000 43131000 43630000 -239174000 13118000 742936000 556503000 -8957000 -813442000 -27134000 -43273000 0.02 -3.16 -0.12 -0.19 0.02 -3.16 -0.12 -0.19 -11974000 -107556000 0 0 124000000 0 0 10100000 0 -0.43 -7.47 -0.77 0.00 -0.77 -3.30 0.01 -3.31 -0.43 -7.47 -0.77 0.00 -0.77 -3.30 0.01 -3.31 3983000 297000 3686000 -608000 0.220 0.092 -0.021 -0.037 45600000 3000000 0 0 -51734000 -51734000 0 0 0 0 0.1 0.095 0.09 0.095 0.095 0.095 0.22 0.095 0.141 504000 1027000 167000 -405000 15440000 23574000 769000 11731000 31617000 91927000 24564000 73298000 262113000 210460000 194787000 13061000 63001000 16256000 98124000 190442000 152098000 10954000 34701000 11775000 71040000 128470000 P11Y P12Y P11Y 2681091000 2304461000 370221000 6409000 3138889000 2740997000 391483000 6409000 622384000 420786000 447157000 481300000 552516000 -7447000 -7447000 0 0 6651575000 6187764000 457402000 6409000 6669205000 6205394000 457402000 6409000 0 0 0 0 -2549000 4305000 -1354000 734000 5 -1300000 2763000 5074000 2866000 29859000 5074000 29859000 -51734000 0 4450082000 828818000 0 3531301000 89963000 4056668000 828818000 2731193000 409108000 87549000 -2414000 0 0 0 -2414000 3661904000 855810000 0 2342500000 2342549000 463545000 4040568000 855810000 0 2733549000 451209000 82600000 45500000 0 25700000 0 288745000 0 0 391000000 0 391000000 391000000 0 0 391000000 0 78300000 89500000 217600000 674177000 461100000 140609000 140600000 217576000 78300000 20600000 180400000 57500000 129676000 129676000 0 0 87900000 87900000 -99687000 -961130000 -146071000 -696288000 -127796000 377955000 -1058647000 1260201000 -143068000 351152000 -671559000 1068267000 -99687000 -961130000 -146071000 -640000 -145431000 -696288000 2131000 -698419000 -0.45 -4.31 -0.65 0.00 -0.65 -3.11 0.01 -3.12 -0.45 -4.31 -0.65 0.00 -0.65 -3.11 0.01 -3.12 3017000 3017000 -705886000 -705900000 -705886000 -27134000 -27134000 -43273000 -43273000 -43300000 3017000 -705886000 -27134000 -43273000 1075000 1163000 -842000 -3163000 -28109000 -97517000 3003000 24729000 12048000 16407000 -159245000 -367979000 -471448000 -31634000 18145000 -4759000 -91047000 -52499000 -11626000 -993000 0 0 0 0 347200000 347200000 93900000 93900000 0 0 0 0 6998775000 6763105000 4317684000 3624216000 -127521000 -127521000 -361267000 -361267000 -131847000 -131847000 -385896000 -385896000 0 2569000 130257000 64647000 156855000 129495000 391437000 332787000 -8402000 341189000 17100000 13300000 124685000 119627000 109897000 83665000 -12352000 -14016000 -1750000 15370000 11635580000 10521662000 2220909000 2021468000 190442000 119899000 0 0 119899000 70543000 0 0 70543000 0 0 190442000 128470000 86209000 0 0 86209000 42261000 0 0 42261000 0 0 128470000 997200000 8276237000 1181243000 295513000 692855000 742048000 55000 390974000 1613446000 3360103000 8262762000 1182859000 295922000 694053000 743083000 0 392439000 1615955000 3338451000 34205000 34150000 7500000000 7900000000 8242032000 8228612000 1087172000 1002100000 100000000 845611000 1087793000 966633000 820200000 210450000 35450000 200000000 3100000000 845600000 0 19000000 71000 -12352000 -14016000 -1750000 15370000 14 20 1505 1205 1456000 1693000 -1450000 0 -1450000 0 -135353000 0 -135353000 -62808000 8964000 78766000 -69802000 -13682000 422162000 -1900000 424062000 196992000 -96670000 -1667016000 -173205000 -640000 -172565000 -739561000 2131000 -741692000 2097000 10843000 1507000 0 1507000 33216000 1000000 32216000 3 4 -2372000 -656489000 -12728000 -318879000 159684000 212906000 59728000 67934000 2962000 64972000 9941000 35415000 4735000 -7033000 188000 333000 0 0 9941000 295000 35415000 522000 4735000 -7033000 9941000 188000 35415000 333000 4735000 0 -7033000 0 0 107000 0 189000 0 0 39561000 39266000 295000 65262000 64740000 522000 4735000 4735000 -7033000 -7033000 39266000 64740000 4735000 -7033000 -29325000 -29325000 0 0 39454000 39266000 188000 65073000 64740000 333000 4735000 4735000 0 -7033000 -7033000 0 0 0 0 0 107000 0 107000 189000 0 189000 0 0 0 0 188000 333000 434178000 411961000 808000 301000 837000 5786000 30000 1789000 -175000 -28348000 63712000 28664000 0 -1678000 18439000 22518000 1949000 10951000 20388000 33469000 57358000 0 1958000 5082000 94102000 56544000 43098000 50697000 10329000 40368000 94200000 96066000 43753000 300000000 0 7000000 0 0 473000 -739561000 0 0 0 523971000 495546000 -29325000 0 -29325000 0 0 0 0 0 -29325000 0 -29325000 0 0 0 0 0 0 0 0 0 0 0 0 0 4912000 3921000 3722413000 25614000 39644000 123522000 39683000 160431000 324400000 312000000 320453000 289667000 0 0 90 0 59800000 19500000 14200000 1100000 4900000 15100000 6900000 3300000 59800000 19500000 7900000 103700000 18500000 2100000 200000 1700000 4800000 5200000 700000 4000000 10800000 3100000 35200000 2600000 0 22100000 9800000 22087000 9779000 2800000 11400000 1705000 9341000 23792000 23800000 19120000 59600000 600000 7900000 12700000 2700000 94200000 1700000 12000000 203700000 0 22975000 650000 1610000 650000 24585000 3648000 10236000 406000 0 4054000 10236000 59800000 60200000 35200000 14200000 -8096539000 -8833024000 5207000 -8838231000 786887000 25335000 0 120020000 14756000 54813000 40634000 70829000 31349000 20638000 113783000 105741000 19102000 52511000 233803000 201905000 294749000 56430000 2700218000 50464000 0 400162000 82056000 171277000 113407000 203252000 93183000 63468000 328988000 300649000 53646000 152113000 729150000 554365000 1227584000 189119000 745466000 -2105000 747571000 35460000 25798000 91902000 0 46115000 43576000 63559000 30730000 20408000 128198000 112333000 15057000 64214000 220100000 237150000 257969000 30247000 2160689000 557000 2160132000 101858000 25798000 272967000 0 135243000 114202000 210804000 93539000 60948000 360005000 332387000 44185000 184855000 632972000 670847000 748445000 108425000 135880000 468675000 163791000 478615000 19800000 41300000 2100000 32700000 13200000 40252000 40300000 13700000 43722000 43700000 P2Y3M18D P2Y P1Y9M18D P3Y 0 5000000.0 484880000 -219459000 487956000 -66000 223299000 223157000 224132000 223829000 223299000 223157000 224132000 223829000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2018</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Leases (Topic 842)&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-02) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for most leases. In July 2018, the FASB issued ASU No. 2018-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Codification Improvements to Topic 842, Leases&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Leases (Topic 842) - Targeted Improvements&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2018-11), which addresses implementation issues related to the new lease standard. This guidance will be effective for the Company beginning in the first quarter of 2019, with early application permitted. The Company plans to adopt this guidance in the first quarter of 2019 using the modified retrospective approach and will recognize a cumulative-effect adjustment to the opening balance of Accumulated deficit in that period. This guidance includes a number of optional practical expedients that the Company may elect to apply, including an expedient that permits lease agreements that are twelve months or less to be excluded from the balance sheet. The Company is continuing to evaluate the impact that this new guidance will have on its consolidated financial statements, including its disclosures. It is expected that the primary impact upon adoption will be the recognition, on a discounted basis, of the Company&#8217;s minimum commitments under noncancelable operating leases as right of use assets and obligations on the consolidated balance sheets. This will result in a significant increase in assets and liabilities on the Company&#8217;s consolidated balance sheets. In preparation for the adoption of this guidance, the Company is continuing the process of identifying and validating the Company&#8217;s lease information and evaluating the impact that this new guidance will have on its processes and controls.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2018, the FASB issued ASU No. 2018-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Codification Improvements&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2018-09). ASU 2018-09 makes changes to a variety of topics to clarify, correct errors in or make minor improvements to the Accounting Standards Codification. Certain of these provisions are effective immediately; however, these provisions did not have a material impact on the Company&#8217;s financial statements or disclosures. The remaining provisions are generally effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. The Company is currently evaluating the impact of these remaining provisions of ASU 2018-09 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Topic 820, Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company&#8217;s disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-15 may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-15 on the Company&#8217;s consolidated results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clarifying the Interaction Between Topic 808 and Topic 606&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should generally be applied retrospectively to the date of initial application of Topic 606 (January 1, 2018 for the Company) and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company&#8217;s consolidated results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted or Otherwise Effective as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2018</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2015-14, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)&#8221; </font><font style="font-family:inherit;font-size:10pt;">(issued in March 2016)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">which clarified the guidance on reporting revenue as a principal versus agent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (issued in April 2016)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrow-Scope Improvements and Practical Expedients&#8221;</font><font style="font-family:inherit;font-size:10pt;"> and ASU No. 2016-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These ASUs have generally been codified in Accounting Standards Codification Topic 606 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#8221;, and are collectively referred to herein as ASC 606. ASC 606 supersedes the revenue recognition requirements in Topic 605 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue Recognition&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), and requires entities to recognize revenue when control of promised goods or services is transferred to customers at an amount that reflects the consideration to which entities expect to be entitled in exchange for those goods or services.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded a net decrease of </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Compensation - Stock Compensation&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the amount of other intangible assets for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are set forth in the table below (in thousands).</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost basis:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total indefinite-lived intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (weighted average life of 12 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology (weighted average life of 11 years)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,187,764</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,676</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,753</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,205,394</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total finite-lived intangibles (weighted average life of 11 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651,575</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,676</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,753</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,669,205</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,998,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(217,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,763,105</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated amortization:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(370,221</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,262</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,483</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,304,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,647</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,740,997</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,681,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(471,662</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,138,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,317,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,624,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other adjustments relate to</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below provides reconciliations of our consolidated </font><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, which is determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), to our </font><font style="font-family:inherit;font-size:10pt;">total segment adjusted income from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consolidated loss from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,058,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">385,896</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,267</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate unallocated costs (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615,490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory step-up</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments to partners</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,731</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">775</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,027</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation benefits and other cost reduction initiatives (2)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain litigation-related and other contingencies, net (3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,750</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,352</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,016</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges (4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023,930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items (5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency impact related to the remeasurement of intercompany debt instruments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,922</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net (6)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment adjusted income from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,260,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts for the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> relate to employee separation costs of </font><font style="font-family:inherit;font-size:8pt;">$2.1 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$32.7 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, charges to increase excess inventory reserves of </font><font style="font-family:inherit;font-size:8pt;">$0.2 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$2.8 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, and other charges of </font><font style="font-family:inherit;font-size:8pt;">$1.7 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$11.4 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, each of which related primarily to our restructuring initiatives. Also included in the amount for the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> is accelerated depreciation of </font><font style="font-family:inherit;font-size:8pt;">$35.2 million</font><font style="font-family:inherit;font-size:8pt;">, which related to the </font><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:8pt;">. During the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;">, amounts primarily relate to employee separation costs of </font><font style="font-family:inherit;font-size:8pt;">$19.8 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$41.3 million</font><font style="font-family:inherit;font-size:8pt;">, accelerated depreciation of </font><font style="font-family:inherit;font-size:8pt;">$59.8 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$60.2 million</font><font style="font-family:inherit;font-size:8pt;">, other charges of </font><font style="font-family:inherit;font-size:8pt;">$1.1 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$18.5 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, and charges to increase excess inventory reserves of </font><font style="font-family:inherit;font-size:8pt;">$7.9 million</font><font style="font-family:inherit;font-size:8pt;"> during the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;">. These charges were related primarily to the 2017 U.S. Generics Pharmaceuticals restructuring initiative. See </font><font style="font-family:inherit;font-size:8pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:8pt;"> for discussion of our material restructuring initiatives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts include adjustments for Litigation-related and other contingencies, net as further described in</font><font style="font-family:inherit;font-size:6pt;"> </font><font style="font-family:inherit;font-size:8pt;">Note 14. Commitments and Contingencies</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts primarily relate to charges to impair goodwill and intangible assets as further described in</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:8pt;">Note 9. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:8pt;">as well as charges to write down certain property, plant and equipment as further described in</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:8pt;">Note 7. Fair Value Measurements</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> are primarily related to </font><font style="font-family:inherit;font-size:8pt;">charge</font><font style="font-family:inherit;font-size:8pt;">s due to changes in the fair value of contingent consideration of </font><font style="font-family:inherit;font-size:8pt;">$0.8 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$11.7 million</font><font style="font-family:inherit;font-size:8pt;">, respectively. Amounts during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;"> include </font><font style="font-family:inherit;font-size:8pt;">charge</font><font style="font-family:inherit;font-size:8pt;">s due to changes in the fair value of contingent consideration of </font><font style="font-family:inherit;font-size:8pt;">$15.4 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$23.6 million</font><font style="font-family:inherit;font-size:8pt;">, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.</font><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> primarily relate to gains on sales of businesses and other assets, as further described in </font><font style="font-family:inherit;font-size:8pt;">Note 17. Other income, net</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred the following goodwill and other intangible asset impairment charges:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill impairment charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible asset impairment charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> include the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Returns and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,034</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalties and other distribution partner payables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 5. ACQUISITIONS</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2018, the Company entered into a Membership Interest and Asset Purchase Agreement (the Somerset Purchase Agreement) with Mendham Holdings, LLC (the Seller) and certain other Seller related parties in connection with the acquisition of all of the limited liability company membership interests (the LLC Interests) of Somerset Therapeutics, LLC (Somerset) and certain of Somerset&#8217;s assets, including intellectual property, product Abbreviated New Drug Applications (ANDAs) and inventory (the Somerset Assets). Somerset is a specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. market. The Somerset acquisition is contingent upon the closing of the acquisition of the Indian-based Wintac business (as defined below).</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the Somerset Purchase Agreement, the Company will acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the LLC Interests of Somerset and the Somerset Assets for an aggregate cash purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$160 million</font><font style="font-family:inherit;font-size:10pt;">, subject to customary adjustments for cash, net working capital and indebtedness as described in the Somerset Purchase Agreement. The Somerset Purchase Agreement contains certain customary representations, warranties and covenants and provides for indemnification rights of the parties in respect of inaccuracies or breaches of certain representations, warranties and covenants, subject to the limitations set forth in the Somerset Purchase Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Somerset acquisition is expected to close in the first quarter of 2019, subject to satisfaction of customary closing conditions, including required regulatory approvals and the closing of the acquisition of the Wintac business. In connection with the Somerset acquisition, the Company&#8217;s Indian subsidiary has entered into separate agreements to acquire the entire business of Somerset&#8217;s Indian-based contract development and manufacturing affiliate, Wintac Limited (Wintac), including certain real property in Bangalore, India and the manufacturing plants thereon and to assume certain debt of Wintac for the expected aggregate amount of the rupee equivalent of approximately </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;">, subject to customary adjustments for net working capital.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 10. LICENSE AND COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, under these agreements: (i) we are required to make upfront payments and other payments upon successful completion of regulatory or sales milestones, (ii) we are required to pay royalties on sales of the products arising from these agreements and (iii) termination is permitted with no significant continuing obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we entered into a development, license and commercialization agreement with a third party pharmaceutical company related to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> sterile injectable product candidates. Pursuant to this agreement, the third party will generally be responsible, at its expense, to develop and seek regulatory approval for these product candidates, and the Company will generally be responsible, at its expense, to launch and distribute any products that are approved. The Company will have exclusive license rights to all of these products launched in the U.S. and a first right of refusal for the Canadian territory. Upon entering into this agreement, the Company became obligated to make an upfront payment, which was recorded as Research and development expense in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended June 30, 2018. The Company could become obligated to make additional payments based on certain potential future milestones being achieved.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no other significant changes to our license, collaboration and discovery agreements since our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 14. COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings and Investigations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief, and an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the aggregate, we will disclose such matters.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies could be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our accrual for loss contingencies totaled </font><font style="font-family:inherit;font-size:10pt;">$1,002.1 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$845.6 million</font><font style="font-family:inherit;font-size:10pt;"> relates to our liability accrual for vaginal mesh cases and other mesh-related matters. During the fourth quarter of 2017, the Company recorded a total increase to its liability accrual of approximately </font><font style="font-family:inherit;font-size:10pt;">$200 million</font><font style="font-family:inherit;font-size:10pt;"> related to testosterone-related product liability matters and LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-related antitrust matters. The accrual for LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-related matters includes an estimated loss for, among other matters, settlement of all remaining claims filed against EPI in multidistrict litigation (MDL) No. 2521, which is further discussed below under the heading &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:normal;">Other Antitrust Matters</font><font style="font-family:inherit;font-size:10pt;">.&#8221; The testosterone-related accrual includes an estimated loss for, among other matters, all testosterone-related product liability cases filed in MDL No. 2545 and in other courts. These cases are further discussed below under the heading &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:normal;">Product Liability and Related Matters</font><font style="font-family:inherit;font-size:10pt;">.&#8221; Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Liability and Related Matters</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries. These and other related matters are described below in more detail.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Vaginal Mesh.</font><font style="font-family:inherit;font-size:10pt;"> Since 2008, we and certain of our subsidiaries, including American Medical Systems Holdings, Inc. (subsequently converted to Astora Women&#8217;s Health Holding LLC and merged into Astora Women&#8217;s Health LLC and referred to herein as AMS) and/or Astora, have been named as defendants in multiple lawsuits in various state and federal courts in the U.S. (including a federal MDL pending in the U.S. District Court for the Southern District of West Virginia (MDL No. 2325)), and in Canada and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). In January 2018, a representative proceeding (class action) was filed in the Federal Court of Australia against American Medical Systems, LLC. In the various class action and individual complaints, plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and certain plaintiffs&#8217; counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately </font><font style="font-family:inherit;font-size:10pt;">71,000</font><font style="font-family:inherit;font-size:10pt;"> filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation requirements regarding the claims represented by each law firm party to the MSA. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant is required to represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, the MDL court entered a case management order which, among other things, requires plaintiffs in newly-filed MDL cases to provide expert disclosures on specific causation within one hundred twenty (120) days of filing a claim (the Order). Under the Order, a plaintiff's failure to meet the foregoing deadline may be grounds for the entry of judgment against such plaintiff. In July 2017, a similar order was entered in Minnesota state court. In June 2018, at the request of the MDL court, the Judicial Panel on Multidistrict Litigation entered a minute order suspending the transfer of cases into the MDL. Subsequently, the MDL court issued a pretrial order discontinuing the direct filing of claims in MDL No. 2325. The MDL court also issued similar orders in other MDLs involving claims against other mesh manufacturers.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company believes it has appropriately estimated the probable total amount of loss associated with all matters as of the date of this report, fact and expert discovery is ongoing in certain cases that have not settled, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in the QSFs and mesh liability accrual balance during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Qualified Settlement Funds</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mesh Liability Accrual</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash contributions to Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes from Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,038</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">845,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. The </font><font style="font-family:inherit;font-size:8pt;">$5.0 million</font><font style="font-family:inherit;font-size:8pt;"> in the table above also includes a second quarter 2018 reclassification adjustment of </font><font style="font-family:inherit;font-size:8pt;">$4.4 million</font><font style="font-family:inherit;font-size:8pt;"> for accrued interest amounts previously recorded in Accounts payable and accrued expenses in the </font><font style="font-family:inherit;font-size:8pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$820.2 million</font><font style="font-family:inherit;font-size:10pt;"> of the mesh liability accrual amount shown above is classified in the Current portion of the legal settlement accrual in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">, with the remainder classified as Long-term legal settlement accrual, less current portion. Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, the Company has made total mesh liability payments of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.1 billion</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$283.8 million</font><font style="font-family:inherit;font-size:10pt;"> of which remains in the QSFs as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. We expect to fund into the QSFs the remaining payments under all settlement agreements during the remainder of 2018 and 2019. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were contacted in October 2012 regarding a civil investigation initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are cooperating with these investigations.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Testosterone.</font><font style="font-family:inherit;font-size:10pt;"> Various manufacturers of prescription medications containing testosterone, including our subsidiaries Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), have been named as defendants in multiple lawsuits alleging personal injury resulting from the use of such medications, including FORTESTA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel, DELATESTRYL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, TESTIM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, TESTOPEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, AVEED</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and STRIANT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Plaintiffs in these suits generally allege various personal injuries, including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and seek compensatory and/or punitive damages, where available.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">November&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">, we were aware of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,205</font><font style="font-family:inherit;font-size:10pt;"> testosterone cases (some of which may have been filed on behalf of multiple plaintiffs) pending against one or more of our subsidiaries in federal or state court. Many of these cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2545). In November 2015, the MDL court entered an order granting defendants&#8217; motion to dismiss claims involving certain testosterone products that were approved pursuant to ANDAs, including TESTOPEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the MDL court granted plaintiffs&#8217; motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing. An MDL trial against Auxilium involving TESTIM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> took place in November 2017 and resulted in a defense verdict. A trial against Auxilium involving TESTIM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> was scheduled for January 2018 in the Philadelphia Court of Common Pleas (PCCP) but resolved prior to trial.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, counsel for plaintiffs, on the one hand, and Auxilium and EPI, on the other, executed an MSA allowing for the resolution of all known testosterone replacement therapy product liability claims against our subsidiaries. The MSA was solely by way of compromise and settlement and was not in any way an admission of fault by us or any of our subsidiaries.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The MSA is subject to a process that includes guidelines and procedures for administering the settlement and the release of funds. Among other things, the MSA provides for the creation of a QSF into which the settlement funds will be deposited, establishes participation requirements, and allows for a reduction of the total settlement payment in the event the participation threshold is not met. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use and injury as determined by a third-party special master, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related product liability matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The MDL also includes a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers that claim to have paid for certain testosterone products. After a series of motions to dismiss, plaintiff filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act (RICO) and negligent misrepresentation based on defendants&#8217; marketing of certain testosterone products. The court denied a motion to dismiss this complaint in August 2016. In July 2018, the court denied plaintiff&#8217;s motion for class certification. In October 2018, defendants moved for summary judgment. This lawsuit is not part of the settlement described above.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unapproved Drug Litigation</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, the state of Louisiana filed a petition for damages against certain of our subsidiaries, including EPI, and more than </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> other pharmaceutical companies in Louisiana state court (19th Judicial District) alleging that the defendants or their subsidiaries marketed products that were not approved by the FDA and seeking damages, fines, penalties, attorneys&#8217; fees and costs under various causes of action. In October 2015, the district court entered judgment for defendants on their exception for no right of action. The state appealed, and in October 2016 the Louisiana First Circuit Court of Appeals reversed the dismissal as to the state&#8217;s Medicaid Assistance Program Integrity Law (MAPIL) and Louisiana Unfair Trade Practices Act (LUTPA) claims but affirmed the dismissal as to the state&#8217;s other claims. The state&#8217;s petition for rehearing was denied in December 2016. Both sides applied to the Louisiana Supreme Court for a writ of certiorari to review the First Circuit&#8217;s decision. Those writs were denied in March 2017. In May 2017, defendants filed exceptions for no cause of action in the district court. In August 2017, the court sustained defendants&#8217; exception as to the MAPIL claim but overruled defendants&#8217; exception as to the LUTPA claim. The state then filed a motion seeking reconsideration with respect to the MAPIL claim, and defendants filed a motion for clarification with respect to the court&#8217;s ruling on the LUTPA claim. In October 2017, the court denied the state&#8217;s motion and entered final judgment against the state with respect to the MAPIL claim. The court also granted defendants&#8217; motion for clarification and dismissed the state&#8217;s LUTPA claim insofar as it sought civil penalties for alleged violations occurring before June 2, 2006. In October 2017, defendants applied for a supervisory writ of certiorari to the Louisiana First Circuit Court of Appeals on the district court&#8217;s August 2017 order overruling defendants&#8217; exception on the state&#8217;s LUTPA claim. The First Circuit Court of Appeals denied defendants&#8217; writ application in July 2018. In August 2018, the defendants filed an application for a supervisory writ of certiorari to the Louisiana Supreme Court. That writ application is fully briefed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the state of Mississippi filed a complaint against our subsidiary EPI in Mississippi state court (Hinds County Chancery Court) alleging that EPI marketed products that were not approved by the FDA and seeking damages, penalties, attorneys&#8217; fees, costs and other relief under various causes of action. In April 2017, EPI removed the case to the U.S. District Court for the Southern District of Mississippi. In May 2017, the state moved to remand the case to state court, and that motion was granted in October 2017. In November 2017, EPI filed a motion to dismiss the state&#8217;s complaint on various grounds. In January 2018, the state filed a motion for leave to amend its complaint. In February 2018, following an unopposed motion by the state, the court consolidated the state&#8217;s case against EPI with </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> substantially similar cases brought by the state against other defendants. The consolidation is solely for purposes of coordinated pretrial proceedings and discovery, not for trial. In March 2018, the court signed an agreed order dismissing EPI and granting the state leave to file a first amended complaint. The first amended complaint names our subsidiary Generics International (US), Inc. (Generics) as the defendant. In April 2018, Generics moved to dismiss on various grounds. The case is currently stayed by agreement of the parties.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Opioid-Related Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against certain of our subsidiaries, including Endo Health Solutions Inc. (EHSI), EPI, Par Pharmaceutical, Inc. (PPI), Par Pharmaceutical Companies, Inc. (Par), Vintage Pharmaceuticals, LLC and/or Generics Bidco I, LLC and, in some instances, the Company, as well as various other manufacturers, distributors and/or others, asserting claims relating to defendants&#8217; alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of </font><font style="font-family:inherit;font-size:10pt;">November&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">, the cases of which we were aware include, but are not limited to, approximately </font><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:10pt;"> cases filed by or on behalf of states; approximately </font><font style="font-family:inherit;font-size:10pt;">1,505</font><font style="font-family:inherit;font-size:10pt;"> cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately </font><font style="font-family:inherit;font-size:10pt;">112</font><font style="font-family:inherit;font-size:10pt;"> cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers; and approximately </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;"> cases filed by individuals. Certain of the cases have been filed as putative class actions. In addition to the litigation in the U.S., in September 2018, an action against Paladin Labs, EPI, the Company and various other manufacturers and distributors was commenced in British Columbia on behalf of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the U.S. cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). In March 2018, the U.S. Department of Justice (DOJ) filed a statement of interest in the case, and in April 2018 it filed a motion to participate in settlement discussions and as a friend of the court, which the MDL court has granted. The MDL court has issued a series of case management orders permitting motions to dismiss addressing threshold legal issues in certain cases, setting a trial date in September 2019 for </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> cases originally filed in the Northern District of Ohio, allowing certain discovery and establishing certain other deadlines and procedures, among other things.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other cases remain pending in various state courts. In some jurisdictions, such as Connecticut, Illinois, New York, Pennsylvania and Texas, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. The state cases are generally at the pleading and/or discovery stage.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaints in the cases assert a variety of claims including, but not limited to, claims for alleged violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability statutes and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys&#8217; fees, costs and/or other relief.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, the Department of Justice for the state of Oregon and the Office of the Attorney General for the Commonwealth of Massachusetts issued CIDs to EHSI and EPI on behalf of a multistate group which we understand currently includes approximately 30 states. Our subsidiaries are cooperating with this investigation. Certain states participating in the multistate investigation had issued their own CIDs, subpoenas or requests for information to the Company prior to their participation in the multistate investigation.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other states are conducting their own investigations outside of the multistate group. These states include New Hampshire (subpoenas received by EPI in August 2015 and December 2017); New Jersey (subpoena received by EPI in March 2017); Washington (CID received by the Company, EHSI and EPI in August 2017); Montana (CID received by EHSI and EPI in January 2018); Alaska (CID received by EPI in February 2018); and South Carolina (CID received by EHSI and EPI in February 2018). We are cooperating with these investigations.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida in connection with an investigation being conducted by the U.S. Attorney&#8217;s Office for the Southern District of Florida in conjunction with the U.S. Food and Drug Administration. The subpoena seeks information related to OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and other oxymorphone products. EPI is cooperating with the investigation.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Generic Drug Pricing Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, we received a grand jury subpoena from the Antitrust Division of the DOJ issued by the U.S. District Court for the Eastern District of Pennsylvania to Par Pharmaceuticals. The subpoena requested documents and information focused primarily on product and pricing information relating to Par&#8217;s authorized generic version of Lanoxin (digoxin) oral tablets and Par&#8217;s generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, EPI received interrogatories and a subpoena from the Connecticut Attorney General&#8217;s Office requesting documents and information regarding pricing of certain of generic products, including doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride. EPI is cooperating with this investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, we and our subsidiary Par each received a CID from the U.S. Department of Justice in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain cases alleging price-fixing and other anticompetitive conduct with respect to various generic pharmaceutical products have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania under the caption </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re Generic Pharmaceuticals Pricing Antitrust Litigation</font><font style="font-family:inherit;font-size:10pt;"> (MDL No. 2724). Among the lawsuits consolidated and/or coordinated in the MDL, the earliest lawsuits naming the Company and/or its subsidiaries were filed in November 2016 and related to digoxin and doxycycline.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The private plaintiffs in the MDL include alleged direct purchasers, end-payers and indirect purchaser resellers who purport to represent not only themselves but also all others similarly situated. At the MDL court&#8217;s direction, in August 2017, each group of private plaintiffs (direct purchasers, end-payers and indirect purchaser resellers) filed separate consolidated amended class action complaints as to each of </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;"> products, except with respect to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> product (propranolol) direct purchaser plaintiffs stated their intention to proceed on a consolidated amended complaint filed in the U.S. District Court for the Southern District of New York prior to MDL transfer (the Southern District of New York had denied a motion to dismiss this complaint). Each of the consolidated amended complaints filed in August 2017 relates to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> product, and our subsidiary PPI was named as a defendant in complaints relating to the following </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> products: digoxin, doxycycline hyclate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. The MDL court divided the various cases into </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> separate product-based tranches for certain administrative and scheduling purposes, including briefing on motions to dismiss, and allowed certain targeted discovery. As to the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> products in the first tranche (including digoxin, doxycycline hyclate and divalproex ER), defendants filed motions to dismiss in October 2017. In October 2018, the MDL court denied portions of these motions and has yet to rule on other aspects.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the Attorney General for the state of Connecticut, leading a coalition of </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> state attorneys general, filed a complaint in the U.S. District Court for the District of Connecticut alleging price-fixing and other anticompetitive conduct with respect to doxycycline hyclate delayed release and glyburide against certain manufacturers of those products. The Company and its subsidiaries were not named in that complaint, or in an amended complaint filed on behalf of </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;"> states in March 2017, or in a separate lawsuit filed by </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> more states and the District of Columbia in the same court in July 2017. In August 2017, the state cases were transferred to MDL No. 2724. In October 2017, the state plaintiffs filed a motion for leave to (1) consolidate their </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> cases, (2) add Alaska and the Commonwealth of Puerto Rico as plaintiffs and (3) assert additional claims against existing and new defendants. In June 2018, the MDL court granted this motion, and the state plaintiffs filed their amended complaint. The amended complaint adds new allegations and claims against </font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;"> new defendants, including our subsidiary Par, relating to </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;"> additional products. The amended complaint alleges anticompetitive conduct by our subsidiary with respect to doxycycline monohydrate. It also alleges that all defendants engaged in an overarching conspiracy to restrain trade across the generic pharmaceutical industry and seeks to hold all defendants, including our subsidiary, jointly and severally liable for harm caused by alleged anticompetitive activity concerning each of the </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> drugs at issue. The amended complaint seeks declaratory and injunctive relief, disgorgement and other equitable relief, compensatory and treble damages, civil penalties, costs and attorneys&#8217; fees.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, The Kroger Co., Albertsons Companies, LLC, and H.E. Butt Grocery Company LP filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against PPI, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> separate generic pharmaceutical products, including </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> products allegedly manufactured by PPI: digoxin, doxycycline hyclate, doxycycline monohydrate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. This lawsuit has been assigned to the MDL court. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> products, as well as product-specific conspiracies relating to each individual product, in violation of federal antitrust law. The complaint seeks monetary damages, including treble damages, attorneys&#8217; fees and injunctive relief.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, direct purchaser, end-payer and indirect purchaser reseller plaintiffs filed additional class action complaints in the U.S. District Court for the Eastern District of Pennsylvania, alleging anticompetitive conduct relating to approximately </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> generic pharmaceuticals (generally those that were the subject of the state plaintiffs&#8217; amended complaint). These lawsuits have also been assigned to the MDL court. The end payer and indirect purchaser reseller complaints name our subsidiaries PPI, Generics Bidco I, LLC and DAVA Pharmaceuticals, LLC, as well as other companies, as defendants. The direct purchaser complaint names our subsidiary Par and other companies as defendants. As to our subsidiaries, these complaints allege anticompetitive conduct with respect to doxycycline hyclate, doxycycline monohydrate, nystatin cream and/or zoledronic acid. These complaints also seek to hold all defendants jointly and severally liable for alleged anticompetitive conduct relating to all products identified in the complaints on the basis of an &#8220;overarching conspiracy&#8221; theory similar to that asserted by the state plaintiffs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, Humana Inc. filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against the Company, PPI and Par, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to approximately </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> generic pharmaceutical products, including amitriptyline, baclofen, digoxin, divalproex, doxycycline (both doxycycline hyclate and doxycycline monohydrate) and propranolol. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> products, as well as product-specific conspiracies relating to each individual product. The complaint asserts claims under state and federal law and seeks monetary damages, including treble damages, attorneys&#8217; fees and equitable relief. The lawsuit has been assigned to the MDL court.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, Marion Diagnostic Center, LLC and Marion HealthCare, LLC filed a class action complaint in the U.S. District Court for the Eastern District of Pennsylvania against Par, as well as other manufacturers and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> distributor of generic pharmaceuticals, McKesson Corporation (McKesson), on behalf of all direct purchasers of all generic drugs from McKesson. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing and market allocation with respect to all generic drugs sold by McKesson, seeking to hold all defendants jointly and severally liable. The complaint asserts claims under state and federal law and seeks monetary damages, including treble damages, attorneys&#8217; fees and equitable relief.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Antitrust Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in November 2013, multiple direct and indirect purchasers of LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. (collectively, Teikoku), and Actavis plc and certain of its subsidiaries (collectively, Actavis, which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries from Allergan plc). Plaintiffs generally alleged that EPI, Teikoku and Actavis entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the &#8216;529 patent) and other patents. Some complaints also alleged that Teikoku wrongfully listed the &#8216;529 patent in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) as related to LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies&#8217; efforts to obtain FDA approval of their versions of LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The complaints asserted claims under Sections 1 and 2 of the Sherman Act (15 U.S.C. &#167;&#167; 1, 2), and/or various state antitrust and consumer protection statutes, as well as common law claims, and generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys&#8217; fees. The cases were consolidated and/or coordinated in April 2014 in a federal MDL in the U.S. District Court for the Northern District of California (MDL No. 2521). The MDL court certified classes of direct and indirect purchasers in February 2017. In June 2017, defendants moved for summary judgment on all claims, and plaintiffs also moved for partial summary judgment on certain elements of their claims. In November 2017, the court granted defendants&#8217; motion in part, ruling in defendants&#8217; favor on the issues of infringement and derivation and also limiting the time period at issue. Defendants&#8217; motions for summary judgment were denied in all other respects. The court also granted plaintiffs&#8217; motions for summary judgment on the issues of agreement and relevant market. EPI settled with certain opt-out retailer plaintiffs in October 2017. EPI reached agreements to settle with the class plaintiffs in March 2018. In connection with the settlements, several indirect purchasers which previously had opted out were permitted to rejoin the class. The class settlement agreements provide for aggregate payments of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100 million</font><font style="font-family:inherit;font-size:10pt;">. In September 2018, the court approved the class settlement agreements and entered judgment dismissing the class cases with prejudice.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in June 2014, multiple direct and indirect purchasers of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER filed cases against our subsidiaries EHSI and EPI and other pharmaceutical companies, including Impax Laboratories Inc. (Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. All cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2580). Plaintiffs generally allege that an agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and EPI&#8217;s introduction of reformulated OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER violated antitrust laws. The complaints assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys&#8217; fees. In February 2016, the MDL court issued orders (i) denying defendants&#8217; motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants&#8217; motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants&#8217; motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the MDL court&#8217;s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers also filed amended complaints. The court has dismissed the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. The cases are currently in discovery. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in February 2009, the FTC and certain private plaintiffs, including distributors and retailers, filed suit against our subsidiary Par Pharmaceutical Companies, Inc. (since June 2016, Endo Generics Holdings, Inc., and referred to in this Commitments and Contingencies note as EGHI) and others alleging violations of antitrust law arising out of EGHI&#8217;s settlement of certain patent litigation concerning the generic version of AndroGel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Generally, the complaints seek damages, treble damages, equitable relief and attorneys&#8217; fees and costs. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia (MDL No. 2084). In September 2012, the MDL court granted summary judgment to defendants on plaintiffs&#8217; claims of sham litigation. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. Claims by certain alleged direct purchasers or their assignees are still pending. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, the court rejected </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of direct purchasers&#8217; </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> causation theories, rejected damages claims related to AndroGel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> 1.62% and granted in part a motion seeking to exclude part of plaintiffs&#8217; proposed manufacturing expert&#8217;s opinions. The motions were denied in all other respects, and the court denied a motion for reconsideration, or in the alternative leave to file an interlocutory appeal, in October 2018. In July 2018, the district court denied certain plaintiffs&#8217; motion for certification of a direct purchaser class. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in February 2018, several alleged indirect purchasers filed proposed class actions against our subsidiary PPI and others alleging a conspiracy to delay generic competition and monopolize the market for Zetia</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (ezetimibe) and its generic equivalents. The complaints generally asserted claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek injunctive relief, damages, treble damages, attorneys&#8217; fees and costs. In June 2018, the cases were consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Virginia (MDL No. 2836). In September 2018, plaintiffs voluntarily dismissed without prejudice all claims against PPI.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in May 2018, multiple alleged direct and indirect purchasers filed complaints in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as others, alleging a conspiracy to delay generic competition and monopolize the market for Exforge</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (amlodipine/valsartan) and its generic equivalents. Some cases were filed on behalf of putative classes of direct and indirect purchasers; another was filed on behalf of individual retailers. The plaintiffs generally assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek damages, treble damages, equitable relief and attorneys&#8217; fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs did the same in November 2018. PPI filed a partial motion to dismiss certain claims in September 2018. We intend to vigorously defend these matters and to explore other options as appropriate in our best interests.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, EPI received a CID from Florida&#8217;s Office of the Attorney General seeking documents and other information concerning EPI&#8217;s agreement with Actavis settling the LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> patent litigation, as well as information concerning marketing and sales of LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. EPI received similar CIDs from South Carolina&#8217;s Office of the Attorney General in February 2016 and from Alaska&#8217;s Office of the Attorney General in February 2015. The Alaska CID was also directed to EHSI and included requests for documents and information concerning agreements with Actavis and Impax settling the OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER patent litigation. We are cooperating with these investigations.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, EGHI and affiliates received a CID from the Office of the Attorney General for the state of Alaska seeking production of certain documents and information regarding EGHI&#8217;s settlement of the AndroGel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> patent litigation as well as documents produced in the aforementioned litigation filed by the FTC. We are cooperating with this investigation.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, a putative class action entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Craig Friedman v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay </font><font style="font-family:inherit;font-size:10pt;">was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the court appointed Steamfitters&#8217; Industry Pension Fund and Steamfitters&#8217; Industry Security Benefit Fund as lead plaintiffs in the action. In October 2016, plaintiffs filed a second amended complaint that, among other things, added Paul Campanelli as a defendant, and we filed a motion to dismiss. In response, and without resolving the motion, the court permitted lead plaintiffs to file a third amended complaint. The amended complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company&#8217;s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par Pharmaceutical Holdings, Inc. and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney&#8217;s Office for the Southern District of New York regarding contracts with pharmacy benefit managers concerning FROVA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Lead plaintiffs sought class certification, damages in an unspecified amount and attorneys&#8217; fees and costs. We filed a motion to dismiss the third amended complaint in December 2016. In January 2018, the court granted our motion and dismissed the case with prejudice. In February 2018, lead plaintiffs filed a motion for relief from the judgment and leave to file a fourth amended complaint; the court denied this motion in April 2018. Lead plaintiffs appealed to the U.S. Court of Appeals for the Second Circuit; that appeal is still pending.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, a putative class action entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Public Employees&#8217; Retirement System of Mississippi v. Endo International plc</font><font style="font-family:inherit;font-size:10pt;"> was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering, on behalf of itself and all similarly situated purchasers. The lawsuit alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against Endo, certain of its current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo&#8217;s generics business. In March 2017, defendants removed the case to the U.S. District Court for the Eastern District of Pennsylvania. In August 2017, the court remanded the case back to the Chester County Court of Common Pleas. In October 2017, plaintiff filed an amended complaint. In December 2017, defendants filed preliminary objections to the amended complaint. The court denied those preliminary objections in April 2018. The case is currently in discovery. Plaintiff filed its motion for class certification in July 2018.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, a putative class action entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay </font><font style="font-family:inherit;font-size:10pt;">was</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo&#8217;s securities between January 11 and May 5, 2016. The statement of claim generally seeks class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act. The statement of claim alleges negligent misrepresentations concerning the Company&#8217;s revenues, profit margins and earnings per share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company&#8217;s U.S. generic pharmaceuticals business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, a putative class action entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bier v. Endo International plc, et al.</font><font style="font-family:inherit;font-size:10pt;"> was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The original complaint alleged violations of Section 10(b) and 20(a) of the Exchange Act against Endo and </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> current and former directors and officers, based on the Company&#8217;s decision to remove reformulated OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER from the market. In December 2017, the court appointed SEB Investment Management AB lead plaintiff in the action. In February 2018, the lead plaintiff filed an amended complaint, which added claims alleging violations of Sections 11 and 15 of the Securities Act in connection with the June 2015 offering. The amended complaint named the Company, EHSI and </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> current and former directors, officers and employees of Endo as defendants. In April 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, a putative class action entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay, and Paul V. Campanelli </font><font style="font-family:inherit;font-size:10pt;">was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park Employees&#8217; Annuity and Benefit Fund of Chicago lead plaintiff in the action. In August 2018, the lead plaintiff filed an amended complaint. In September 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Related Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its affiliate Par Sterile Products, LLC (PSP) in the U.S. District Court for the District of New Jersey alleging that Par and its affiliate engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par&#8217;s VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that Par and its affiliate entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that, as a result, Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages, attorneys&#8217; fees and costs, and injunctive relief. In September 2016, Par and its affiliate filed a motion to dismiss, which the district court denied in February 2017. The case is currently in discovery.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, our subsidiaries PPI and PSP filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa Pharma, Inc. (QuVa), Stuart Hinchen, Peter Jenkins, and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey&#8217;s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, a vasopressin-based cardiopulmonary drug. In October 2017, defendants answered the complaint and QuVa asserted counterclaims against PPI and PSP alleging unfair competition under New Jersey common law and seeking declaratory judgment of non-infringement as to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> U.S. Patents assigned to PPI that are listed in FDA&#8217;s Orange Book for VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The counterclaims seek actual, exemplary and punitive damages, injunctive relief and other relief. We filed a motion to dismiss the unfair competition counterclaim in November 2017. This motion is still pending. Also in November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In January 2018, we filed a first amended complaint adding </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> former employees of PSP as defendants and numerous causes of action against some or all of those former employees, including misappropriation under the federal Defend Trade Secrets Act, New Jersey&#8217;s Trade Secrets Act and New Jersey common law, as well as breach of contract, breach of the duty of loyalty and breach of the duty of confidence. In March 2018, the court granted in part our motion for preliminary injunction and enjoined QuVa from marketing and releasing its planned vasopressin product through the conclusion of trial. We subsequently deposited a bond to the court&#8217;s interest-bearing account to secure the preliminary injunction. Defendants have filed a motion asking the court to reconsider the bond amount, which remains pending. Also in March 2018, QuVa and </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> of the individual defendants filed a motion to dismiss the New Jersey common law claims, </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> of the individual defendants filed a motion to dismiss for lack of personal jurisdiction and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of the individuals filed a motion to dismiss the breach of contract claim. In April 2018, another individual defendant filed a motion to dismiss asserting numerous arguments, including lack of personal jurisdiction, improper venue and choice of law. These motions are still pending. Full discovery began in May 2018, but the court has not yet set a trial date. Also in May 2018, defendants filed a notice of appeal to the Third Circuit Court of Appeal indicating intent to appeal the court&#8217;s preliminary injunction, and in October 2018, defendants filed their opening appellate brief.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, Endo Par Innovation Company, LLC (EPIC) and PSP filed a complaint in the United States District Court for the District of Columbia challenging the legality of the FDA&#8217;s </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act </font><font style="font-family:inherit;font-size:10pt;">(January 2017) with respect to the listing of vasopressin in Category 1 of the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy</font><font style="font-family:inherit;font-size:10pt;">. The complaint contends that the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy</font><font style="font-family:inherit;font-size:10pt;"> is unlawful because it is inconsistent with the Federal Food, Drug, and Cosmetic Act, including, but not limited to, Section 503B of that Act. The complaint seeks (i) a declaration that FDA&#8217;s </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy </font><font style="font-family:inherit;font-size:10pt;">and its listing of vasopressin in Category 1 of the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy </font><font style="font-family:inherit;font-size:10pt;">are unlawful, and (ii) an order enjoining and vacating the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy</font><font style="font-family:inherit;font-size:10pt;"> and FDA&#8217;s listing of vasopressin in Category 1 of the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Policy</font><font style="font-family:inherit;font-size:10pt;">. In January 2018, EPIC and PSP agreed to a temporary </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">-day stay of the litigation in light of the FDA&#8217;s announcement that forthcoming guidance would address the concerns set forth in the Company&#8217;s complaint. In March 2018, the FDA released new draft guidance for industry entitled &#8220;Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.&#8221; Shortly thereafter, the parties agreed to extend the temporary stay for an additional </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days. In August 2018, before the </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;">-day stay period expired, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC announced they had commenced bulk compounding of vasopressin, and moved to intervene in EPIC and PSP&#8217;s case against the FDA. Later that month, EPIC and PSP invoked their ability to terminate the stay and filed a Motion for Preliminary Injunction. Before responding to the Motion for Preliminary Injunction, the FDA issued a notice containing a proposed finding that there is no clinical need to bulk compound vasopressin under Section 503B in August 2018. In September 2018, the FDA advised EPIC and PSP that it would agree to use its best efforts to finalize the vasopressin clinical need rulemaking by December 31, 2018, if the case were again stayed. As a result of the preliminary finding and the FDA&#8217;s commitment to use best efforts to finalize the rulemaking by December 31, 2018, EPIC and PSP agreed to again stay the case until December 31, 2018. In a related action, in August 2018, Athenex filed a declaratory judgment action in the U.S. District Court for the Western District of New York, a case styled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Athenex v. Par</font><font style="font-family:inherit;font-size:10pt;">, alleging non-infringement and/or invalidity of the patents the Company has listed in the Orange Book in view of VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company also moved to dismiss Athenex&#8217;s case on multiple grounds in October 2018.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, PSP and PPI received a notice letter from Eagle Pharmaceuticals, Inc. (Eagle) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (vasopressin IV solution (infusion)) 20 units/ml. In May 2018, PSP and PPI received a second notice letter from Eagle advising of the same filing, but adding an additional patent. The Paragraph IV Notices refer to U.S. Patent Nos. 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; and 9,937,223, which variously cover either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage form to increase blood pressure in humans. In May 2018, PPI, PSP and EPIC filed a lawsuit against Eagle in the United States District Court for the District of Delaware within the </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">-day deadline to invoke a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In August 2018, Eagle filed an answer and a counterclaim for non-infringement and invalidity of asserted patents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, PSP and PPI received a notice letter from Sandoz Inc. (Sandoz) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (vasopressin IV solution (infusion)) 200 units/10 ml. In October 2018, PPI, PSP and EPIC filed a lawsuit against Sandoz in the United States District Court for the District of New Jersey within the </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">-day deadline to invoke a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In October 2018, PSP and PPI received an additional notice letter from Sandoz advising of the filing by such company of an ANDA for a generic version of the 20 units/1 ml presentation for VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">-day deadline to invoke a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme with respect to the additional notice letter has not yet expired. The Company continues to vigorously defend its intellectual property.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s legal reserves include, among other things, an estimated accrual for certain VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-related matters. We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional accruals that could be required.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paragraph IV Certifications on OPANA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> ER</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and a highly pure version of the API of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal and Sandoz Inc. based on their ANDAs filed against both the INTAC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> technology and non-INTAC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> technology versions of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the &#8216;737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the &#8216;779 patent. In July 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the &#8216;779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029. A trial for infringement of the &#8216;799 patent by Actavis was held in February 2017 in the same court (U.S. District Court for the District of Delaware) in front of the same judge. In August 2017, the District Court issued an Opinion holding that Actavis infringed the claims of U.S. Patent No. 8,871,779, and that Actavis had failed to show that U.S. Patent No. 8,871,779 was invalid. Teva, Amneal and Actavis have appealed these holdings. We have appealed the holding that the &#8216;737 patent is invalid. A hearing on that appeal has been set for December 2018.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to vigorously defend or prosecute the foregoing matter as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests in defense of our intellectual property, including enforcement of the product&#8217;s intellectual property rights and approved labeling. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Proceedings and Investigations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 15. OTHER COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Set forth below are the tax effects allocated to each component of </font><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Net-of-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Net-of-Tax Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for (gain) loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gains on securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation gain arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for (gain) loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gains on securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (loss) gain on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation (loss) gain arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation (loss) gain</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification adjustments out of Other comprehensive income related to foreign currency translation were recorded upon the liquidation of Litha in the third quarter of 2017.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantially all of the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> consists of </font><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$ Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets, net (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities, net (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">At </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">January 1, 2018</font><font style="font-family:inherit;font-size:8pt;">, approximately </font><font style="font-family:inherit;font-size:8pt;">$10.3 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$8.2 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company&#8217;s </font><font style="font-family:inherit;font-size:8pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:8pt;">. The remaining amounts are classified as non-current and are included in Other assets. The net </font><font style="font-family:inherit;font-size:8pt;">increase</font><font style="font-family:inherit;font-size:8pt;"> in contract assets during the </font><font style="font-family:inherit;font-size:8pt;">nine months</font><font style="font-family:inherit;font-size:8pt;"> ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;"> was primarily due to certain sales activity during the period, partially offset by reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company&#8217;s rights to consideration for the sale of certain goods.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">At </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">January 1, 2018</font><font style="font-family:inherit;font-size:8pt;">, approximately </font><font style="font-family:inherit;font-size:8pt;">$1.7 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$1.9 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company&#8217;s </font><font style="font-family:inherit;font-size:8pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:8pt;">. The remaining amounts are classified as non-current and are included in Other liabilities. During the </font><font style="font-family:inherit;font-size:8pt;">nine months</font><font style="font-family:inherit;font-size:8pt;"> ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:8pt;">$1.3 million</font><font style="font-family:inherit;font-size:8pt;"> that was included in the contract liability balance at </font><font style="font-family:inherit;font-size:8pt;">January 1, 2018</font><font style="font-family:inherit;font-size:8pt;">, resulting in a corresponding </font><font style="font-family:inherit;font-size:8pt;">decrease</font><font style="font-family:inherit;font-size:8pt;"> in contract liabilities.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 13. DEBT</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents information about the Company&#8217;s total indebtedness at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">7.25% Senior Notes due 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">392,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.75% Senior Notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.375% Senior Notes due 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">742,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,615,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,613,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.875% Senior Secured Notes due 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,181,243</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Term Loan B Facility Due 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,372,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,397,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,360,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Other debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,357,313</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,262,762</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,382,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,276,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, less current portion, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,323,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,228,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,348,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,242,032</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The senior unsecured notes are unsecured and effectively subordinated in right of priority to our credit agreement (the 2017 Credit Agreement) and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate estimated fair value of the Company&#8217;s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was </font><font style="font-family:inherit;font-size:10pt;">$7.9 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.5 billion</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">$997.2 million</font><font style="font-family:inherit;font-size:10pt;"> of remaining credit available through our revolving credit facility as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we were in compliance with all covenants contained in our credit agreement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Branded - Specialty &amp; Established Pharmaceuticals:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Specialty Products:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XIAFLEX&#174;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SUPPRELIN&#174; LA</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Specialty (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Specialty Products</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,783</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,005</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Established Products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PERCOCET&#174;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,349</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VOLTAREN&#174; Gel</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPANA&#174; ER</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,056</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Established (2)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Established Products</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total U.S. Branded - Specialty &amp; Established Pharmaceuticals (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Branded - Sterile Injectables:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VASOSTRICT&#174;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ADRENALIN&#174;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,464</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ertapenem for injection</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Sterile Injectables (4)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,804</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total U.S. Branded - Sterile Injectables (3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">670,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total U.S. Generic Pharmaceuticals (5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,969</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,749</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">748,445</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,227,584</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total International Pharmaceuticals (6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,466</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786,887</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Products included within Other Specialty include TESTOPEL</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">, NASCOBAL</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></font><font style="font-family:inherit;font-size:8pt;">Nasal Spray and AVEED</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Products included within Other Established include, but are not limited to, LIDODERM</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">, EDEX</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">, TESTIM</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> and FORTESTA</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> Gel, including the authorized generics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of </font><font style="font-family:inherit;font-size:8pt;">$25 million</font><font style="font-family:inherit;font-size:8pt;"> during any quarterly period in </font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;"> or </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Products included within Other Sterile Injectables include, but are not limited to, APLISOL</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> and ephedrine sulfate injection.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The U.S. Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the </font><font style="font-family:inherit;font-size:8pt;">nine months</font><font style="font-family:inherit;font-size:8pt;"> ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:8pt;">, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up </font><font style="font-family:inherit;font-size:8pt;">9%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenue. No other individual product within this segment has exceeded </font><font style="font-family:inherit;font-size:8pt;">5%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenues for the periods presented.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The International Pharmaceuticals segment, which accounted for </font><font style="font-family:inherit;font-size:8pt;">4%</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">5%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenues during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;">, respectively, and </font><font style="font-family:inherit;font-size:8pt;">7%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenues during both the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;">, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs, Inc. (Paladin). This segment also included: (i) our South African business, which was sold in July 2017 and consisted of Litha and certain assets acquired from Aspen Holdings in October 2015 and (ii) our Latin American business consisting of Somar, which was sold in October 2017.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 3. DISCONTINUED OPERATIONS AND DIVESTITURES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Astora</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Astora business ceased business operations on March 31, 2016. The operating results of Astora are reported as Discontinued operations, net of tax in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for all periods presented. The following table provides the operating results of Astora for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation-related and other contingencies, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">775,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,134</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,957</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,273</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(813,442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,134</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,017</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,273</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(705,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reported in the table above as Litigation-related and other contingencies, net relate to charges for vaginal-mesh-related matters. </font><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations before income taxes</font><font style="font-family:inherit;font-size:10pt;"> also includes mesh-related legal defense costs and certain other items.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cash flows from discontinued operating activities related to Astora included the impact of net losses of </font><font style="font-family:inherit;font-size:10pt;">$43.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$705.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and the impact of cash activity related to vaginal mesh cases. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> net cash used in discontinued investing activities related to Astora during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> depreciation or amortization during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> related to Astora.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to </font><font style="font-family:inherit;font-size:10pt;">Note 14. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for amounts and additional information relating to vaginal mesh-related matters.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Litha</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2016, the Company initiated a process to sell its Litha Healthcare Group Limited and related Sub-Sahara African business assets (Litha) and, on February 27, 2017, the Company entered into a definitive agreement to sell Litha to Acino Pharma AG (Acino). The sale closed on July 3, 2017 and the Company received net cash proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$94.2 million</font><font style="font-family:inherit;font-size:10pt;">, after giving effect to cash and net working capital purchase price adjustments, as well as a short-term receivable of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">, which was subsequently collected in October 2017. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> additional gain or loss was recognized upon sale. However, in December 2017, Acino became obligated to pay </font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;"> of additional consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on the sale of Litha for this amount. The gain was recorded in </font><font style="font-family:inherit;font-size:10pt;">Other income, net</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. Litha was part of the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. Litha does not meet the requirements for treatment as a discontinued operation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Somar</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 30, 2017, the Company entered into a definitive agreement to sell Grupo Farmac&#233;utico Somar, S.A.P.I. de C.V. (Somar) and all of the securities thereof, to AI Global Investments (Netherlands) PCC Limited acting for and on behalf of the Soar Cell (the Purchaser). The sale closed on October 25, 2017 and the Purchaser paid an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$124 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, after giving effect to estimated cash, debt and net working capital purchase price adjustments. The Company recognized a </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> loss upon sale. Somar was part of the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. Somar does not meet the requirements for treatment as a discontinued operation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 19. NET LOSS PER SHARE</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the numerator and denominator of basic and diluted net </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(146,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99,687</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(696,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(961,130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from discontinued operations, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(705,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,667,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For basic per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ordinary share equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For diluted per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,157</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net </font><font style="font-family:inherit;font-size:10pt;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted </font><font style="font-family:inherit;font-size:10pt;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and awards that have been issued but for which a grant date has not yet been established, such as the performance share units discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 16. Shareholders' (Deficit) Equity</font><font style="font-family:inherit;font-size:10pt;">, are not considered in the calculation of basic or diluted weighted average shares.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All</font><font style="font-family:inherit;font-size:10pt;"> potentially dilutive items were excluded from the diluted share calculation for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> because their effect would have been anti-dilutive, as the Company was in a loss position.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a nonrecurring basis during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Expense for the Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, excluding goodwill (Note 9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(217,576</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain property, plant and equipment (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amount includes </font><font style="font-family:inherit;font-size:8pt;">$2.6 million</font><font style="font-family:inherit;font-size:8pt;"> related to the </font><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:8pt;">, which is described further in </font><font style="font-family:inherit;font-size:8pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 7. FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial instruments recorded in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had combined restricted cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$312.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$324.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$289.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$320.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, are classified as current assets and reported in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> as Restricted cash and cash equivalents. The remaining amounts, which are classified as non-current assets, are reported in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> as Other assets. Approximately </font><font style="font-family:inherit;font-size:10pt;">$283.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$313.8 million</font><font style="font-family:inherit;font-size:10pt;"> of our restricted cash and cash equivalents are held in qualified settlement funds (QSFs) for mesh-related matters at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The remaining amount of restricted cash and cash equivalents at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> primarily relates to other litigation-related matters. See </font><font style="font-family:inherit;font-size:10pt;">Note 14. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for further information.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in </font><font style="font-family:inherit;font-size:10pt;">Marketable securities</font><font style="font-family:inherit;font-size:10pt;"> in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition-Related Contingent Consideration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of contingent consideration liabilities is determined using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recurring Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time deposits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">744,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, money market funds include </font><font style="font-family:inherit;font-size:10pt;">$57.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$35.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See </font><font style="font-family:inherit;font-size:10pt;">Note 14. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of our product liability cases. The differences between the amortized cost and fair value of our money market funds and equity securities were not material, individually or in the aggregate, at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, nor were any of the related gross unrealized gains or losses.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts settled</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,617</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,298</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,927</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in fair value recorded in earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,027</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from approximately </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">22%</font><font style="font-family:inherit;font-size:10pt;"> (weighted average rate of approximately </font><font style="font-family:inherit;font-size:10pt;">14.1%</font><font style="font-family:inherit;font-size:10pt;">). </font><font style="font-family:inherit;font-size:10pt;">Changes in fair value recorded in earnings</font><font style="font-family:inherit;font-size:10pt;"> related to acquisition-related contingent consideration are included in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> as </font><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items</font><font style="font-family:inherit;font-size:10pt;">, and amounts recorded for the short-term and long-term portions of acquisition-related contingent consideration are included in </font><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> and Other liabilities, respectively, in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> by acquisition (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustments and Accretion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments and Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Auxilium acquisition</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Lehigh Valley Technologies, Inc. acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,469</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">VOLTAREN</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Gel acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,014</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,775</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonrecurring Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a nonrecurring basis during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Expense for the Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, excluding goodwill (Note 9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(217,576</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain property, plant and equipment (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(222,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amount includes </font><font style="font-family:inherit;font-size:8pt;">$2.6 million</font><font style="font-family:inherit;font-size:8pt;"> related to the </font><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:8pt;">, which is described further in </font><font style="font-family:inherit;font-size:8pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the Company recorded aggregate goodwill impairment charges during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$391.0 million</font><font style="font-family:inherit;font-size:10pt;">. Refer to </font><font style="font-family:inherit;font-size:10pt;">Note 9. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:10pt;"> for further description, including the valuation methodologies utilized.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> by acquisition (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustments and Accretion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments and Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Auxilium acquisition</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Lehigh Valley Technologies, Inc. acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,469</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">VOLTAREN</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Gel acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,014</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,467</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,775</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts settled</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,617</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,298</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,927</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in fair value recorded in earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,027</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 9. GOODWILL AND OTHER INTANGIBLES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of our goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Sterile Injectables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill as of December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">828,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,531,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,450,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation to current segments (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,731,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,731,193</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill impairment charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">828,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,731,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">409,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,056,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">This allocation relates to the change in segments described in </font><font style="font-family:inherit;font-size:8pt;">Note 6. Segment Results</font><font style="font-family:inherit;font-size:8pt;">. The amount of goodwill initially attributed to the new </font><font style="font-family:inherit;font-size:8pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:8pt;"> segments was determined using a relative fair value methodology in accordance with U.S. GAAP.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of goodwill at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are net of the following accumulated impairments (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Sterile Injectables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">855,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,342,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">463,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,661,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses as of September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">855,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,733,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,040,568</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Intangible Assets</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the amount of other intangible assets for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are set forth in the table below (in thousands).</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost basis:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total indefinite-lived intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (weighted average life of 12 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology (weighted average life of 11 years)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,187,764</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,676</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,753</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,205,394</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total finite-lived intangibles (weighted average life of 11 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651,575</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,676</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,753</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,669,205</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,998,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(217,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,763,105</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated amortization:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(370,221</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,262</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,483</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,304,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,647</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,740,997</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,681,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(471,662</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,138,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,317,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,624,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other adjustments relate to reclassification adjustments of </font><font style="font-family:inherit;font-size:8pt;">$165.4 million</font><font style="font-family:inherit;font-size:8pt;"> for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> and the removal of certain fully amortized intangible assets.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> totaled </font><font style="font-family:inherit;font-size:10pt;">$161.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$471.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> totaled </font><font style="font-family:inherit;font-size:10pt;">$161.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$615.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense is included in Cost of revenues in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552,516</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairments</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach. The discounted cash flow models are dependent upon our estimates of future cash flows and other factors. These estimates of future cash flows involve assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, tax rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows are based on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to </font><font style="font-family:inherit;font-size:10pt;">Asset impairment charges</font><font style="font-family:inherit;font-size:10pt;"> in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred the following goodwill and other intangible asset impairment charges:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill impairment charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible asset impairment charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of significant goodwill and other intangible asset impairment tests and related charges is included below. Other intangible asset impairment charges that are not included in the below narrative totaled </font><font style="font-family:inherit;font-size:10pt;">$140.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$78.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$217.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$461.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. These charges relate primarily to certain in-process research and development and/or developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first quarter 2018 change in segments described in </font><font style="font-family:inherit;font-size:10pt;">Note 6. Segment Results</font><font style="font-family:inherit;font-size:10pt;"> resulted in changes to our reporting units for goodwill impairment testing purposes, including the creation of a new </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;"> reporting unit, which was previously part of our Generics reporting unit. As a result of these changes, under U.S. GAAP, we tested the goodwill of the former Generics reporting unit immediately before the segment realignment and the goodwill of both the new </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> reporting units immediately after the segment realignment. These goodwill tests were performed using an income approach that utilizes a discounted cash flow model. The results of these goodwill impairment tests were as follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The former Generics reporting unit&#8217;s estimated fair value (determined using a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;">) exceeded its carrying amount, resulting in </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> related goodwill impairment charge.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;"> reporting unit&#8217;s estimated fair value (determined using a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;">) exceeded its carrying amount, resulting in </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> related goodwill impairment charge.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> reporting unit&#8217;s carrying amount exceeded its estimated fair value (determined using a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;">), resulting in a pre-tax non-cash goodwill impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$391.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we announced that the Food and Drug Administration&#8217;s (FDA) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA&#8217;s request that we voluntarily withdraw OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">ER from the market, and in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">ER from the market. As a result of our decision, the Company determined that the carrying amount of its OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER intangible asset was no longer recoverable, resulting in a pre-tax, non-cash impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;"> in the second quarter of 2017, representing the remaining carrying amount.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the withdrawal of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER from the market and the continued erosion of our U.S. Branded Pharmaceuticals segment&#8217;s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during the second quarter of 2017. We recorded a pre-tax, non-cash goodwill impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$180.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended June 30, 2017 for the amount by which the carrying amount exceeded the reporting unit&#8217;s fair value. We estimated the fair value of the Branded reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Branded goodwill impairment test was </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As further described in </font><font style="font-family:inherit;font-size:10pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:10pt;">, the Company announced the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;"> in July 2017, which includes the discontinuation of certain commercial products. As a result, the Company assessed the recoverability of the impacted products, resulting in pre-tax, non-cash intangible asset impairment charges of approximately </font><font style="font-family:inherit;font-size:10pt;">$57.5 million</font><font style="font-family:inherit;font-size:10pt;"> during the second quarter of 2017. The Company also initiated an interim goodwill impairment analysis of its Generics reporting unit during the second quarter of 2017 as a result of the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;"> and determined that the estimated fair value of the Generics reporting unit exceeded its carrying amount. Accordingly, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> related goodwill impairment was recorded. The Company estimated the fair value of the Generics reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Generics goodwill impairment test was </font><font style="font-family:inherit;font-size:10pt;">9.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to an existing agreement with a wholly owned subsidiary of Novartis AG (Novartis), Paladin licensed the Canadian rights to commercialize serelaxin, an investigational drug for the treatment of acute heart failure (AHF). In March 2017, Novartis announced that a Phase 3 study of serelaxin in patients with AHF failed to meet its primary endpoints. As a result, we concluded that the full carrying amount of our serelaxin in-process research and development intangible asset was impaired, resulting in a </font><font style="font-family:inherit;font-size:10pt;">$45.5 million</font><font style="font-family:inherit;font-size:10pt;"> pre-tax non-cash impairment charge for the three months ended March 31, 2017. In addition and as a result of the serelaxin impairment, we assessed the recoverability of our Paladin goodwill balance and determined that the estimated fair value of the Paladin reporting unit was below its carrying amount. We recorded a pre-tax, non-cash goodwill impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$82.6 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit&#8217;s fair value. We estimated the fair value of the Paladin reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Paladin goodwill impairment test was </font><font style="font-family:inherit;font-size:10pt;">10.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As further discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 3. Discontinued Operations and Divestitures</font><font style="font-family:inherit;font-size:10pt;">, we entered into a definitive agreement to sell Somar on June 30, 2017, which resulted in Somar&#8217;s assets and liabilities being classified as held for sale. The initiation of held-for-sale accounting, together with the agreed upon sale price, triggered an impairment review. Accordingly, we performed an impairment analysis using a market approach and determined that impairment charges were required. We recorded pre-tax, non-cash impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$25.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$89.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to Somar&#8217;s goodwill and other intangible assets, respectively, during the second quarter of 2017, each of which represented the remaining carrying amounts of the corresponding assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 18. INCOME TAXES</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays our </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Income tax expense (benefit)</font><font style="font-family:inherit;font-size:10pt;"> and Effective tax rate for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,058,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense (benefit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,109</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,517</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">22.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax </font><font style="font-family:inherit;font-size:10pt;">expense</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> primarily relates to </font><font style="font-family:inherit;font-size:10pt;">the geographic mix of pre-tax earnings.</font><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">valuation allowances established against our deferred tax assets in most</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">jurisdictions in which we operate, with the exception of Canada and India</font><font style="font-family:inherit;font-size:10pt;">. The income tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> for the comparable </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> period primarily relates to </font><font style="font-family:inherit;font-size:10pt;">the geographic mix of pre-tax earnings and a discrete tax benefit primarily associated with the filing of the Company&#8217;s 2016 U.S. federal income tax return and an intangible asset impairment.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax </font><font style="font-family:inherit;font-size:10pt;">expense</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> primarily relates to </font><font style="font-family:inherit;font-size:10pt;">the geographic mix of pre-tax earnings and discrete tax expense incurred in connection with an intercompany asset restructuring.</font><font style="font-family:inherit;font-size:10pt;"> The income tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> for the comparable </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> period relates primarily to </font><font style="font-family:inherit;font-size:10pt;">the geographic mix of pre-tax earnings and the discrete tax benefits associated with goodwill and intangible asset impairments and the favorable return to provision adjustments resulting from the filing of the Company&#8217;s 2016 U.S. federal income tax return.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, we recorded a benefit of </font><font style="font-family:inherit;font-size:10pt;">$36.2 million</font><font style="font-family:inherit;font-size:10pt;"> as our estimate of the impact of the TCJA. This benefit, which is primarily related to the remeasurement of deferred tax liabilities related to tax deductible goodwill, was recorded in our Consolidated Statements of Operations as Income tax benefit during the three months ended December 31, 2017.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded the aforementioned net benefit based on currently available information and interpretations of the TCJA. In accordance with authoritative guidance issued by the SEC, the income tax effect for certain aspects of the TCJA may represent provisional amounts for which our accounting is incomplete but a reasonable estimate could be determined. We consider amounts related to the various transition rules and interpretations of the TCJA to be provisional. Accordingly, we will continue to evaluate the impacts of the TCJA, including administrative and regulatory guidance as it becomes available. The measurement and existence of current and non-current income tax payables and/or the remeasurement of deferred tax assets and liabilities may change upon finalization of our analysis, which is expected to occur no later than one year from December 22, 2017, the date of the TCJA&#8217;s enactment. Any adjustment to a provisional amount identified during the one-year measurement period will be recorded as an income tax expense or benefit in the period the adjustment is determined.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we did not record any adjustments to the provisional amounts recognized in 2017. We will continue to monitor for any significant impact on the Company&#8217;s consolidated financial statements with respect to the TCJA as more refined information and further guidance become available.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 8. INVENTORIES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) The components of inventory shown in the table above are net of allowance for obsolescence.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> inventory, is classified as long-term inventory and is not included in the table above. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$17.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of long-term inventory was included in Other assets in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> included approximately </font><font style="font-family:inherit;font-size:10pt;">$13.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of capitalized pre-launch inventories related to generic products that were not yet available to be sold.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 1. BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients&#8217; needs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise indicated or required by the context, references throughout to &#8220;Endo,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to financial information and transactions of Endo International plc and its subsidiaries.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and the results of our operations and our cash flows for the periods presented. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The year-end Condensed Consolidated Balance Sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was derived from audited financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior period amounts have been reclassified to conform to the current period presentation as a result of our fourth-quarter 2017 adoption of Accounting Standards Update (ASU) No. 2016-18 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Statement of Cash Flows (Topic 230) - Restricted Cash&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2016-18). The table below presents the effects of ASU 2016-18 on the Company&#8217;s Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Prior to Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Subsequent to Adoption</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">424,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of foreign exchange rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Movement in cash held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning-of-period balance (2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">805,180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End-of-period balance (2)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,393</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103,486</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">This line refers to the &#8220;Net increase in cash and cash equivalents&#8221; prior to the adoption of ASU 2016-18 and the &#8220;Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents&#8221; after the adoption.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">These lines refer to the beginning or end of period amounts of &#8220;Cash and cash equivalents&#8221; prior to the adoption of ASU 2016-18 and the beginning or end of period amounts of &#8220;Cash, cash equivalents, restricted cash and restricted cash equivalents&#8221; after the adoption.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the information in this Quarterly Report on Form 10-Q has been retrospectively recast to reflect the change in reportable segments referenced in </font><font style="font-family:inherit;font-size:10pt;">Note 6. Segment Results</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 17. OTHER INCOME, NET</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Other income, net</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain on sale of business and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency loss (gain), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(734</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,305</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss (gain) from our investments in the equity of other companies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other miscellaneous, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(808</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(301</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain on sale of business and other assets</font><font style="font-family:inherit;font-size:10pt;"> primarily relates to proceeds received from the sale of various ANDAs during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">Foreign currency loss (gain), net</font><font style="font-family:inherit;font-size:10pt;"> results from the remeasurement of the Company&#8217;s foreign currency denominated assets and liabilities. </font><font style="font-family:inherit;font-size:10pt;">Net loss (gain) from our investments in the equity of other companies</font><font style="font-family:inherit;font-size:10pt;"> includes the income statement impacts of our investments in the equity of other companies, including those accounted for under the equity method and those classified as marketable securities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 4. RESTRUCTURING</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">January 2017 Restructuring Initiative</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 26, 2017, the Company announced a restructuring initiative implemented as part of its ongoing organizational review (the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">January 2017 Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">). This restructuring was intended to further integrate, streamline and optimize the Company&#8217;s operations by aligning certain corporate and research and development (R&amp;D) functions with its recently restructured U.S. generics and U.S. branded business units in order to create efficiencies and cost savings. As part of this restructuring, the Company undertook certain cost reduction initiatives, including a reduction of approximately </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> positions of its workforce, primarily related to corporate and branded R&amp;D functions in Malvern, Pennsylvania and Chestnut Ridge, New York, a streamlining of general and administrative expenses, an optimization of commercial spend and a refocusing of research and development efforts.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not incur any pre-tax charges during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> as a result of the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">January 2017 Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred total pre-tax charges of approximately </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;"> related to employee separation and other benefit-related costs. Of the total charges incurred, </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> was included in Corporate unallocated costs and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> was included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. These charges were included in </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> charges related to this restructuring initiative for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments were made by the end of 2017 and substantially all of the actions associated with this restructuring were completed by the end of April 2017.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 21, 2017, the Company announced that after completing a comprehensive review of its manufacturing network, the Company would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">). The closure of the facilities was completed in June 2018. Employee separation, retention and certain other employee benefit-related costs are expensed ratably over the requisite service period. Other costs including, but not limited to, contract termination fees and product technology transfer costs, are expensed as incurred.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred pre-tax charges of </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$59.6 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the expenses consisted of employee separation and other benefit-related costs of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and certain other charges of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the expenses consisted of charges relating to accelerated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$35.2 million</font><font style="font-family:inherit;font-size:10pt;">, employee separation, retention and other benefit-related costs of </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">, asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and certain other charges of </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred pre-tax charges of </font><font style="font-family:inherit;font-size:10pt;">$94.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$203.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">. The amounts incurred during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> included accelerated depreciation charges of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$59.8 million</font><font style="font-family:inherit;font-size:10pt;">, employee separation, retention and other benefit-related costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19.5 million</font><font style="font-family:inherit;font-size:10pt;">, certain property, plant and equipment impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;"> and certain other charges of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">. The amounts incurred during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> included accelerated depreciation charges of </font><font style="font-family:inherit;font-size:10pt;">$59.8 million</font><font style="font-family:inherit;font-size:10pt;">, employee separation, retention and other benefit-related costs of </font><font style="font-family:inherit;font-size:10pt;">$19.5 million</font><font style="font-family:inherit;font-size:10pt;">, certain intangible asset and property, plant and equipment impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$103.7 million</font><font style="font-family:inherit;font-size:10pt;">, charges to increase excess inventory reserves of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;"> and certain other charges of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">. In the third quarter of 2017, the Company recorded a correcting entry to increase Property, plant and equipment impairment charges resulting from certain assets that should have been impaired during the second quarter of 2017. The pre-tax impact for the three months ended September 30, 2017 includes a correcting adjustment of </font><font style="font-family:inherit;font-size:10pt;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">, which had a corresponding decrease to Property, plant and equipment, net. The Company determined that the impact to the prior period and the current period are not material to the quarterly periods presented and have no impact on 2017 full year results.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These charges are included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. Accelerated depreciation and employee separation, retention and other benefit-related costs are included in Cost of revenues. Certain other charges are included in both Cost of revenues and </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments are expected to be made by the end of the third quarter in 2019.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The liability related to the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;"> is primarily included in Accounts payable and accrued expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Changes to this liability during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">January 2018 Restructuring Initiative</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, the Company initiated a restructuring initiative that included a reorganization of its </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment&#8217;s research and development network, a further simplification of the Company&#8217;s manufacturing networks and a company-wide unification of certain corporate functions (the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">January 2018 Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">January 2018 Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred pre-tax charges of </font><font style="font-family:inherit;font-size:10pt;">$23.8 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The expenses consisted primarily of employee separation, retention and other benefit-related costs of </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;"> and certain other charges of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">. Of the total charges incurred, </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;"> are included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> are included in Corporate unallocated costs, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> are included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;"> segment, </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> are included in the </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> are included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. The Company did not incur material charges related to this restructuring initiative during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and administrative and Research and development expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. Certain other charges are primarily included in Selling, general and administrative expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments are expected to be made by the end of the second quarter in 2019.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The liability related to the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">January 2018 Restructuring Initiative</font><font style="font-family:inherit;font-size:10pt;"> is primarily included in Accounts payable and accrued expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Changes to this liability during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 11. CONTRACT ASSETS AND LIABILITIES</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$ Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets, net (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities, net (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,319</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">At </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">January 1, 2018</font><font style="font-family:inherit;font-size:8pt;">, approximately </font><font style="font-family:inherit;font-size:8pt;">$10.3 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$8.2 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company&#8217;s </font><font style="font-family:inherit;font-size:8pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:8pt;">. The remaining amounts are classified as non-current and are included in Other assets. The net </font><font style="font-family:inherit;font-size:8pt;">increase</font><font style="font-family:inherit;font-size:8pt;"> in contract assets during the </font><font style="font-family:inherit;font-size:8pt;">nine months</font><font style="font-family:inherit;font-size:8pt;"> ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;"> was primarily due to certain sales activity during the period, partially offset by reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company&#8217;s rights to consideration for the sale of certain goods.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">At </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">January 1, 2018</font><font style="font-family:inherit;font-size:8pt;">, approximately </font><font style="font-family:inherit;font-size:8pt;">$1.7 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$1.9 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company&#8217;s </font><font style="font-family:inherit;font-size:8pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:8pt;">. The remaining amounts are classified as non-current and are included in Other liabilities. During the </font><font style="font-family:inherit;font-size:8pt;">nine months</font><font style="font-family:inherit;font-size:8pt;"> ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:8pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:8pt;">$1.3 million</font><font style="font-family:inherit;font-size:8pt;"> that was included in the contract liability balance at </font><font style="font-family:inherit;font-size:8pt;">January 1, 2018</font><font style="font-family:inherit;font-size:8pt;">, resulting in a corresponding </font><font style="font-family:inherit;font-size:8pt;">decrease</font><font style="font-family:inherit;font-size:8pt;"> in contract liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">revenue</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;"> The Company adopted </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Codification Topic 606, Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (ASC 606) on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. For further discussion of the impact of adoption, refer to the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Recent Accounting Pronouncements Adopted or Otherwise Effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#8221; section below. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party&#8217;s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order and invoice the customer upon shipment. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract&#8217;s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, distribution service agreement (DSA) and other fees for services, returns and allowances. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days of invoicing. Our most significant components of variable consideration are further described below. Our estimates for these components are based on factors such as historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets and Contract Liabilities</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;"> Contract assets represent the Company&#8217;s right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time including, for example, the entity&#8217;s future performance. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company&#8217;s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities represent the Company&#8217;s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing the corresponding performance obligation, the contract liability amount is reversed and revenue is recognized.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in </font><font style="font-family:inherit;font-size:10pt;">Note 11. Contract Assets and Liabilities</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> include the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Returns and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,034</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued royalties and other distribution partner payables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Set forth below are the tax effects allocated to each component of </font><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Net-of-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Net-of-Tax Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for (gain) loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gains on securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation gain arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for (gain) loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gains on securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (loss) gain on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation (loss) gain arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,415</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation (loss) gain</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays our </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Income tax expense (benefit)</font><font style="font-family:inherit;font-size:10pt;"> and Effective tax rate for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,058,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense (benefit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,109</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,517</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">22.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(3.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents information about the Company&#8217;s total indebtedness at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Interest Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">7.25% Senior Notes due 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">392,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.75% Senior Notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.375% Senior Notes due 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">742,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,615,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,613,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.875% Senior Secured Notes due 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,181,243</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Term Loan B Facility Due 2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,372,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,397,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,360,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Other debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,357,313</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,262,762</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,382,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,276,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, less current portion, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,323,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,228,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,348,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,242,032</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the operating results of Astora for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation-related and other contingencies, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">775,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,134</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,957</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,273</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(813,442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,134</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,017</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,273</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(705,886</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the numerator and denominator of basic and diluted net </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(146,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99,687</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(696,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(961,130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from discontinued operations, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,273</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(705,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,667,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For basic per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ordinary share equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For diluted per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,829</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,157</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">September&#160;30, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,470</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time deposits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">744,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amounts of goodwill at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are net of the following accumulated impairments (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Sterile Injectables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">855,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,342,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">463,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,661,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses as of September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">855,810</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,733,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,040,568</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of our goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded - Sterile Injectables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill as of December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">828,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,531,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,450,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation to current segments (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,731,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,731,193</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill impairment charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">828,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,731,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">409,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,056,668</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">This allocation relates to the change in segments described in </font><font style="font-family:inherit;font-size:8pt;">Note 6. Segment Results</font><font style="font-family:inherit;font-size:8pt;">. The amount of goodwill initially attributed to the new </font><font style="font-family:inherit;font-size:8pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:8pt;"> segments was determined using a relative fair value methodology in accordance with U.S. GAAP.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><div style="line-height:120%;text-align:left;padding-left:42px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) The components of inventory shown in the table above are net of allowance for obsolescence.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in the QSFs and mesh liability accrual balance during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Qualified Settlement Funds</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Mesh Liability Accrual</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash contributions to Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes from Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248,485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,038</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">845,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. The </font><font style="font-family:inherit;font-size:8pt;">$5.0 million</font><font style="font-family:inherit;font-size:8pt;"> in the table above also includes a second quarter 2018 reclassification adjustment of </font><font style="font-family:inherit;font-size:8pt;">$4.4 million</font><font style="font-family:inherit;font-size:8pt;"> for accrued interest amounts previously recorded in Accounts payable and accrued expenses in the </font><font style="font-family:inherit;font-size:8pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below presents the effects of ASU 2016-18 on the Company&#8217;s Condensed Consolidated Statement of Cash Flows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Prior to Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Subsequent to Adoption</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">424,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,766</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of foreign exchange rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Movement in cash held for sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change (1)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning-of-period balance (2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">805,180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End-of-period balance (2)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,393</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103,486</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">This line refers to the &#8220;Net increase in cash and cash equivalents&#8221; prior to the adoption of ASU 2016-18 and the &#8220;Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents&#8221; after the adoption.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">These lines refer to the beginning or end of period amounts of &#8220;Cash and cash equivalents&#8221; prior to the adoption of ASU 2016-18 and the beginning or end of period amounts of &#8220;Cash, cash equivalents, restricted cash and restricted cash equivalents&#8221; after the adoption.</font></div></td></tr></table></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The current period impact of adoption on our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statement of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Amounts reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Amounts assuming continued application of ASC 605</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Effect of adoption of ASC 606 (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts assuming continued application of ASC 605</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of adoption of ASC 606 (1)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">747,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,465</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,199,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(574</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(146,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(145,431</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(696,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(698,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(741,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share&#8212;Basic:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share&#8212;Diluted:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">At September 30, </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts assuming continued application of ASC 605</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,402</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,934</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(318</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders' (defici</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">t) equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,833,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,838,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Other income, net</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain on sale of business and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency loss (gain), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(734</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,305</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss (gain) from our investments in the equity of other companies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other miscellaneous, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(808</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(301</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes to this liability during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes to this liability during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,951</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents selected information for the Company&#8217;s reportable segments for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues from external customers:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">670,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">748,445</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,227,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues from external customers</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,466</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786,887</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted income from continuing operations before income tax:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,555</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment adjusted income from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,260,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Revenues generated by our </font><font style="font-family:inherit;font-size:8pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:8pt;"> segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays a reconciliation of our beginning and ending balances in </font><font style="font-family:inherit;font-size:10pt;">Total shareholders' equity (deficit)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Shareholders' Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders' equity at January 1, 2018, prior to the adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of adopting ASC 606 (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders' equity at January 1, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation related to share-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax withholding for restricted shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders' deficit at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Refer to </font><font style="font-family:inherit;font-size:8pt;">Note 2. Summary of Significant Accounting Policies</font><font style="font-family:inherit;font-size:8pt;"> for further description of ASC 606.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization of intangibles for the five fiscal years subsequent to December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552,516</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 6. SEGMENT RESULTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of January 1, 2018, we made changes to our reportable segments. Following these changes, the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> reportable business segments in which we operate are: (1) </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;">, (2) </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;">, (3) </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> and (4) </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;">. Previously, we had </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> reportable segments: (1) U.S. Generic Pharmaceuticals, (2) U.S. Branded Pharmaceuticals and (3) International Pharmaceuticals. The updates to our reportable segments were made based on first quarter 2018 changes to the way we manage and evaluate our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our new </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;"> segment consists of our sterile injectables product portfolio, which was previously part of our former U.S. Generic Pharmaceuticals segment. Our new </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment represents the remainder of our former U.S. Generic Pharmaceuticals segment. Additionally, our former U.S. Branded Pharmaceuticals segment has been renamed &#8220;</font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;">.&#8221;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate segment performance based on each segment&#8217;s </font><font style="font-family:inherit;font-size:10pt;">adjusted income from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, which we define as </font><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> and before </font><font style="font-family:inherit;font-size:10pt;">certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company&#8217;s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of the corporate expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company&#8217;s segments and are included in the results below as &#8220;Corporate unallocated costs.&#8221; Interest income and expense are also considered corporate items and not allocated to any of the Company&#8217;s segments. The Company&#8217;s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate items.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment </font><font style="font-family:inherit;font-size:10pt;">includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products in this segment include XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, SUPPRELIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">LA, TESTOPEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, NASCOBAL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Nasal Spray, AVEED</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, PERCOCET</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, VOLTAREN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Gel, LIDODERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, EDEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, TESTIM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and FORTESTA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Gel, among others.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Branded - Sterile Injectables</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font><font style="font-family:inherit;font-size:10pt;"> segment consists primarily of branded sterile injectable products such as VASOSTRICT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, ADRENALIN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and APLISOL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women&#8217;s health and cardiovascular disease markets, among others.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International Pharmaceuticals</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment </font><font style="font-family:inherit;font-size:10pt;">includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs Inc. (Paladin). This segment&#8217;s key products serve growing therapeutic areas, including attention deficit hyperactivity disorder (ADHD), pain, women&#8217;s health and oncology.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">This segment also included: (i) our South African Litha business, which was sold in July 2017</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;"> and (ii) our Latin American Somar business, which was sold in October 2017.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents selected information for the Company&#8217;s reportable segments for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues from external customers:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">670,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">748,445</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,227,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues from external customers</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,466</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786,887</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted income from continuing operations before income tax:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Specialty &amp; Established Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded - Sterile Injectables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,555</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment adjusted income from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,260,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Revenues generated by our </font><font style="font-family:inherit;font-size:8pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:8pt;"> segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> material revenues from external customers attributed to an individual country outside of the United States during any of the periods presented. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> material tangible long-lived assets in an individual country other than the United States as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below provides reconciliations of our consolidated </font><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, which is determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), to our </font><font style="font-family:inherit;font-size:10pt;">total segment adjusted income from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consolidated loss from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,058,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,847</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">385,896</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,267</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate unallocated costs (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">471,662</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615,490</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory step-up</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments to partners</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,731</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">775</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,027</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation benefits and other cost reduction initiatives (2)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain litigation-related and other contingencies, net (3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,750</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,352</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,016</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges (4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023,930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items (5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency impact related to the remeasurement of intercompany debt instruments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,922</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net (6)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment adjusted income from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">351,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,955</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,260,201</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts for the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> relate to employee separation costs of </font><font style="font-family:inherit;font-size:8pt;">$2.1 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$32.7 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, charges to increase excess inventory reserves of </font><font style="font-family:inherit;font-size:8pt;">$0.2 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$2.8 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, and other charges of </font><font style="font-family:inherit;font-size:8pt;">$1.7 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$11.4 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, each of which related primarily to our restructuring initiatives. Also included in the amount for the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> is accelerated depreciation of </font><font style="font-family:inherit;font-size:8pt;">$35.2 million</font><font style="font-family:inherit;font-size:8pt;">, which related to the </font><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:normal;">2017 U.S. Generic Pharmaceuticals Restructuring Initiative</font><font style="font-family:inherit;font-size:8pt;">. During the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;">, amounts primarily relate to employee separation costs of </font><font style="font-family:inherit;font-size:8pt;">$19.8 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$41.3 million</font><font style="font-family:inherit;font-size:8pt;">, accelerated depreciation of </font><font style="font-family:inherit;font-size:8pt;">$59.8 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$60.2 million</font><font style="font-family:inherit;font-size:8pt;">, other charges of </font><font style="font-family:inherit;font-size:8pt;">$1.1 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$18.5 million</font><font style="font-family:inherit;font-size:8pt;">, respectively, and charges to increase excess inventory reserves of </font><font style="font-family:inherit;font-size:8pt;">$7.9 million</font><font style="font-family:inherit;font-size:8pt;"> during the </font><font style="font-family:inherit;font-size:8pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;">. These charges were related primarily to the 2017 U.S. Generics Pharmaceuticals restructuring initiative. See </font><font style="font-family:inherit;font-size:8pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:8pt;"> for discussion of our material restructuring initiatives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts include adjustments for Litigation-related and other contingencies, net as further described in</font><font style="font-family:inherit;font-size:6pt;"> </font><font style="font-family:inherit;font-size:8pt;">Note 14. Commitments and Contingencies</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts primarily relate to charges to impair goodwill and intangible assets as further described in</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:8pt;">Note 9. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:8pt;">as well as charges to write down certain property, plant and equipment as further described in</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:8pt;">Note 7. Fair Value Measurements</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> are primarily related to </font><font style="font-family:inherit;font-size:8pt;">charge</font><font style="font-family:inherit;font-size:8pt;">s due to changes in the fair value of contingent consideration of </font><font style="font-family:inherit;font-size:8pt;">$0.8 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$11.7 million</font><font style="font-family:inherit;font-size:8pt;">, respectively. Amounts during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;"> include </font><font style="font-family:inherit;font-size:8pt;">charge</font><font style="font-family:inherit;font-size:8pt;">s due to changes in the fair value of contingent consideration of </font><font style="font-family:inherit;font-size:8pt;">$15.4 million</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">$23.6 million</font><font style="font-family:inherit;font-size:8pt;">, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.</font><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;"> primarily relate to gains on sales of businesses and other assets, as further described in </font><font style="font-family:inherit;font-size:8pt;">Note 17. Other income, net</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Branded - Specialty &amp; Established Pharmaceuticals:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Specialty Products:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XIAFLEX&#174;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SUPPRELIN&#174; LA</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Specialty (1)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Specialty Products</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,783</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,005</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,988</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Established Products:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PERCOCET&#174;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,349</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VOLTAREN&#174; Gel</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OPANA&#174; ER</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,056</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Established (2)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Established Products</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total U.S. Branded - Specialty &amp; Established Pharmaceuticals (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Branded - Sterile Injectables:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VASOSTRICT&#174;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ADRENALIN&#174;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,464</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ertapenem for injection</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Sterile Injectables (4)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,804</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total U.S. Branded - Sterile Injectables (3)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">670,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">554,365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total U.S. Generic Pharmaceuticals (5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,969</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294,749</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">748,445</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,227,584</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total International Pharmaceuticals (6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,466</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786,887</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Products included within Other Specialty include TESTOPEL</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">, NASCOBAL</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></font><font style="font-family:inherit;font-size:8pt;">Nasal Spray and AVEED</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Products included within Other Established include, but are not limited to, LIDODERM</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">, EDEX</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;">, TESTIM</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> and FORTESTA</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> Gel, including the authorized generics.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of </font><font style="font-family:inherit;font-size:8pt;">$25 million</font><font style="font-family:inherit;font-size:8pt;"> during any quarterly period in </font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;"> or </font><font style="font-family:inherit;font-size:8pt;">2017</font><font style="font-family:inherit;font-size:8pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Products included within Other Sterile Injectables include, but are not limited to, APLISOL</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:8pt;"> and ephedrine sulfate injection.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The U.S. Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the </font><font style="font-family:inherit;font-size:8pt;">nine months</font><font style="font-family:inherit;font-size:8pt;"> ended </font><font style="font-family:inherit;font-size:8pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:8pt;">, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up </font><font style="font-family:inherit;font-size:8pt;">9%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenue. No other individual product within this segment has exceeded </font><font style="font-family:inherit;font-size:8pt;">5%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenues for the periods presented.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The International Pharmaceuticals segment, which accounted for </font><font style="font-family:inherit;font-size:8pt;">4%</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">5%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenues during the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:8pt;">, respectively, and </font><font style="font-family:inherit;font-size:8pt;">7%</font><font style="font-family:inherit;font-size:8pt;"> of consolidated total revenues during both the </font><font style="font-family:inherit;font-size:8pt;">three and nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:8pt;">, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs, Inc. (Paladin). This segment also included: (i) our South African business, which was sold in July 2017 and consisted of Litha and certain assets acquired from Aspen Holdings in October 2015 and (ii) our Latin American business consisting of Somar, which was sold in October 2017.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies Updated since December 31, 2017</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant changes to our significant accounting policies since December 31, 2017 are detailed below. For additional discussion of the Company&#8217;s significant accounting policies, see </font><font style="font-family:inherit;font-size:10pt;">Note 2. Summary of Significant Accounting Policies</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements</font><font style="font-family:inherit;font-size:10pt;">, included in </font><font style="font-family:inherit;font-size:10pt;">Part IV, Item 15</font><font style="font-family:inherit;font-size:10pt;"> of our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, filed with the Securities and Exchange Commission on February 27, 2018.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;"> The Company adopted </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Codification Topic 606, Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (ASC 606) on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. For further discussion of the impact of adoption, refer to the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Recent Accounting Pronouncements Adopted or Otherwise Effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#8221; section below. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party&#8217;s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order and invoice the customer upon shipment. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract&#8217;s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, distribution service agreement (DSA) and other fees for services, returns and allowances. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days of invoicing. Our most significant components of variable consideration are further described below. Our estimates for these components are based on factors such as historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors.</font></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Returns and Allowances. </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified period of time both subsequent to and, in certain cases, prior to the products&#8217; expiration date. Our return policy generally allows customers to receive credit for expired products within six months prior to expiration and within one year after expiration. Our provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and delivery errors.</font></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates. </font><font style="font-family:inherit;font-size:10pt;">Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">direct rebates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indirect rebates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">managed-care rebates.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer&#8217;s purchases from us, including fees paid to wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers which have purchased our products from a wholesaler under a contract with us.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes with respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and group purchasing organizations. For example, we are required to provide a </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> discount on our brand-name drugs to patients who fall within the Medicare Part D coverage gap, also referred to as the donut hole.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We participate in various federal and state government-managed programs whereby discounts and rebates are provided to participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal requirements with public sector (Medicaid) benefit providers after the final dispensing of the product by a pharmacy to a benefit plan participant.</font></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks. </font><font style="font-family:inherit;font-size:10pt;">We market and sell products to both: (i) direct customers including wholesalers, distributors, warehousing pharmacy chains and other direct purchasing groups and (ii) indirect customers including independent pharmacies, non-warehousing chains, managed-care organizations, group purchasing organizations and government entities. We enter into agreements with certain of our indirect customers to establish contract pricing for certain products. These indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler&#8217;s invoice price. Such credit is called a chargeback.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Significant Accounting Policies Added since December 31, 2017</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets and Contract Liabilities</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:10pt;"> Contract assets represent the Company&#8217;s right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time including, for example, the entity&#8217;s future performance. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company&#8217;s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities represent the Company&#8217;s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing the corresponding performance obligation, the contract liability amount is reversed and revenue is recognized.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in </font><font style="font-family:inherit;font-size:10pt;">Note 11. Contract Assets and Liabilities</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2018</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Leases (Topic 842)&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-02) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for most leases. In July 2018, the FASB issued ASU No. 2018-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Codification Improvements to Topic 842, Leases&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Leases (Topic 842) - Targeted Improvements&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2018-11), which addresses implementation issues related to the new lease standard. This guidance will be effective for the Company beginning in the first quarter of 2019, with early application permitted. The Company plans to adopt this guidance in the first quarter of 2019 using the modified retrospective approach and will recognize a cumulative-effect adjustment to the opening balance of Accumulated deficit in that period. This guidance includes a number of optional practical expedients that the Company may elect to apply, including an expedient that permits lease agreements that are twelve months or less to be excluded from the balance sheet. The Company is continuing to evaluate the impact that this new guidance will have on its consolidated financial statements, including its disclosures. It is expected that the primary impact upon adoption will be the recognition, on a discounted basis, of the Company&#8217;s minimum commitments under noncancelable operating leases as right of use assets and obligations on the consolidated balance sheets. This will result in a significant increase in assets and liabilities on the Company&#8217;s consolidated balance sheets. In preparation for the adoption of this guidance, the Company is continuing the process of identifying and validating the Company&#8217;s lease information and evaluating the impact that this new guidance will have on its processes and controls.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2018, the FASB issued ASU No. 2018-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Codification Improvements&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2018-09). ASU 2018-09 makes changes to a variety of topics to clarify, correct errors in or make minor improvements to the Accounting Standards Codification. Certain of these provisions are effective immediately; however, these provisions did not have a material impact on the Company&#8217;s financial statements or disclosures. The remaining provisions are generally effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. The Company is currently evaluating the impact of these remaining provisions of ASU 2018-09 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Topic 820, Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company&#8217;s disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-15 may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-15 on the Company&#8217;s consolidated results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clarifying the Interaction Between Topic 808 and Topic 606&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should generally be applied retrospectively to the date of initial application of Topic 606 (January 1, 2018 for the Company) and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company&#8217;s consolidated results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted or Otherwise Effective as of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2018</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2015-14, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)&#8221; </font><font style="font-family:inherit;font-size:10pt;">(issued in March 2016)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">which clarified the guidance on reporting revenue as a principal versus agent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (issued in April 2016)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrow-Scope Improvements and Practical Expedients&#8221;</font><font style="font-family:inherit;font-size:10pt;"> and ASU No. 2016-20, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These ASUs have generally been codified in Accounting Standards Codification Topic 606 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#8221;, and are collectively referred to herein as ASC 606. ASC 606 supersedes the revenue recognition requirements in Topic 605 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue Recognition&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), and requires entities to recognize revenue when control of promised goods or services is transferred to customers at an amount that reflects the consideration to which entities expect to be entitled in exchange for those goods or services.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded a net decrease of </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The current period impact of adoption on our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statement of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Amounts reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Amounts assuming continued application of ASC 605</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;">Effect of adoption of ASC 606 (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts assuming continued application of ASC 605</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of adoption of ASC 606 (1)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">747,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,965</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,465</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,198,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,199,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(574</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(146,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(145,431</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(696,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(698,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(172,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(741,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share&#8212;Basic:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share&#8212;Diluted:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts may not add due to rounding.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">At September 30, </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amounts assuming continued application of ASC 605</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,402</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,934</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(318</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders' (defici</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">t) equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,833,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,838,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Compensation - Stock Compensation&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 16. SHAREHOLDERS' (DEFICIT) EQUITY</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Shareholders' (Deficit) Equity</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays a reconciliation of our beginning and ending balances in </font><font style="font-family:inherit;font-size:10pt;">Total shareholders' equity (deficit)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Shareholders' Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders' equity at January 1, 2018, prior to the adoption of ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of adopting ASC 606 (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders' equity at January 1, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation related to share-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,722</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax withholding for restricted shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders' deficit at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Refer to </font><font style="font-family:inherit;font-size:8pt;">Note 2. Summary of Significant Accounting Policies</font><font style="font-family:inherit;font-size:8pt;"> for further description of ASC 606.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, the Company&#8217;s shareholders approved an amendment to the Endo International plc Amended and Restated 2015 Stock Incentive Plan (the Plan). The Plan was amended and restated to increase the number of the Company&#8217;s ordinary shares that may be issued with respect to awards under the Plan by </font><font style="font-family:inherit;font-size:10pt;">5.0 million</font><font style="font-family:inherit;font-size:10pt;"> ordinary shares and to make certain other changes to the Plan&#8217;s terms.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized share-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$43.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$40.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the total remaining unrecognized compensation cost related to non-vested share-based compensation awards amounted to </font><font style="font-family:inherit;font-size:10pt;">$45.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the third quarter of 2017, the Company issued approximately </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> stock options and </font><font style="font-family:inherit;font-size:10pt;">0.1 million</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units that were initially subject to shareholder approval and were subsequently approved by shareholders on June 7, 2018 at the Company&#8217;s Annual General Meeting of Shareholders. The options have an exercise price equal to the closing share price on their issuance date in August 2017.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are </font><font style="font-family:inherit;font-size:10pt;">0.5 million</font><font style="font-family:inherit;font-size:10pt;"> performance share units outstanding as of </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, representing target amounts, for which a grant date has not been established. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> fair value has been ascribed to these awards as no grant date has been established. Accordingly, they are not reflected in the remaining unrecognized compensation cost above or the weighted average remaining requisite service period below.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in 2017, long-term cash incentive (LTCI) awards were provided to certain employees. LTCI awards were designed to vest ratably, in equal amounts, over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year service period. Upon vesting, each vested LTCI unit would be settled in cash in an amount equal to the price of Endo&#8217;s ordinary shares on the vest date. As of September 30, 2018, approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3.0 million</font><font style="font-family:inherit;font-size:10pt;"> unvested LTCI awards were outstanding with a weighted average remaining requisite service period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.3 years</font><font style="font-family:inherit;font-size:10pt;">. A corresponding liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14.9 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded as of September 30, 2018 in </font><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> and Other liabilities in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. On October 1, 2018, the Compensation Committee of the Company&#8217;s Board of Directors authorized the Company to settle each of the outstanding unvested LTCI awards in shares, rather than cash, upon vesting in accordance with the original vesting terms of the awards. With the authorization of the Compensation Committee, management&#8217;s intent to settle the awards in shares rather than cash is a modification that changes the awards&#8217; classification from liability to equity, effective October 1, 2018. The accounting for the modification will occur in the fourth quarter of 2018. As of September 30, 2018, the LTCI awards are not reflected in the remaining unrecognized compensation cost above or the weighted average remaining requisite service period below.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the weighted average remaining requisite service period for non-vested stock options was </font><font style="font-family:inherit;font-size:10pt;">1.8 years</font><font style="font-family:inherit;font-size:10pt;"> and for non-vested restricted stock units was </font><font style="font-family:inherit;font-size:10pt;">2.0 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> Other adjustments relate to reclassification adjustments of $165.4 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the nine months ended September 30, 2018 and the removal of certain fully amortized intangible assets. EX-101.SCH 10 endp-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - Accounts Payable And Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Accounts Payable And Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Accounts Payable And Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2405418 - Disclosure - Acquisitions (Other Acquisition) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation - Schedule of Effect of Adoption of ASU 2016-18 (Details) link:presentationLink link:calculationLink link:definitionLink 2301301 - Disclosure - Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Commitments And Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Commitments And Contingencies - Schedule of Loss Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Commitments And Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Contract Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Contract Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Debt (Components Of Total Indebtedness) (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Debt (Credit Facility) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Discontinued Operations and Divestitures link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Discontinued Operations and Divestitures - Astora (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - Discontinued Operations and Divestitures - Lithia (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2403409 - Disclosure - Discontinued Operations and Divestitures - Somar (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Discontinued Operations and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Fair Value Measurements - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Fair Value Measurements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Goodwill And Other Intangibles link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Goodwill And Other Intangibles - Accumulated Impairment (Details) link:presentationLink link:calculationLink link:definitionLink 2410409 - Disclosure - Goodwill And Other Intangibles - Impairments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Goodwill And Other Intangibles - Other Intangibles (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Goodwill And Other Intangibles - Schedule Of Changes In The Carrying Amount Of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - Goodwill And Other Intangibles - Schedule Of Estimated Amortization Of Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 2410408 - Disclosure - Goodwill And Other Intangibles - Schedule of Intangible Asset Impairment Charges Including Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Goodwill And Other Intangibles - Schedule Of Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Goodwill And Other Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - License And Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - License And Collaboration Agreements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Other Comprehensive Income (Loss) (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Other Comprehensive Income (Loss) (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Other Income, Net link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Other Income, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Other Income, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Restructuring - 2017 Restructuring Initiatives (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Restructuring - Schedule of Restructuring Roll Forward (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Segment Results link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Segment Results - Schedule of Disaggregation of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Segment Results - Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Segment Results - Schedule Of Reportable Segments Information (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Segment Results (Tables) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Shareholders' (Deficit) Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Shareholders' (Deficit) Equity - Schedule of Changes in Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Shareholders' (Deficit) Equity Shareholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Shareholders' (Deficit) Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impact of ASC 606 (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 endp-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 endp-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 endp-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Component of Operating Income [Abstract] Schedule of components of other income, net Schedule of Other Nonoperating Income, by Component [Table Text Block] Equity [Abstract] Shareholders' (Deficit) Equity Stockholders' Equity Note Disclosure [Text Block] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts Payable And Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] U.S. Branded - Specialty & Established Pharmaceuticals Branded Specialty and Established Pharmaceuticals [Member] Branded Specialty and Established Pharmaceuticals [Member] U.S. Branded - Sterile Injectables Branded Sterile Injectables [Member] Branded Sterile Injectables [Member] U.S. Generic Pharmaceuticals Generic Pharmaceuticals [Member] Generic Pharmaceuticals [Member] International Pharmaceuticals International Pharmaceuticals [Member] International Pharmaceuticals [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of reportable segments Number of Reportable Segments Total net revenues from external customers Revenues Total segment adjusted income from continuing operations before income tax Adjusted Income (Loss) Before Income Tax Adjusted income (loss) before income tax. Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Vaginal Mesh Cases Vaginal Mesh Cases [Member] Vaginal Mesh Cases [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Mesh Product Liability Accrual Product Liability [Member] Product Liability [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Qualified Settlement Funds Settlement Funds [Roll Forward] Settlement Funds [Roll Forward] Beginning balance Settlement Funds Settlement Funds Cash contributions to Qualified Settlement Funds Settlement Funds, Additions Settlement Funds, Additions Cash distributions to settle disputes from Qualified Settlement Funds Settlement Funds, Payments To Plaintiff Counsel From Qualified Settlement Funds Settlement Funds, Payments To Plaintiff Counsel From Qualified Settlement Funds Other (1) Settlement Funds, Other Settlement Funds, Other Ending balance Mesh Liability Accrual Loss Contingency Accrual [Roll Forward] Beginning balance Loss Contingency Accrual Additional charges Loss Contingency Accrual, Provision Cash distributions to settle disputes from Qualified Settlement Funds Loss Contingency Accrual, Payments To Plaintiff Counsel From Qualified Settlement Funds Loss Contingency Accrual, Payments To Plaintiff Counsel From Qualified Settlement Funds Cash distributions to settle disputes Loss Contingency Accrual, Payments To Plaintiff Counsel Loss Contingency Accrual, Payments To Plaintiff Counsel Ending balance Loss Contingency Accrual, Accrued Interest Loss Contingency Accrual, Accrued Interest Loss Contingency Accrual, Accrued Interest Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Net unrealized gain (loss) on securities Accumulated Net Investment Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Net unrealized gain (loss) on foreign currency Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Before Reclassification, Before Tax Amount Other Comprehensive Income (Loss), before Reclassifications, before Tax Before Reclassification, Tax Benefit (Expense) Other Comprehensive Income (Loss) before Reclassifications, Tax Before Reclassification, Net-of-Tax Amount Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification, Before Tax Amount Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification, Tax Benefit (Expense) Reclassification from AOCI, Current Period, Tax Reclassification, Net-of-Tax Amount Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Before- Tax Amount Other Comprehensive Income (Loss), before Tax Tax Benefit (Expense) Other Comprehensive Income (Loss), Tax OTHER COMPREHENSIVE INCOME (LOSS) Other Comprehensive Income (Loss), Net of Tax Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 7.25% Senior Notes due 2022 Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member] Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member]. 5.75% Senior Notes due 2022 Five Point Seven Five Senior Notes Due On Two Thousand Twenty Two [Member] Five Point Seven Five Senior Notes Due On Two Thousand Twenty Two [Member] 5.375% Senior Notes due 2023 Five Point Three Seven Five Senior Notes Due On Two Thousand Twenty Three [Member] Five Point Three Seven Five Senior Notes Due On Two Thousand Twenty Three [Member] 6.00% Senior Notes due 2023 Six Point Zero Percent Senior Notes Due Two Thousand Twenty Three [Member] Six Point Zero Percent Senior Notes Due Two Thousand Twenty Three [Member] 5.875% Senior Secured Notes due 2024 Five Point Eight Seven Five Percent Senior Secured Notes Due Twenty Twenty Four [Member] Five Point Eight Seven Five Percent Senior Secured Notes Due Twenty Twenty Four [Member] 6.00% Senior Notes due 2025 6.00% Senior Notes Due 2025 [Member] 6.00% Senior Notes Due 2025 [Member] Term Loan B Facility Due 2024 Term Loan B Facility Due Two Thousand Twenty Four [Member] Term Loan B Facility Due Two Thousand Twenty Four [Member] Other debt Other Debt [Member] Other Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Effective interest rate (as percent) Debt Instrument, Interest Rate, Effective Percentage Principal Amount Debt Instrument, Face Amount Carrying Amount Long-term Debt Less current portion, net Long-term Debt, Current Maturities Principal amount of total long-term debt, less current portion, net Debt Instrument, Face Amount, Excluding Current Maturities Debt Instrument, Face Amount, Excluding Current Maturities Carrying amount of total long-term debt, less current portion, net Long-term Debt, Excluding Current Maturities Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Fair value of long term debt Long-term Debt, Fair Value SEGMENT RESULTS Segment Reporting Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash and cash equivalents Restricted Cash, Current Accounts receivable Accounts Receivable, Net, Current Inventories, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income taxes receivable Income Taxes Receivable, Current Total current assets Assets, Current MARKETABLE SECURITIES Marketable Securities, Noncurrent PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment, Net GOODWILL Goodwill OTHER INTANGIBLES, NET Intangible Assets, Net (Excluding Goodwill) DEFERRED INCOME TAXES Deferred Income Tax Assets, Net OTHER ASSETS Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Current portion of legal settlement accrual Loss Contingency, Accrual, Current Current portion of long-term debt Income taxes payable Accrued Income Taxes, Current Total current liabilities Liabilities, Current DEFERRED INCOME TAXES Deferred Income Tax Liabilities, Net LONG-TERM DEBT, LESS CURRENT PORTION, NET LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION Loss Contingency, Accrual, Noncurrent OTHER LIABILITIES Other Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES (NOTE 14) Commitments and Contingencies SHAREHOLDERS' (DEFICIT) EQUITY: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both September 30, 2018 and December 31, 2017 Euro Deferred Stock, Value, Issued Euro Deferred Stock, Value, Issued Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 224,288,553 and 223,331,706 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total shareholders' (deficit) equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY Liabilities and Equity Income Statement [Abstract] TOTAL REVENUES COSTS AND EXPENSES: Costs and Expenses [Abstract] Cost of revenues Cost of Revenue Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Litigation-related and other contingencies, net Legal Fees Asset impairment charges Asset Impairment Charges Acquisition-related and integration items Business Combination, Acquisition Related Costs OPERATING LOSS FROM CONTINUING OPERATIONS Operating Income (Loss) INTEREST EXPENSE, NET Interest Income (Expense), Net LOSS ON EXTINGUISHMENT OF DEBT Extinguishment of Debt, Gain (Loss), Net of Tax OTHER INCOME, NET Nonoperating Income (Expense) LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest INCOME TAX EXPENSE (BENEFIT) Income Tax Expense (Benefit) LOSS FROM CONTINUING OPERATIONS Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3) Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest NET LOSS Net Income (Loss) Attributable to Parent NET (LOSS) INCOME PER SHARE—BASIC: Earnings Per Share, Basic [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Basic (in dollars per share) Earnings Per Share, Basic NET (LOSS) INCOME PER SHARE—DILUTED: Earnings Per Share, Diluted [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Diluted (in dollars per share) Earnings Per Share, Diluted WEIGHTED AVERAGE SHARES: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Statement of Comprehensive Income [Abstract] NET LOSS OTHER COMPREHENSIVE INCOME (LOSS): Other Comprehensive Income (Loss), Net of Tax [Abstract] Net unrealized gain on securities, net of tax: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax [Abstract] Unrealized gain arising during the period Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Less: reclassification adjustments for (gain) loss realized in net loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Net unrealized gain (loss) on securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Net unrealized gain (loss) on foreign currency: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Foreign currency translation gain (loss) arising during the period Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Less: reclassification adjustments for loss realized in net loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax COMPREHENSIVE LOSS Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of new accounting pronouncements Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-18 Accounting Standards Update 2016-18 [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Prior to Adoption Scenario, Previously Reported [Member] Impact of Adoption Restatement Adjustment [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate Effect of Exchange Rate on Cash and Cash Equivalents Movement in cash held for sale Net Cash Provided by (Used in) Discontinued Operations NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD Contract with Customer, Asset and Liability [Abstract] Contract Assets and Liabilities Revenue from Contract with Customer [Text Block] DEBT Debt Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair value, measurements, nonrecurring Fair Value, Measurements, Nonrecurring [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Intangible assets Intangible Assets [Member] Intangible Assets [Member] Certain property, plant and equipment Property, Plant and Equipment [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] 2017 US Generic Pharmaceuticals Restructuring US Generic Pharmaceuticals Restructuring 2017 [Member] US Generic Pharmaceuticals Restructuring 2017 [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Asset impairment charges Asset Impairment Charges [Member] Asset Impairment Charges [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Restructuring expenses Restructuring Charges Assets: Assets, Fair Value Disclosure [Abstract] Intangible assets, excluding goodwill Intangible Assets (Excluding Goodwill), Fair Value Disclosure Intangible Assets (Excluding Goodwill), Fair Value Disclosure Certain property, plant and equipment Property, Plant, and Equipment, Fair Value Disclosure Total Assets, Fair Value Disclosure Total expense for the year Schedule of long-term debt instruments Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Restructuring and Related Activities [Abstract] Schedule of restructuring reserve by type of cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of tax effects allocated to each component of other comprehensive income Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Amortization of intangible assets Amortization of Intangible Assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Nonvested Restricted Stock Non Vested Restricted Stock [Member] Non Vested Restricted Stock [Member] Performance Stock Units Performance Stock Units [Member] Performance Stock Units [Member] Long-term Cash Incentive Long-term Cash Incentive [Member] Long-term Cash Incentive [Member] Nonvested Stock Options Non Vested Stock Options [Member] Non Vested Stock Options [Member] Plan Scenario, Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Additional ordinary shares authorized for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-based compensation Share-based Compensation Share-based compensation awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Stock options issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Awarded in Period, Not Yet Granted, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Awarded in Period, Not Yet Granted, Gross Target amount of share-based compensation awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period, Not Yet Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period, Not Yet Granted Award fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Unvested awards outstanding Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Corresponding liability Deferred Compensation Share-based Arrangements, Liability, Current Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Money market funds Money Market Funds [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Restricted cash and cash equivalents Restricted Cash And Cash Equivalents [Member] Restricted Cash And Cash Equivalents [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Weighted Average Weighted Average [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Restricted cash and cash equivalents classified as current assets Settlement funds Discount rate range (percent) Fair Value Inputs, Discount Rate Goodwill impairment charges Goodwill, Impairment Loss Accumulated Deficit Retained Earnings [Member] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shareholders' equity, beginning balance Effect of adopting ASC 606 Cumulative Effect of New Accounting Principle in Period of Adoption Shareholders' equity at January 1, 2018 Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive loss Compensation related to share-based awards Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Exercise of options Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options Tax withholding for restricted shares Adjustments Related to Tax Withholding for Share-based Compensation Other Stockholders' Equity, Other Shareholders' equity, ending balance Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Somar Somar [Member] Somar [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Aggregate purchase price Disposal Group, Including Discontinued Operation, Consideration Net gain on sale of business and other assets Gain (Loss) on Disposition of Assets Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Forecast Scenario, Forecast [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Corporate unallocated costs Segment Reconciling Items [Member] Operating Segments Operating Segments [Member] Employee Separation, Retention, and Other Benefit Related Costs Employee Separation, Retention, and Other Benefit Related Costs [Member] Employee Separation, Retention, and Other Benefit Related Costs [Member] Other restructuring charges Other Restructuring [Member] January 2018 Restructuring Initiative January 2018 Restructuring [Member] January 2018 Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring charges Restructuring Costs and Asset Impairment Charges Expected restructuring costs remaining Restructuring and Related Cost, Expected Cost Remaining Inventory Disclosure [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Long-term inventory Inventory, Noncurrent Inventories not yet available for sale Inventory, Not Yet Available For Sale, Net Inventory, Not Yet Available For Sale, Net Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] AMS American Medical Systems [Member] American Medical Systems [Member] Par Pharmaceutical, Inc. Par Pharmaceutical, Inc. [Member] Par Pharmaceutical, Inc. [Member] Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. [Member] Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. [Member] Testosterone Cases Testosterone Cases [Member] Testosterone Cases [Member] Unapproved Drug Litigation Unapproved Drug Litigation [Member] Unapproved Drug Litigation [Member] Opioid-Related Matters Opioid-Related Matters [Member] Opioid-Related Matters [Member] Pricing Matters Cases Pricing Matters Cases [Member] Pricing Matters Cases [Member] Lidoderm cases Lidoderm [Member] Lidoderm [Member] AndroGel 1.62% AndroGel 1.62% [Member] AndroGel 1.62% [Member] Bier v. Endo International plc, et al. Bier v. Endo International plc, et al. [Member] Bier v. Endo International plc, et al. [Member] VASOSTRICT Related Matters VASOSTRICT Related Matters [Member] VASOSTRICT Related Matters [Member] OPANA® ER Opana [Member] Opana [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Current and Former Directors and Officers Current and Former Directors and Officers [Member] Current and Former Directors and Officers [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Tranche [Axis] Tranche [Axis] Tranche [Axis] Tranche [Domain] Tranche [Domain] [Domain] for Tranche [Axis] First tranche Tranche 1 [Member] Tranche 1 [Member] Reserve for loss contingencies Product liability accrual, period expense Loss Contingency Accrual, Product Liability, Gross Increase in legal reserves Loss Contingency Accrual, Period Increase (Decrease) Loss contingency, claims settled, number Loss Contingency, Claims Settled, Number Payments to plaintiffs and qualified settlement funds Loss Contingency Accrual, Payments Pending claims, number Loss Contingency, Pending Claims, Number Number of additional defendants Loss Contingency, Number Of Additional Defendants Named Loss Contingency, Number Of Additional Defendants Named Number of claims consolidated Loss Contingency, Number of Claims Consolidated Loss Contingency, Number of Claims Consolidated Number of cases filed by states Loss Contingency, Claims Filed By States, Number Loss Contingency, Claims Filed By States, Number Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party Loss Contingency, Number Of Cases Filed By Hospitals, Health Systems, Unions, Welfare Funds Or Other Third-Party Loss Contingency, Number Of Cases Filed By Hospitals, Health Systems, Unions, Welfare Funds Or Other Third-Party Number of cases alleging personal injury and/or wrongful death Loss Contingency, Number Of Cases Alleging Personal Injury And/Or Wrongful Death Loss Contingency, Number Of Cases Alleging Personal Injury And/Or Wrongful Death Number of claims set for trial Loss Contingency, Cases Set For Trial, Number Loss Contingency, Cases Set For Trial, Number Number of products involved in claims Loss Contingency, Number of Products Involved in Claims Loss Contingency, Number of Products Involved in Claims Loss Contingency, Number of Distributors Loss Contingency, Number of Distributors Loss Contingency, Number of Distributors Number of tranches for claims Loss Contingency, Number of Tranches for Claims Loss Contingency, Number of Tranches for Claims Number of state attorney generals State Attorney Generals, Number State Attorney Generals, Number Number of defendants Loss Contingency, Number of Defendants Number of products allegedly manufactured by PPI Loss Contingency, Number Of Products Allegedly Manufactured By PPI Loss Contingency, Number Of Products Allegedly Manufactured By PPI Number of causation theories rejected Number of Causation Theories Rejected Number of Causation Theories Rejected Number of causation theories Number of Causation Theories Number of Causation Theories Number of patents allegedly infringed upon Gain Contingency, Patents Allegedly Infringed upon, Number Number of defendants filing motion to dismiss the breach of contract claim Loss Contingency, Number Of Defendants Filing Motion To Dismiss Loss Contingency, Number Of Defendants Filing Motion To Dismiss Number of defendants filing motion to dismiss for lack of personal injury jurisdiction Loss Contingency, Number Of Defendants Filing Motion To Dismiss, Lack Of Personal Injury Jurisdiction Loss Contingency, Number Of Defendants Filing Motion To Dismiss, Lack Of Personal Injury Jurisdiction Number of defendants filing motion to dismiss breach of contract claim Loss Contingency, Number Of Defendants Filing Motion To Dismiss Breach of Contract Claim Loss Contingency, Number Of Defendants Filing Motion To Dismiss Breach of Contract Claim Stay of litigation, number of days Loss Contingency, Stay Of Proceedings, Number Of Days Loss Contingency, Stay Of Proceedings, Number Of Days Loss Contingency, Extension of Temporary Stay, Number of Days Loss Contingency, Extension of Temporary Stay, Number of Days Loss Contingency, Extension of Temporary Stay, Number of Days Lawsuit filing period Loss Contingency, Lawsuit Filing Period Loss Contingency, Lawsuit Filing Period Stay of approval period, hatch-waxman act Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Accumulated Deficit Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Amounts assuming continued application of ASC 605 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Effect of adoption of ASC 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] ASC 606 Accounting Standards Update 2014-09 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Discount on brand-name drugs Discount On Brand Name Drugs Discount On Brand Name Drugs Decrease to accumulated deficit Statement of Operations: OTHER EXPENSE (INCOME), NET Loss from continuing operations Basic (in dollars per share) Net loss per share—Diluted: Diluted (in dollars per share) Statement of Financial Position [Abstract] Prepaid expenses and other current assets Liabilities: Liabilities [Abstract] Accounts payable and accrued expenses Shareholders' (deficit) equity: Statement of Stockholders' Equity [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Axis] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Domain] Time deposits Bank Time Deposits [Member] Equity securities Equity Securities [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Acquisition-related contingent consideration—short-term Acquisition Related Contingent Consideration Short Term [Member] Acquisition Related Contingent Consideration-Short Term [Member] Acquisition-related contingent consideration—long-term Acquisition Related Contingent Consideration Long Term [Member] Acquisition-Related Contingent Consideration-Long Term [Member] Assets: Fair value of financial assets measured on recurring basis Assets, Fair Value Disclosure, Recurring Fair value of financial liabilities measured on recurring basis Liabilities, Fair Value Disclosure, Recurring Contract assets, net Contract with Customer, Asset, Net Contract assets, net - $ change Contract with Customer, Asset, Increase (Decrease) Contract with Customer, Asset, Increase (Decrease) Contract assets, net - % change Contract with Customer, Asset, Increase (Decrease), Percentage Contract with Customer, Asset, Increase (Decrease), Percentage Contract liabilities, net Contract with Customer, Liability Contract liabilities, net - $ change Contract with Customer, Liability, Increase (Decrease) Contract with Customer, Liability, Increase (Decrease) Contract liabilities, net - % change Contract with Customer, Liability, Increase (Decrease), Percentage Contract with Customer, Liability, Increase (Decrease), Percentage Contract asset amounts classified as current Contract with Customer, Asset, Net, Current Contract liability amounts classified as current Contract with Customer, Liability, Current Revenue recognized Contract with Customer, Liability, Revenue Recognized Reduction in revenue relating to performance obligation satisfied in prior periods Contract with Customer, Performance Obligation Satisfied in Previous Period Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Somerset Somerset Therapeutics, LLC [Member] Somerset Therapeutics, LLC [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Aggregate consideration transferred Business Combination, Consideration Transferred Debt to be assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Schedule of reportable segments information Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of reconciliations of consolidated loss from continuing operations before income tax Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax To Consolidated Income Before Income Tax [Table Text Block] Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax To Consolidated Income Before Income Tax [Table Text Block] Disaggregation of revenue Disaggregation of Revenue [Table Text Block] January 2017 Restructuring January 2017 Restructuring [Member] January 2017 Restructuring [Member] Property, Plant and Equipment Impairment Charges Property, Plant and Equipment Impairment Charges [Member] Property, Plant and Equipment Impairment Charges [Member] Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Asset Impairment Charges Inventory Reserve Inventory Valuation Reserve [Member] U.S. Branded - Specialty & Established Pharmaceuticals Branded Pharmaceuticals [Member] Branded Pharmaceuticals [Member] Expected number of positions to be eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Restructuring reserve correcting adjustment Restructuring Reserve, Accrual Adjustment Foreign currency loss (gain), net Foreign Currency Transaction Gain (Loss), before Tax Net loss (gain) from our investments in the equity of other companies Income (Loss) from Equity Method Investments Other miscellaneous, net Other Nonoperating Income (Expense) Other income, net Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of Goodwill And Other Intangibles [Table] Schedule of Goodwill And Other Intangibles [Table] Schedule of Goodwill and Other Intangibles [Table]. Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process research and development In Process Research and Development [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licenses Licensing Agreements [Member] Tradenames Trade Names [Member] Developed technology Developed Technology Rights [Member] Other Intangible Assets [Line Items] Other Intangible Assets [Line Items] Other Intangible Assets [Line Items] Cost basis: Other Intangible Assets, Cost Basis [Abstract] Other Intangible Assets, Cost Basis [Abstract] Indefinite-lived intangibles: Indefinite-lived Intangible Assets [Roll Forward] Beginning Balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Acquisitions Indefinite-lived Intangible Assets Acquired Impairments Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Other Indefinite-lived Intangible Assets, Other Indefinite-lived Intangible Assets, Other Effect of Currency Translation Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss) Ending Balance Finite-lived intangibles: Finite-lived Intangible Assets [Roll Forward] Beginning Balance Finite-Lived Intangible Assets, Gross Acquisitions Finite-lived Intangible Assets Acquired Impairments Impairment of Intangible Assets, Finite-lived Other Finite-Lived Intangible Assets, Other Finite-Lived Intangible Assets, Other Effect of Currency Translation Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Ending Balance Total other intangibles Intangible Assets, Gross [Roll Forward] Intangible Assets, Gross [Roll Forward] Beginning balance Intangible Assets, Gross (Excluding Goodwill) Acquisitions Intangible Assets Acquired Intangible Assets Acquired Impairments Impairment of Intangible Assets (Excluding Goodwill) Other Intangible Assets, Other Intangible Assets, Other Effect of Currency Translation Intangible Assets, Foreign Currency Translation Gain (Loss) Intangible Assets, Foreign Currency Translation Gain (Loss) Ending balance Accumulated amortization: Finite-Lived Intangible Assets, Accumulated Amortization [Roll Forward] Finite-Lived Intangible Assets, Accumulated Amortization [Roll Forward] Beginning Balance Finite-Lived Intangible Assets, Accumulated Amortization Amortization Impairments Impairment of Intangible Assets, Finite-lived, Effect On Accumulated Amortization Impairment of Intangible Assets, Finite-lived, Effect On Accumulated Amortization Other Finite-Lived Intangible Assets, Other Adjustments, Increase (Decrease) In Accumulated Amortization Finite-Lived Intangible Assets, Other Adjustments, Increase (Decrease) In Accumulated Amortization Effect of Currency Translation Finite-Lived Intangible Assets, Translation Adjustments, Effect On Accumulated Amortization Finite-Lived Intangible Assets, Translation Adjustments, Effect On Accumulated Amortization Ending Balance Net other intangibles Intangible life (years) Finite-Lived Intangible Asset, Useful Life Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] OTHER INCOME, NET Other Income and Other Expense Disclosure [Text Block] RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Segment Reconciling Items Inventory Write-Offs Inventory Write-Offs [Member] Inventory Write-Offs [Member] Total consolidated loss from continuing operations before income tax Interest expense, net Corporate unallocated costs Segment Reporting Information, Unallocated Corporate Expense Segment Reporting Information, Unallocated Corporate Expense Amortization of intangible assets Inventory step-up Inventory Step Up Inventory Step Up Upfront and milestone payments to partners Upfront And Milestone Payments To Partners Upfront and milestone payments to partners. Separation benefits and other cost reduction initiatives Cost Reduction Initiatives Cost Reduction Initiatives Certain litigation-related and other contingencies, net Loss Contingency, Loss in Period Acquisition-related costs Loss on extinguishment of debt Foreign currency impact related to the remeasurement of intercompany debt instruments Adjustment for Long-term Intercompany Transactions, Gross of Tax Other, net Other Nonrecurring (Income) Expense Severance costs Severance Costs Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Income Tax Disclosure [Abstract] Income tax expense (benefit) Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Provisional tax benefit related to Tax Cuts And Jobs Act Of 2017 Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill, beginning balance Allocation to current segments Goodwill, Allocation To Current Segments Goodwill, Allocation To Current Segments Effect of currency translation on gross balance Goodwill, Foreign Currency Translation Gain (Loss) Goodwill impairment charges Goodwill, ending balance Financial assets and liabilities measured at fair value on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Changes to liability for acquisition-related contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of nonrecurring fair value measurements Fair Value Measurements, Nonrecurring [Table Text Block] Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile Net loss to Net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Amortization of debt issuance costs and discount Amortization of Debt Issuance Costs and Discounts Deferred income taxes Deferred Income Taxes and Tax Credits Change in fair value of contingent consideration Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Asset impairment charges Gain on sale of business and other assets Gain (Loss) on Disposition of Business Changes in assets and liabilities which provided (used) cash: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income taxes payable/receivable Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Net cash provided by operating activities INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment, excluding capitalized interest Payments to Acquire Property, Plant, and Equipment Capitalized interest payments Interest Paid, Capitalized Decrease in notes receivable Proceeds from Sale and Collection of Notes Receivable Proceeds from sale of business and other assets, net Proceeds from Divestiture of Businesses Other investing activities Payments for (Proceeds from) Other Investing Activities Net cash (used in) provided by investing activities FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of notes Proceeds from Notes Payable Proceeds from issuance of term loans Proceeds from Issuance of Debt, Loans Proceeds from Issuance of Debt, Loans Principal payments on term loans Repayments of Other Long-term Debt Principal payments on other indebtedness Repayments of Debt Deferred financing fees Payments of Financing Costs Payments for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Payments of tax withholding for restricted shares Payments Related to Tax Withholding for Share-based Compensation Exercise of options Proceeds from Stock Options Exercised Net cash used in financing activities SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash paid into Qualified Settlement Funds for mesh legal settlements Cash paid out of Qualified Settlement Funds for mesh legal settlements Settlement Funds, Payments Settlement Funds, Payments Other cash distributions for mesh legal settlements Other Payments For Legal Settlements Other Payments For Legal Settlements INVENTORIES Inventory Disclosure [Text Block] Changes in Qualified Settlement Funds accounts and product liability balance Schedule of Loss Contingencies by Contingency [Table Text Block] Trade accounts payable Accounts Payable, Trade, Current Returns and allowances Accrued Liabilities Returns And Allowances Accrued liabilities returns and allowances. Rebates Accrued Liabilities, Rebates Accrued Liabilities, Rebates Chargebacks Accrued Liabilities Chargebacks Accrued liabilities chargebacks. Accrued interest Interest Payable, Current Accrued payroll and related benefits Accrued Employee Benefits, Current Accrued royalties and other distribution partner payables Accrued Royalties and Other Distribution Partner Payables, Current Accrued Royalties and Other Distribution Partner Payables, Current Acquisition-related contingent consideration—short-term Business Combination, Contingent Consideration, Liability, Current Other Other Accrued Liabilities, Current Total Schedule of inventory Schedule of Inventory, Current [Table Text Block] Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Schedule of other intangible assets Schedule Of Other Intangible Assets [Table Text Block] Schedule of other intangible assets table text block Schedule of future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of intangible asset impairment charges including goodwill Schedule of Intangible Asset Impairment Charges Including Goodwill [Table Text Block] Schedule of Intangible Asset Impairment Charges Including Goodwill [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity INCOME TAXES Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Numerator: Earnings Per Share Reconciliation [Abstract] Loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent (Loss) income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] For basic per share data—weighted average shares (shares) Dilutive effect of ordinary share equivalents (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements For diluted per share data—weighted average shares (shares) Schedule of changes in stockholders' equity Schedule of Stockholders Equity [Table Text Block] Acquisition-related contingent consideration Acquisition Related Contingent Consideration [Member] Acquisition-Related Contingent Consideration [Member] Auxilium acquisition Auxilium Pharmaceuticals, Inc. [Member] Auxilium Pharmaceuticals, Inc. [Member] Lehigh Valley Technologies, Inc. acquisitions Lehigh Valley Technologies, Inc. [Member] Lehigh Valley Technologies, Inc. [Member] VOLTAREN® Gel acquisition Voltaren Gel [Member] Voltaren Gel [Member] Other Other Acquisitions [Member] Other Acquisitions [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning of period Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Amounts settled Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Changes in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Effect of currency translation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Gain (Loss) Included in Other Comprehensive Income (Loss) Fair Value Adjustments and Accretion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments And Accretion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments And Accretion Payments and Other Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements And Effect Of Currency Translation Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements And Effect Of Currency Translation End of period License And Collaboration Agreements [Abstract] License and Collaboration Agreements Abstract LICENSE AND COLLABORATION AGREEMENTS Collaborative Arrangement Disclosure [Text Block] 2018 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Recent Accounting Pronouncements Recent Accounting Pronouncements [Policy Text Block] Recent Accounting Pronouncements [Text Block] DISCONTINUED OPERATIONS AND DIVESTITURES Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Former U.S. Generic Pharmaceuticals Former U.S. Generic Pharmaceuticals [Member] Former U.S. Generic Pharmaceuticals [Member] Goodwill [Line Items] Goodwill [Line Items] Accumulated impairment losses Goodwill, Impaired, Accumulated Impairment Loss Number of sterile injectable product candidates Number of Sterile Injectable Product Candidates Number of Sterile Injectable Product Candidates Litha Healthcare Group Limited Litha Healthcare Group Limited [Member] Litha Healthcare Group Limited [Member] Proceeds from sale of business, net Consideration receivable Disposal Group Not Discontinued Operation Consideration Receivable Upon Sale Disposal Group Not Discontinued Operation Consideration Receivable Upon Sale Gain on sale of business Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Goodwill impairment charges Impairment of intangible assets Document And Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Ordinary Shares Outstanding Entity Common Stock, Shares Outstanding Euro deferred shares, par value (in dollars per share) Euro Deferred Shares, Par or Stated Value Per Share Euro Deferred Shares, Par or Stated Value Per Share Euro deferred shares, shares authorized Euro Deferred Shares, Shares Authorized Euro Deferred Shares, Shares Authorized Euro deferred shares, shares issued Euro Deferred Shares, Shares Issued Euro Deferred Shares, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Employee separation, retention and other benefit-related costs Employee Severence and Other Benefit Related Costs [Member] Employee Severence and Other Benefit Related Costs [Member] Other Restructuring Costs Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning liability balance Restructuring Reserve Expenses Cash distributions Payments for Restructuring Ending liability balance ACQUISITIONS Business Combination Disclosure [Text Block] Schedule of Income Tax Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Contract Assets and Liabilities Contract with Customer, Asset and Liability [Table Text Block] NET LOSS PER SHARE Earnings Per Share [Text Block] Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Astora Astora [Member] Astora [Member] Litigation-related and other contingencies, net Disposal Group Including Discontinued Operation, Litigation Related And Other Contingencies Disposal Group Including Discontinued Operation, Litigation Related And Other Contingencies Loss from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax benefit Discontinued Operation, Tax Effect of Discontinued Operation Income (loss) from discontinued operations, net of tax Cash used in discontinued investing activities Operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Depreciation and amortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] In process research and development or developed technology In Process Research and Development Or Developed Technology [Member] In Process Research and Development Or Developed Technology [Member] Paladin Labs Inc. Paladin Labs Inc. [Member] Paladin Labs Inc. [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Serelaxin In-Process Research and Development Intangible Assets Serelaxin In-Process Research and Development Intangible Assets [Member] Serelaxin In-Process Research and Development Intangible Assets [Member] Discount rate applied (percent) Goodwill impairment charges (reduction) Non-cash intangible asset impairment charge FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Reconciliation of the numerator and denominator of basic and diluted net loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Product Concentration Risk Product Concentration Risk [Member] XIAFLEX® Xiaflex [Member] Xiaflex [Member] SUPPRELIN® LA SUPPRELIN LA [Member] SUPPRELIN LA [Member] Other Specialty Other Specialty Products [Member] Other Specialty Products [Member] Total Specialty Products Total Specialty Products [Member] Total Specialty Products [Member] PERCOCET® PERCOCET [Member] PERCOCET [Member] VOLTAREN® Gel Other Established Other Established Products [Member] Other Established Products [Member] Total Established Products Established Products [Member] Established Products [Member] Vasostrict® Vasostrict [Member] Vasostrict [Member] ADRENALIN® Adrenalin [Member] Adrenalin [Member] Ertapenem For Injection Ertapenem For Injection [Member] Ertapenem For Injection [Member] Other Sterile Injectables Other Sterile Injectables [Member] Other Sterile Injectables [Member] Ezetimibe and Quetiapine ER Tablets Ezetimibe and Quetiapine ER Tablets [Member] Ezetimibe and Quetiapine ER Tablets [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Product line revenue reporting threshold Product Line Revenue Reporting Threshold Product Line Revenue Reporting Threshold Concentration risk, percentage Concentration Risk, Percentage EX-101.PRE 14 endp-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 15 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document And Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 01, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Trading Symbol ENDP  
Entity Registrant Name Endo International plc  
Entity Central Index Key 0001593034  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Ordinary Shares Outstanding   224,344,760
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
CURRENT ASSETS:    
Cash and cash equivalents $ 1,118,885 $ 986,605
Restricted cash and cash equivalents 289,667 320,453
Accounts receivable 467,156 517,436
Inventories, net 332,787 391,437
Prepaid expenses and other current assets 50,697 43,098
Income taxes receivable 16,407 12,048
Total current assets 2,275,599 2,271,077
MARKETABLE SECURITIES 1,693 1,456
PROPERTY, PLANT AND EQUIPMENT, NET 495,546 523,971
GOODWILL 4,056,668 4,450,082
OTHER INTANGIBLES, NET 3,624,216 4,317,684
DEFERRED INCOME TAXES 6 11,582
OTHER ASSETS 67,934 59,728
TOTAL ASSETS 10,521,662 11,635,580
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 1,019,004 1,096,825
Current portion of legal settlement accrual 966,633 1,087,793
Current portion of long-term debt 34,150 34,205
Income taxes payable 1,681 2,086
Total current liabilities 2,021,468 2,220,909
DEFERRED INCOME TAXES 43,630 43,131
LONG-TERM DEBT, LESS CURRENT PORTION, NET 8,228,612 8,242,032
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION 35,450 210,450
OTHER LIABILITIES 411,961 434,178
COMMITMENTS AND CONTINGENCIES (NOTE 14)
SHAREHOLDERS' (DEFICIT) EQUITY:    
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both September 30, 2018 and December 31, 2017 46 48
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 224,288,553 and 223,331,706 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 22 22
Additional paid-in capital 8,830,351 8,791,170
Accumulated deficit (8,833,024) (8,096,539)
Accumulated other comprehensive loss (216,854) (209,821)
Total shareholders' (deficit) equity (219,459) 484,880
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY $ 10,521,662 $ 11,635,580
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Euro deferred shares, par value (in dollars per share) $ 0.01 $ 0.01
Euro deferred shares, shares authorized 4,000,000 4,000,000
Euro deferred shares, shares issued 4,000,000 4,000,000
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 224,288,553 223,331,706
Common stock, shares outstanding 224,288,553 223,331,706
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
TOTAL REVENUES $ 745,466 $ 786,887 $ 2,160,689 $ 2,700,218
COSTS AND EXPENSES:        
Cost of revenues 412,965 514,522 1,198,468 1,722,885
Selling, general and administrative 163,791 135,880 478,615 468,675
Research and development 39,683 39,644 160,431 123,522
Litigation-related and other contingencies, net (1,750) (12,352) 15,370 (14,016)
Asset impairment charges 142,217 94,924 613,400 1,023,930
Acquisition-related and integration items 1,288 16,641 13,284 31,711
OPERATING LOSS FROM CONTINUING OPERATIONS (12,728) (2,372) (318,879) (656,489)
INTEREST EXPENSE, NET 131,847 127,521 385,896 361,267
LOSS ON EXTINGUISHMENT OF DEBT 0 0 0 (51,734)
OTHER INCOME, NET (1,507) (2,097) (33,216) (10,843)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX (143,068) (127,796) (671,559) (1,058,647)
INCOME TAX EXPENSE (BENEFIT) 3,003 (28,109) 24,729 (97,517)
LOSS FROM CONTINUING OPERATIONS (146,071) (99,687) (696,288) (961,130)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3) (27,134) 3,017 (43,273) (705,886)
NET LOSS $ (173,205) $ (96,670) $ (739,561) $ (1,667,016)
NET (LOSS) INCOME PER SHARE—BASIC:        
Continuing operations (in dollars per share) $ (0.65) $ (0.45) $ (3.11) $ (4.31)
Discontinued operations (in dollars per share) (0.12) 0.02 (0.19) (3.16)
Basic (in dollars per share) (0.77) (0.43) (3.30) (7.47)
NET (LOSS) INCOME PER SHARE—DILUTED:        
Continuing operations (in dollars per share) (0.65) (0.45) (3.11) (4.31)
Discontinued operations (in dollars per share) (0.12) 0.02 (0.19) (3.16)
Diluted (in dollars per share) $ (0.77) $ (0.43) $ (3.30) $ (7.47)
WEIGHTED AVERAGE SHARES:        
Basic (shares) 224,132 223,299 223,829 223,157
Diluted (shares) 224,132 223,299 223,829 223,157
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
NET LOSS $ (173,205) $ (96,670) $ (739,561) $ (1,667,016)
Net unrealized gain on securities, net of tax:        
Unrealized gain arising during the period   188   333
Less: reclassification adjustments for (gain) loss realized in net loss 0 0 0 0
Net unrealized gain (loss) on securities 0 188 0 333
Net unrealized gain (loss) on foreign currency:        
Foreign currency translation gain (loss) arising during the period 4,735 9,941 (7,033) 35,415
Less: reclassification adjustments for loss realized in net loss 0 29,325 0 29,325
Foreign currency translation gain (loss) 4,735 39,266 (7,033) 64,740
OTHER COMPREHENSIVE INCOME (LOSS) 4,735 39,454 (7,033) 65,073
COMPREHENSIVE LOSS $ (168,470) $ (57,216) $ (746,594) $ (1,601,943)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
OPERATING ACTIVITIES:    
NET LOSS $ (739,561) $ (1,667,016)
Adjustments to reconcile Net loss to Net cash provided by operating activities:    
Depreciation and amortization 556,503 742,936
Inventory step-up 261 281
Share-based compensation 43,722 40,252
Amortization of debt issuance costs and discount 15,289 17,698
Deferred income taxes 13,118 (239,174)
Change in fair value of contingent consideration 11,731 23,574
Loss on extinguishment of debt 0 51,734
Asset impairment charges 613,400 1,023,930
Gain on sale of business and other assets (29,859) (5,074)
Changes in assets and liabilities which provided (used) cash:    
Accounts receivable 31,634 471,448
Inventories 52,499 91,047
Prepaid and other assets 993 11,626
Accounts payable, accrued expenses and other liabilities (367,979) (159,245)
Income taxes payable/receivable (4,759) 18,145
Net cash provided by operating activities 196,992 422,162
INVESTING ACTIVITIES:    
Purchases of property, plant and equipment, excluding capitalized interest (56,544) (94,102)
Capitalized interest payments (2,569) 0
Decrease in notes receivable 0 7,000
Proceeds from sale of business and other assets, net 43,753 96,066
Other investing activities 1,678 0
Net cash (used in) provided by investing activities (13,682) 8,964
FINANCING ACTIVITIES:    
Proceeds from issuance of notes 0 300,000
Proceeds from issuance of term loans 0 3,415,000
Principal payments on term loans (25,614) (3,722,413)
Principal payments on other indebtedness (3,921) (4,912)
Deferred financing fees 0 (57,358)
Payments for contingent consideration (28,664) (63,712)
Payments of tax withholding for restricted shares (5,082) (1,958)
Exercise of options 473 0
Net cash used in financing activities (62,808) (135,353)
Effect of foreign exchange rate (608) 3,983
Movement in cash held for sale 0 (1,450)
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS 119,894 298,306
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD 1,311,014 805,180
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD 1,430,908 1,103,486
SUPPLEMENTAL INFORMATION:    
Cash paid into Qualified Settlement Funds for mesh legal settlements 216,770 623,128
Cash paid out of Qualified Settlement Funds for mesh legal settlements 248,485 545,379
Other cash distributions for mesh legal settlements $ 17,114 $ 3,625
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE 1. BASIS OF PRESENTATION
Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs.
Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our,” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries.
The accompanying unaudited Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2018 and the results of our operations and our cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The year-end Condensed Consolidated Balance Sheet data as of December 31, 2017 was derived from audited financial statements.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2017.
Certain prior period amounts have been reclassified to conform to the current period presentation as a result of our fourth-quarter 2017 adoption of Accounting Standards Update (ASU) No. 2016-18 “Statement of Cash Flows (Topic 230) - Restricted Cash” (ASU 2016-18). The table below presents the effects of ASU 2016-18 on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 (in thousands):
 
Prior to Adoption
 
Impact of Adoption
 
Subsequent to Adoption
Net cash provided by operating activities
$
424,062

 
$
(1,900
)
 
$
422,162

Net cash (used in) provided by investing activities
(69,802
)
 
78,766

 
8,964

Net cash used in financing activities
(135,353
)
 
—

 
(135,353
)
Effect of foreign exchange rate
3,686

 
297

 
3,983

Movement in cash held for sale
(1,450
)
 
—

 
(1,450
)
Net change (1)
$
221,143

 
$
77,163

 
$
298,306

Beginning-of-period balance (2)
517,250

 
287,930

 
805,180

End-of-period balance (2)
$
738,393

 
$
365,093

 
$
1,103,486

__________
(1)
This line refers to the “Net increase in cash and cash equivalents” prior to the adoption of ASU 2016-18 and the “Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
(2)
These lines refer to the beginning or end of period amounts of “Cash and cash equivalents” prior to the adoption of ASU 2016-18 and the beginning or end of period amounts of “Cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
Additionally, the information in this Quarterly Report on Form 10-Q has been retrospectively recast to reflect the change in reportable segments referenced in Note 6. Segment Results.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Significant Accounting Policies Updated since December 31, 2017
Significant changes to our significant accounting policies since December 31, 2017 are detailed below. For additional discussion of the Company’s significant accounting policies, see Note 2. Summary of Significant Accounting Policies in the Consolidated Financial Statements, included in Part IV, Item 15 of our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on February 27, 2018.
Revenue Recognition. The Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. For further discussion of the impact of adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2018” section below. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.
Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order and invoice the customer upon shipment. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract’s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, distribution service agreement (DSA) and other fees for services, returns and allowances. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within 30 to 90 days of invoicing. Our most significant components of variable consideration are further described below. Our estimates for these components are based on factors such as historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors.
Returns and Allowances. Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified period of time both subsequent to and, in certain cases, prior to the products’ expiration date. Our return policy generally allows customers to receive credit for expired products within six months prior to expiration and within one year after expiration. Our provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and delivery errors.
Rebates. Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:
•
direct rebates;
•
indirect rebates;
•
governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and
•
managed-care rebates.
We establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers which have purchased our products from a wholesaler under a contract with us.
We are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes with respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and group purchasing organizations. For example, we are required to provide a 50% discount on our brand-name drugs to patients who fall within the Medicare Part D coverage gap, also referred to as the donut hole.
We participate in various federal and state government-managed programs whereby discounts and rebates are provided to participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal requirements with public sector (Medicaid) benefit providers after the final dispensing of the product by a pharmacy to a benefit plan participant.
Chargebacks. We market and sell products to both: (i) direct customers including wholesalers, distributors, warehousing pharmacy chains and other direct purchasing groups and (ii) indirect customers including independent pharmacies, non-warehousing chains, managed-care organizations, group purchasing organizations and government entities. We enter into agreements with certain of our indirect customers to establish contract pricing for certain products. These indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler’s invoice price. Such credit is called a chargeback.
New Significant Accounting Policies Added since December 31, 2017
Contract Assets and Contract Liabilities. Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time including, for example, the entity’s future performance. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company’s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.
Contract liabilities represent the Company’s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing the corresponding performance obligation, the contract liability amount is reversed and revenue is recognized.
Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in Note 11. Contract Assets and Liabilities.
Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2018
In February 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for most leases. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, “Leases (Topic 842) - Targeted Improvements” (ASU 2018-11), which addresses implementation issues related to the new lease standard. This guidance will be effective for the Company beginning in the first quarter of 2019, with early application permitted. The Company plans to adopt this guidance in the first quarter of 2019 using the modified retrospective approach and will recognize a cumulative-effect adjustment to the opening balance of Accumulated deficit in that period. This guidance includes a number of optional practical expedients that the Company may elect to apply, including an expedient that permits lease agreements that are twelve months or less to be excluded from the balance sheet. The Company is continuing to evaluate the impact that this new guidance will have on its consolidated financial statements, including its disclosures. It is expected that the primary impact upon adoption will be the recognition, on a discounted basis, of the Company’s minimum commitments under noncancelable operating leases as right of use assets and obligations on the consolidated balance sheets. This will result in a significant increase in assets and liabilities on the Company’s consolidated balance sheets. In preparation for the adoption of this guidance, the Company is continuing the process of identifying and validating the Company’s lease information and evaluating the impact that this new guidance will have on its processes and controls.
In February 2018, the FASB issued ASU No. 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02 on the Company’s consolidated results of operations and financial position.
In July 2018, the FASB issued ASU No. 2018-09, “Codification Improvements” (ASU 2018-09). ASU 2018-09 makes changes to a variety of topics to clarify, correct errors in or make minor improvements to the Accounting Standards Codification. Certain of these provisions are effective immediately; however, these provisions did not have a material impact on the Company’s financial statements or disclosures. The remaining provisions are generally effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. The Company is currently evaluating the impact of these remaining provisions of ASU 2018-09 on the Company’s consolidated results of operations and financial position.
In August 2018, the FASB issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company’s disclosures.
In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-15 may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-15 on the Company’s consolidated results of operations, financial position and disclosures.
In November 2018, the FASB issued ASU No. 2018-18, “Clarifying the Interaction Between Topic 808 and Topic 606” (ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should generally be applied retrospectively to the date of initial application of Topic 606 (January 1, 2018 for the Company) and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company’s consolidated results of operations, financial position and disclosures.
Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2018
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:
•
ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;
•
ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” (issued in March 2016), which clarified the guidance on reporting revenue as a principal versus agent;
•
ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (issued in April 2016), which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and
•
ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” and ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.
These ASUs have generally been codified in Accounting Standards Codification Topic 606 “Revenue from Contracts with Customers”, and are collectively referred to herein as ASC 606. ASC 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (ASC 605), and requires entities to recognize revenue when control of promised goods or services is transferred to customers at an amount that reflects the consideration to which entities expect to be entitled in exchange for those goods or services.
The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded a net decrease of $3.1 million to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.
The current period impact of adoption on our Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets is as follows (in thousands, except per share amounts):
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Statement of Operations:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
 
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
Total revenues
$
745,466

 
$
747,571

 
$
(2,105
)
 
$
2,160,689

 
$
2,160,132

 
$
557

Cost of revenues
$
412,965

 
$
414,430

 
$
(1,465
)
 
$
1,198,468

 
$
1,199,042

 
$
(574
)
Other income, net
$
(1,507
)
 
$
(1,507
)
 
$
—

 
$
(33,216
)
 
$
(32,216
)
 
$
(1,000
)
Loss from continuing operations
$
(146,071
)
 
$
(145,431
)
 
$
(640
)
 
$
(696,288
)
 
$
(698,419
)
 
$
2,131

Net loss
$
(173,205
)
 
$
(172,565
)
 
$
(640
)
 
$
(739,561
)
 
$
(741,692
)
 
$
2,131

Net loss per share—Basic:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total basic
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

Net loss per share—Diluted:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total diluted
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

__________
(1)
Amounts may not add due to rounding.
 
At September 30, 2018
Balance Sheet:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606
Assets:
 
 
 
 
 
Inventories, net
$
332,787

 
$
341,189

 
$
(8,402
)
Prepaid expenses and other current assets
$
50,697

 
$
40,368

 
$
10,329

Other assets
$
67,934

 
$
64,972

 
$
2,962

Liabilities:
 
 
 
 
 
Accounts payable and accrued expenses
$
1,019,004

 
$
1,019,322

 
$
(318
)
Shareholders' (deficit) equity:
 
 
 
 
 
Accumulated deficit
$
(8,833,024
)
 
$
(8,838,231
)
 
$
5,207


In May 2017, the FASB issued ASU No. 2017-09 “Compensation - Stock Compensation” (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Discontinued Operations and Divestitures
 9 Months Ended
Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS AND DIVESTITURES
NOTE 3. DISCONTINUED OPERATIONS AND DIVESTITURES
Astora
The Company’s Astora business ceased business operations on March 31, 2016. The operating results of Astora are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. The following table provides the operating results of Astora for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Litigation-related and other contingencies, net
$
19,000

 
$
—

 
$
19,000

 
$
775,684

Loss from discontinued operations before income taxes
$
(27,134
)
 
$
(8,957
)
 
$
(43,273
)
 
$
(813,442
)
Income tax benefit
$
—

 
$
(11,974
)
 
$
—

 
$
(107,556
)
Discontinued operations, net of tax
$
(27,134
)
 
$
3,017

 
$
(43,273
)
 
$
(705,886
)

Amounts reported in the table above as Litigation-related and other contingencies, net relate to charges for vaginal-mesh-related matters. Loss from discontinued operations before income taxes also includes mesh-related legal defense costs and certain other items.
The cash flows from discontinued operating activities related to Astora included the impact of net losses of $43.3 million and $705.9 million for the nine months ended September 30, 2018 and 2017, respectively, and the impact of cash activity related to vaginal mesh cases. There was no net cash used in discontinued investing activities related to Astora during the nine months ended September 30, 2018 or 2017. There was no depreciation or amortization during the nine months ended September 30, 2018 or 2017 related to Astora.
Refer to Note 14. Commitments and Contingencies for amounts and additional information relating to vaginal mesh-related matters.
Litha
During the fourth quarter of 2016, the Company initiated a process to sell its Litha Healthcare Group Limited and related Sub-Sahara African business assets (Litha) and, on February 27, 2017, the Company entered into a definitive agreement to sell Litha to Acino Pharma AG (Acino). The sale closed on July 3, 2017 and the Company received net cash proceeds of approximately $94.2 million, after giving effect to cash and net working capital purchase price adjustments, as well as a short-term receivable of $4.4 million, which was subsequently collected in October 2017. No additional gain or loss was recognized upon sale. However, in December 2017, Acino became obligated to pay $10.1 million of additional consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on the sale of Litha for this amount. The gain was recorded in Other income, net in the Condensed Consolidated Statements of Operations. Litha was part of the Company’s International Pharmaceuticals segment. Litha does not meet the requirements for treatment as a discontinued operation.
Somar
On June 30, 2017, the Company entered into a definitive agreement to sell Grupo Farmacéutico Somar, S.A.P.I. de C.V. (Somar) and all of the securities thereof, to AI Global Investments (Netherlands) PCC Limited acting for and on behalf of the Soar Cell (the Purchaser). The sale closed on October 25, 2017 and the Purchaser paid an aggregate purchase price of approximately $124 million in cash, after giving effect to estimated cash, debt and net working capital purchase price adjustments. The Company recognized a $1.3 million loss upon sale. Somar was part of the Company’s International Pharmaceuticals segment. Somar does not meet the requirements for treatment as a discontinued operation.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
RESTRUCTURING
NOTE 4. RESTRUCTURING
January 2017 Restructuring Initiative
On January 26, 2017, the Company announced a restructuring initiative implemented as part of its ongoing organizational review (the January 2017 Restructuring Initiative). This restructuring was intended to further integrate, streamline and optimize the Company’s operations by aligning certain corporate and research and development (R&D) functions with its recently restructured U.S. generics and U.S. branded business units in order to create efficiencies and cost savings. As part of this restructuring, the Company undertook certain cost reduction initiatives, including a reduction of approximately 90 positions of its workforce, primarily related to corporate and branded R&D functions in Malvern, Pennsylvania and Chestnut Ridge, New York, a streamlining of general and administrative expenses, an optimization of commercial spend and a refocusing of research and development efforts.
The Company did not incur any pre-tax charges during the three and nine months ended September 30, 2018 as a result of the January 2017 Restructuring Initiative. During the nine months ended September 30, 2017, the Company incurred total pre-tax charges of approximately $15.1 million related to employee separation and other benefit-related costs. Of the total charges incurred, $6.9 million was included in the U.S. Branded - Specialty & Established Pharmaceuticals segment, $4.9 million was included in Corporate unallocated costs and $3.3 million was included in the U.S. Generic Pharmaceuticals segment. These charges were included in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. There were no charges related to this restructuring initiative for the three months ended September 30, 2017. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments were made by the end of 2017 and substantially all of the actions associated with this restructuring were completed by the end of April 2017.
2017 U.S. Generic Pharmaceuticals Restructuring Initiative
On July 21, 2017, the Company announced that after completing a comprehensive review of its manufacturing network, the Company would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative). The closure of the facilities was completed in June 2018. Employee separation, retention and certain other employee benefit-related costs are expensed ratably over the requisite service period. Other costs including, but not limited to, contract termination fees and product technology transfer costs, are expensed as incurred.
As a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $4.8 million and $59.6 million during the three and nine months ended September 30, 2018, respectively. During the three months ended September 30, 2018, the expenses consisted of employee separation and other benefit-related costs of $2.1 million and certain other charges of $2.7 million. During the nine months ended September 30, 2018, the expenses consisted of charges relating to accelerated depreciation of $35.2 million, employee separation, retention and other benefit-related costs of $9.8 million, asset impairment charges of $2.6 million and certain other charges of $12.0 million.
During the three and nine months ended September 30, 2017, the Company incurred pre-tax charges of $94.2 million and $203.7 million, respectively, related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. The amounts incurred during the three months ended September 30, 2017 included accelerated depreciation charges of $59.8 million, employee separation, retention and other benefit-related costs of $19.5 million, certain property, plant and equipment impairment charges of $14.2 million and certain other charges of $0.6 million. The amounts incurred during the nine months ended September 30, 2017 included accelerated depreciation charges of $59.8 million, employee separation, retention and other benefit-related costs of $19.5 million, certain intangible asset and property, plant and equipment impairment charges of $103.7 million, charges to increase excess inventory reserves of $7.9 million and certain other charges of $12.7 million. In the third quarter of 2017, the Company recorded a correcting entry to increase Property, plant and equipment impairment charges resulting from certain assets that should have been impaired during the second quarter of 2017. The pre-tax impact for the three months ended September 30, 2017 includes a correcting adjustment of $14.2 million, which had a corresponding decrease to Property, plant and equipment, net. The Company determined that the impact to the prior period and the current period are not material to the quarterly periods presented and have no impact on 2017 full year results.
These charges are included in the U.S. Generic Pharmaceuticals segment. Accelerated depreciation and employee separation, retention and other benefit-related costs are included in Cost of revenues. Certain other charges are included in both Cost of revenues and Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments are expected to be made by the end of the third quarter in 2019.
The liability related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this liability during the nine months ended September 30, 2018 were as follows (in thousands):
 
Employee Separation and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2018
$
22,975

 
$
1,610

 
$
24,585

Expenses
9,779

 
9,341

 
19,120

Cash distributions
(22,518
)
 
(10,951
)
 
(33,469
)
Liability balance as of September 30, 2018
$
10,236

 
$
—

 
$
10,236


January 2018 Restructuring Initiative
In January 2018, the Company initiated a restructuring initiative that included a reorganization of its U.S. Generic Pharmaceuticals segment’s research and development network, a further simplification of the Company’s manufacturing networks and a company-wide unification of certain corporate functions (the January 2018 Restructuring Initiative).
As a result of the January 2018 Restructuring Initiative, the Company incurred pre-tax charges of $23.8 million during the nine months ended September 30, 2018. The expenses consisted primarily of employee separation, retention and other benefit-related costs of $22.1 million and certain other charges of $1.7 million. Of the total charges incurred, $10.8 million are included in the U.S. Generic Pharmaceuticals segment, $5.2 million are included in Corporate unallocated costs, $4.0 million are included in the U.S. Branded - Sterile Injectables segment, $3.1 million are included in the International Pharmaceuticals segment and $0.7 million are included in the U.S. Branded - Specialty & Established Pharmaceuticals segment. The Company did not incur material charges related to this restructuring initiative during the three months ended September 30, 2018.
Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and administrative and Research and development expenses in the Condensed Consolidated Statements of Operations. Certain other charges are primarily included in Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all cash payments are expected to be made by the end of the second quarter in 2019.
The liability related to the January 2018 Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this liability during the nine months ended September 30, 2018 were as follows (in thousands):
 
Employee Separation and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2018
$
—

 
$
650

 
$
650

Expenses
22,087

 
1,705

 
23,792

Cash distributions
(18,439
)
 
(1,949
)
 
(20,388
)
Liability balance as of September 30, 2018
$
3,648

 
$
406

 
$
4,054
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions
 9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
ACQUISITIONS
NOTE 5. ACQUISITIONS
On April 26, 2018, the Company entered into a Membership Interest and Asset Purchase Agreement (the Somerset Purchase Agreement) with Mendham Holdings, LLC (the Seller) and certain other Seller related parties in connection with the acquisition of all of the limited liability company membership interests (the LLC Interests) of Somerset Therapeutics, LLC (Somerset) and certain of Somerset’s assets, including intellectual property, product Abbreviated New Drug Applications (ANDAs) and inventory (the Somerset Assets). Somerset is a specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. market. The Somerset acquisition is contingent upon the closing of the acquisition of the Indian-based Wintac business (as defined below).
Pursuant to the terms of the Somerset Purchase Agreement, the Company will acquire 100% of the LLC Interests of Somerset and the Somerset Assets for an aggregate cash purchase price of approximately $160 million, subject to customary adjustments for cash, net working capital and indebtedness as described in the Somerset Purchase Agreement. The Somerset Purchase Agreement contains certain customary representations, warranties and covenants and provides for indemnification rights of the parties in respect of inaccuracies or breaches of certain representations, warranties and covenants, subject to the limitations set forth in the Somerset Purchase Agreement.
The Somerset acquisition is expected to close in the first quarter of 2019, subject to satisfaction of customary closing conditions, including required regulatory approvals and the closing of the acquisition of the Wintac business. In connection with the Somerset acquisition, the Company’s Indian subsidiary has entered into separate agreements to acquire the entire business of Somerset’s Indian-based contract development and manufacturing affiliate, Wintac Limited (Wintac), including certain real property in Bangalore, India and the manufacturing plants thereon and to assume certain debt of Wintac for the expected aggregate amount of the rupee equivalent of approximately $30 million, subject to customary adjustments for net working capital.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Results
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
SEGMENT RESULTS
NOTE 6. SEGMENT RESULTS
As of January 1, 2018, we made changes to our reportable segments. Following these changes, the four reportable business segments in which we operate are: (1) U.S. Branded - Specialty & Established Pharmaceuticals, (2) U.S. Branded - Sterile Injectables, (3) U.S. Generic Pharmaceuticals and (4) International Pharmaceuticals. Previously, we had three reportable segments: (1) U.S. Generic Pharmaceuticals, (2) U.S. Branded Pharmaceuticals and (3) International Pharmaceuticals. The updates to our reportable segments were made based on first quarter 2018 changes to the way we manage and evaluate our business.
Our new U.S. Branded - Sterile Injectables segment consists of our sterile injectables product portfolio, which was previously part of our former U.S. Generic Pharmaceuticals segment. Our new U.S. Generic Pharmaceuticals segment represents the remainder of our former U.S. Generic Pharmaceuticals segment. Additionally, our former U.S. Branded Pharmaceuticals segment has been renamed “U.S. Branded - Specialty & Established Pharmaceuticals.”
Our segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
We evaluate segment performance based on each segment’s adjusted income from continuing operations before income tax, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items.
Certain of the corporate expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate items.
U.S. Branded - Specialty & Established Pharmaceuticals
Our U.S. Branded - Specialty & Established Pharmaceuticals segment includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products in this segment include XIAFLEX®, SUPPRELIN® LA, TESTOPEL®, NASCOBAL® Nasal Spray, AVEED®, PERCOCET®, VOLTAREN® Gel, LIDODERM®, EDEX®, TESTIM® and FORTESTA® Gel, among others.
U.S. Branded - Sterile Injectables
Our U.S. Branded - Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT®, ADRENALIN® and APLISOL®, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others.
U.S. Generic Pharmaceuticals
Our U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.
International Pharmaceuticals
Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs Inc. (Paladin). This segment’s key products serve growing therapeutic areas, including attention deficit hyperactivity disorder (ADHD), pain, women’s health and oncology. This segment also included: (i) our South African Litha business, which was sold in July 2017, and (ii) our Latin American Somar business, which was sold in October 2017.
The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net revenues from external customers:
 
 
 
 
 
 
 
U.S. Branded - Specialty & Established Pharmaceuticals
$
220,100

 
$
233,803

 
$
632,972

 
$
729,150

U.S. Branded - Sterile Injectables
237,150

 
201,905

 
670,847

 
554,365

U.S. Generic Pharmaceuticals
257,969

 
294,749

 
748,445

 
1,227,584

International Pharmaceuticals (1)
30,247

 
56,430

 
108,425

 
189,119

Total net revenues from external customers
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

Adjusted income from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded - Specialty & Established Pharmaceuticals
$
84,891


$
123,754


$
262,454


$
380,841

U.S. Branded - Sterile Injectables
170,329


150,531


513,082


417,060

U.S. Generic Pharmaceuticals
82,555


86,236


247,137


415,172

International Pharmaceuticals
13,377


17,434


45,594


47,128

Total segment adjusted income from continuing operations before income tax
$
351,152


$
377,955


$
1,068,267


$
1,260,201

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.
There were no material revenues from external customers attributed to an individual country outside of the United States during any of the periods presented. There were no material tangible long-lived assets in an individual country other than the United States as of September 30, 2018 or December 31, 2017.
The table below provides reconciliations of our consolidated Loss from continuing operations before income tax, which is determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), to our total segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Total consolidated loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Interest expense, net
131,847

 
127,521

 
385,896

 
361,267

Corporate unallocated costs (1)
49,187

 
33,035

 
144,693

 
114,655

Amortization of intangible assets
161,275

 
161,413

 
471,662

 
615,490

Inventory step-up
71

 
66

 
261

 
281

Upfront and milestone payments to partners
4,731

 
775

 
43,027

 
6,952

Separation benefits and other cost reduction initiatives (2)
4,001

 
80,693

 
82,141

 
127,977

Certain litigation-related and other contingencies, net (3)
(1,750
)
 
(12,352
)
 
15,370

 
(14,016
)
Asset impairment charges (4)
142,217

 
94,924

 
613,400

 
1,023,930

Acquisition-related and integration items (5)
1,288

 
16,641

 
13,284

 
31,711

Loss on extinguishment of debt
—

 
—

 
—

 
51,734

Foreign currency impact related to the remeasurement of intercompany debt instruments
1,528

 
3,005

 
(1,560
)
 
(2,922
)
Other, net (6)
(175
)
 
30

 
(28,348
)
 
1,789

Total segment adjusted income from continuing operations before income tax
$
351,152

 
$
377,955

 
$
1,068,267

 
$
1,260,201

__________
(1)
Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Amounts for the three and nine months ended September 30, 2018 relate to employee separation costs of $2.1 million and $32.7 million, respectively, charges to increase excess inventory reserves of $0.2 million and $2.8 million, respectively, and other charges of $1.7 million and $11.4 million, respectively, each of which related primarily to our restructuring initiatives. Also included in the amount for the nine months ended September 30, 2018 is accelerated depreciation of $35.2 million, which related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. During the three and nine months ended September 30, 2017, amounts primarily relate to employee separation costs of $19.8 million and $41.3 million, accelerated depreciation of $59.8 million and $60.2 million, other charges of $1.1 million and $18.5 million, respectively, and charges to increase excess inventory reserves of $7.9 million during the nine months ended September 30, 2017. These charges were related primarily to the 2017 U.S. Generics Pharmaceuticals restructuring initiative. See Note 4. Restructuring for discussion of our material restructuring initiatives.
(3)
Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.
(4)
Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 7. Fair Value Measurements.
(5)
Amounts during the three and nine months ended September 30, 2018 are primarily related to charges due to changes in the fair value of contingent consideration of $0.8 million and $11.7 million, respectively. Amounts during the three and nine months ended September 30, 2017 include charges due to changes in the fair value of contingent consideration of $15.4 million and $23.6 million, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.
(6)
Amounts during the three and nine months ended September 30, 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 17. Other income, net.
Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.
The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.

Three Months Ended September 30,

Nine Months Ended September 30,

2018

2017

2018

2017
U.S. Branded - Specialty & Established Pharmaceuticals:
 
 
 
 
 
 
 
Specialty Products:
 
 
 
 
 
 
 
XIAFLEX®
$
64,214

 
$
52,511

 
$
184,855

 
$
152,113

SUPPRELIN® LA
20,408

 
20,638

 
60,948

 
63,468

Other Specialty (1)
43,576

 
40,634

 
114,202

 
113,407

Total Specialty Products
$
128,198

 
$
113,783

 
$
360,005

 
$
328,988

Established Products:
 
 
 
 
 
 
 
PERCOCET®
$
30,730

 
$
31,349

 
$
93,539

 
$
93,183

VOLTAREN® Gel
15,057

 
19,102

 
44,185

 
53,646

OPANA® ER
—

 
14,756

 
—

 
82,056

Other Established (2)
46,115

 
54,813

 
135,243

 
171,277

Total Established Products
$
91,902

 
$
120,020

 
$
272,967

 
$
400,162

Total U.S. Branded - Specialty & Established Pharmaceuticals (3)
$
220,100

 
$
233,803

 
$
632,972

 
$
729,150

U.S. Branded - Sterile Injectables:
 
 
 
 
 
 
 
VASOSTRICT®
$
112,333


$
105,741


$
332,387


$
300,649

ADRENALIN®
35,460


25,335


101,858


50,464

Ertapenem for injection
25,798

 
—

 
25,798

 
—

Other Sterile Injectables (4)
63,559


70,829


210,804


203,252

Total U.S. Branded - Sterile Injectables (3)
$
237,150


$
201,905


$
670,847


$
554,365

Total U.S. Generic Pharmaceuticals (5)
$
257,969

 
$
294,749

 
$
748,445

 
$
1,227,584

Total International Pharmaceuticals (6)
$
30,247

 
$
56,430

 
$
108,425

 
$
189,119

Total Revenues
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

__________
(1)
Products included within Other Specialty include TESTOPEL®, NASCOBAL® Nasal Spray and AVEED®.
(2)
Products included within Other Established include, but are not limited to, LIDODERM®, EDEX®, TESTIM® and FORTESTA® Gel, including the authorized generics.
(3)
Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $25 million during any quarterly period in 2018 or 2017.
(4)
Products included within Other Sterile Injectables include, but are not limited to, APLISOL® and ephedrine sulfate injection.
(5)
The U.S. Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the nine months ended September 30, 2017, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up 9% of consolidated total revenue. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.
(6)
The International Pharmaceuticals segment, which accounted for 4% and 5% of consolidated total revenues during the three and nine months ended September 30, 2018, respectively, and 7% of consolidated total revenues during both the three and nine months ended September 30, 2017, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs, Inc. (Paladin). This segment also included: (i) our South African business, which was sold in July 2017 and consisted of Litha and certain assets acquired from Aspen Holdings in October 2015 and (ii) our Latin American business consisting of Somar, which was sold in October 2017.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 7. FAIR VALUE MEASUREMENTS
Financial Instruments
The financial instruments recorded in our Condensed Consolidated Balance Sheets include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.
At September 30, 2018 and December 31, 2017, the Company had combined restricted cash and cash equivalents of $312.0 million and $324.4 million, respectively, of which $289.7 million and $320.5 million, respectively, are classified as current assets and reported in our Condensed Consolidated Balance Sheets as Restricted cash and cash equivalents. The remaining amounts, which are classified as non-current assets, are reported in our Condensed Consolidated Balance Sheets as Other assets. Approximately $283.8 million and $313.8 million of our restricted cash and cash equivalents are held in qualified settlement funds (QSFs) for mesh-related matters at September 30, 2018 and December 31, 2017, respectively. The remaining amount of restricted cash and cash equivalents at September 30, 2018 primarily relates to other litigation-related matters. See Note 14. Commitments and Contingencies for further information.
Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
•
Level 1—Quoted prices in active markets for identical assets or liabilities.
•
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Marketable Securities
Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in our Condensed Consolidated Balance Sheets at September 30, 2018 and December 31, 2017.
Acquisition-Related Contingent Consideration
The fair value of contingent consideration liabilities is determined using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.
Recurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2018 and December 31, 2017 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
September 30, 2018
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
691,579

 
$
—

 
$
—

 
$
691,579

Equity securities
1,693

 
—

 
—

 
1,693

Total
$
693,272

 
$
—

 
$
—

 
$
693,272

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
42,261

 
$
42,261

Acquisition-related contingent consideration—long-term
—

 
—

 
86,209

 
86,209

Total
$
—

 
$
—

 
$
128,470

 
$
128,470

 
Fair Value Measurements at Reporting Date using:
December 31, 2017
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
439,831

 
$
—

 
$
—

 
$
439,831

Time deposits
—

 
303,410

 
—

 
303,410

Equity securities
1,456

 
—

 
—

 
1,456

Total
$
441,287

 
$
303,410

 
$
—

 
$
744,697

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
70,543

 
$
70,543

Acquisition-related contingent consideration—long-term
—

 
—

 
119,899

 
119,899

Total
$
—

 
$
—

 
$
190,442

 
$
190,442


At September 30, 2018 and December 31, 2017, money market funds include $57.0 million and $35.6 million, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See Note 14. Commitments and Contingencies for further discussion of our product liability cases. The differences between the amortized cost and fair value of our money market funds and equity securities were not material, individually or in the aggregate, at September 30, 2018 or December 31, 2017, nor were any of the related gross unrealized gains or losses.
Fair Value Measurements Using Significant Unobservable Inputs
The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Beginning of period
$
152,098

 
$
210,460

 
$
190,442

 
$
262,113

Amounts settled
(24,564
)
 
(31,617
)
 
(73,298
)
 
(91,927
)
Changes in fair value recorded in earnings
769

 
15,440

 
11,731

 
23,574

Effect of currency translation
167

 
504

 
(405
)
 
1,027

End of period
$
128,470

 
$
194,787

 
$
128,470

 
$
194,787


At September 30, 2018, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from approximately 10% to 22% (weighted average rate of approximately 14.1%). Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Condensed Consolidated Statements of Operations as Acquisition-related and integration items, and amounts recorded for the short-term and long-term portions of acquisition-related contingent consideration are included in Accounts payable and accrued expenses and Other liabilities, respectively, in our Condensed Consolidated Balance Sheets.
The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2018 by acquisition (in thousands):
 
Balance as of December 31, 2017
 
Fair Value Adjustments and Accretion
 
Payments and Other
 
Balance as of September 30, 2018
Auxilium acquisition
$
13,061

 
$
(263
)
 
$
(1,844
)
 
$
10,954

Lehigh Valley Technologies, Inc. acquisitions
63,001

 
11,169

 
(39,469
)
 
34,701

VOLTAREN® Gel acquisition
98,124

 
3,839

 
(30,923
)
 
71,040

Other
16,256

 
(3,014
)
 
(1,467
)
 
11,775

Total
$
190,442

 
$
11,731

 
$
(73,703
)
 
$
128,470


Nonrecurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2018 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
 
Total Expense for the Nine Months Ended September 30, 2018
 
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Assets:
 
 
 
 
 
 
 
Intangible assets, excluding goodwill (Note 9)
$
—

 
$
—

 
$
239,857

 
$
(217,576
)
Certain property, plant and equipment (1)
—

 
—

 
—

 
(4,824
)
Total
$
—

 
$
—

 
$
239,857

 
$
(222,400
)
__________
(1)
Amount includes $2.6 million related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring.
Additionally, the Company recorded aggregate goodwill impairment charges during the nine months ended September 30, 2018 of $391.0 million. Refer to Note 9. Goodwill and Other Intangibles for further description, including the valuation methodologies utilized.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
INVENTORIES
NOTE 8. INVENTORIES
Inventories consist of the following at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
Raw materials (1)
$
119,627

 
$
124,685

Work-in-process (1)
83,665

 
109,897

Finished goods (1)
129,495

 
156,855

Total
$
332,787

 
$
391,437


__________
(1) The components of inventory shown in the table above are net of allowance for obsolescence.
Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX® inventory, is classified as long-term inventory and is not included in the table above. At September 30, 2018 and December 31, 2017, $13.3 million and $17.1 million, respectively, of long-term inventory was included in Other assets in the Condensed Consolidated Balance Sheets. As of September 30, 2018 and December 31, 2017, the Company’s Condensed Consolidated Balance Sheets included approximately $13.6 million and $5.9 million, respectively, of capitalized pre-launch inventories related to generic products that were not yet available to be sold.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles
 9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLES
NOTE 9. GOODWILL AND OTHER INTANGIBLES
Goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2018 were as follows (in thousands):
 
U.S. Branded - Specialty & Established Pharmaceuticals
 
U.S. Branded - Sterile Injectables
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2017
$
828,818

 
$
—

 
$
3,531,301

 
$
89,963

 
$
4,450,082

Allocation to current segments (1)
—

 
2,731,193

 
(2,731,193
)
 
—

 
—

Effect of currency translation
—

 
—

 
—

 
(2,414
)
 
(2,414
)
Goodwill impairment charges
—

 
—

 
(391,000
)
 
—

 
(391,000
)
Goodwill as of September 30, 2018
$
828,818

 
$
2,731,193

 
$
409,108

 
$
87,549

 
$
4,056,668


__________
(1)
This allocation relates to the change in segments described in Note 6. Segment Results. The amount of goodwill initially attributed to the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals segments was determined using a relative fair value methodology in accordance with U.S. GAAP.
The carrying amounts of goodwill at September 30, 2018 and December 31, 2017 are net of the following accumulated impairments (in thousands):

U.S. Branded - Specialty & Established Pharmaceuticals
 
U.S. Branded - Sterile Injectables
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2017
$
855,810

 
$
—

 
$
2,342,549

 
$
463,545

 
$
3,661,904

Accumulated impairment losses as of September 30, 2018
$
855,810

 
$
—

 
$
2,733,549

 
$
451,209

 
$
4,040,568

Other Intangible Assets
Changes in the amount of other intangible assets for the nine months ended September 30, 2018 are set forth in the table below (in thousands).
Cost basis:
Balance as of December 31, 2017
 
Acquisitions
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2018
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
347,200

 
$
—

 
$
(87,900
)
 
$
(165,400
)
 
$
—

 
$
93,900

Total indefinite-lived intangibles
$
347,200

 
$
—

 
$
(87,900
)
 
$
(165,400
)
 
$
—

 
$
93,900

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
457,402

 
$
—

 
$
—

 
$
—

 
$
—

 
$
457,402

Tradenames
6,409

 
—

 
—

 
—

 
—

 
6,409

Developed technology (weighted average life of 11 years)
6,187,764

 
—

 
(129,676
)
 
154,753

 
(7,447
)
 
6,205,394

Total finite-lived intangibles (weighted average life of 11 years)
$
6,651,575

 
$
—

 
$
(129,676
)
 
$
154,753

 
$
(7,447
)
 
$
6,669,205

Total other intangibles
$
6,998,775

 
$
—

 
$
(217,576
)
 
$
(10,647
)
 
$
(7,447
)
 
$
6,763,105

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2017
 
Amortization
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2018
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(370,221
)
 
$
(21,262
)
 
$
—

 
$
—

 
$
—

 
$
(391,483
)
Tradenames
(6,409
)
 
—

 
—

 
—

 
—

 
(6,409
)
Developed technology
(2,304,461
)
 
(450,400
)
 
—

 
10,647

 
3,217

 
(2,740,997
)
Total other intangibles
$
(2,681,091
)
 
$
(471,662
)
 
$
—

 
$
10,647

 
$
3,217

 
$
(3,138,889
)
Net other intangibles
$
4,317,684

 
 
 
 
 
 
 
 
 
$
3,624,216

__________
(1)
Other adjustments relate to reclassification adjustments of $165.4 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the nine months ended September 30, 2018 and the removal of certain fully amortized intangible assets.
Amortization expense for the three and nine months ended September 30, 2018 totaled $161.3 million and $471.7 million, respectively. Amortization expense for the three and nine months ended September 30, 2017 totaled $161.4 million and $615.5 million, respectively. Amortization expense is included in Cost of revenues in the Condensed Consolidated Statements of Operations. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2017 is as follows (in thousands):
2018
$
622,384

2019
$
552,516

2020
$
481,300

2021
$
447,157

2022
$
420,786


Impairments
Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.
As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach. The discounted cash flow models are dependent upon our estimates of future cash flows and other factors. These estimates of future cash flows involve assumptions concerning (i) future operating performance, including future sales, long-term growth rates, operating margins, tax rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows are based on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Condensed Consolidated Statements of Operations.
During the three and nine months ended September 30, 2018 and 2017, the Company incurred the following goodwill and other intangible asset impairment charges:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Goodwill impairment charges
$
—

 
$
—

 
$
391,000

 
$
288,745

Other intangible asset impairment charges
$
140,609

 
$
78,300

 
$
217,576

 
$
674,177


A summary of significant goodwill and other intangible asset impairment tests and related charges is included below. Other intangible asset impairment charges that are not included in the below narrative totaled $140.6 million and $78.3 million during the three months ended September 30, 2018 and 2017, respectively, and $217.6 million and $461.1 million during the nine months ended September 30, 2018 and 2017, respectively. These charges relate primarily to certain in-process research and development and/or developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.
Our first quarter 2018 change in segments described in Note 6. Segment Results resulted in changes to our reporting units for goodwill impairment testing purposes, including the creation of a new U.S. Branded - Sterile Injectables reporting unit, which was previously part of our Generics reporting unit. As a result of these changes, under U.S. GAAP, we tested the goodwill of the former Generics reporting unit immediately before the segment realignment and the goodwill of both the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals reporting units immediately after the segment realignment. These goodwill tests were performed using an income approach that utilizes a discounted cash flow model. The results of these goodwill impairment tests were as follows:
•
The former Generics reporting unit’s estimated fair value (determined using a discount rate of 9.5%) exceeded its carrying amount, resulting in no related goodwill impairment charge.
•
The new U.S. Branded - Sterile Injectables reporting unit’s estimated fair value (determined using a discount rate of 9.5%) exceeded its carrying amount, resulting in no related goodwill impairment charge.
•
The new U.S. Generic Pharmaceuticals reporting unit’s carrying amount exceeded its estimated fair value (determined using a discount rate of 9.5%), resulting in a pre-tax non-cash goodwill impairment charge of $391.0 million.
In March 2017, we announced that the Food and Drug Administration’s (FDA) Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA® ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA’s request that we voluntarily withdraw OPANA® ER from the market, and in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA® ER from the market. As a result of our decision, the Company determined that the carrying amount of its OPANA® ER intangible asset was no longer recoverable, resulting in a pre-tax, non-cash impairment charge of $20.6 million in the second quarter of 2017, representing the remaining carrying amount.
As a result of the withdrawal of OPANA® ER from the market and the continued erosion of our U.S. Branded Pharmaceuticals segment’s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during the second quarter of 2017. We recorded a pre-tax, non-cash goodwill impairment charge of $180.4 million during the three months ended June 30, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Branded reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Branded goodwill impairment test was 9.5%.
As further described in Note 4. Restructuring, the Company announced the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative in July 2017, which includes the discontinuation of certain commercial products. As a result, the Company assessed the recoverability of the impacted products, resulting in pre-tax, non-cash intangible asset impairment charges of approximately $57.5 million during the second quarter of 2017. The Company also initiated an interim goodwill impairment analysis of its Generics reporting unit during the second quarter of 2017 as a result of the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative and determined that the estimated fair value of the Generics reporting unit exceeded its carrying amount. Accordingly, no related goodwill impairment was recorded. The Company estimated the fair value of the Generics reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Generics goodwill impairment test was 9.0%.
Pursuant to an existing agreement with a wholly owned subsidiary of Novartis AG (Novartis), Paladin licensed the Canadian rights to commercialize serelaxin, an investigational drug for the treatment of acute heart failure (AHF). In March 2017, Novartis announced that a Phase 3 study of serelaxin in patients with AHF failed to meet its primary endpoints. As a result, we concluded that the full carrying amount of our serelaxin in-process research and development intangible asset was impaired, resulting in a $45.5 million pre-tax non-cash impairment charge for the three months ended March 31, 2017. In addition and as a result of the serelaxin impairment, we assessed the recoverability of our Paladin goodwill balance and determined that the estimated fair value of the Paladin reporting unit was below its carrying amount. We recorded a pre-tax, non-cash goodwill impairment charge of $82.6 million during the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Paladin reporting unit using an income approach that utilized a discounted cash flow model. The discount rate applied to the estimated cash flows for our Paladin goodwill impairment test was 10.0%.
As further discussed in Note 3. Discontinued Operations and Divestitures, we entered into a definitive agreement to sell Somar on June 30, 2017, which resulted in Somar’s assets and liabilities being classified as held for sale. The initiation of held-for-sale accounting, together with the agreed upon sale price, triggered an impairment review. Accordingly, we performed an impairment analysis using a market approach and determined that impairment charges were required. We recorded pre-tax, non-cash impairment charges of $25.7 million and $89.5 million related to Somar’s goodwill and other intangible assets, respectively, during the second quarter of 2017, each of which represented the remaining carrying amounts of the corresponding assets.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
License And Collaboration Agreements
 9 Months Ended
Sep. 30, 2018
License And Collaboration Agreements [Abstract]  
LICENSE AND COLLABORATION AGREEMENTS
NOTE 10. LICENSE AND COLLABORATION AGREEMENTS
Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products.
Generally, under these agreements: (i) we are required to make upfront payments and other payments upon successful completion of regulatory or sales milestones, (ii) we are required to pay royalties on sales of the products arising from these agreements and (iii) termination is permitted with no significant continuing obligation.
During the second quarter of 2018, we entered into a development, license and commercialization agreement with a third party pharmaceutical company related to five sterile injectable product candidates. Pursuant to this agreement, the third party will generally be responsible, at its expense, to develop and seek regulatory approval for these product candidates, and the Company will generally be responsible, at its expense, to launch and distribute any products that are approved. The Company will have exclusive license rights to all of these products launched in the U.S. and a first right of refusal for the Canadian territory. Upon entering into this agreement, the Company became obligated to make an upfront payment, which was recorded as Research and development expense in the Condensed Consolidated Statements of Operations during the three months ended June 30, 2018. The Company could become obligated to make additional payments based on certain potential future milestones being achieved.
There have been no other significant changes to our license, collaboration and discovery agreements since our Annual Report on Form 10-K for the year ended December 31, 2017.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contract Assets and Liabilities
 9 Months Ended
Sep. 30, 2018
Contract with Customer, Asset and Liability [Abstract]  
Contract Assets and Liabilities
NOTE 11. CONTRACT ASSETS AND LIABILITIES
Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At September 30, 2018, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within one week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.
Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.
The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):
 
September 30, 2018
 
January 1, 2018
 
$ Change
 
% Change
Contract assets, net (1)
$
13,291

 
$
11,287

 
$
2,004

 
18
 %
Contract liabilities, net (2)
$
19,635

 
$
20,954

 
$
(1,319
)
 
(6
)%
__________
(1)
At September 30, 2018 and January 1, 2018, approximately $10.3 million and $8.2 million, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other assets. The net increase in contract assets during the nine months ended September 30, 2018 was primarily due to certain sales activity during the period, partially offset by reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company’s rights to consideration for the sale of certain goods.
(2)
At September 30, 2018 and January 1, 2018, approximately $1.7 million and $1.9 million, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other liabilities. During the nine months ended September 30, 2018, the Company recognized revenue of $1.3 million that was included in the contract liability balance at January 1, 2018, resulting in a corresponding decrease in contract liabilities.
During the nine months ended September 30, 2018, we recognized revenue of $4.6 million relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accounts Payable And Accrued Expenses
 9 Months Ended
Sep. 30, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Accounts Payable And Accrued Expenses
NOTE 12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses include the following at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
Trade accounts payable
$
106,321

 
$
85,348

Returns and allowances
250,637

 
291,034

Rebates
152,297

 
168,333

Chargebacks
2,022

 
14,604

Accrued interest
64,647

 
130,257

Accrued payroll and related benefits
84,240

 
113,908

Accrued royalties and other distribution partner payables
103,673

 
63,114

Acquisition-related contingent consideration—short-term
42,261

 
70,543

Other
212,906

 
159,684

Total
$
1,019,004


$
1,096,825
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
DEBT
NOTE 13. DEBT
The following table presents information about the Company’s total indebtedness at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
 
Effective Interest Rate
 
Principal Amount
 
Carrying Amount
 
Effective Interest Rate
 
Principal Amount
 
Carrying Amount
7.25% Senior Notes due 2022
7.91
%
 
$
400,000

 
$
392,439

 
7.91
%
 
$
400,000

 
$
390,974

5.75% Senior Notes due 2022
6.04
%
 
700,000

 
694,053

 
6.04
%
 
700,000

 
692,855

5.375% Senior Notes due 2023
5.62
%
 
750,000

 
743,083

 
5.62
%
 
750,000

 
742,048

6.00% Senior Notes due 2023
6.28
%
 
1,635,000

 
1,615,955

 
6.28
%
 
1,635,000

 
1,613,446

5.875% Senior Secured Notes due 2024
6.14
%
 
300,000

 
295,922

 
6.14
%
 
300,000

 
295,513

6.00% Senior Notes due 2025
6.27
%
 
1,200,000

 
1,182,859

 
6.27
%
 
1,200,000

 
1,181,243

Term Loan B Facility Due 2024
5.46
%
 
3,372,313

 
3,338,451

 
5.46
%
 
3,397,925

 
3,360,103

Other debt
 
 
—

 
—

 
1.50
%
 
55

 
55

Total long-term debt, net
 
 
$
8,357,313

 
$
8,262,762

 
 
 
$
8,382,980

 
$
8,276,237

Less current portion, net
 
 
34,150

 
34,150

 
 
 
34,205

 
34,205

Total long-term debt, less current portion, net
 
 
$
8,323,163

 
$
8,228,612

 
 
 
$
8,348,775

 
$
8,242,032


The senior unsecured notes are unsecured and effectively subordinated in right of priority to our credit agreement (the 2017 Credit Agreement) and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto.
The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $7.9 billion and $7.5 billion at September 30, 2018 and December 31, 2017, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.
Credit Facility
We have $997.2 million of remaining credit available through our revolving credit facility as of September 30, 2018. As of September 30, 2018, we were in compliance with all covenants contained in our credit agreement.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 14. COMMITMENTS AND CONTINGENCIES
Legal Proceedings and Investigations
We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief, and an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the aggregate, we will disclose such matters.
We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies could be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.
As of September 30, 2018, our accrual for loss contingencies totaled $1,002.1 million, of which $845.6 million relates to our liability accrual for vaginal mesh cases and other mesh-related matters. During the fourth quarter of 2017, the Company recorded a total increase to its liability accrual of approximately $200 million related to testosterone-related product liability matters and LIDODERM®-related antitrust matters. The accrual for LIDODERM®-related matters includes an estimated loss for, among other matters, settlement of all remaining claims filed against EPI in multidistrict litigation (MDL) No. 2521, which is further discussed below under the heading “Other Antitrust Matters.” The testosterone-related accrual includes an estimated loss for, among other matters, all testosterone-related product liability cases filed in MDL No. 2545 and in other courts. These cases are further discussed below under the heading “Product Liability and Related Matters.” Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.
Product Liability and Related Matters
We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries. These and other related matters are described below in more detail.
Vaginal Mesh. Since 2008, we and certain of our subsidiaries, including American Medical Systems Holdings, Inc. (subsequently converted to Astora Women’s Health Holding LLC and merged into Astora Women’s Health LLC and referred to herein as AMS) and/or Astora, have been named as defendants in multiple lawsuits in various state and federal courts in the U.S. (including a federal MDL pending in the U.S. District Court for the Southern District of West Virginia (MDL No. 2325)), and in Canada and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). In January 2018, a representative proceeding (class action) was filed in the Federal Court of Australia against American Medical Systems, LLC. In the various class action and individual complaints, plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.
We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately 71,000 filed and unfiled mesh claims handled or controlled by the participating counsel. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries.
All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation requirements regarding the claims represented by each law firm party to the MSA. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents.
Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant is required to represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlements.
In June 2017, the MDL court entered a case management order which, among other things, requires plaintiffs in newly-filed MDL cases to provide expert disclosures on specific causation within one hundred twenty (120) days of filing a claim (the Order). Under the Order, a plaintiff's failure to meet the foregoing deadline may be grounds for the entry of judgment against such plaintiff. In July 2017, a similar order was entered in Minnesota state court. In June 2018, at the request of the MDL court, the Judicial Panel on Multidistrict Litigation entered a minute order suspending the transfer of cases into the MDL. Subsequently, the MDL court issued a pretrial order discontinuing the direct filing of claims in MDL No. 2325. The MDL court also issued similar orders in other MDLs involving claims against other mesh manufacturers.
Although the Company believes it has appropriately estimated the probable total amount of loss associated with all matters as of the date of this report, fact and expert discovery is ongoing in certain cases that have not settled, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.
The following table presents the changes in the QSFs and mesh liability accrual balance during the nine months ended September 30, 2018 (in thousands):
 
Qualified Settlement Funds
 
Mesh Liability Accrual
Balance as of January 1, 2018
$
313,814

 
$
1,087,172

Additional charges
—

 
19,000

Cash contributions to Qualified Settlement Funds
216,770

 
—

Cash distributions to settle disputes from Qualified Settlement Funds
(248,485
)
 
(248,485
)
Cash distributions to settle disputes
—

 
(17,114
)
Other (1)
1,653

 
5,038

Balance as of September 30, 2018
$
283,752

 
$
845,611

__________
(1)
Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. The $5.0 million in the table above also includes a second quarter 2018 reclassification adjustment of $4.4 million for accrued interest amounts previously recorded in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets.
As of September 30, 2018, $820.2 million of the mesh liability accrual amount shown above is classified in the Current portion of the legal settlement accrual in the Condensed Consolidated Balance Sheets, with the remainder classified as Long-term legal settlement accrual, less current portion. Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Condensed Consolidated Statements of Operations.
To date, the Company has made total mesh liability payments of approximately $3.1 billion, $283.8 million of which remains in the QSFs as of September 30, 2018. We expect to fund into the QSFs the remaining payments under all settlement agreements during the remainder of 2018 and 2019. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.
We were contacted in October 2012 regarding a civil investigation initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are cooperating with these investigations.
We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.
Testosterone. Various manufacturers of prescription medications containing testosterone, including our subsidiaries Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), have been named as defendants in multiple lawsuits alleging personal injury resulting from the use of such medications, including FORTESTA® Gel, DELATESTRYL®, TESTIM®, TESTOPEL®, AVEED® and STRIANT®. Plaintiffs in these suits generally allege various personal injuries, including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and seek compensatory and/or punitive damages, where available.
As of November 1, 2018, we were aware of approximately 1,205 testosterone cases (some of which may have been filed on behalf of multiple plaintiffs) pending against one or more of our subsidiaries in federal or state court. Many of these cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2545). In November 2015, the MDL court entered an order granting defendants’ motion to dismiss claims involving certain testosterone products that were approved pursuant to ANDAs, including TESTOPEL®. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the MDL court granted plaintiffs’ motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing. An MDL trial against Auxilium involving TESTIM® took place in November 2017 and resulted in a defense verdict. A trial against Auxilium involving TESTIM® was scheduled for January 2018 in the Philadelphia Court of Common Pleas (PCCP) but resolved prior to trial.
In June 2018, counsel for plaintiffs, on the one hand, and Auxilium and EPI, on the other, executed an MSA allowing for the resolution of all known testosterone replacement therapy product liability claims against our subsidiaries. The MSA was solely by way of compromise and settlement and was not in any way an admission of fault by us or any of our subsidiaries.
The MSA is subject to a process that includes guidelines and procedures for administering the settlement and the release of funds. Among other things, the MSA provides for the creation of a QSF into which the settlement funds will be deposited, establishes participation requirements, and allows for a reduction of the total settlement payment in the event the participation threshold is not met. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use and injury as determined by a third-party special master, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.
Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related product liability matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to our liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.
The MDL also includes a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers that claim to have paid for certain testosterone products. After a series of motions to dismiss, plaintiff filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act (RICO) and negligent misrepresentation based on defendants’ marketing of certain testosterone products. The court denied a motion to dismiss this complaint in August 2016. In July 2018, the court denied plaintiff’s motion for class certification. In October 2018, defendants moved for summary judgment. This lawsuit is not part of the settlement described above.
We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.
Unapproved Drug Litigation
In September 2013, the state of Louisiana filed a petition for damages against certain of our subsidiaries, including EPI, and more than 50 other pharmaceutical companies in Louisiana state court (19th Judicial District) alleging that the defendants or their subsidiaries marketed products that were not approved by the FDA and seeking damages, fines, penalties, attorneys’ fees and costs under various causes of action. In October 2015, the district court entered judgment for defendants on their exception for no right of action. The state appealed, and in October 2016 the Louisiana First Circuit Court of Appeals reversed the dismissal as to the state’s Medicaid Assistance Program Integrity Law (MAPIL) and Louisiana Unfair Trade Practices Act (LUTPA) claims but affirmed the dismissal as to the state’s other claims. The state’s petition for rehearing was denied in December 2016. Both sides applied to the Louisiana Supreme Court for a writ of certiorari to review the First Circuit’s decision. Those writs were denied in March 2017. In May 2017, defendants filed exceptions for no cause of action in the district court. In August 2017, the court sustained defendants’ exception as to the MAPIL claim but overruled defendants’ exception as to the LUTPA claim. The state then filed a motion seeking reconsideration with respect to the MAPIL claim, and defendants filed a motion for clarification with respect to the court’s ruling on the LUTPA claim. In October 2017, the court denied the state’s motion and entered final judgment against the state with respect to the MAPIL claim. The court also granted defendants’ motion for clarification and dismissed the state’s LUTPA claim insofar as it sought civil penalties for alleged violations occurring before June 2, 2006. In October 2017, defendants applied for a supervisory writ of certiorari to the Louisiana First Circuit Court of Appeals on the district court’s August 2017 order overruling defendants’ exception on the state’s LUTPA claim. The First Circuit Court of Appeals denied defendants’ writ application in July 2018. In August 2018, the defendants filed an application for a supervisory writ of certiorari to the Louisiana Supreme Court. That writ application is fully briefed.
In March 2017, the state of Mississippi filed a complaint against our subsidiary EPI in Mississippi state court (Hinds County Chancery Court) alleging that EPI marketed products that were not approved by the FDA and seeking damages, penalties, attorneys’ fees, costs and other relief under various causes of action. In April 2017, EPI removed the case to the U.S. District Court for the Southern District of Mississippi. In May 2017, the state moved to remand the case to state court, and that motion was granted in October 2017. In November 2017, EPI filed a motion to dismiss the state’s complaint on various grounds. In January 2018, the state filed a motion for leave to amend its complaint. In February 2018, following an unopposed motion by the state, the court consolidated the state’s case against EPI with five substantially similar cases brought by the state against other defendants. The consolidation is solely for purposes of coordinated pretrial proceedings and discovery, not for trial. In March 2018, the court signed an agreed order dismissing EPI and granting the state leave to file a first amended complaint. The first amended complaint names our subsidiary Generics International (US), Inc. (Generics) as the defendant. In April 2018, Generics moved to dismiss on various grounds. The case is currently stayed by agreement of the parties.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Opioid-Related Matters
Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against certain of our subsidiaries, including Endo Health Solutions Inc. (EHSI), EPI, Par Pharmaceutical, Inc. (PPI), Par Pharmaceutical Companies, Inc. (Par), Vintage Pharmaceuticals, LLC and/or Generics Bidco I, LLC and, in some instances, the Company, as well as various other manufacturers, distributors and/or others, asserting claims relating to defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of November 1, 2018, the cases of which we were aware include, but are not limited to, approximately 11 cases filed by or on behalf of states; approximately 1,505 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 112 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers; and approximately 48 cases filed by individuals. Certain of the cases have been filed as putative class actions. In addition to the litigation in the U.S., in September 2018, an action against Paladin Labs, EPI, the Company and various other manufacturers and distributors was commenced in British Columbia on behalf of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids.
Many of the U.S. cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio (MDL No. 2804). In March 2018, the U.S. Department of Justice (DOJ) filed a statement of interest in the case, and in April 2018 it filed a motion to participate in settlement discussions and as a friend of the court, which the MDL court has granted. The MDL court has issued a series of case management orders permitting motions to dismiss addressing threshold legal issues in certain cases, setting a trial date in September 2019 for three cases originally filed in the Northern District of Ohio, allowing certain discovery and establishing certain other deadlines and procedures, among other things.
Other cases remain pending in various state courts. In some jurisdictions, such as Connecticut, Illinois, New York, Pennsylvania and Texas, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. The state cases are generally at the pleading and/or discovery stage.
The complaints in the cases assert a variety of claims including, but not limited to, claims for alleged violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability statutes and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:
In September 2017, the Department of Justice for the state of Oregon and the Office of the Attorney General for the Commonwealth of Massachusetts issued CIDs to EHSI and EPI on behalf of a multistate group which we understand currently includes approximately 30 states. Our subsidiaries are cooperating with this investigation. Certain states participating in the multistate investigation had issued their own CIDs, subpoenas or requests for information to the Company prior to their participation in the multistate investigation.
Other states are conducting their own investigations outside of the multistate group. These states include New Hampshire (subpoenas received by EPI in August 2015 and December 2017); New Jersey (subpoena received by EPI in March 2017); Washington (CID received by the Company, EHSI and EPI in August 2017); Montana (CID received by EHSI and EPI in January 2018); Alaska (CID received by EPI in February 2018); and South Carolina (CID received by EHSI and EPI in February 2018). We are cooperating with these investigations.
In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida in connection with an investigation being conducted by the U.S. Attorney’s Office for the Southern District of Florida in conjunction with the U.S. Food and Drug Administration. The subpoena seeks information related to OPANA® ER and other oxymorphone products. EPI is cooperating with the investigation.
Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Generic Drug Pricing Matters
In December 2014, we received a grand jury subpoena from the Antitrust Division of the DOJ issued by the U.S. District Court for the Eastern District of Pennsylvania to Par Pharmaceuticals. The subpoena requested documents and information focused primarily on product and pricing information relating to Par’s authorized generic version of Lanoxin (digoxin) oral tablets and Par’s generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.
In December 2015, EPI received interrogatories and a subpoena from the Connecticut Attorney General’s Office requesting documents and information regarding pricing of certain of generic products, including doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride. EPI is cooperating with this investigation.
In May 2018, we and our subsidiary Par each received a CID from the U.S. Department of Justice in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.
Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Certain cases alleging price-fixing and other anticompetitive conduct with respect to various generic pharmaceutical products have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania under the caption In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724). Among the lawsuits consolidated and/or coordinated in the MDL, the earliest lawsuits naming the Company and/or its subsidiaries were filed in November 2016 and related to digoxin and doxycycline.
The private plaintiffs in the MDL include alleged direct purchasers, end-payers and indirect purchaser resellers who purport to represent not only themselves but also all others similarly situated. At the MDL court’s direction, in August 2017, each group of private plaintiffs (direct purchasers, end-payers and indirect purchaser resellers) filed separate consolidated amended class action complaints as to each of 18 products, except with respect to one product (propranolol) direct purchaser plaintiffs stated their intention to proceed on a consolidated amended complaint filed in the U.S. District Court for the Southern District of New York prior to MDL transfer (the Southern District of New York had denied a motion to dismiss this complaint). Each of the consolidated amended complaints filed in August 2017 relates to one product, and our subsidiary PPI was named as a defendant in complaints relating to the following six products: digoxin, doxycycline hyclate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. The MDL court divided the various cases into three separate product-based tranches for certain administrative and scheduling purposes, including briefing on motions to dismiss, and allowed certain targeted discovery. As to the six products in the first tranche (including digoxin, doxycycline hyclate and divalproex ER), defendants filed motions to dismiss in October 2017. In October 2018, the MDL court denied portions of these motions and has yet to rule on other aspects.
In December 2016, the Attorney General for the state of Connecticut, leading a coalition of 20 state attorneys general, filed a complaint in the U.S. District Court for the District of Connecticut alleging price-fixing and other anticompetitive conduct with respect to doxycycline hyclate delayed release and glyburide against certain manufacturers of those products. The Company and its subsidiaries were not named in that complaint, or in an amended complaint filed on behalf of 40 states in March 2017, or in a separate lawsuit filed by four more states and the District of Columbia in the same court in July 2017. In August 2017, the state cases were transferred to MDL No. 2724. In October 2017, the state plaintiffs filed a motion for leave to (1) consolidate their two cases, (2) add Alaska and the Commonwealth of Puerto Rico as plaintiffs and (3) assert additional claims against existing and new defendants. In June 2018, the MDL court granted this motion, and the state plaintiffs filed their amended complaint. The amended complaint adds new allegations and claims against 14 new defendants, including our subsidiary Par, relating to 13 additional products. The amended complaint alleges anticompetitive conduct by our subsidiary with respect to doxycycline monohydrate. It also alleges that all defendants engaged in an overarching conspiracy to restrain trade across the generic pharmaceutical industry and seeks to hold all defendants, including our subsidiary, jointly and severally liable for harm caused by alleged anticompetitive activity concerning each of the 15 drugs at issue. The amended complaint seeks declaratory and injunctive relief, disgorgement and other equitable relief, compensatory and treble damages, civil penalties, costs and attorneys’ fees.
In January 2018, The Kroger Co., Albertsons Companies, LLC, and H.E. Butt Grocery Company LP filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against PPI, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to 30 separate generic pharmaceutical products, including seven products allegedly manufactured by PPI: digoxin, doxycycline hyclate, doxycycline monohydrate, divalproex ER, propranolol, baclofen and amitriptyline hydrochloride. This lawsuit has been assigned to the MDL court. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all 30 products, as well as product-specific conspiracies relating to each individual product, in violation of federal antitrust law. The complaint seeks monetary damages, including treble damages, attorneys’ fees and injunctive relief.
In June 2018, direct purchaser, end-payer and indirect purchaser reseller plaintiffs filed additional class action complaints in the U.S. District Court for the Eastern District of Pennsylvania, alleging anticompetitive conduct relating to approximately 15 generic pharmaceuticals (generally those that were the subject of the state plaintiffs’ amended complaint). These lawsuits have also been assigned to the MDL court. The end payer and indirect purchaser reseller complaints name our subsidiaries PPI, Generics Bidco I, LLC and DAVA Pharmaceuticals, LLC, as well as other companies, as defendants. The direct purchaser complaint names our subsidiary Par and other companies as defendants. As to our subsidiaries, these complaints allege anticompetitive conduct with respect to doxycycline hyclate, doxycycline monohydrate, nystatin cream and/or zoledronic acid. These complaints also seek to hold all defendants jointly and severally liable for alleged anticompetitive conduct relating to all products identified in the complaints on the basis of an “overarching conspiracy” theory similar to that asserted by the state plaintiffs.
In August 2018, Humana Inc. filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against the Company, PPI and Par, as well as numerous other manufacturers of generic pharmaceuticals, alleging anticompetitive conduct relating to approximately 16 generic pharmaceutical products, including amitriptyline, baclofen, digoxin, divalproex, doxycycline (both doxycycline hyclate and doxycycline monohydrate) and propranolol. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing for all 16 products, as well as product-specific conspiracies relating to each individual product. The complaint asserts claims under state and federal law and seeks monetary damages, including treble damages, attorneys’ fees and equitable relief. The lawsuit has been assigned to the MDL court.
In September 2018, Marion Diagnostic Center, LLC and Marion HealthCare, LLC filed a class action complaint in the U.S. District Court for the Eastern District of Pennsylvania against Par, as well as other manufacturers and one distributor of generic pharmaceuticals, McKesson Corporation (McKesson), on behalf of all direct purchasers of all generic drugs from McKesson. The complaint alleges an overarching conspiracy among all named defendants to engage in price-fixing and market allocation with respect to all generic drugs sold by McKesson, seeking to hold all defendants jointly and severally liable. The complaint asserts claims under state and federal law and seeks monetary damages, including treble damages, attorneys’ fees and equitable relief.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Other Antitrust Matters
Beginning in November 2013, multiple direct and indirect purchasers of LIDODERM® filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. (collectively, Teikoku), and Actavis plc and certain of its subsidiaries (collectively, Actavis, which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries from Allergan plc). Plaintiffs generally alleged that EPI, Teikoku and Actavis entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ‘529 patent) and other patents. Some complaints also alleged that Teikoku wrongfully listed the ‘529 patent in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) as related to LIDODERM®, that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies’ efforts to obtain FDA approval of their versions of LIDODERM®. The complaints asserted claims under Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), and/or various state antitrust and consumer protection statutes, as well as common law claims, and generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. The cases were consolidated and/or coordinated in April 2014 in a federal MDL in the U.S. District Court for the Northern District of California (MDL No. 2521). The MDL court certified classes of direct and indirect purchasers in February 2017. In June 2017, defendants moved for summary judgment on all claims, and plaintiffs also moved for partial summary judgment on certain elements of their claims. In November 2017, the court granted defendants’ motion in part, ruling in defendants’ favor on the issues of infringement and derivation and also limiting the time period at issue. Defendants’ motions for summary judgment were denied in all other respects. The court also granted plaintiffs’ motions for summary judgment on the issues of agreement and relevant market. EPI settled with certain opt-out retailer plaintiffs in October 2017. EPI reached agreements to settle with the class plaintiffs in March 2018. In connection with the settlements, several indirect purchasers which previously had opted out were permitted to rejoin the class. The class settlement agreements provide for aggregate payments of approximately $100 million. In September 2018, the court approved the class settlement agreements and entered judgment dismissing the class cases with prejudice.
Beginning in June 2014, multiple direct and indirect purchasers of OPANA® ER filed cases against our subsidiaries EHSI and EPI and other pharmaceutical companies, including Impax Laboratories Inc. (Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. All cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois (MDL No. 2580). Plaintiffs generally allege that an agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA® ER and EPI’s introduction of reformulated OPANA® ER violated antitrust laws. The complaints assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In February 2016, the MDL court issued orders (i) denying defendants’ motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants’ motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants’ motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the MDL court’s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers also filed amended complaints. The court has dismissed the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. The cases are currently in discovery. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.
Beginning in February 2009, the FTC and certain private plaintiffs, including distributors and retailers, filed suit against our subsidiary Par Pharmaceutical Companies, Inc. (since June 2016, Endo Generics Holdings, Inc., and referred to in this Commitments and Contingencies note as EGHI) and others alleging violations of antitrust law arising out of EGHI’s settlement of certain patent litigation concerning the generic version of AndroGel®. Generally, the complaints seek damages, treble damages, equitable relief and attorneys’ fees and costs. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia (MDL No. 2084). In September 2012, the MDL court granted summary judgment to defendants on plaintiffs’ claims of sham litigation. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. Claims by certain alleged direct purchasers or their assignees are still pending. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, the court rejected two of direct purchasers’ three causation theories, rejected damages claims related to AndroGel® 1.62% and granted in part a motion seeking to exclude part of plaintiffs’ proposed manufacturing expert’s opinions. The motions were denied in all other respects, and the court denied a motion for reconsideration, or in the alternative leave to file an interlocutory appeal, in October 2018. In July 2018, the district court denied certain plaintiffs’ motion for certification of a direct purchaser class. We will continue to vigorously defend these matters and to explore other options as appropriate in our best interests.
Beginning in February 2018, several alleged indirect purchasers filed proposed class actions against our subsidiary PPI and others alleging a conspiracy to delay generic competition and monopolize the market for Zetia® (ezetimibe) and its generic equivalents. The complaints generally asserted claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek injunctive relief, damages, treble damages, attorneys’ fees and costs. In June 2018, the cases were consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Virginia (MDL No. 2836). In September 2018, plaintiffs voluntarily dismissed without prejudice all claims against PPI.
Beginning in May 2018, multiple alleged direct and indirect purchasers filed complaints in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as others, alleging a conspiracy to delay generic competition and monopolize the market for Exforge® (amlodipine/valsartan) and its generic equivalents. Some cases were filed on behalf of putative classes of direct and indirect purchasers; another was filed on behalf of individual retailers. The plaintiffs generally assert claims under Sections 1 and 2 of the Sherman Act, various state antitrust and consumer protection statutes and state common law and seek damages, treble damages, equitable relief and attorneys’ fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs did the same in November 2018. PPI filed a partial motion to dismiss certain claims in September 2018. We intend to vigorously defend these matters and to explore other options as appropriate in our best interests.
In November 2014, EPI received a CID from Florida’s Office of the Attorney General seeking documents and other information concerning EPI’s agreement with Actavis settling the LIDODERM® patent litigation, as well as information concerning marketing and sales of LIDODERM®. EPI received similar CIDs from South Carolina’s Office of the Attorney General in February 2016 and from Alaska’s Office of the Attorney General in February 2015. The Alaska CID was also directed to EHSI and included requests for documents and information concerning agreements with Actavis and Impax settling the OPANA® ER patent litigation. We are cooperating with these investigations.
In February 2015, EGHI and affiliates received a CID from the Office of the Attorney General for the state of Alaska seeking production of certain documents and information regarding EGHI’s settlement of the AndroGel® patent litigation as well as documents produced in the aforementioned litigation filed by the FTC. We are cooperating with this investigation.
Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.
Securities Litigation
In May 2016, a putative class action entitled Craig Friedman v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the court appointed Steamfitters’ Industry Pension Fund and Steamfitters’ Industry Security Benefit Fund as lead plaintiffs in the action. In October 2016, plaintiffs filed a second amended complaint that, among other things, added Paul Campanelli as a defendant, and we filed a motion to dismiss. In response, and without resolving the motion, the court permitted lead plaintiffs to file a third amended complaint. The amended complaint alleged violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company’s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par Pharmaceutical Holdings, Inc. and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney’s Office for the Southern District of New York regarding contracts with pharmacy benefit managers concerning FROVA®. Lead plaintiffs sought class certification, damages in an unspecified amount and attorneys’ fees and costs. We filed a motion to dismiss the third amended complaint in December 2016. In January 2018, the court granted our motion and dismissed the case with prejudice. In February 2018, lead plaintiffs filed a motion for relief from the judgment and leave to file a fourth amended complaint; the court denied this motion in April 2018. Lead plaintiffs appealed to the U.S. Court of Appeals for the Second Circuit; that appeal is still pending.
In February 2017, a putative class action entitled Public Employees’ Retirement System of Mississippi v. Endo International plc was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering, on behalf of itself and all similarly situated purchasers. The lawsuit alleges violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against Endo, certain of its current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo’s generics business. In March 2017, defendants removed the case to the U.S. District Court for the Eastern District of Pennsylvania. In August 2017, the court remanded the case back to the Chester County Court of Common Pleas. In October 2017, plaintiff filed an amended complaint. In December 2017, defendants filed preliminary objections to the amended complaint. The court denied those preliminary objections in April 2018. The case is currently in discovery. Plaintiff filed its motion for class certification in July 2018.
In April 2017, a putative class action entitled Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo’s securities between January 11 and May 5, 2016. The statement of claim generally seeks class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act. The statement of claim alleges negligent misrepresentations concerning the Company’s revenues, profit margins and earnings per share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company’s U.S. generic pharmaceuticals business.
In August 2017, a putative class action entitled Bier v. Endo International plc, et al. was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The original complaint alleged violations of Section 10(b) and 20(a) of the Exchange Act against Endo and four current and former directors and officers, based on the Company’s decision to remove reformulated OPANA® ER from the market. In December 2017, the court appointed SEB Investment Management AB lead plaintiff in the action. In February 2018, the lead plaintiff filed an amended complaint, which added claims alleging violations of Sections 11 and 15 of the Securities Act in connection with the June 2015 offering. The amended complaint named the Company, EHSI and 20 current and former directors, officers and employees of Endo as defendants. In April 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.
In November 2017, a putative class action entitled Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay, and Paul V. Campanelli was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park Employees’ Annuity and Benefit Fund of Chicago lead plaintiff in the action. In August 2018, the lead plaintiff filed an amended complaint. In September 2018, the defendants moved to dismiss the amended complaint. That motion remains pending.
We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
VASOSTRICT® Related Matters
In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its affiliate Par Sterile Products, LLC (PSP) in the U.S. District Court for the District of New Jersey alleging that Par and its affiliate engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par’s VASOSTRICT® (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that Par and its affiliate entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that, as a result, Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages, attorneys’ fees and costs, and injunctive relief. In September 2016, Par and its affiliate filed a motion to dismiss, which the district court denied in February 2017. The case is currently in discovery.
In August 2017, our subsidiaries PPI and PSP filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa Pharma, Inc. (QuVa), Stuart Hinchen, Peter Jenkins, and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT®, a vasopressin-based cardiopulmonary drug. In October 2017, defendants answered the complaint and QuVa asserted counterclaims against PPI and PSP alleging unfair competition under New Jersey common law and seeking declaratory judgment of non-infringement as to five U.S. Patents assigned to PPI that are listed in FDA’s Orange Book for VASOSTRICT®. The counterclaims seek actual, exemplary and punitive damages, injunctive relief and other relief. We filed a motion to dismiss the unfair competition counterclaim in November 2017. This motion is still pending. Also in November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In January 2018, we filed a first amended complaint adding five former employees of PSP as defendants and numerous causes of action against some or all of those former employees, including misappropriation under the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as breach of contract, breach of the duty of loyalty and breach of the duty of confidence. In March 2018, the court granted in part our motion for preliminary injunction and enjoined QuVa from marketing and releasing its planned vasopressin product through the conclusion of trial. We subsequently deposited a bond to the court’s interest-bearing account to secure the preliminary injunction. Defendants have filed a motion asking the court to reconsider the bond amount, which remains pending. Also in March 2018, QuVa and seven of the individual defendants filed a motion to dismiss the New Jersey common law claims, four of the individual defendants filed a motion to dismiss for lack of personal jurisdiction and one of the individuals filed a motion to dismiss the breach of contract claim. In April 2018, another individual defendant filed a motion to dismiss asserting numerous arguments, including lack of personal jurisdiction, improper venue and choice of law. These motions are still pending. Full discovery began in May 2018, but the court has not yet set a trial date. Also in May 2018, defendants filed a notice of appeal to the Third Circuit Court of Appeal indicating intent to appeal the court’s preliminary injunction, and in October 2018, defendants filed their opening appellate brief.
In October 2017, Endo Par Innovation Company, LLC (EPIC) and PSP filed a complaint in the United States District Court for the District of Columbia challenging the legality of the FDA’s Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (January 2017) with respect to the listing of vasopressin in Category 1 of the Interim Policy. The complaint contends that the Interim Policy is unlawful because it is inconsistent with the Federal Food, Drug, and Cosmetic Act, including, but not limited to, Section 503B of that Act. The complaint seeks (i) a declaration that FDA’s Interim Policy and its listing of vasopressin in Category 1 of the Interim Policy are unlawful, and (ii) an order enjoining and vacating the Interim Policy and FDA’s listing of vasopressin in Category 1 of the Interim Policy. In January 2018, EPIC and PSP agreed to a temporary 60-day stay of the litigation in light of the FDA’s announcement that forthcoming guidance would address the concerns set forth in the Company’s complaint. In March 2018, the FDA released new draft guidance for industry entitled “Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” Shortly thereafter, the parties agreed to extend the temporary stay for an additional 180 days. In August 2018, before the 180-day stay period expired, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC announced they had commenced bulk compounding of vasopressin, and moved to intervene in EPIC and PSP’s case against the FDA. Later that month, EPIC and PSP invoked their ability to terminate the stay and filed a Motion for Preliminary Injunction. Before responding to the Motion for Preliminary Injunction, the FDA issued a notice containing a proposed finding that there is no clinical need to bulk compound vasopressin under Section 503B in August 2018. In September 2018, the FDA advised EPIC and PSP that it would agree to use its best efforts to finalize the vasopressin clinical need rulemaking by December 31, 2018, if the case were again stayed. As a result of the preliminary finding and the FDA’s commitment to use best efforts to finalize the rulemaking by December 31, 2018, EPIC and PSP agreed to again stay the case until December 31, 2018. In a related action, in August 2018, Athenex filed a declaratory judgment action in the U.S. District Court for the Western District of New York, a case styled Athenex v. Par, alleging non-infringement and/or invalidity of the patents the Company has listed in the Orange Book in view of VASOSTRICT®. The Company also moved to dismiss Athenex’s case on multiple grounds in October 2018.
In April 2018, PSP and PPI received a notice letter from Eagle Pharmaceuticals, Inc. (Eagle) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT® (vasopressin IV solution (infusion)) 20 units/ml. In May 2018, PSP and PPI received a second notice letter from Eagle advising of the same filing, but adding an additional patent. The Paragraph IV Notices refer to U.S. Patent Nos. 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; and 9,937,223, which variously cover either vasopressin-containing pharmaceutical compositions or methods of using a vasopressin-containing dosage form to increase blood pressure in humans. In May 2018, PPI, PSP and EPIC filed a lawsuit against Eagle in the United States District Court for the District of Delaware within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In August 2018, Eagle filed an answer and a counterclaim for non-infringement and invalidity of asserted patents.
In September 2018, PSP and PPI received a notice letter from Sandoz Inc. (Sandoz) advising of the filing by such company of an ANDA for a generic version of VASOSTRICT® (vasopressin IV solution (infusion)) 200 units/10 ml. In October 2018, PPI, PSP and EPIC filed a lawsuit against Sandoz in the United States District Court for the District of New Jersey within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. In October 2018, PSP and PPI received an additional notice letter from Sandoz advising of the filing by such company of an ANDA for a generic version of the 20 units/1 ml presentation for VASOSTRICT®. The 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme with respect to the additional notice letter has not yet expired. The Company continues to vigorously defend its intellectual property.
The Company’s legal reserves include, among other things, an estimated accrual for certain VASOSTRICT®-related matters. We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional accruals that could be required.
Paragraph IV Certifications on OPANA® ER
In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA® ER and a highly pure version of the API of OPANA® ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal and Sandoz Inc. based on their ANDAs filed against both the INTAC® technology and non-INTAC® technology versions of OPANA® ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the ‘737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the ‘779 patent. In July 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the ‘779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029. A trial for infringement of the ‘799 patent by Actavis was held in February 2017 in the same court (U.S. District Court for the District of Delaware) in front of the same judge. In August 2017, the District Court issued an Opinion holding that Actavis infringed the claims of U.S. Patent No. 8,871,779, and that Actavis had failed to show that U.S. Patent No. 8,871,779 was invalid. Teva, Amneal and Actavis have appealed these holdings. We have appealed the holding that the ‘737 patent is invalid. A hearing on that appeal has been set for December 2018.
We will continue to vigorously defend or prosecute the foregoing matter as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests in defense of our intellectual property, including enforcement of the product’s intellectual property rights and approved labeling. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred.
Other Proceedings and Investigations
Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Other Comprehensive Income (Loss)
NOTE 15. OTHER COMPREHENSIVE INCOME (LOSS)
Set forth below are the tax effects allocated to each component of Other comprehensive income (loss) for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
2018
 
2017
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
Net unrealized gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
$
—

 
$
—

 
$
295

 
$
(107
)
 
$
188

Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
—

 
—

 
—

Net unrealized gains on securities
$
—

 
$
—

 
$
—

 
$
295

 
$
(107
)
 
$
188

Net unrealized gain on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation gain arising during the period
4,735

 
—

 
4,735

 
9,941

 
—

 
9,941

Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
29,325

 
—

 
29,325

Foreign currency translation gain
$
4,735

 
$
—

 
$
4,735

 
$
39,266

 
$
—

 
$
39,266

Other comprehensive income
$
4,735

 
$
—

 
$
4,735

 
$
39,561

 
$
(107
)
 
$
39,454


 
Nine Months Ended September 30,
 
2018
 
2017
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
Net unrealized gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
$
—

 
$
—

 
$
522

 
$
(189
)
 
$
333

Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
—

 
—

 
—

Net unrealized gains on securities
$
—

 
$
—

 
$
—

 
$
522

 
$
(189
)
 
$
333

Net unrealized (loss) gain on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation (loss) gain arising during the period
(7,033
)
 
—

 
(7,033
)
 
35,415

 
—

 
35,415

Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
29,325

 
—

 
29,325

Foreign currency translation (loss) gain
$
(7,033
)
 
$
—

 
$
(7,033
)
 
$
64,740

 
$
—

 
$
64,740

Other comprehensive (loss) income
$
(7,033
)
 
$
—

 
$
(7,033
)
 
$
65,262

 
$
(189
)
 
$
65,073


Reclassification adjustments out of Other comprehensive income related to foreign currency translation were recorded upon the liquidation of Litha in the third quarter of 2017.
Substantially all of the Company’s Accumulated other comprehensive loss at September 30, 2018 and December 31, 2017 consists of Foreign currency translation loss.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' (Deficit) Equity Shareholders' (Deficit) Equity
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Shareholders' (Deficit) Equity
NOTE 16. SHAREHOLDERS' (DEFICIT) EQUITY
Changes in Shareholders' (Deficit) Equity
The following table displays a reconciliation of our beginning and ending balances in Total shareholders' equity (deficit) for the nine months ended September 30, 2018 (in thousands):
 
Total Shareholders' Equity (Deficit)
Shareholders' equity at January 1, 2018, prior to the adoption of ASC 606
$
484,880

Effect of adopting ASC 606 (1)
3,076

Shareholders' equity at January 1, 2018
$
487,956

Net loss
(739,561
)
Other comprehensive loss
(7,033
)
Compensation related to share-based awards
43,722

Tax withholding for restricted shares
(5,082
)
Exercise of options
473

Other
66

Shareholders' deficit at September 30, 2018
$
(219,459
)
__________
(1)
Refer to Note 2. Summary of Significant Accounting Policies for further description of ASC 606.
Share-Based Compensation
During the second quarter of 2018, the Company’s shareholders approved an amendment to the Endo International plc Amended and Restated 2015 Stock Incentive Plan (the Plan). The Plan was amended and restated to increase the number of the Company’s ordinary shares that may be issued with respect to awards under the Plan by 5.0 million ordinary shares and to make certain other changes to the Plan’s terms.
The Company recognized share-based compensation expense of $13.7 million and $13.2 million during the three months ended September 30, 2018 and 2017, respectively, and $43.7 million and $40.3 million during the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018, the total remaining unrecognized compensation cost related to non-vested share-based compensation awards amounted to $45.6 million.
During the third quarter of 2017, the Company issued approximately 1.0 million stock options and 0.1 million restricted stock units that were initially subject to shareholder approval and were subsequently approved by shareholders on June 7, 2018 at the Company’s Annual General Meeting of Shareholders. The options have an exercise price equal to the closing share price on their issuance date in August 2017.
There are 0.5 million performance share units outstanding as of September 30, 2018, representing target amounts, for which a grant date has not been established. No fair value has been ascribed to these awards as no grant date has been established. Accordingly, they are not reflected in the remaining unrecognized compensation cost above or the weighted average remaining requisite service period below.
Beginning in 2017, long-term cash incentive (LTCI) awards were provided to certain employees. LTCI awards were designed to vest ratably, in equal amounts, over a three-year service period. Upon vesting, each vested LTCI unit would be settled in cash in an amount equal to the price of Endo’s ordinary shares on the vest date. As of September 30, 2018, approximately 3.0 million unvested LTCI awards were outstanding with a weighted average remaining requisite service period of 2.3 years. A corresponding liability of $14.9 million was recorded as of September 30, 2018 in Accounts payable and accrued expenses and Other liabilities in the Company’s Condensed Consolidated Balance Sheets. On October 1, 2018, the Compensation Committee of the Company’s Board of Directors authorized the Company to settle each of the outstanding unvested LTCI awards in shares, rather than cash, upon vesting in accordance with the original vesting terms of the awards. With the authorization of the Compensation Committee, management’s intent to settle the awards in shares rather than cash is a modification that changes the awards’ classification from liability to equity, effective October 1, 2018. The accounting for the modification will occur in the fourth quarter of 2018. As of September 30, 2018, the LTCI awards are not reflected in the remaining unrecognized compensation cost above or the weighted average remaining requisite service period below.
As of September 30, 2018, the weighted average remaining requisite service period for non-vested stock options was 1.8 years and for non-vested restricted stock units was 2.0 years.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Income, Net
 9 Months Ended
Sep. 30, 2018
Component of Operating Income [Abstract]  
OTHER INCOME, NET
NOTE 17. OTHER INCOME, NET
The components of Other income, net for the three and nine months ended September 30, 2018 and 2017 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net gain on sale of business and other assets
$
(2,866
)
 
$
(2,763
)
 
$
(29,859
)
 
$
(5,074
)
Foreign currency loss (gain), net
1,354

 
2,549

 
(734
)

(4,305
)
Net loss (gain) from our investments in the equity of other companies
842

 
(1,075
)
 
3,163


(1,163
)
Other miscellaneous, net
(837
)
 
(808
)
 
(5,786
)

(301
)
Other income, net
$
(1,507
)
 
$
(2,097
)
 
$
(33,216
)

$
(10,843
)

Net gain on sale of business and other assets primarily relates to proceeds received from the sale of various ANDAs during the three and nine months ended September 30, 2018. Foreign currency loss (gain), net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. Net loss (gain) from our investments in the equity of other companies includes the income statement impacts of our investments in the equity of other companies, including those accounted for under the equity method and those classified as marketable securities.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE 18. INCOME TAXES
The following table displays our Loss from continuing operations before income tax, Income tax expense (benefit) and Effective tax rate for the three and nine months ended September 30, 2018 and 2017 (dollars in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Income tax expense (benefit)
$
3,003

 
$
(28,109
)
 
$
24,729

 
$
(97,517
)
Effective tax rate
(2.1
)%
 
22.0
%
 
(3.7
)%
 
9.2
%

The income tax expense for the three months ended September 30, 2018 primarily relates to the geographic mix of pre-tax earnings. As of September 30, 2018, we had valuation allowances established against our deferred tax assets in most jurisdictions in which we operate, with the exception of Canada and India. The income tax benefit for the comparable 2017 period primarily relates to the geographic mix of pre-tax earnings and a discrete tax benefit primarily associated with the filing of the Company’s 2016 U.S. federal income tax return and an intangible asset impairment.
The income tax expense for the nine months ended September 30, 2018 primarily relates to the geographic mix of pre-tax earnings and discrete tax expense incurred in connection with an intercompany asset restructuring. The income tax benefit for the comparable 2017 period relates primarily to the geographic mix of pre-tax earnings and the discrete tax benefits associated with goodwill and intangible asset impairments and the favorable return to provision adjustments resulting from the filing of the Company’s 2016 U.S. federal income tax return.
During the year ended December 31, 2017, we recorded a benefit of $36.2 million as our estimate of the impact of the TCJA. This benefit, which is primarily related to the remeasurement of deferred tax liabilities related to tax deductible goodwill, was recorded in our Consolidated Statements of Operations as Income tax benefit during the three months ended December 31, 2017.
We recorded the aforementioned net benefit based on currently available information and interpretations of the TCJA. In accordance with authoritative guidance issued by the SEC, the income tax effect for certain aspects of the TCJA may represent provisional amounts for which our accounting is incomplete but a reasonable estimate could be determined. We consider amounts related to the various transition rules and interpretations of the TCJA to be provisional. Accordingly, we will continue to evaluate the impacts of the TCJA, including administrative and regulatory guidance as it becomes available. The measurement and existence of current and non-current income tax payables and/or the remeasurement of deferred tax assets and liabilities may change upon finalization of our analysis, which is expected to occur no later than one year from December 22, 2017, the date of the TCJA’s enactment. Any adjustment to a provisional amount identified during the one-year measurement period will be recorded as an income tax expense or benefit in the period the adjustment is determined.
During the nine months ended September 30, 2018, we did not record any adjustments to the provisional amounts recognized in 2017. We will continue to monitor for any significant impact on the Company’s consolidated financial statements with respect to the TCJA as more refined information and further guidance become available.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
NET LOSS PER SHARE
NOTE 19. NET LOSS PER SHARE
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations
$
(146,071
)
 
$
(99,687
)
 
$
(696,288
)
 
$
(961,130
)
(Loss) income from discontinued operations, net of tax
(27,134
)
 
3,017

 
(43,273
)
 
(705,886
)
Net loss
$
(173,205
)
 
$
(96,670
)
 
$
(739,561
)
 
$
(1,667,016
)
Denominator:
 
 
 
 
 
 
 
For basic per share data—weighted average shares
224,132

 
223,299

 
223,829

 
223,157

Dilutive effect of ordinary share equivalents
—

 
—

 
—

 
—

For diluted per share data—weighted average shares
224,132

 
223,299

 
223,829

 
223,157


Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period.
Stock options and awards that have been issued but for which a grant date has not yet been established, such as the performance share units discussed in Note 16. Shareholders' (Deficit) Equity, are not considered in the calculation of basic or diluted weighted average shares.
All potentially dilutive items were excluded from the diluted share calculation for the three and nine months ended September 30, 2018 and 2017 because their effect would have been anti-dilutive, as the Company was in a loss position.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Revenue Recognition
Revenue Recognition. The Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. For further discussion of the impact of adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2018” section below. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.
Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order and invoice the customer upon shipment. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract’s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, distribution service agreement (DSA) and other fees for services, returns and allowances. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within 30 to 90 days of invoicing. Our most significant components of variable consideration are further described below. Our estimates for these components are based on factors such as historical experience, estimated future trends, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors.
Contract Assets and Contract Liabilities. Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditioned on something other than the passage of time including, for example, the entity’s future performance. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company’s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.
Contract liabilities represent the Company’s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing the corresponding performance obligation, the contract liability amount is reversed and revenue is recognized.
Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in Note 11. Contract Assets and Liabilities.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted as of September 30, 2018
In February 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for most leases. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, “Leases (Topic 842) - Targeted Improvements” (ASU 2018-11), which addresses implementation issues related to the new lease standard. This guidance will be effective for the Company beginning in the first quarter of 2019, with early application permitted. The Company plans to adopt this guidance in the first quarter of 2019 using the modified retrospective approach and will recognize a cumulative-effect adjustment to the opening balance of Accumulated deficit in that period. This guidance includes a number of optional practical expedients that the Company may elect to apply, including an expedient that permits lease agreements that are twelve months or less to be excluded from the balance sheet. The Company is continuing to evaluate the impact that this new guidance will have on its consolidated financial statements, including its disclosures. It is expected that the primary impact upon adoption will be the recognition, on a discounted basis, of the Company’s minimum commitments under noncancelable operating leases as right of use assets and obligations on the consolidated balance sheets. This will result in a significant increase in assets and liabilities on the Company’s consolidated balance sheets. In preparation for the adoption of this guidance, the Company is continuing the process of identifying and validating the Company’s lease information and evaluating the impact that this new guidance will have on its processes and controls.
In February 2018, the FASB issued ASU No. 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (ASU 2018-02). ASU 2018-02 allows for a reclassification from accumulated other comprehensive income or loss to retained earnings or accumulated deficit for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (TCJA). ASU 2018-02 also requires certain related disclosures. ASU 2018-02 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018 and should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-02 on the Company’s consolidated results of operations and financial position.
In July 2018, the FASB issued ASU No. 2018-09, “Codification Improvements” (ASU 2018-09). ASU 2018-09 makes changes to a variety of topics to clarify, correct errors in or make minor improvements to the Accounting Standards Codification. Certain of these provisions are effective immediately; however, these provisions did not have a material impact on the Company’s financial statements or disclosures. The remaining provisions are generally effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. The Company is currently evaluating the impact of these remaining provisions of ASU 2018-09 on the Company’s consolidated results of operations and financial position.
In August 2018, the FASB issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (ASU 2018-13). ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Certain aspects of ASU 2018-13 require prospective treatment, while others require retrospective treatment. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-13 on the Company’s disclosures.
In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (ASU 2018-15). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-15 may be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-15 on the Company’s consolidated results of operations, financial position and disclosures.
In November 2018, the FASB issued ASU No. 2018-18, “Clarifying the Interaction Between Topic 808 and Topic 606” (ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should generally be applied retrospectively to the date of initial application of Topic 606 (January 1, 2018 for the Company) and early adoption is permitted. The Company is currently evaluating the impact of ASU 2018-18 on the Company’s consolidated results of operations, financial position and disclosures.
Recent Accounting Pronouncements Adopted or Otherwise Effective as of September 30, 2018
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09), which was subsequently amended and supplemented by several additional ASUs including:
•
ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” (issued in August 2015), which deferred the effective date of ASU 2014-09 by one year, such that ASU 2014-09 became effective for Endo for annual and interim reporting periods beginning after December 15, 2017;
•
ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” (issued in March 2016), which clarified the guidance on reporting revenue as a principal versus agent;
•
ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (issued in April 2016), which clarified the guidance on identifying performance obligations and accounting for intellectual property licenses; and
•
ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients” and ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” (issued in May 2016 and December 2016, respectively), which amended certain narrow aspects of Topic 606.
These ASUs have generally been codified in Accounting Standards Codification Topic 606 “Revenue from Contracts with Customers”, and are collectively referred to herein as ASC 606. ASC 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (ASC 605), and requires entities to recognize revenue when control of promised goods or services is transferred to customers at an amount that reflects the consideration to which entities expect to be entitled in exchange for those goods or services.
The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. Under the modified retrospective method, results beginning on January 1, 2018 are presented under ASC 606, while the comparative prior period results continue to be presented under ASC 605 based on the accounting standards originally in effect for such periods. As a result of adopting ASC 606, the Company recorded a net decrease of $3.1 million to its accumulated deficit at January 1, 2018, representing the cumulative impact of adopting ASC 606.
In May 2017, the FASB issued ASU No. 2017-09 “Compensation - Stock Compensation” (ASU 2017-09). ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. It is intended to reduce both (1) diversity in practice and (2) cost and complexity when accounting for changes to the terms or conditions of share-based payment awards. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company adopted the new standard on January 1, 2018 and the amendments in this update will be applied prospectively to any award modified on or after the adoption date.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation (Tables)
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of new accounting pronouncements
The table below presents the effects of ASU 2016-18 on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 (in thousands):
 
Prior to Adoption
 
Impact of Adoption
 
Subsequent to Adoption
Net cash provided by operating activities
$
424,062

 
$
(1,900
)
 
$
422,162

Net cash (used in) provided by investing activities
(69,802
)
 
78,766

 
8,964

Net cash used in financing activities
(135,353
)
 
—

 
(135,353
)
Effect of foreign exchange rate
3,686

 
297

 
3,983

Movement in cash held for sale
(1,450
)
 
—

 
(1,450
)
Net change (1)
$
221,143

 
$
77,163

 
$
298,306

Beginning-of-period balance (2)
517,250

 
287,930

 
805,180

End-of-period balance (2)
$
738,393

 
$
365,093

 
$
1,103,486

__________
(1)
This line refers to the “Net increase in cash and cash equivalents” prior to the adoption of ASU 2016-18 and the “Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
(2)
These lines refer to the beginning or end of period amounts of “Cash and cash equivalents” prior to the adoption of ASU 2016-18 and the beginning or end of period amounts of “Cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
The current period impact of adoption on our Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets is as follows (in thousands, except per share amounts):
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Statement of Operations:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
 
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
Total revenues
$
745,466

 
$
747,571

 
$
(2,105
)
 
$
2,160,689

 
$
2,160,132

 
$
557

Cost of revenues
$
412,965

 
$
414,430

 
$
(1,465
)
 
$
1,198,468

 
$
1,199,042

 
$
(574
)
Other income, net
$
(1,507
)
 
$
(1,507
)
 
$
—

 
$
(33,216
)
 
$
(32,216
)
 
$
(1,000
)
Loss from continuing operations
$
(146,071
)
 
$
(145,431
)
 
$
(640
)
 
$
(696,288
)
 
$
(698,419
)
 
$
2,131

Net loss
$
(173,205
)
 
$
(172,565
)
 
$
(640
)
 
$
(739,561
)
 
$
(741,692
)
 
$
2,131

Net loss per share—Basic:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total basic
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

Net loss per share—Diluted:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total diluted
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

__________
(1)
Amounts may not add due to rounding.
 
At September 30, 2018
Balance Sheet:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606
Assets:
 
 
 
 
 
Inventories, net
$
332,787

 
$
341,189

 
$
(8,402
)
Prepaid expenses and other current assets
$
50,697

 
$
40,368

 
$
10,329

Other assets
$
67,934

 
$
64,972

 
$
2,962

Liabilities:
 
 
 
 
 
Accounts payable and accrued expenses
$
1,019,004

 
$
1,019,322

 
$
(318
)
Shareholders' (deficit) equity:
 
 
 
 
 
Accumulated deficit
$
(8,833,024
)
 
$
(8,838,231
)
 
$
5,207
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Schedule of new accounting pronouncements
The table below presents the effects of ASU 2016-18 on the Company’s Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 (in thousands):
 
Prior to Adoption
 
Impact of Adoption
 
Subsequent to Adoption
Net cash provided by operating activities
$
424,062

 
$
(1,900
)
 
$
422,162

Net cash (used in) provided by investing activities
(69,802
)
 
78,766

 
8,964

Net cash used in financing activities
(135,353
)
 
—

 
(135,353
)
Effect of foreign exchange rate
3,686

 
297

 
3,983

Movement in cash held for sale
(1,450
)
 
—

 
(1,450
)
Net change (1)
$
221,143

 
$
77,163

 
$
298,306

Beginning-of-period balance (2)
517,250

 
287,930

 
805,180

End-of-period balance (2)
$
738,393

 
$
365,093

 
$
1,103,486

__________
(1)
This line refers to the “Net increase in cash and cash equivalents” prior to the adoption of ASU 2016-18 and the “Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
(2)
These lines refer to the beginning or end of period amounts of “Cash and cash equivalents” prior to the adoption of ASU 2016-18 and the beginning or end of period amounts of “Cash, cash equivalents, restricted cash and restricted cash equivalents” after the adoption.
The current period impact of adoption on our Condensed Consolidated Statements of Operations and Condensed Consolidated Balance Sheets is as follows (in thousands, except per share amounts):
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Statement of Operations:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
 
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606 (1)
Total revenues
$
745,466

 
$
747,571

 
$
(2,105
)
 
$
2,160,689

 
$
2,160,132

 
$
557

Cost of revenues
$
412,965

 
$
414,430

 
$
(1,465
)
 
$
1,198,468

 
$
1,199,042

 
$
(574
)
Other income, net
$
(1,507
)
 
$
(1,507
)
 
$
—

 
$
(33,216
)
 
$
(32,216
)
 
$
(1,000
)
Loss from continuing operations
$
(146,071
)
 
$
(145,431
)
 
$
(640
)
 
$
(696,288
)
 
$
(698,419
)
 
$
2,131

Net loss
$
(173,205
)
 
$
(172,565
)
 
$
(640
)
 
$
(739,561
)
 
$
(741,692
)
 
$
2,131

Net loss per share—Basic:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total basic
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

Net loss per share—Diluted:
 
 
 
 
 
 
 
 
 
 
 
Continuing operations
$
(0.65
)
 
$
(0.65
)
 
$
—

 
$
(3.11
)
 
$
(3.12
)
 
$
0.01

Total diluted
$
(0.77
)
 
$
(0.77
)
 
$
—

 
$
(3.30
)
 
$
(3.31
)
 
$
0.01

__________
(1)
Amounts may not add due to rounding.
 
At September 30, 2018
Balance Sheet:
Amounts reported under ASC 606
 
Amounts assuming continued application of ASC 605
 
Effect of adoption of ASC 606
Assets:
 
 
 
 
 
Inventories, net
$
332,787

 
$
341,189

 
$
(8,402
)
Prepaid expenses and other current assets
$
50,697

 
$
40,368

 
$
10,329

Other assets
$
67,934

 
$
64,972

 
$
2,962

Liabilities:
 
 
 
 
 
Accounts payable and accrued expenses
$
1,019,004

 
$
1,019,322

 
$
(318
)
Shareholders' (deficit) equity:
 
 
 
 
 
Accumulated deficit
$
(8,833,024
)
 
$
(8,838,231
)
 
$
5,207
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Discontinued Operations and Divestitures (Tables)
 9 Months Ended
Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures
The following table provides the operating results of Astora for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Litigation-related and other contingencies, net
$
19,000

 
$
—

 
$
19,000

 
$
775,684

Loss from discontinued operations before income taxes
$
(27,134
)
 
$
(8,957
)
 
$
(43,273
)
 
$
(813,442
)
Income tax benefit
$
—

 
$
(11,974
)
 
$
—

 
$
(107,556
)
Discontinued operations, net of tax
$
(27,134
)
 
$
3,017

 
$
(43,273
)
 
$
(705,886
)
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring (Tables)
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Schedule of restructuring reserve by type of cost
Changes to this liability during the nine months ended September 30, 2018 were as follows (in thousands):
 
Employee Separation and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2018
$
—

 
$
650

 
$
650

Expenses
22,087

 
1,705

 
23,792

Cash distributions
(18,439
)
 
(1,949
)
 
(20,388
)
Liability balance as of September 30, 2018
$
3,648

 
$
406

 
$
4,054

Changes to this liability during the nine months ended September 30, 2018 were as follows (in thousands):
 
Employee Separation and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2018
$
22,975

 
$
1,610

 
$
24,585

Expenses
9,779

 
9,341

 
19,120

Cash distributions
(22,518
)
 
(10,951
)
 
(33,469
)
Liability balance as of September 30, 2018
$
10,236

 
$
—

 
$
10,236
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Results (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Schedule of reportable segments information
The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net revenues from external customers:
 
 
 
 
 
 
 
U.S. Branded - Specialty & Established Pharmaceuticals
$
220,100

 
$
233,803

 
$
632,972

 
$
729,150

U.S. Branded - Sterile Injectables
237,150

 
201,905

 
670,847

 
554,365

U.S. Generic Pharmaceuticals
257,969

 
294,749

 
748,445

 
1,227,584

International Pharmaceuticals (1)
30,247

 
56,430

 
108,425

 
189,119

Total net revenues from external customers
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

Adjusted income from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded - Specialty & Established Pharmaceuticals
$
84,891


$
123,754


$
262,454


$
380,841

U.S. Branded - Sterile Injectables
170,329


150,531


513,082


417,060

U.S. Generic Pharmaceuticals
82,555


86,236


247,137


415,172

International Pharmaceuticals
13,377


17,434


45,594


47,128

Total segment adjusted income from continuing operations before income tax
$
351,152


$
377,955


$
1,068,267


$
1,260,201

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha on July 3, 2017 and Somar on October 25, 2017, South Africa and Latin America.
Schedule of reconciliations of consolidated loss from continuing operations before income tax
The table below provides reconciliations of our consolidated Loss from continuing operations before income tax, which is determined in accordance with U.S. generally accepted accounting principles (U.S. GAAP), to our total segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Total consolidated loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Interest expense, net
131,847

 
127,521

 
385,896

 
361,267

Corporate unallocated costs (1)
49,187

 
33,035

 
144,693

 
114,655

Amortization of intangible assets
161,275

 
161,413

 
471,662

 
615,490

Inventory step-up
71

 
66

 
261

 
281

Upfront and milestone payments to partners
4,731

 
775

 
43,027

 
6,952

Separation benefits and other cost reduction initiatives (2)
4,001

 
80,693

 
82,141

 
127,977

Certain litigation-related and other contingencies, net (3)
(1,750
)
 
(12,352
)
 
15,370

 
(14,016
)
Asset impairment charges (4)
142,217

 
94,924

 
613,400

 
1,023,930

Acquisition-related and integration items (5)
1,288

 
16,641

 
13,284

 
31,711

Loss on extinguishment of debt
—

 
—

 
—

 
51,734

Foreign currency impact related to the remeasurement of intercompany debt instruments
1,528

 
3,005

 
(1,560
)
 
(2,922
)
Other, net (6)
(175
)
 
30

 
(28,348
)
 
1,789

Total segment adjusted income from continuing operations before income tax
$
351,152

 
$
377,955

 
$
1,068,267

 
$
1,260,201

__________
(1)
Amounts include certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Amounts for the three and nine months ended September 30, 2018 relate to employee separation costs of $2.1 million and $32.7 million, respectively, charges to increase excess inventory reserves of $0.2 million and $2.8 million, respectively, and other charges of $1.7 million and $11.4 million, respectively, each of which related primarily to our restructuring initiatives. Also included in the amount for the nine months ended September 30, 2018 is accelerated depreciation of $35.2 million, which related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative. During the three and nine months ended September 30, 2017, amounts primarily relate to employee separation costs of $19.8 million and $41.3 million, accelerated depreciation of $59.8 million and $60.2 million, other charges of $1.1 million and $18.5 million, respectively, and charges to increase excess inventory reserves of $7.9 million during the nine months ended September 30, 2017. These charges were related primarily to the 2017 U.S. Generics Pharmaceuticals restructuring initiative. See Note 4. Restructuring for discussion of our material restructuring initiatives.
(3)
Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 14. Commitments and Contingencies.
(4)
Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 7. Fair Value Measurements.
(5)
Amounts during the three and nine months ended September 30, 2018 are primarily related to charges due to changes in the fair value of contingent consideration of $0.8 million and $11.7 million, respectively. Amounts during the three and nine months ended September 30, 2017 include charges due to changes in the fair value of contingent consideration of $15.4 million and $23.6 million, respectively. All other amounts are directly related to costs associated with acquisition and integration efforts.
(6)
Amounts during the three and nine months ended September 30, 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 17. Other income, net.
Disaggregation of revenue
The Company disaggregates its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.

Three Months Ended September 30,

Nine Months Ended September 30,

2018

2017

2018

2017
U.S. Branded - Specialty & Established Pharmaceuticals:
 
 
 
 
 
 
 
Specialty Products:
 
 
 
 
 
 
 
XIAFLEX®
$
64,214

 
$
52,511

 
$
184,855

 
$
152,113

SUPPRELIN® LA
20,408

 
20,638

 
60,948

 
63,468

Other Specialty (1)
43,576

 
40,634

 
114,202

 
113,407

Total Specialty Products
$
128,198

 
$
113,783

 
$
360,005

 
$
328,988

Established Products:
 
 
 
 
 
 
 
PERCOCET®
$
30,730

 
$
31,349

 
$
93,539

 
$
93,183

VOLTAREN® Gel
15,057

 
19,102

 
44,185

 
53,646

OPANA® ER
—

 
14,756

 
—

 
82,056

Other Established (2)
46,115

 
54,813

 
135,243

 
171,277

Total Established Products
$
91,902

 
$
120,020

 
$
272,967

 
$
400,162

Total U.S. Branded - Specialty & Established Pharmaceuticals (3)
$
220,100

 
$
233,803

 
$
632,972

 
$
729,150

U.S. Branded - Sterile Injectables:
 
 
 
 
 
 
 
VASOSTRICT®
$
112,333


$
105,741


$
332,387


$
300,649

ADRENALIN®
35,460


25,335


101,858


50,464

Ertapenem for injection
25,798

 
—

 
25,798

 
—

Other Sterile Injectables (4)
63,559


70,829


210,804


203,252

Total U.S. Branded - Sterile Injectables (3)
$
237,150


$
201,905


$
670,847


$
554,365

Total U.S. Generic Pharmaceuticals (5)
$
257,969

 
$
294,749

 
$
748,445

 
$
1,227,584

Total International Pharmaceuticals (6)
$
30,247

 
$
56,430

 
$
108,425

 
$
189,119

Total Revenues
$
745,466

 
$
786,887

 
$
2,160,689

 
$
2,700,218

__________
(1)
Products included within Other Specialty include TESTOPEL®, NASCOBAL® Nasal Spray and AVEED®.
(2)
Products included within Other Established include, but are not limited to, LIDODERM®, EDEX®, TESTIM® and FORTESTA® Gel, including the authorized generics.
(3)
Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $25 million during any quarterly period in 2018 or 2017.
(4)
Products included within Other Sterile Injectables include, but are not limited to, APLISOL® and ephedrine sulfate injection.
(5)
The U.S. Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the nine months ended September 30, 2017, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up 9% of consolidated total revenue. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.
(6)
The International Pharmaceuticals segment, which accounted for 4% and 5% of consolidated total revenues during the three and nine months ended September 30, 2018, respectively, and 7% of consolidated total revenues during both the three and nine months ended September 30, 2017, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs, Inc. (Paladin). This segment also included: (i) our South African business, which was sold in July 2017 and consisted of Litha and certain assets acquired from Aspen Holdings in October 2015 and (ii) our Latin American business consisting of Somar, which was sold in October 2017.
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Financial assets and liabilities measured at fair value on recurring basis
The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2018 and December 31, 2017 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
September 30, 2018
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
691,579

 
$
—

 
$
—

 
$
691,579

Equity securities
1,693

 
—

 
—

 
1,693

Total
$
693,272

 
$
—

 
$
—

 
$
693,272

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
42,261

 
$
42,261

Acquisition-related contingent consideration—long-term
—

 
—

 
86,209

 
86,209

Total
$
—

 
$
—

 
$
128,470

 
$
128,470

 
Fair Value Measurements at Reporting Date using:
December 31, 2017
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
439,831

 
$
—

 
$
—

 
$
439,831

Time deposits
—

 
303,410

 
—

 
303,410

Equity securities
1,456

 
—

 
—

 
1,456

Total
$
441,287

 
$
303,410

 
$
—

 
$
744,697

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
70,543

 
$
70,543

Acquisition-related contingent consideration—long-term
—

 
—

 
119,899

 
119,899

Total
$
—

 
$
—

 
$
190,442

 
$
190,442
Changes to liability for acquisition-related contingent consideration
The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2018 by acquisition (in thousands):
 
Balance as of December 31, 2017
 
Fair Value Adjustments and Accretion
 
Payments and Other
 
Balance as of September 30, 2018
Auxilium acquisition
$
13,061

 
$
(263
)
 
$
(1,844
)
 
$
10,954

Lehigh Valley Technologies, Inc. acquisitions
63,001

 
11,169

 
(39,469
)
 
34,701

VOLTAREN® Gel acquisition
98,124

 
3,839

 
(30,923
)
 
71,040

Other
16,256

 
(3,014
)
 
(1,467
)
 
11,775

Total
$
190,442

 
$
11,731

 
$
(73,703
)
 
$
128,470

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Beginning of period
$
152,098

 
$
210,460

 
$
190,442

 
$
262,113

Amounts settled
(24,564
)
 
(31,617
)
 
(73,298
)
 
(91,927
)
Changes in fair value recorded in earnings
769

 
15,440

 
11,731

 
23,574

Effect of currency translation
167

 
504

 
(405
)
 
1,027

End of period
$
128,470

 
$
194,787

 
$
128,470

 
$
194,787
Summary of nonrecurring fair value measurements
The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2018 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
 
Total Expense for the Nine Months Ended September 30, 2018
 
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
 
Assets:
 
 
 
 
 
 
 
Intangible assets, excluding goodwill (Note 9)
$
—

 
$
—

 
$
239,857

 
$
(217,576
)
Certain property, plant and equipment (1)
—

 
—

 
—

 
(4,824
)
Total
$
—

 
$
—

 
$
239,857

 
$
(222,400
)
__________
(1)
Amount includes $2.6 million related to the 2017 U.S. Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring.
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventories consist of the following at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
Raw materials (1)
$
119,627

 
$
124,685

Work-in-process (1)
83,665

 
109,897

Finished goods (1)
129,495

 
156,855

Total
$
332,787

 
$
391,437


__________
(1) The components of inventory shown in the table above are net of allowance for obsolescence.
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles (Tables)
 9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
The carrying amounts of goodwill at September 30, 2018 and December 31, 2017 are net of the following accumulated impairments (in thousands):

U.S. Branded - Specialty & Established Pharmaceuticals
 
U.S. Branded - Sterile Injectables
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2017
$
855,810

 
$
—

 
$
2,342,549

 
$
463,545

 
$
3,661,904

Accumulated impairment losses as of September 30, 2018
$
855,810

 
$
—

 
$
2,733,549

 
$
451,209

 
$
4,040,568

Changes in the carrying amount of our goodwill for the nine months ended September 30, 2018 were as follows (in thousands):
 
U.S. Branded - Specialty & Established Pharmaceuticals
 
U.S. Branded - Sterile Injectables
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2017
$
828,818

 
$
—

 
$
3,531,301

 
$
89,963

 
$
4,450,082

Allocation to current segments (1)
—

 
2,731,193

 
(2,731,193
)
 
—

 
—

Effect of currency translation
—

 
—

 
—

 
(2,414
)
 
(2,414
)
Goodwill impairment charges
—

 
—

 
(391,000
)
 
—

 
(391,000
)
Goodwill as of September 30, 2018
$
828,818

 
$
2,731,193

 
$
409,108

 
$
87,549

 
$
4,056,668


__________
(1)
This allocation relates to the change in segments described in Note 6. Segment Results. The amount of goodwill initially attributed to the new U.S. Branded - Sterile Injectables and U.S. Generic Pharmaceuticals segments was determined using a relative fair value methodology in accordance with U.S. GAAP.
Schedule of other intangible assets
Changes in the amount of other intangible assets for the nine months ended September 30, 2018 are set forth in the table below (in thousands).
Cost basis:
Balance as of December 31, 2017
 
Acquisitions
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2018
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
347,200

 
$
—

 
$
(87,900
)
 
$
(165,400
)
 
$
—

 
$
93,900

Total indefinite-lived intangibles
$
347,200

 
$
—

 
$
(87,900
)
 
$
(165,400
)
 
$
—

 
$
93,900

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
457,402

 
$
—

 
$
—

 
$
—

 
$
—

 
$
457,402

Tradenames
6,409

 
—

 
—

 
—

 
—

 
6,409

Developed technology (weighted average life of 11 years)
6,187,764

 
—

 
(129,676
)
 
154,753

 
(7,447
)
 
6,205,394

Total finite-lived intangibles (weighted average life of 11 years)
$
6,651,575

 
$
—

 
$
(129,676
)
 
$
154,753

 
$
(7,447
)
 
$
6,669,205

Total other intangibles
$
6,998,775

 
$
—

 
$
(217,576
)
 
$
(10,647
)
 
$
(7,447
)
 
$
6,763,105

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2017
 
Amortization
 
Impairments
 
Other (1)
 
Effect of Currency Translation
 
Balance as of September 30, 2018
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(370,221
)
 
$
(21,262
)
 
$
—

 
$
—

 
$
—

 
$
(391,483
)
Tradenames
(6,409
)
 
—

 
—

 
—

 
—

 
(6,409
)
Developed technology
(2,304,461
)
 
(450,400
)
 
—

 
10,647

 
3,217

 
(2,740,997
)
Total other intangibles
$
(2,681,091
)
 
$
(471,662
)
 
$
—

 
$
10,647

 
$
3,217

 
$
(3,138,889
)
Net other intangibles
$
4,317,684

 
 
 
 
 
 
 
 
 
$
3,624,216

__________
(1)
Other adjustments relate to
Schedule of future amortization expense
Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2017 is as follows (in thousands):
2018
$
622,384

2019
$
552,516

2020
$
481,300

2021
$
447,157

2022
$
420,786
Schedule of intangible asset impairment charges including goodwill
During the three and nine months ended September 30, 2018 and 2017, the Company incurred the following goodwill and other intangible asset impairment charges:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Goodwill impairment charges
$
—

 
$
—

 
$
391,000

 
$
288,745

Other intangible asset impairment charges
$
140,609

 
$
78,300

 
$
217,576

 
$
674,177
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contract Assets and Liabilities (Tables)
 9 Months Ended
Sep. 30, 2018
Contract with Customer, Asset and Liability [Abstract]  
Contract Assets and Liabilities
The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):
 
September 30, 2018
 
January 1, 2018
 
$ Change
 
% Change
Contract assets, net (1)
$
13,291

 
$
11,287

 
$
2,004

 
18
 %
Contract liabilities, net (2)
$
19,635

 
$
20,954

 
$
(1,319
)
 
(6
)%
__________
(1)
At September 30, 2018 and January 1, 2018, approximately $10.3 million and $8.2 million, respectively, of these contract asset amounts are classified as current assets and are included in Prepaid expenses and other current assets in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other assets. The net increase in contract assets during the nine months ended September 30, 2018 was primarily due to certain sales activity during the period, partially offset by reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company’s rights to consideration for the sale of certain goods.
(2)
At September 30, 2018 and January 1, 2018, approximately $1.7 million and $1.9 million, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as non-current and are included in Other liabilities. During the nine months ended September 30, 2018, the Company recognized revenue of $1.3 million that was included in the contract liability balance at January 1, 2018, resulting in a corresponding decrease in contract liabilities.
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accounts Payable And Accrued Expenses (Tables)
 9 Months Ended
Sep. 30, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable and accrued expenses include the following at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
Trade accounts payable
$
106,321

 
$
85,348

Returns and allowances
250,637

 
291,034

Rebates
152,297

 
168,333

Chargebacks
2,022

 
14,604

Accrued interest
64,647

 
130,257

Accrued payroll and related benefits
84,240

 
113,908

Accrued royalties and other distribution partner payables
103,673

 
63,114

Acquisition-related contingent consideration—short-term
42,261

 
70,543

Other
212,906

 
159,684

Total
$
1,019,004


$
1,096,825
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Schedule of long-term debt instruments
The following table presents information about the Company’s total indebtedness at September 30, 2018 and December 31, 2017 (in thousands):
 
September 30, 2018
 
December 31, 2017
 
Effective Interest Rate
 
Principal Amount
 
Carrying Amount
 
Effective Interest Rate
 
Principal Amount
 
Carrying Amount
7.25% Senior Notes due 2022
7.91
%
 
$
400,000

 
$
392,439

 
7.91
%
 
$
400,000

 
$
390,974

5.75% Senior Notes due 2022
6.04
%
 
700,000

 
694,053

 
6.04
%
 
700,000

 
692,855

5.375% Senior Notes due 2023
5.62
%
 
750,000

 
743,083

 
5.62
%
 
750,000

 
742,048

6.00% Senior Notes due 2023
6.28
%
 
1,635,000

 
1,615,955

 
6.28
%
 
1,635,000

 
1,613,446

5.875% Senior Secured Notes due 2024
6.14
%
 
300,000

 
295,922

 
6.14
%
 
300,000

 
295,513

6.00% Senior Notes due 2025
6.27
%
 
1,200,000

 
1,182,859

 
6.27
%
 
1,200,000

 
1,181,243

Term Loan B Facility Due 2024
5.46
%
 
3,372,313

 
3,338,451

 
5.46
%
 
3,397,925

 
3,360,103

Other debt
 
 
—

 
—

 
1.50
%
 
55

 
55

Total long-term debt, net
 
 
$
8,357,313

 
$
8,262,762

 
 
 
$
8,382,980

 
$
8,276,237

Less current portion, net
 
 
34,150

 
34,150

 
 
 
34,205

 
34,205

Total long-term debt, less current portion, net
 
 
$
8,323,163

 
$
8,228,612

 
 
 
$
8,348,775

 
$
8,242,032
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies (Tables)
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Changes in Qualified Settlement Funds accounts and product liability balance
The following table presents the changes in the QSFs and mesh liability accrual balance during the nine months ended September 30, 2018 (in thousands):
 
Qualified Settlement Funds
 
Mesh Liability Accrual
Balance as of January 1, 2018
$
313,814

 
$
1,087,172

Additional charges
—

 
19,000

Cash contributions to Qualified Settlement Funds
216,770

 
—

Cash distributions to settle disputes from Qualified Settlement Funds
(248,485
)
 
(248,485
)
Cash distributions to settle disputes
—

 
(17,114
)
Other (1)
1,653

 
5,038

Balance as of September 30, 2018
$
283,752

 
$
845,611

__________
(1)
Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. The $5.0 million in the table above also includes a second quarter 2018 reclassification adjustment of $4.4 million for accrued interest amounts previously recorded in Accounts payable and accrued expenses in the Condensed Consolidated Balance Sheets.
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Schedule of tax effects allocated to each component of other comprehensive income
Set forth below are the tax effects allocated to each component of Other comprehensive income (loss) for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
2018
 
2017
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
Net unrealized gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
$
—

 
$
—

 
$
295

 
$
(107
)
 
$
188

Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
—

 
—

 
—

Net unrealized gains on securities
$
—

 
$
—

 
$
—

 
$
295

 
$
(107
)
 
$
188

Net unrealized gain on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation gain arising during the period
4,735

 
—

 
4,735

 
9,941

 
—

 
9,941

Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
29,325

 
—

 
29,325

Foreign currency translation gain
$
4,735

 
$
—

 
$
4,735

 
$
39,266

 
$
—

 
$
39,266

Other comprehensive income
$
4,735

 
$
—

 
$
4,735

 
$
39,561

 
$
(107
)
 
$
39,454


 
Nine Months Ended September 30,
 
2018
 
2017
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
 
Before-Tax Amount
 
Tax (Expense) Benefit
 
Net-of-Tax Amount
Net unrealized gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain arising during the period
$
—

 
$
—

 
$
—

 
$
522

 
$
(189
)
 
$
333

Less: reclassification adjustments for (gain) loss realized in net loss
—

 
—

 
—

 
—

 
—

 
—

Net unrealized gains on securities
$
—

 
$
—

 
$
—

 
$
522

 
$
(189
)
 
$
333

Net unrealized (loss) gain on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation (loss) gain arising during the period
(7,033
)
 
—

 
(7,033
)
 
35,415

 
—

 
35,415

Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
29,325

 
—

 
29,325

Foreign currency translation (loss) gain
$
(7,033
)
 
$
—

 
$
(7,033
)
 
$
64,740

 
$
—

 
$
64,740

Other comprehensive (loss) income
$
(7,033
)
 
$
—

 
$
(7,033
)
 
$
65,262

 
$
(189
)
 
$
65,073
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' (Deficit) Equity (Tables)
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Schedule of changes in stockholders' equity
The following table displays a reconciliation of our beginning and ending balances in Total shareholders' equity (deficit) for the nine months ended September 30, 2018 (in thousands):
 
Total Shareholders' Equity (Deficit)
Shareholders' equity at January 1, 2018, prior to the adoption of ASC 606
$
484,880

Effect of adopting ASC 606 (1)
3,076

Shareholders' equity at January 1, 2018
$
487,956

Net loss
(739,561
)
Other comprehensive loss
(7,033
)
Compensation related to share-based awards
43,722

Tax withholding for restricted shares
(5,082
)
Exercise of options
473

Other
66

Shareholders' deficit at September 30, 2018
$
(219,459
)
__________
(1)
Refer to Note 2. Summary of Significant Accounting Policies for further description of ASC 606.
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Income, Net (Tables)
 9 Months Ended
Sep. 30, 2018
Component of Operating Income [Abstract]  
Schedule of components of other income, net
The components of Other income, net for the three and nine months ended September 30, 2018 and 2017 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net gain on sale of business and other assets
$
(2,866
)
 
$
(2,763
)
 
$
(29,859
)
 
$
(5,074
)
Foreign currency loss (gain), net
1,354

 
2,549

 
(734
)

(4,305
)
Net loss (gain) from our investments in the equity of other companies
842

 
(1,075
)
 
3,163


(1,163
)
Other miscellaneous, net
(837
)
 
(808
)
 
(5,786
)

(301
)
Other income, net
$
(1,507
)
 
$
(2,097
)
 
$
(33,216
)

$
(10,843
)
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Schedule of Income Tax
The following table displays our Loss from continuing operations before income tax, Income tax expense (benefit) and Effective tax rate for the three and nine months ended September 30, 2018 and 2017 (dollars in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Loss from continuing operations before income tax
$
(143,068
)
 
$
(127,796
)
 
$
(671,559
)
 
$
(1,058,647
)
Income tax expense (benefit)
$
3,003

 
$
(28,109
)
 
$
24,729

 
$
(97,517
)
Effective tax rate
(2.1
)%
 
22.0
%
 
(3.7
)%
 
9.2
%
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Reconciliation of the numerator and denominator of basic and diluted net loss per share
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2018 and 2017 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations
$
(146,071
)
 
$
(99,687
)
 
$
(696,288
)
 
$
(961,130
)
(Loss) income from discontinued operations, net of tax
(27,134
)
 
3,017

 
(43,273
)
 
(705,886
)
Net loss
$
(173,205
)
 
$
(96,670
)
 
$
(739,561
)
 
$
(1,667,016
)
Denominator:
 
 
 
 
 
 
 
For basic per share data—weighted average shares
224,132

 
223,299

 
223,829

 
223,157

Dilutive effect of ordinary share equivalents
—

 
—

 
—

 
—

For diluted per share data—weighted average shares
224,132

 
223,299

 
223,829

 
223,157
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation - Schedule of Effect of Adoption of ASU 2016-18 (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Net cash provided by operating activities $ 196,992 $ 422,162
Net cash (used in) provided by investing activities (13,682) 8,964
Net cash used in financing activities (62,808) (135,353)
Effect of foreign exchange rate (608) 3,983
Movement in cash held for sale 0 (1,450)
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS 119,894 298,306
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD 1,311,014 805,180
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD $ 1,430,908 1,103,486
Prior to Adoption    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Net cash provided by operating activities   424,062
Net cash (used in) provided by investing activities   (69,802)
Net cash used in financing activities   (135,353)
Effect of foreign exchange rate   3,686
Movement in cash held for sale   (1,450)
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS   221,143
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD   517,250
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD   738,393
Accounting Standards Update 2016-18 | Impact of Adoption    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Net cash provided by operating activities   (1,900)
Net cash (used in) provided by investing activities   78,766
Net cash used in financing activities   0
Effect of foreign exchange rate   297
Movement in cash held for sale   0
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS   77,163
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD   287,930
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD   $ 365,093
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Schedule of Impact of ASC 606 (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Discount on brand-name drugs     50.00%    
Decrease to accumulated deficit         $ (3,076)
Statement of Operations:          
TOTAL REVENUES $ 745,466 $ 786,887 $ 2,160,689 $ 2,700,218  
Cost of revenues 412,965 514,522 1,198,468 1,722,885  
OTHER EXPENSE (INCOME), NET (1,507) (2,097) (33,216) (10,843)  
Loss from continuing operations (146,071) (99,687) (696,288) (961,130)  
NET LOSS $ (173,205) $ (96,670) $ (739,561) $ (1,667,016)  
NET (LOSS) INCOME PER SHARE—BASIC:          
Continuing operations (in dollars per share) $ (0.65) $ (0.45) $ (3.11) $ (4.31)  
Basic (in dollars per share) (0.77) (0.43) (3.30) (7.47)  
Net loss per share—Diluted:          
Continuing operations (in dollars per share) (0.65) (0.45) (3.11) (4.31)  
Diluted (in dollars per share) $ (0.77) $ (0.43) $ (3.30) $ (7.47)  
ASSETS          
Inventories, net $ 332,787   $ 332,787   391,437
Prepaid expenses and other current assets 50,697   50,697   43,098
OTHER ASSETS 67,934   67,934   59,728
Liabilities:          
Accounts payable and accrued expenses 1,019,004   1,019,004   1,096,825
Shareholders' (deficit) equity:          
Accumulated deficit (8,833,024)   (8,833,024)   (8,096,539)
Amounts assuming continued application of ASC 605          
Statement of Operations:          
TOTAL REVENUES 747,571   2,160,132    
Cost of revenues 414,430   1,199,042    
OTHER EXPENSE (INCOME), NET (1,507)   (32,216)    
Loss from continuing operations (145,431)   (698,419)    
NET LOSS $ (172,565)   $ (741,692)    
NET (LOSS) INCOME PER SHARE—BASIC:          
Continuing operations (in dollars per share) $ (0.65)   $ (3.12)    
Basic (in dollars per share) (0.77)   (3.31)    
Net loss per share—Diluted:          
Continuing operations (in dollars per share) (0.65)   (3.12)    
Diluted (in dollars per share) $ (0.77)   $ (3.31)    
ASSETS          
Inventories, net $ 341,189   $ 341,189    
Prepaid expenses and other current assets 40,368   40,368    
OTHER ASSETS 64,972   64,972    
Liabilities:          
Accounts payable and accrued expenses 1,019,322   1,019,322    
Shareholders' (deficit) equity:          
Accumulated deficit (8,838,231)   (8,838,231)    
Effect of adoption of ASC 606 | ASC 606          
Statement of Operations:          
TOTAL REVENUES (2,105)   557    
Cost of revenues (1,465)   (574)    
OTHER EXPENSE (INCOME), NET 0   (1,000)    
Loss from continuing operations (640)   2,131    
NET LOSS $ (640)   $ 2,131    
NET (LOSS) INCOME PER SHARE—BASIC:          
Continuing operations (in dollars per share) $ 0.00   $ 0.01    
Basic (in dollars per share) 0.00   0.01    
Net loss per share—Diluted:          
Continuing operations (in dollars per share) 0.00   0.01    
Diluted (in dollars per share) $ 0.00   $ 0.01    
ASSETS          
Inventories, net $ (8,402)   $ (8,402)    
Prepaid expenses and other current assets 10,329   10,329    
OTHER ASSETS 2,962   2,962    
Liabilities:          
Accounts payable and accrued expenses (318)   (318)    
Shareholders' (deficit) equity:          
Accumulated deficit $ 5,207   $ 5,207    
Accumulated Deficit | ASC 606          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Decrease to accumulated deficit         $ 3,100
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Discontinued Operations and Divestitures - Astora (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Income (loss) from discontinued operations, net of tax $ (27,134,000) $ 3,017,000 $ (43,273,000) $ (705,886,000)
Discontinued Operations, Disposed of by Sale | Astora        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Litigation-related and other contingencies, net 19,000,000 0 19,000,000 775,684,000
Loss from discontinued operations before income taxes (27,134,000) (8,957,000) (43,273,000) (813,442,000)
Income tax benefit 0 (11,974,000) 0 (107,556,000)
Income (loss) from discontinued operations, net of tax $ (27,134,000) $ 3,017,000 (43,273,000) (705,886,000)
Cash used in discontinued investing activities Operations     0 0
Depreciation and amortization     $ 0 $ 0
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Discontinued Operations and Divestitures - Lithia (Narrative) (Details) - USD ($)
 1 Months Ended 9 Months Ended
Jul. 03, 2017
Dec. 31, 2017
Oct. 31, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of business, net       $ 43,753,000 $ 96,066,000
Litha Healthcare Group Limited | Disposal Group, Held-for-sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of business, net $ 94,200,000        
Consideration receivable     $ 4,400,000    
Gain on sale of business $ 0 $ 10,100,000      
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Discontinued Operations and Divestitures - Somar (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 25, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Net gain on sale of business and other assets   $ (2,866) $ (2,763) $ (29,859) $ (5,074)
Somar | Disposal Group, Held-for-sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Aggregate purchase price $ 124,000        
Net gain on sale of business and other assets $ 1,300        
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring - 2017 Restructuring Initiatives (Narrative) (Details)
 3 Months Ended 9 Months Ended
Jan. 26, 2017
position
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Other restructuring charges          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses   $ 1,700,000 $ 1,100,000 $ 11,400,000 $ 18,500,000
January 2017 Restructuring          
Restructuring Cost and Reserve [Line Items]          
Expected number of positions to be eliminated | position 90        
Restructuring charges   94,200,000   203,700,000  
Restructuring reserve correcting adjustment     14,200,000    
January 2017 Restructuring | Corporate unallocated costs          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses         4,900,000
January 2017 Restructuring | U.S. Branded - Specialty & Established Pharmaceuticals | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses         6,900,000
January 2017 Restructuring | U.S. Generic Pharmaceuticals | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses         3,300,000
January 2017 Restructuring | Employee Separation, Retention, and Other Benefit Related Costs          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       0  
Expected restructuring costs remaining   0   0  
January 2017 Restructuring | Employee Separation, Retention, and Other Benefit Related Costs | U.S. Branded - Specialty & Established Pharmaceuticals | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses     0   15,100,000
January 2017 Restructuring | Other restructuring charges          
Restructuring Cost and Reserve [Line Items]          
Restructuring charges         12,700,000
January 2017 Restructuring | Inventory Reserve          
Restructuring Cost and Reserve [Line Items]          
Restructuring charges         7,900,000
2017 US Generic Pharmaceuticals Restructuring          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       19,120,000  
2017 US Generic Pharmaceuticals Restructuring | U.S. Generic Pharmaceuticals          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses   4,800,000   59,600,000  
2017 US Generic Pharmaceuticals Restructuring | Employee Separation, Retention, and Other Benefit Related Costs          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses   2,100,000 19,500,000 9,800,000 19,500,000
2017 US Generic Pharmaceuticals Restructuring | Property, Plant and Equipment Impairment Charges          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses     14,200,000   103,700,000
2017 US Generic Pharmaceuticals Restructuring | Accelerated Depreciation          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses     59,800,000 35,200,000 $ 59,800,000
2017 US Generic Pharmaceuticals Restructuring | Asset Impairment Charges          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       2,600,000  
2017 US Generic Pharmaceuticals Restructuring | Other restructuring charges          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       9,341,000  
Restructuring charges   2,700,000 $ 600,000 12,000,000  
January 2018 Restructuring Initiative          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       23,792,000  
January 2018 Restructuring Initiative | Corporate unallocated costs          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       5,200,000  
January 2018 Restructuring Initiative | U.S. Generic Pharmaceuticals          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       23,800,000  
January 2018 Restructuring Initiative | U.S. Generic Pharmaceuticals | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       10,800,000  
January 2018 Restructuring Initiative | Employee Separation, Retention, and Other Benefit Related Costs          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       22,100,000  
Expected restructuring costs remaining   $ 0   0  
January 2018 Restructuring Initiative | Other restructuring charges          
Restructuring Cost and Reserve [Line Items]          
Restructuring expenses       1,705,000  
Restructuring charges       $ 1,700,000  
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     $ 23,792,000  
Employee Separation, Retention, and Other Benefit Related Costs | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     22,100,000  
Expected restructuring costs remaining $ 0   0  
Other restructuring charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses $ 1,700,000 $ 1,100,000 11,400,000 $ 18,500,000
Other restructuring charges | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     1,705,000  
Restructuring charges     1,700,000  
U.S. Generic Pharmaceuticals | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     23,800,000  
Corporate unallocated costs | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     5,200,000  
Operating Segments | U.S. Generic Pharmaceuticals | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     10,800,000  
Operating Segments | U.S. Branded - Sterile Injectables | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     4,000,000  
Operating Segments | International Pharmaceuticals | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     3,100,000  
Operating Segments | U.S. Branded - Specialty & Established Pharmaceuticals | January 2018 Restructuring Initiative        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses     $ 700,000  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring - Schedule of Restructuring Roll Forward (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Other Restructuring Costs        
Restructuring Reserve [Roll Forward]        
Expenses $ 1,700 $ 1,100 $ 11,400 $ 18,500
2017 US Generic Pharmaceuticals Restructuring        
Restructuring Reserve [Roll Forward]        
Beginning liability balance     24,585  
Expenses     19,120  
Cash distributions     (33,469)  
Ending liability balance 10,236   10,236  
2017 US Generic Pharmaceuticals Restructuring | Employee separation, retention and other benefit-related costs        
Restructuring Reserve [Roll Forward]        
Beginning liability balance     22,975  
Expenses     9,779  
Cash distributions     (22,518)  
Ending liability balance 10,236   10,236  
2017 US Generic Pharmaceuticals Restructuring | Other Restructuring Costs        
Restructuring Reserve [Roll Forward]        
Beginning liability balance     1,610  
Expenses     9,341  
Cash distributions     (10,951)  
Ending liability balance 0   0  
January 2018 Restructuring Initiative        
Restructuring Reserve [Roll Forward]        
Beginning liability balance     650  
Expenses     23,792  
Cash distributions     (20,388)  
Ending liability balance 4,054   4,054  
January 2018 Restructuring Initiative | Employee separation, retention and other benefit-related costs        
Restructuring Reserve [Roll Forward]        
Beginning liability balance     0  
Expenses     22,087  
Cash distributions     (18,439)  
Ending liability balance 3,648   3,648  
January 2018 Restructuring Initiative | Other Restructuring Costs        
Restructuring Reserve [Roll Forward]        
Beginning liability balance     650  
Expenses     1,705  
Cash distributions     (1,949)  
Ending liability balance $ 406   $ 406  
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions (Other Acquisition) (Narrative) (Details) - Forecast - Somerset
$ in Millions
 3 Months Ended
Dec. 31, 2018
USD ($)
Business Acquisition [Line Items]  
Percentage of voting interests acquired 100.00%
Aggregate consideration transferred $ 160
Debt to be assumed $ 30
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Results - Schedule Of Reportable Segments Information (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2017
Reportable_Business_Segments
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Reportable_Business_Segments
Sep. 30, 2017
USD ($)
Segment Reporting Information [Line Items]          
Number of reportable segments | Reportable_Business_Segments 3     4  
Total net revenues from external customers   $ 745,466 $ 786,887 $ 2,160,689 $ 2,700,218
Total segment adjusted income from continuing operations before income tax   351,152 377,955 1,068,267 1,260,201
U.S. Branded - Specialty & Established Pharmaceuticals          
Segment Reporting Information [Line Items]          
Total net revenues from external customers   220,100 233,803 632,972 729,150
Total segment adjusted income from continuing operations before income tax   84,891 123,754 262,454 380,841
U.S. Branded - Sterile Injectables          
Segment Reporting Information [Line Items]          
Total net revenues from external customers   237,150 201,905 670,847 554,365
Total segment adjusted income from continuing operations before income tax   170,329 150,531 513,082 417,060
U.S. Generic Pharmaceuticals          
Segment Reporting Information [Line Items]          
Total net revenues from external customers   257,969 294,749 748,445 1,227,584
Total segment adjusted income from continuing operations before income tax   82,555 86,236 247,137 415,172
International Pharmaceuticals          
Segment Reporting Information [Line Items]          
Total net revenues from external customers   30,247 56,430 108,425 189,119
Total segment adjusted income from continuing operations before income tax   $ 13,377 $ 17,434 $ 45,594 $ 47,128
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Results - Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]        
Total consolidated loss from continuing operations before income tax $ (143,068) $ (127,796) $ (671,559) $ (1,058,647)
Interest expense, net 131,847 127,521 385,896 361,267
Amortization of intangible assets 161,300 161,400 471,662 615,500
Inventory step-up     261 281
Asset impairment charges 142,217 94,924 613,400 1,023,930
Acquisition-related costs 1,288 16,641 13,284 31,711
Loss on extinguishment of debt 0 0 0 51,734
Severance costs 2,100 19,800 32,700 41,300
Accelerated depreciation   59,800 35,200 60,200
Change in fair value of contingent consideration 800 15,400 11,731 23,574
Inventory Write-Offs        
Segment Reporting Information [Line Items]        
Restructuring expenses 200   2,800 7,900
Other restructuring charges        
Segment Reporting Information [Line Items]        
Restructuring expenses 1,700 1,100 11,400 18,500
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Interest expense, net 131,847 127,521 385,896 361,267
Corporate unallocated costs 49,187 33,035 144,693 114,655
Amortization of intangible assets 161,275 161,413 471,662 615,490
Inventory step-up 71 66 261 281
Upfront and milestone payments to partners 4,731 775 43,027 6,952
Separation benefits and other cost reduction initiatives 4,001 80,693 82,141 127,977
Certain litigation-related and other contingencies, net (1,750) (12,352) 15,370 (14,016)
Asset impairment charges 142,217 94,924 613,400 1,023,930
Acquisition-related costs 1,288 16,641 13,284 31,711
Loss on extinguishment of debt 0 0 0 51,734
Foreign currency impact related to the remeasurement of intercompany debt instruments 1,528 3,005 (1,560) (2,922)
Other, net (175) 30 (28,348) 1,789
Operating Segments        
Segment Reporting Information [Line Items]        
Total consolidated loss from continuing operations before income tax $ 351,152 $ 377,955 $ 1,068,267 $ 1,260,201
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Results - Schedule of Disaggregation of Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES $ 745,466 $ 786,887 $ 2,160,689 $ 2,700,218
Product line revenue reporting threshold     25,000 25,000
U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 220,100 233,803 632,972 729,150
U.S. Branded - Sterile Injectables        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 237,150 201,905 670,847 554,365
U.S. Generic Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 257,969 294,749 748,445 1,227,584
International Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES $ 30,247 $ 56,430 $ 108,425 $ 189,119
Concentration risk, percentage 4.00% 7.00% 5.00% 7.00%
XIAFLEX® | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES $ 64,214 $ 52,511 $ 184,855 $ 152,113
SUPPRELIN® LA | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 20,408 20,638 60,948 63,468
Other Specialty | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 43,576 40,634 114,202 113,407
Total Specialty Products | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 128,198 113,783 360,005 328,988
PERCOCET® | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 30,730 31,349 93,539 93,183
VOLTAREN® Gel | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 15,057 19,102 44,185 53,646
OPANA® ER | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 0 14,756 0 82,056
Other Established | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 46,115 54,813 135,243 171,277
Total Established Products | U.S. Branded - Specialty & Established Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 91,902 120,020 272,967 400,162
Vasostrict® | U.S. Branded - Sterile Injectables        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 112,333 105,741 332,387 300,649
ADRENALIN® | U.S. Branded - Sterile Injectables        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 35,460 25,335 101,858 50,464
Ertapenem For Injection | U.S. Branded - Sterile Injectables        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES 25,798 0 25,798 0
Other Sterile Injectables | U.S. Branded - Sterile Injectables        
Disaggregation of Revenue [Line Items]        
TOTAL REVENUES $ 63,559 $ 70,829 $ 210,804 $ 203,252
Product Concentration Risk | U.S. Generic Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
Concentration risk, percentage       5.00%
Product Concentration Risk | Ezetimibe and Quetiapine ER Tablets | U.S. Generic Pharmaceuticals        
Disaggregation of Revenue [Line Items]        
Concentration risk, percentage       9.00%
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Restricted cash and cash equivalents $ 312,000   $ 312,000   $ 324,400
Restricted cash and cash equivalents classified as current assets 289,667   289,667   320,453
Goodwill impairment charges 0 $ 0 $ 391,000 $ 288,745  
Minimum          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Discount rate range (percent)     9.50%    
Maximum          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Discount rate range (percent)     22.00%    
Weighted Average          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Discount rate range (percent)     14.10%    
Vaginal Mesh Cases          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Settlement funds 283,752   $ 283,752   313,814
Money market funds | Restricted cash and cash equivalents          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Settlement funds $ 57,000   $ 57,000   $ 35,600
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Assets:    
Fair value of financial assets measured on recurring basis $ 693,272 $ 744,697
Liabilities:    
Fair value of financial liabilities measured on recurring basis 128,470 190,442
Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 42,261 70,543
Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 86,209 119,899
Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 691,579 439,831
Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis   303,410
Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis 1,693 1,456
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Fair value of financial assets measured on recurring basis 693,272 441,287
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 691,579 439,831
Quoted Prices in Active Markets for Identical Assets (Level 1) | Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis 1,693 1,456
Significant Other Observable Inputs (Level 2)    
Assets:    
Fair value of financial assets measured on recurring basis 0 303,410
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis   303,410
Significant Other Observable Inputs (Level 2) | Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Significant Unobservable Inputs (Level 3)    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Liabilities:    
Fair value of financial liabilities measured on recurring basis 128,470 190,442
Significant Unobservable Inputs (Level 3) | Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 42,261 70,543
Significant Unobservable Inputs (Level 3) | Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 86,209 119,899
Significant Unobservable Inputs (Level 3) | Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Significant Unobservable Inputs (Level 3) | Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis   0
Significant Unobservable Inputs (Level 3) | Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis $ 0 $ 0
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) - Acquisition-related contingent consideration - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period $ 152,098 $ 210,460 $ 190,442 $ 262,113
Amounts settled (24,564) (31,617) (73,298) (91,927)
Changes in fair value recorded in earnings 769 15,440 11,731 23,574
Effect of currency translation 167 504 (405) 1,027
Fair Value Adjustments and Accretion     11,731  
Payments and Other     (73,703)  
End of period 128,470 $ 194,787 128,470 $ 194,787
Auxilium acquisition        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     13,061  
Fair Value Adjustments and Accretion     (263)  
Payments and Other     (1,844)  
End of period 10,954   10,954  
Lehigh Valley Technologies, Inc. acquisitions        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     63,001  
Fair Value Adjustments and Accretion     11,169  
Payments and Other     (39,469)  
End of period 34,701   34,701  
VOLTAREN® Gel acquisition        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     98,124  
Fair Value Adjustments and Accretion     3,839  
Payments and Other     (30,923)  
End of period 71,040   71,040  
Other        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     16,256  
Fair Value Adjustments and Accretion     (3,014)  
Payments and Other     (1,467)  
End of period $ 11,775   $ 11,775  
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Assets:        
Total expense for the year $ (142,217) $ (94,924) $ (613,400) $ (1,023,930)
2017 US Generic Pharmaceuticals Restructuring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Restructuring expenses     19,120  
2017 US Generic Pharmaceuticals Restructuring | Asset impairment charges        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Restructuring expenses     2,600  
Fair value, measurements, nonrecurring        
Assets:        
Total expense for the year     (222,400)  
Fair value, measurements, nonrecurring | Intangible assets        
Assets:        
Total expense for the year     (217,576)  
Fair value, measurements, nonrecurring | Certain property, plant and equipment        
Assets:        
Total expense for the year     (4,824)  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value, measurements, nonrecurring        
Assets:        
Intangible assets, excluding goodwill 0   0  
Certain property, plant and equipment 0   0  
Total 0   0  
Significant Other Observable Inputs (Level 2) | Fair value, measurements, nonrecurring        
Assets:        
Intangible assets, excluding goodwill 0   0  
Certain property, plant and equipment 0   0  
Total 0   0  
Significant Unobservable Inputs (Level 3) | Fair value, measurements, nonrecurring        
Assets:        
Intangible assets, excluding goodwill 239,857   239,857  
Certain property, plant and equipment 0   0  
Total $ 239,857   $ 239,857  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Inventory Disclosure [Abstract]    
Raw materials $ 119,627 $ 124,685
Work-in-process 83,665 109,897
Finished goods 129,495 156,855
Total 332,787 391,437
Long-term inventory 13,300 17,100
Inventories not yet available for sale $ 13,600 $ 5,900
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Schedule Of Changes In The Carrying Amount Of Goodwill (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Goodwill [Roll Forward]          
Goodwill, beginning balance   $ 4,450,082,000   $ 4,450,082,000  
Allocation to current segments       0  
Effect of currency translation on gross balance       (2,414,000)  
Goodwill impairment charges $ 0   $ 0 (391,000,000) $ (288,745,000)
Goodwill, ending balance 4,056,668,000     4,056,668,000  
U.S. Branded - Specialty & Established Pharmaceuticals          
Goodwill [Roll Forward]          
Goodwill, beginning balance   828,818,000   828,818,000  
Allocation to current segments       0  
Effect of currency translation on gross balance       0  
Goodwill impairment charges       0  
Goodwill, ending balance 828,818,000     828,818,000  
U.S. Branded - Sterile Injectables          
Goodwill [Roll Forward]          
Goodwill, beginning balance   0   0  
Allocation to current segments       2,731,193,000  
Effect of currency translation on gross balance       0  
Goodwill impairment charges   0   0  
Goodwill, ending balance 2,731,193,000     2,731,193,000  
U.S. Generic Pharmaceuticals          
Goodwill [Roll Forward]          
Goodwill, beginning balance   3,531,301,000   3,531,301,000  
Allocation to current segments       (2,731,193,000)  
Effect of currency translation on gross balance       0  
Goodwill impairment charges   (391,000,000)   (391,000,000)  
Goodwill, ending balance 409,108,000     409,108,000  
International Pharmaceuticals          
Goodwill [Roll Forward]          
Goodwill, beginning balance   $ 89,963,000   89,963,000  
Allocation to current segments       0  
Effect of currency translation on gross balance       (2,414,000)  
Goodwill impairment charges       0  
Goodwill, ending balance $ 87,549,000     $ 87,549,000  
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Accumulated Impairment (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Goodwill [Line Items]    
Accumulated impairment losses $ 4,040,568 $ 3,661,904
U.S. Branded - Specialty & Established Pharmaceuticals    
Goodwill [Line Items]    
Accumulated impairment losses 855,810 855,810
U.S. Branded - Sterile Injectables    
Goodwill [Line Items]    
Accumulated impairment losses 0 0
U.S. Generic Pharmaceuticals    
Goodwill [Line Items]    
Accumulated impairment losses 2,733,549 2,342,549
International Pharmaceuticals    
Goodwill [Line Items]    
Accumulated impairment losses $ 451,209 463,545
Former U.S. Generic Pharmaceuticals    
Goodwill [Line Items]    
Accumulated impairment losses   $ 2,342,500
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Schedule Of Other Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Indefinite-lived intangibles:          
Beginning Balance     $ 347,200    
Acquisitions     0    
Impairments     (87,900)    
Other [1]     (165,400)    
Effect of Currency Translation     0    
Ending Balance $ 93,900   93,900    
Finite-lived intangibles:          
Beginning Balance     6,651,575    
Acquisitions     0    
Impairments     (129,676)    
Other [1]     154,753    
Effect of Currency Translation     (7,447)    
Ending Balance 6,669,205   6,669,205    
Total other intangibles          
Beginning balance     6,998,775    
Acquisitions     0    
Impairments (140,609) $ (78,300) (217,576) $ (674,177)  
Other [1]     (10,647)    
Effect of Currency Translation     (7,447)    
Ending balance 6,763,105   6,763,105    
Accumulated amortization:          
Beginning Balance     (2,681,091)    
Amortization (161,300) (161,400) (471,662) $ (615,500)  
Impairments     0    
Other [1]     10,647    
Effect of Currency Translation     3,217    
Ending Balance (3,138,889)   (3,138,889)    
Net other intangibles 3,624,216   3,624,216   $ 4,317,684
Licenses          
Finite-lived intangibles:          
Beginning Balance     457,402    
Acquisitions     0    
Impairments     0    
Other [1]     0    
Effect of Currency Translation     0    
Ending Balance 457,402   457,402    
Accumulated amortization:          
Beginning Balance     (370,221)    
Amortization     (21,262)    
Impairments     0    
Other [1]     0    
Effect of Currency Translation     0    
Ending Balance (391,483)   (391,483)    
Tradenames          
Finite-lived intangibles:          
Beginning Balance     6,409    
Acquisitions     0    
Impairments     0    
Other [1]     0    
Effect of Currency Translation     0    
Ending Balance 6,409   6,409    
Accumulated amortization:          
Beginning Balance     (6,409)    
Amortization     0    
Impairments     0    
Other [1]     0    
Effect of Currency Translation     0    
Ending Balance (6,409)   (6,409)    
Developed technology          
Finite-lived intangibles:          
Beginning Balance     6,187,764    
Acquisitions     0    
Impairments   $ (20,600) (129,676)    
Other [1]     154,753    
Effect of Currency Translation     (7,447)    
Ending Balance 6,205,394   6,205,394    
Accumulated amortization:          
Beginning Balance     (2,304,461)    
Amortization     (450,400)    
Impairments     0    
Other [1]     10,647    
Effect of Currency Translation     3,217    
Ending Balance (2,740,997)   (2,740,997)    
In-process research and development          
Indefinite-lived intangibles:          
Beginning Balance     347,200    
Acquisitions     0    
Impairments     (87,900)    
Other [1]     (165,400)    
Effect of Currency Translation     0    
Ending Balance $ 93,900   $ 93,900    
Weighted Average          
Accumulated amortization:          
Intangible life (years)     11 years    
Weighted Average | Licenses          
Accumulated amortization:          
Intangible life (years)     12 years    
Weighted Average | Developed technology          
Accumulated amortization:          
Intangible life (years)     11 years    
[1] Other adjustments relate to reclassification adjustments of $165.4 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the nine months ended September 30, 2018 and the removal of certain fully amortized intangible assets.
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Other Intangibles (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 161,300 $ 161,400 $ 471,662 $ 615,500
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Schedule Of Estimated Amortization Of Intangibles (Details)
$ in Thousands
Sep. 30, 2018
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2018 $ 622,384
2019 552,516
2020 481,300
2021 447,157
2022 $ 420,786
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Schedule of Intangible Asset Impairment Charges Including Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]        
Goodwill impairment charges $ 0 $ 0 $ 391,000 $ 288,745
Impairment of intangible assets $ 140,609 $ 78,300 $ 217,576 $ 674,177
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill And Other Intangibles - Impairments Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Mar. 31, 2017
Sep. 30, 2018
Sep. 30, 2017
Goodwill [Line Items]            
Impairment of intangible assets $ 140,609,000   $ 78,300,000   $ 217,576,000 $ 674,177,000
Goodwill impairment charges (reduction) 0   $ 0   391,000,000 288,745,000
Non-cash intangible asset impairment charge         129,676,000  
Serelaxin In-Process Research and Development Intangible Assets            
Goodwill [Line Items]            
Goodwill impairment charges (reduction)       $ 45,500,000    
Paladin Labs Inc.            
Goodwill [Line Items]            
Discount rate applied (percent)       10.00%    
Goodwill impairment charges (reduction)       $ 82,600,000    
Former U.S. Generic Pharmaceuticals            
Goodwill [Line Items]            
Discount rate applied (percent)   9.50%        
Goodwill impairment charges (reduction)   $ 0        
U.S. Branded - Sterile Injectables            
Goodwill [Line Items]            
Discount rate applied (percent)   9.50%        
Goodwill impairment charges (reduction)   $ 0     0  
U.S. Generic Pharmaceuticals            
Goodwill [Line Items]            
Discount rate applied (percent)   9.50% 9.00%      
Goodwill impairment charges (reduction)   $ 391,000,000     391,000,000  
U.S. Branded - Specialty & Established Pharmaceuticals            
Goodwill [Line Items]            
Discount rate applied (percent)     9.50%      
In process research and development or developed technology            
Goodwill [Line Items]            
Impairment of intangible assets $ 140,600,000   $ 217,600,000   78,300,000 $ 461,100,000
Developed technology            
Goodwill [Line Items]            
Non-cash intangible asset impairment charge     20,600,000   $ 129,676,000  
Developed technology | U.S. Generic Pharmaceuticals            
Goodwill [Line Items]            
Goodwill impairment charges (reduction)     0      
Non-cash intangible asset impairment charge     57,500,000      
Developed technology | U.S. Branded - Specialty & Established Pharmaceuticals            
Goodwill [Line Items]            
Non-cash intangible asset impairment charge     180,400,000      
Somar | Disposal Group, Held-for-sale, Not Discontinued Operations            
Goodwill [Line Items]            
Impairment of intangible assets     89,500,000      
Goodwill impairment charges (reduction)     $ 25,700,000      
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
License And Collaboration Agreements (Narrative) (Details)
 3 Months Ended
Sep. 30, 2018
product_candidates
License And Collaboration Agreements [Abstract]  
Number of sterile injectable product candidates 5
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Jan. 01, 2018
Contract with Customer, Asset and Liability [Abstract]    
Contract assets, net $ 13,291 $ 11,287
Contract assets, net - $ change $ 2,004  
Contract assets, net - % change 18.00%  
Contract liabilities, net $ 19,635 20,954
Contract liabilities, net - $ change $ (1,319)  
Contract liabilities, net - % change (6.00%)  
Contract asset amounts classified as current $ 10,300 8,200
Contract liability amounts classified as current 1,700 $ 1,900
Revenue recognized (1,300)  
Reduction in revenue relating to performance obligation satisfied in prior periods $ 4,600  
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accounts Payable And Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]    
Trade accounts payable $ 106,321 $ 85,348
Returns and allowances 250,637 291,034
Rebates 152,297 168,333
Chargebacks 2,022 14,604
Accrued interest 64,647 130,257
Accrued payroll and related benefits 84,240 113,908
Accrued royalties and other distribution partner payables 103,673 63,114
Acquisition-related contingent consideration—short-term 42,261 70,543
Other 212,906 159,684
Total $ 1,019,004 $ 1,096,825
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Components Of Total Indebtedness) (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Principal Amount $ 8,357,313 $ 8,382,980
Carrying Amount 8,262,762 8,276,237
Less current portion, net 34,150 34,205
Principal amount of total long-term debt, less current portion, net 8,323,163 8,348,775
Carrying amount of total long-term debt, less current portion, net 8,228,612 8,242,032
Fair value of long term debt $ 7,900,000 $ 7,500,000
7.25% Senior Notes due 2022    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 7.91% 7.91%
Principal Amount $ 400,000 $ 400,000
Carrying Amount $ 392,439 $ 390,974
Interest rate (as percent) 7.25%  
5.75% Senior Notes due 2022    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 6.04% 6.04%
Principal Amount $ 700,000 $ 700,000
Carrying Amount $ 694,053 $ 692,855
Interest rate (as percent) 5.75%  
5.375% Senior Notes due 2023    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 5.62% 5.62%
Principal Amount $ 750,000 $ 750,000
Carrying Amount $ 743,083 $ 742,048
Interest rate (as percent) 5.375%  
6.00% Senior Notes due 2023    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 6.28% 6.28%
Principal Amount $ 1,635,000 $ 1,635,000
Carrying Amount $ 1,615,955 $ 1,613,446
Interest rate (as percent) 6.00%  
5.875% Senior Secured Notes due 2024    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 6.14% 6.14%
Principal Amount $ 300,000 $ 300,000
Carrying Amount $ 295,922 $ 295,513
Interest rate (as percent) 5.875%  
6.00% Senior Notes due 2025    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 6.27% 6.27%
Principal Amount $ 1,200,000 $ 1,200,000
Carrying Amount $ 1,182,859 $ 1,181,243
Interest rate (as percent) 6.00%  
Term Loan B Facility Due 2024    
Debt Instrument [Line Items]    
Effective interest rate (as percent) 5.46% 5.46%
Principal Amount $ 3,372,313 $ 3,397,925
Carrying Amount 3,338,451 $ 3,360,103
Other debt    
Debt Instrument [Line Items]    
Effective interest rate (as percent)   1.50%
Principal Amount 0 $ 55
Carrying Amount $ 0 $ 55
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Credit Facility) (Narrative) (Details) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Line of Credit Facility [Line Items]    
Fair value of long term debt $ 7,900.0 $ 7,500.0
Revolving Credit Facility    
Line of Credit Facility [Line Items]    
Credit facility, remaining borrowing capacity $ 997.2  
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies (Narrative) (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2018
Sep. 30, 2018
USD ($)
distributor
Aug. 31, 2018
d
product
Jun. 30, 2018
product
theory
May 31, 2018
Apr. 30, 2018
case
Mar. 31, 2018
d
defendant
Feb. 28, 2018
defendant
claim
Jan. 31, 2018
d
product
employee
Oct. 31, 2017
patent
product
case
defendant
Aug. 31, 2017
tranche
product
defendant
Dec. 31, 2016
state_attorney_general
Sep. 30, 2013
company
Sep. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
case
Nov. 01, 2018
case
claim
Dec. 31, 2017
USD ($)
Jul. 31, 2017
state
Mar. 31, 2017
state
Loss Contingencies [Line Items]                                      
Reserve for loss contingencies   $ 1,002,100                       $ 1,002,100 $ 1,002,100        
Increase in legal reserves                           200,000          
Current portion of legal settlement accrual   966,633                       966,633 966,633   $ 1,087,793    
Vaginal Mesh Cases                                      
Loss Contingencies [Line Items]                                      
Current portion of legal settlement accrual   820,200                       820,200 820,200        
Payments to plaintiffs and qualified settlement funds                             3,100,000        
Settlement funds   283,752                       283,752 283,752   $ 313,814    
Testosterone Cases | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Pending claims, number | claim                               1,205      
Unapproved Drug Litigation                                      
Loss Contingencies [Line Items]                                      
Number of additional defendants | company                         50            
Number of claims consolidated | claim               5                      
Opioid-Related Matters                                      
Loss Contingencies [Line Items]                                      
Number of claims set for trial | case           3                          
Opioid-Related Matters | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Pending claims, number | case                               1,505      
Number of cases filed by states | case                               11      
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party | case                               112      
Number of cases alleging personal injury and/or wrongful death | case                               48      
Pricing Matters Cases                                      
Loss Contingencies [Line Items]                                      
Number of claims consolidated | case                   2                  
Number of cases filed by states | state                                   4 40
Number of products involved in claims | product       18           15                  
Number of state attorney generals | state_attorney_general                       20              
Number of defendants | defendant                   14                  
Lidoderm cases                                      
Loss Contingencies [Line Items]                                      
Reserve for loss contingencies   100,000                       100,000 100,000        
AndroGel 1.62%                                      
Loss Contingencies [Line Items]                                      
Number of causation theories rejected | theory       2                              
Number of causation theories | theory       3                              
Bier v. Endo International plc, et al. | Current and Former Directors and Officers                                      
Loss Contingencies [Line Items]                                      
Number of additional defendants | defendant                     4                
Number of defendants | defendant               20                      
AMS | Vaginal Mesh Cases                                      
Loss Contingencies [Line Items]                                      
Product liability accrual, period expense   $ 845,600                       $ 845,600 $ 845,600        
Loss contingency, claims settled, number | case                             71,000        
Par Pharmaceutical, Inc. | Pricing Matters Cases                                      
Loss Contingencies [Line Items]                                      
Number of products involved in claims | product                 30 13 1                
Number of tranches for claims | tranche                     3                
Number of products allegedly manufactured by PPI | product                 7                    
Par Pharmaceutical, Inc. | Pricing Matters Cases | First tranche                                      
Loss Contingencies [Line Items]                                      
Number of products involved in claims | product                   6                  
Par Pharmaceutical, Inc. | VASOSTRICT Related Matters                                      
Loss Contingencies [Line Items]                                      
Number of additional defendants | employee                 5                    
Number of patents allegedly infringed upon | patent                   5                  
Number of defendants filing motion to dismiss the breach of contract claim | defendant             7                        
Number of defendants filing motion to dismiss for lack of personal injury jurisdiction | defendant             4                        
Number of defendants filing motion to dismiss breach of contract claim | defendant             1                        
Stay of litigation, number of days | d                 60                    
Loss Contingency, Extension of Temporary Stay, Number of Days | d     180       180                        
Lawsuit filing period         45 days                            
Stay of approval period, hatch-waxman act         30 months                            
Par Pharmaceutical, Inc. | VASOSTRICT Related Matters | Subsequent Event                                      
Loss Contingencies [Line Items]                                      
Lawsuit filing period 45 days                                    
Stay of approval period, hatch-waxman act 30 months                                    
Endo Pharmaceuticals Inc. and Par Pharmaceuticals Inc. | Pricing Matters Cases                                      
Loss Contingencies [Line Items]                                      
Number of products involved in claims | product     16                                
Loss Contingency, Number of Distributors | distributor   1                                  
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies - Schedule of Loss Contingencies (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jun. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Qualified Settlement Funds      
Cash contributions to Qualified Settlement Funds   $ 216,770 $ 623,128
Mesh Liability Accrual      
Ending balance   1,002,100  
Vaginal Mesh Cases      
Qualified Settlement Funds      
Beginning balance   313,814  
Cash contributions to Qualified Settlement Funds   216,770  
Cash distributions to settle disputes from Qualified Settlement Funds   (248,485)  
Other (1)   1,653  
Ending balance   283,752  
Mesh Liability Accrual      
Additional charges   0  
Cash distributions to settle disputes   0  
Vaginal Mesh Cases | Mesh Product Liability Accrual      
Qualified Settlement Funds      
Cash contributions to Qualified Settlement Funds   0  
Other (1)   5,038  
Mesh Liability Accrual      
Beginning balance   1,087,172  
Additional charges   19,000  
Cash distributions to settle disputes from Qualified Settlement Funds   (248,485)  
Cash distributions to settle disputes   (17,114)  
Ending balance   $ 845,611  
Loss Contingency Accrual, Accrued Interest $ 4,400    
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Comprehensive Income (Loss) (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Before- Tax Amount $ 4,735 $ 39,561 $ (7,033) $ 65,262
Tax Benefit (Expense) 0 (107) 0 (189)
OTHER COMPREHENSIVE INCOME (LOSS) 4,735 39,454 (7,033) 65,073
Net unrealized gain (loss) on securities        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Before Reclassification, Before Tax Amount   295   522
Before Reclassification, Tax Benefit (Expense)   (107)   (189)
Before Reclassification, Net-of-Tax Amount 0 188 0 333
Reclassification, Before Tax Amount 0 0 0 0
Reclassification, Tax Benefit (Expense) 0 0 0 0
Reclassification, Net-of-Tax Amount 0 0 0 0
Before- Tax Amount   295   522
Tax Benefit (Expense)   (107)   (189)
OTHER COMPREHENSIVE INCOME (LOSS) 0 188 0 333
Net unrealized gain (loss) on foreign currency        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Before Reclassification, Before Tax Amount 4,735 9,941 (7,033) 35,415
Before Reclassification, Tax Benefit (Expense) 0 0 0 0
Before Reclassification, Net-of-Tax Amount 4,735 9,941 (7,033) 35,415
Reclassification, Before Tax Amount 0 29,325 0 29,325
Reclassification, Tax Benefit (Expense) 0 0 0 0
Reclassification, Net-of-Tax Amount 0 29,325 0 29,325
Before- Tax Amount 4,735 39,266 (7,033) 64,740
Tax Benefit (Expense) 0 0 0 0
OTHER COMPREHENSIVE INCOME (LOSS) $ 4,735 $ 39,266 $ (7,033) $ 64,740
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' (Deficit) Equity - Schedule of Changes in Shareholders' Equity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Increase (Decrease) in Shareholders' Equity [Roll Forward]          
Shareholders' equity, beginning balance     $ 484,880    
Effect of adopting ASC 606         $ 3,076
Shareholders' equity at January 1, 2018         $ 487,956
Net loss     (739,561)    
Other comprehensive loss $ 4,735 $ 39,454 (7,033) $ 65,073  
Compensation related to share-based awards     43,722    
Exercise of options     473    
Tax withholding for restricted shares     (5,082)    
Other     66    
Shareholders' equity, ending balance $ (219,459)   $ (219,459)    
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' (Deficit) Equity (Details) - USD ($)
$ in Thousands, $ / shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Additional ordinary shares authorized for issuance (in shares) 5,000,000.0      
Share-based compensation $ 13,700 $ 13,200 $ 43,722 $ 40,252
Share-based compensation awards $ 45,600   $ 45,600  
Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options issued (in shares)   1,000,000    
Nonvested Restricted Stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Service period     2 years  
Nonvested Restricted Stock | Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target amount of share-based compensation awards (in shares)   100,000    
Performance Stock Units | Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target amount of share-based compensation awards (in shares)     500,000  
Award fair value (in dollars per share) $ 0.0   $ 0.0  
Long-term Cash Incentive        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period     3 years  
Unvested awards outstanding $ 3,000   $ 3,000  
Service period     2 years 3 months 18 days  
Corresponding liability $ 14,900   $ 14,900  
Nonvested Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Service period     1 year 9 months 18 days  
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Income, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Component of Operating Income [Abstract]        
Net gain on sale of business and other assets $ (2,866) $ (2,763) $ (29,859) $ (5,074)
Foreign currency loss (gain), net 1,354 2,549 (734) (4,305)
Net loss (gain) from our investments in the equity of other companies 842 (1,075) 3,163 (1,163)
Other miscellaneous, net (837) (808) (5,786) (301)
Other income, net $ (1,507) $ (2,097) $ (33,216) $ (10,843)
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Income Tax Disclosure [Abstract]          
Total consolidated loss from continuing operations before income tax $ (143,068) $ (127,796) $ (671,559) $ (1,058,647)  
Income tax expense (benefit) $ 3,003 $ (28,109) $ 24,729 $ (97,517)  
Effective Income Tax Rate Reconciliation, Percent (2.10%) 22.00% (3.70%) 9.20%  
Provisional tax benefit related to Tax Cuts And Jobs Act Of 2017         $ 36,200
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Numerator:        
Loss from continuing operations $ (146,071) $ (99,687) $ (696,288) $ (961,130)
(Loss) income from discontinued operations, net of tax (27,134) 3,017 (43,273) (705,886)
NET LOSS $ (173,205) $ (96,670) $ (739,561) $ (1,667,016)
Denominator:        
For basic per share data—weighted average shares (shares) 224,132 223,299 223,829 223,157
Dilutive effect of ordinary share equivalents (shares) 0 0 0 0
For diluted per share data—weighted average shares (shares) 224,132 223,299 223,829 223,157
EXCEL 95 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 96 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 97 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 99 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 354 335 1 true 107 0 false 20 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.endo.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.endo.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.endo.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.endo.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Discontinued Operations and Divestitures Sheet http://www.endo.com/role/DiscontinuedOperationsAndDivestitures Discontinued Operations and Divestitures Notes 9 false false R10.htm 2104100 - Disclosure - Restructuring Sheet http://www.endo.com/role/Restructuring Restructuring Notes 10 false false R11.htm 2105100 - Disclosure - Acquisitions Sheet http://www.endo.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 2106100 - Disclosure - Segment Results Sheet http://www.endo.com/role/SegmentResults Segment Results Notes 12 false false R13.htm 2107100 - Disclosure - Fair Value Measurements Sheet http://www.endo.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2108100 - Disclosure - Inventories Sheet http://www.endo.com/role/Inventories Inventories Notes 14 false false R15.htm 2110100 - Disclosure - Goodwill And Other Intangibles Sheet http://www.endo.com/role/GoodwillAndOtherIntangibles Goodwill And Other Intangibles Notes 15 false false R16.htm 2111100 - Disclosure - License And Collaboration Agreements Sheet http://www.endo.com/role/LicenseAndCollaborationAgreements License And Collaboration Agreements Notes 16 false false R17.htm 2113100 - Disclosure - Contract Assets and Liabilities Sheet http://www.endo.com/role/ContractAssetsAndLiabilities Contract Assets and Liabilities Notes 17 false false R18.htm 2114100 - Disclosure - Accounts Payable And Accrued Expenses Sheet http://www.endo.com/role/AccountsPayableAndAccruedExpenses Accounts Payable And Accrued Expenses Notes 18 false false R19.htm 2115100 - Disclosure - Debt Sheet http://www.endo.com/role/Debt Debt Notes 19 false false R20.htm 2116100 - Disclosure - Commitments And Contingencies Sheet http://www.endo.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 20 false false R21.htm 2117100 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.endo.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 21 false false R22.htm 2117100 - Disclosure - Shareholders' (Deficit) Equity Shareholders' (Deficit) Equity Sheet http://www.endo.com/role/ShareholdersDeficitEquityShareholdersDeficitEquity Shareholders' (Deficit) Equity Shareholders' (Deficit) Equity Notes 22 false false R23.htm 2120100 - Disclosure - Other Income, Net Sheet http://www.endo.com/role/OtherIncomeNet Other Income, Net Notes 23 false false R24.htm 2123100 - Disclosure - Income Taxes Sheet http://www.endo.com/role/IncomeTaxes Income Taxes Notes 24 false false R25.htm 2127100 - Disclosure - Net Loss Per Share Sheet http://www.endo.com/role/NetLossPerShare Net Loss Per Share Notes 25 false false R26.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.endo.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.endo.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 2301301 - Disclosure - Basis of Presentation (Tables) Sheet http://www.endo.com/role/BasisOfPresentationTables Basis of Presentation (Tables) Tables http://www.endo.com/role/BasisOfPresentation 27 false false R28.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.endo.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.endo.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 2303301 - Disclosure - Discontinued Operations and Divestitures (Tables) Sheet http://www.endo.com/role/DiscontinuedOperationsAndDivestituresTables Discontinued Operations and Divestitures (Tables) Tables http://www.endo.com/role/DiscontinuedOperationsAndDivestitures 29 false false R30.htm 2304301 - Disclosure - Restructuring (Tables) Sheet http://www.endo.com/role/RestructuringTables Restructuring (Tables) Tables http://www.endo.com/role/Restructuring 30 false false R31.htm 2306301 - Disclosure - Segment Results (Tables) Sheet http://www.endo.com/role/SegmentResultsTables Segment Results (Tables) Tables http://www.endo.com/role/SegmentResults 31 false false R32.htm 2307301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.endo.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.endo.com/role/FairValueMeasurements 32 false false R33.htm 2308301 - Disclosure - Inventories (Tables) Sheet http://www.endo.com/role/InventoriesTables Inventories (Tables) Tables http://www.endo.com/role/Inventories 33 false false R34.htm 2310301 - Disclosure - Goodwill And Other Intangibles (Tables) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesTables Goodwill And Other Intangibles (Tables) Tables http://www.endo.com/role/GoodwillAndOtherIntangibles 34 false false R35.htm 2313301 - Disclosure - Contract Assets and Liabilities (Tables) Sheet http://www.endo.com/role/ContractAssetsAndLiabilitiesTables Contract Assets and Liabilities (Tables) Tables http://www.endo.com/role/ContractAssetsAndLiabilities 35 false false R36.htm 2314301 - Disclosure - Accounts Payable And Accrued Expenses (Tables) Sheet http://www.endo.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable And Accrued Expenses (Tables) Tables http://www.endo.com/role/AccountsPayableAndAccruedExpenses 36 false false R37.htm 2315301 - Disclosure - Debt (Tables) Sheet http://www.endo.com/role/DebtTables Debt (Tables) Tables http://www.endo.com/role/Debt 37 false false R38.htm 2316301 - Disclosure - Commitments And Contingencies (Tables) Sheet http://www.endo.com/role/CommitmentsAndContingenciesTables Commitments And Contingencies (Tables) Tables http://www.endo.com/role/CommitmentsAndContingencies 38 false false R39.htm 2317301 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.endo.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.endo.com/role/OtherComprehensiveIncomeLoss 39 false false R40.htm 2317301 - Disclosure - Shareholders' (Deficit) Equity (Tables) Sheet http://www.endo.com/role/ShareholdersDeficitEquityTables Shareholders' (Deficit) Equity (Tables) Tables http://www.endo.com/role/ShareholdersDeficitEquityShareholdersDeficitEquity 40 false false R41.htm 2320301 - Disclosure - Other Income, Net (Tables) Sheet http://www.endo.com/role/OtherIncomeNetTables Other Income, Net (Tables) Tables http://www.endo.com/role/OtherIncomeNet 41 false false R42.htm 2323301 - Disclosure - Income Taxes (Tables) Sheet http://www.endo.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.endo.com/role/IncomeTaxes 42 false false R43.htm 2327301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.endo.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.endo.com/role/NetLossPerShare 43 false false R44.htm 2401402 - Disclosure - Basis of Presentation - Schedule of Effect of Adoption of ASU 2016-18 (Details) Sheet http://www.endo.com/role/BasisOfPresentationScheduleOfEffectOfAdoptionOfAsu201618Details Basis of Presentation - Schedule of Effect of Adoption of ASU 2016-18 (Details) Details 44 false false R45.htm 2402403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impact of ASC 606 (Details) Sheet http://www.endo.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAsc606Details Summary of Significant Accounting Policies - Schedule of Impact of ASC 606 (Details) Details 45 false false R46.htm 2403403 - Disclosure - Discontinued Operations and Divestitures - Astora (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndDivestituresAstoraDetails Discontinued Operations and Divestitures - Astora (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndDivestituresTables 46 false false R47.htm 2403408 - Disclosure - Discontinued Operations and Divestitures - Lithia (Narrative) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndDivestituresLithiaNarrativeDetails Discontinued Operations and Divestitures - Lithia (Narrative) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndDivestituresTables 47 false false R48.htm 2403409 - Disclosure - Discontinued Operations and Divestitures - Somar (Narrative) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndDivestituresSomarNarrativeDetails Discontinued Operations and Divestitures - Somar (Narrative) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndDivestituresTables 48 false false R49.htm 2404402 - Disclosure - Restructuring - 2017 Restructuring Initiatives (Narrative) (Details) Sheet http://www.endo.com/role/Restructuring2017RestructuringInitiativesNarrativeDetails Restructuring - 2017 Restructuring Initiatives (Narrative) (Details) Details 49 false false R50.htm 2404404 - Disclosure - Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) Sheet http://www.endo.com/role/RestructuringJanuary2018RestructuringInitiativeNarrativeDetails Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) Details 50 false false R51.htm 2404405 - Disclosure - Restructuring - Schedule of Restructuring Roll Forward (Details) Sheet http://www.endo.com/role/RestructuringScheduleOfRestructuringRollForwardDetails Restructuring - Schedule of Restructuring Roll Forward (Details) Details 51 false false R52.htm 2405418 - Disclosure - Acquisitions (Other Acquisition) (Narrative) (Details) Sheet http://www.endo.com/role/AcquisitionsOtherAcquisitionNarrativeDetails Acquisitions (Other Acquisition) (Narrative) (Details) Details http://www.endo.com/role/Acquisitions 52 false false R53.htm 2406402 - Disclosure - Segment Results - Schedule Of Reportable Segments Information (Details) Sheet http://www.endo.com/role/SegmentResultsScheduleOfReportableSegmentsInformationDetails Segment Results - Schedule Of Reportable Segments Information (Details) Details 53 false false R54.htm 2406403 - Disclosure - Segment Results - Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax (Details) Sheet http://www.endo.com/role/SegmentResultsScheduleOfReconciliationsOfConsolidatedAdjustedIncomeLossBeforeIncomeTaxDetails Segment Results - Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax (Details) Details 54 false false R55.htm 2406405 - Disclosure - Segment Results - Schedule of Disaggregation of Revenues (Details) Sheet http://www.endo.com/role/SegmentResultsScheduleOfDisaggregationOfRevenuesDetails Segment Results - Schedule of Disaggregation of Revenues (Details) Details 55 false false R56.htm 2407402 - Disclosure - Fair Value Measurements (Narrative) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements (Narrative) (Details) Details http://www.endo.com/role/FairValueMeasurementsTables 56 false false R57.htm 2407403 - Disclosure - Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) Sheet http://www.endo.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) Details 57 false false R58.htm 2407404 - Disclosure - Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) Sheet http://www.endo.com/role/FairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) Details 58 false false R59.htm 2407405 - Disclosure - Fair Value Measurements - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnNonrecurringBasisDetails Fair Value Measurements - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) Details 59 false false R60.htm 2408402 - Disclosure - Inventories (Details) Sheet http://www.endo.com/role/InventoriesDetails Inventories (Details) Details http://www.endo.com/role/InventoriesTables 60 false false R61.htm 2410402 - Disclosure - Goodwill And Other Intangibles - Schedule Of Changes In The Carrying Amount Of Goodwill (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfChangesInCarryingAmountOfGoodwillDetails Goodwill And Other Intangibles - Schedule Of Changes In The Carrying Amount Of Goodwill (Details) Details 61 false false R62.htm 2410403 - Disclosure - Goodwill And Other Intangibles - Accumulated Impairment (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesAccumulatedImpairmentDetails Goodwill And Other Intangibles - Accumulated Impairment (Details) Details 62 false false R63.htm 2410404 - Disclosure - Goodwill And Other Intangibles - Schedule Of Other Intangible Assets (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfOtherIntangibleAssetsDetails Goodwill And Other Intangibles - Schedule Of Other Intangible Assets (Details) Details 63 false false R64.htm 2410405 - Disclosure - Goodwill And Other Intangibles - Other Intangibles (Narrative) (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesOtherIntangiblesNarrativeDetails Goodwill And Other Intangibles - Other Intangibles (Narrative) (Details) Details 64 false false R65.htm 2410407 - Disclosure - Goodwill And Other Intangibles - Schedule Of Estimated Amortization Of Intangibles (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfEstimatedAmortizationOfIntangiblesDetails Goodwill And Other Intangibles - Schedule Of Estimated Amortization Of Intangibles (Details) Details 65 false false R66.htm 2410408 - Disclosure - Goodwill And Other Intangibles - Schedule of Intangible Asset Impairment Charges Including Goodwill (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfIntangibleAssetImpairmentChargesIncludingGoodwillDetails Goodwill And Other Intangibles - Schedule of Intangible Asset Impairment Charges Including Goodwill (Details) Details 66 false false R67.htm 2410409 - Disclosure - Goodwill And Other Intangibles - Impairments Narrative (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesImpairmentsNarrativeDetails Goodwill And Other Intangibles - Impairments Narrative (Details) Details 67 false false R68.htm 2411401 - Disclosure - License And Collaboration Agreements (Narrative) (Details) Sheet http://www.endo.com/role/LicenseAndCollaborationAgreementsNarrativeDetails License And Collaboration Agreements (Narrative) (Details) Details http://www.endo.com/role/LicenseAndCollaborationAgreements 68 false false R69.htm 2413402 - Disclosure - Contract Assets and Liabilities (Details) Sheet http://www.endo.com/role/ContractAssetsAndLiabilitiesDetails Contract Assets and Liabilities (Details) Details http://www.endo.com/role/ContractAssetsAndLiabilitiesTables 69 false false R70.htm 2414402 - Disclosure - Accounts Payable And Accrued Expenses (Details) Sheet http://www.endo.com/role/AccountsPayableAndAccruedExpensesDetails Accounts Payable And Accrued Expenses (Details) Details http://www.endo.com/role/AccountsPayableAndAccruedExpensesTables 70 false false R71.htm 2415402 - Disclosure - Debt (Components Of Total Indebtedness) (Details) Sheet http://www.endo.com/role/DebtComponentsOfTotalIndebtednessDetails Debt (Components Of Total Indebtedness) (Details) Details http://www.endo.com/role/DebtTables 71 false false R72.htm 2415403 - Disclosure - Debt (Credit Facility) (Narrative) (Details) Sheet http://www.endo.com/role/DebtCreditFacilityNarrativeDetails Debt (Credit Facility) (Narrative) (Details) Details http://www.endo.com/role/DebtTables 72 false false R73.htm 2416402 - Disclosure - Commitments And Contingencies (Narrative) (Details) Sheet http://www.endo.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments And Contingencies (Narrative) (Details) Details http://www.endo.com/role/CommitmentsAndContingenciesTables 73 false false R74.htm 2416403 - Disclosure - Commitments And Contingencies - Schedule of Loss Contingencies (Details) Sheet http://www.endo.com/role/CommitmentsAndContingenciesScheduleOfLossContingenciesDetails Commitments And Contingencies - Schedule of Loss Contingencies (Details) Details 74 false false R75.htm 2417402 - Disclosure - Other Comprehensive Income (Loss) (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) Sheet http://www.endo.com/role/OtherComprehensiveIncomeLossScheduleOfTaxEffectsAllocatedToEachComponentOfOtherComprehensiveIncomeDetails Other Comprehensive Income (Loss) (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) Details http://www.endo.com/role/OtherComprehensiveIncomeLossTables 75 false false R76.htm 2417402 - Disclosure - Shareholders' (Deficit) Equity - Schedule of Changes in Shareholders' Equity (Details) Sheet http://www.endo.com/role/ShareholdersDeficitEquityScheduleOfChangesInShareholdersEquityDetails Shareholders' (Deficit) Equity - Schedule of Changes in Shareholders' Equity (Details) Details http://www.endo.com/role/ShareholdersDeficitEquityTables 76 false false R77.htm 2417403 - Disclosure - Shareholders' (Deficit) Equity (Details) Sheet http://www.endo.com/role/ShareholdersDeficitEquityDetails Shareholders' (Deficit) Equity (Details) Details http://www.endo.com/role/ShareholdersDeficitEquityTables 77 false false R78.htm 2420402 - Disclosure - Other Income, Net (Details) Sheet http://www.endo.com/role/OtherIncomeNetDetails Other Income, Net (Details) Details http://www.endo.com/role/OtherIncomeNetTables 78 false false R79.htm 2423402 - Disclosure - Income Taxes (Details) Sheet http://www.endo.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.endo.com/role/IncomeTaxesTables 79 false false R80.htm 2427402 - Disclosure - Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) Sheet http://www.endo.com/role/NetLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedNetLossPerShareDetails Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) Details http://www.endo.com/role/NetLossPerShareTables 80 false false All Reports Book All Reports endp-20180930.xml endp-20180930.xsd endp-20180930_cal.xml endp-20180930_def.xml endp-20180930_lab.xml endp-20180930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 101 0001593034-18-000036-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001593034-18-000036-xbrl.zip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

+?Q3+,)/Y0"9_I M6+"SU_,O6M=C:',K@1H88]&S9Y8XH;)$6$DL51]Z#)]""BM[UP5SB8EUH8(. M)3&"7#C4:DS/5*@-@_6?H8T+/9*/R<>>3S. [=AU7&!#[#90Z!C#B9%,)Z,>$[!HZXAI^1#,P[3N.GHB>C?\VG&8@W/5Y_;BE&? M\%TID200KL$E7%5D]&A26'4WG2O)L%Q'URMB16T3(@DK3-:I9XL-G$]&_YY/ M,:M%+47';66,.B\6G;A?U[4BVRZ^GSQ("OUH.OOWH],KP8OOKBXOYM4G5V?S MP5/+#)*]J<+YZF)Z-KFX2,<2G]W(3\VAQV]'IT_4LK<'Y:5T&30^VV MLKA1# A V49C(547=9I\7CY9\@:47\'' ]B]=6._5"%]Y/O%Y/67_,N3],D^W-7WSHW^A%UY7 M_?Z7A&%'_SJ=K.6_NQ2"B\2U*(@,R0* 2;8TG=*>[N)_SZ>_O0#Z^>SM9/:/ MGU[\=#\]\'+C>9YH#KJO$(DD$G0Q.*@F=+YCA-[AR>%^W(-%$T7;BT\50^E9 M($R!WK!JC5MY(ANPX.U^U^S<@H/[<_KVZNW:(;G5Y@KL$T2#JMTI=@K FACV M/2\?Y.W<4S,W/=N$.>,%=.E$T> =5DNL042USF&OC8?9^?_NIC,WJM)O?X)GS'5''O]KI.(9P)]M*;EXA/BN:[]U:%N\UR!)AAF MDS>3LXO/"3+]JDWB:$550LJMMIC\X7:VY08.^GTR?Y>[XQO7P3_7C6 _UTQ! M]'(_O!@%"J688FQJ0T(=S>UX["ED>)!G^,^G.T,!AKCQ*/ MA28ASC">23D4[7&H;E! MYX*8SF!SBZ#41W..?UA#>-J M$S"8Y2M@% ML_3$KB5]9C:Q+[92_.6OSF/L[K:;U;=)Z\*9)-C7V).:--PNZR-"Z/1OX7S>C&Y MO#R]KGH[-'>%S"4Z8["VB-&W;+FG4)JMR:8*^(Z4>O##*5@#83=1Y^&=@G^J M4Q!]][7W'KV6E'?FV@3.=D>4;2(_6"7+.@/B&ST%V*S@(EW]*3_GZNW"P^.7 MXHLG.TQN33?N40"'%"QG;PELB!4$B?$09XI1"[N)7+[:L_QE\F;Z^HW\E-/) MAY>3XS=GYZ?GKZ>3 SC,^3"32 D".F3;$A;/W;(/0&S&(:VZY>H[/\QYHO?& M9Q9G'#TVXHN9,K00;4 L*%%1#@Y2-:9T"F5(B-O@%H:S?GVR<&7P,@@(%@OB",+X*LEG+&AWE@$!%=CSH&R:0@-[/[A$%L M:S&01HS6[*AJ MXI#/[K%?GD*.">120&(P59W53A ?^Q2F0L+DE^E[?;J] M/#I[/96?.%_Q_8^+R:NKTU^FK]:7%=_]0R[RA[\?_=?Y;#X<^/;(G\G[R>GY MN\G)9[?UX7AN7+'^9K]$EGBW-94Z$& NQ%4P1&[4>6!3]+W_]S=I_ MWI#Q!B(X")'],CW6$K&SU^GU;'+]./)@8;7 G$/KU62!TM28L*3>D73'F^U6 MA>6>6EC;LV4E.";L$@R7@-G$K$4N1OZ /<;H_/YT0!S#\?7@ILF*0?@?@]<[ M38>#@2':N7G6(,FGUO,-G_UTKO37*Q(+)E@O$O .6D[@>A4J=J' MYB/T/G:!^VB<^];$]G)V=#+Y]>CMLIZ]VQC+%+ER(I=<"XI+9]^;=R%;-*SS M=88D.!@^,%DMCF&YI0RU8Z7?#U9<4!>'I]+G!!$71CH4A:%^_]+8W09&#J5J&PCUAS35$97/7_7IQ?'1Z3\G1[/M;%(Q!0/;8%"BJEAR(H>Z MX;X4*[!N+%8.SGF"C3G>D.;[BT"_N\O7;LZ>@2X4;Y 57>T2U1.5 M.BR1 6?BPLC ^Y'Y0$;/K[8\WD:U]]:]W'W MF7>3^3!&7[X1X[8=I\''"HVCBZ:C29",R;H=TSK?,8^*#&3]PH"M>]+Y0%;_ M.-^.46$NSG,XDDS\K53*U;#Z^!8DDB#M^3Q-+65^;:0VFY=QO$;(T+;"/ QCJ\GMZ] M,_XT$9VK(3I.;$!@ 'C*@7+U(<1H2DGCM*[O2:C;HRP*R5;+L94(J"/+78W6 M^*!OIC'T5:.%OF$Y;@R[+ 7&V(/'%M'I#B?Y"$"G:$GGW3ZQ^/XV&R2T+M]$ M"+%Z';0C0#)GY,!%;EP#\5+RJ2'8"T&"PL77GC44/9CZ)[$\6-"R0&F+5<[: M0L)2JH0F\UL#8YU'L K7-L:HGE( +8#.:Q"9K5Z'S.C8R$4 M2Z,FR*P(W/:URRD.2=(0 KO%KOA]4_\D5SZ$8G51=K*@BP,@1RO G*V8Q1KC MXE8JC3(->G[,*__X>9D@'@)"*RXW@P%B$M_@NKWNJBOC@\2C7_E'R[D8Z"TI MT[FC0%$=+VK$XF1R3N?<#U!T!U?^='E^YG^NIK/)B=TZ0K$^>D$K*1574$,2 MP7V"I8WCEJBY(6LTT+Z:GEW1_R1WOZ;D?,8^WWU*-$'SEGANAZ&9&[VONA3EJ*<" Q\ O(IHGX&G- M3.L0:C8Q< 5/F'4!9*BZBR34(IXE#NW28M\7RV*?AJF5(YZCK2QJIWN!!#A[ MLL%XK^M 3=>I6F/'\4Y8TD]^+N8Z_O#;T>5\;.?IZ>3UY.3TP\]GK[1F:G+R MCW?G9[_.1Q@NV8(.SX\OC7TFOWK[GR>3Z7_^,GE]=-KDIUY^N#GZ>':[PGI) M3>XOT\OIZWF(7XXN;E2@_7MZ\?S%R]]_+B\_%J#]_>CR MV 'W[2V3?W'^]FBV9M,&1.V)3*9TT[$*CJ0:Q*U@D8/D.CX%/!M> E9+_IYG MM(D+,0T29RM10R,$:R:=U@1\!" M;%.C%K]X@?W8=>!;U[(?B0>R&-,X7)+'XF?34?<+=A5"L2DZDSP&DU/6VKB* MKC4*97'7^E_^ZB4L]0L-8GOE2N+SR>SLZ!H+;L=;T?WVXMD,%P'B4>?.0A<' MTDL1732#+2#F15RT%6>KLOR]8S>A)F>SR%F7/'93(R3O0$0RSE !(P8L/.0V MW$S$/O;-=U5N?.IL==4SN]1#%R2M<_@DSA]WD#[XYM^3UZUOOG!D.#L!'19+ MD[M2(L?0@7.$G$;,%[VU_$"5VKL)\%B 42LXDM,WQ"0J";4R:#44I*$( ;3! MX1%/ZP$6(#5!M3F K8 ZM#BA.!ZQ"BAXG7%\0:*XF%M;Q=D>BI:\"V(7:@\N M-:R)$I?NP:,:Z&YAP.;/G!CPI01O5\7P<):>RM:D:#$3AE+)(763:NP8:BRB MNX;'V/DTF.L3DD_@S[R7H:T[@^EB_OFNS M\_/;=T?ZZ'*CUOWZ0\KB*)^U551D2@2MIH@2?W@)^R@'O0<(PJ4;PF\?@HZ% M6<0.8_&2W#+ )Q7.JI@>(*3D(T5P M$C]!RJ9+<*BK(AE3*8/7!)VS?4=,_XC\/)F;<=GU'+3[DC";0"5G@:.Q8>OR MQ^%N'(";>:R\@K6,/OD*2>^%)<]: B9X+&H>.2=BO2]H]R(65D&.'7/XV.S^Y.KY\ M/GLQF;V?'M\H(9$/3$Z/_IR>_7PF7W0LDOA]F_9(C5*M?DB M1M\UQ[ZU54U.NZ;QNR]RD1-H(20PXEH$P7=.G9O3QQ]7>N/Q[7_>UKM/M7F4 MX55[6Q0=!>DW"+I_-V,G 7X2#25G*L@?P6V24MJ)(%<^ZI<0A"BMDQ?+0(*V M;=.]]L6G[O)X_QQ17(FZ'T+K(ZYR-RTA9=,,B[5Q$%@3Q0[$;&; );VJ!\+O M0S>WL_6NNQ HIH+(,57G!!P5,;@8).@Z4+;OE8;H28*NQI&MDR/6==C9@Q7E M%B#=8AV: OU\--?>5'MUG7=/5.7V&>X&&Z $036Y$L5O0Z.VR4/%3FA<666E MNZZ;(^M[19<].8+>,\?660#G$*#O6YZ+M-X\^\AB<;T0Z"2JMB5PR)A1"2I0 M0QGG(NV?UJ>*K"4@\*8G;<'7X@)/6:=TQ(S)=A/3$!(PVC-#TS+ M'Q#G9@I.QQN;(->O%M%F^_,CX%Y>P;!! MQ(,Y8 )@#]UB[45M9^X@9^BC$W4=FBIHL91\*_IVSMAW'R9)-"36%+L8F80V MAVQ<"^12!QNKK6,!$R]&UP=R@-L$51\O[,HLQ?/9DI!K7:HB J>:4/>]ZY"P MK%G=U!L5)P:*L5\$:Y:J(RBUVF'-%WB32,!=&9H04Y MBO[$ ^+LH/0DAJ(CN'I'[R5P$S-?G!$0VJDUB4C'E%:P]D#T9 WT9V;+46+/ M[AN&!-G;F@TA)$XHH@91$@5E+ MY0>T.Y?FP>C)*GO2.\0,7*($-E@SD;@<8W4C&!.V\4%1+"7&<$"<'92>2!QK M8NXV@7?HK">C=/D1.]4UR.!'$7FWJH7A"W^.HJ MP;6H'4$OR8RCSK>Z53>X_DH$=8](=KOD52JBA%!*Q^8Q"F!(/8K30[GQB=M8 M#:%[<'](_"'I0A>;M\&$['+&:,3 M@H=NBNU$HQ#C:\GJSV5P-8\ MF4^8O"<"L"@Q<^_D$8>TOG4+P-B($*,GCT4 MP9DFA9 RLQAK6SOV5>.9=BR2G\6YO/KR;0\'FA05+O?:HL#H!*33A#J(U4!# MH;8AMZ;/%IL;PG7D[IOM&VFE3S]@.Q49P&BZ!4;7[OP*$-%A38+B [A4Q"AS M: 9T\=&XO6./PIVGU33WV6?G;Z]'BES)UWY)BVU?S %0C2=A*38D8Q):?32J MG 3%L!NG%3&'A5WPZZG: 0\KFZPB>U\9-?Y&GXH$5YY2BBGK,?0A,'C&P5X/ M^WA,)M;-G^C90$P2TS1&)F;7M$I=[).@1!B?$Y]9"";:QV=BY4F(8];GQES% MJC:Y)<;UW)-P!?I$.O:=! Z.:*],7,\KNOZZET=_BIN8GIW/IIU_KN33?Y].LJ\-"46(&@TV;&MA!:5%UO5"RHUC%67L3MO5SWZI8]Z7LU=GJQ,M6 M0CF+ +J]OL5H]2%NLV)^7/A*W.WG MVH_?= W1^5FZO)Q-_W4U+R9[>?[K^9D*>W9^>BI?\HF2[=&Y3[V+]&+H";U8 M"4A:Q=E= @A^[+NY5^1['TZ>2%:K;$ SV61-E^EBENR JE<#@-5U0V)J=Q-A M?RW"6@,.H"2+X-&)U 024/*D!9PA!X(/+E:>CS=WW^HA>71VO?N]&-QVV^3V?3\I%PWQ4W?3]JK5Y/CR_DPBR\=;%^*W^2S M.NUBDB>7?TPF9[]/WD_.KB9_NQ+K+1_]^>SZVZ^-H]:SO1+F7YZ_FQY+*+DN M^BS.Z0Q&H3HB9]8!8J%V+Q>&G1^?K)[-5]Y\#YKQP%,K1Z?'URV/_]"]DBO/ M;,.S$IQC7"J>M-%->VL,1.UE[URD5$",E#ZSJ5!8DZ M8PPYQUXI(=>QF?-^J;^O2U@_K-[GTAW@GEF7N5GTP:=H0-"7KO_0IY2Q%L5^ MX]?H@*V>CBB(J50;742(.5'WOO3432?OXO@B%)C ;AOO[?^X1([YZ&)Z_.+- MT6RR273@;CZHYEY<=5!STT:TD!-J*JVXUE@"K@7 *__4_%\189B? +>1PRTJ M=\W@/^]FT-04HXY/;?IFUFLN.EB972EJR!O^E:94T@UE!4G& [D!'] YYL'6IIKY(H3Q]!1KB*78D-&O:=1 M0$>[ZT#-3]M9ID<[SX,P_36-P_4.98 HW.1L$RB:4@N M%$L.2R?*"'V%33C,\SPXFY"*@,"6(GJ,6%OFW,D$:/+AG 3XK;HR[O%$7*>G M5\+UO; >)'#5BTV0.!][;10"6.C.QQPIKH!"]\!Z-^G MF?QAXS\">8^#GYKNST9TNC3>BKFO+>F>J&YVB $?[TP/SCY0++UB]]$!8P&7 MD9H)NM6^Q^RKWR4.W$S,R^="_#JY?/[J/FM[N7?;(Z5NOUL^\BI_T#5U3SC5(UUH*F"1NRP2)5*K)OHTML@;@[[$:$(IZH+^M]D&,;&H5^'-MC MVQ ?0V^:X\1:T>VUS.=HCGR!EYC_8/CZ3K6Q1Y>-SD36:K60$@=76M,*CJ+* M. "L'Z=V"$@D8'8I]>"U>*&+%S"]&F>A"UI.D4;+#WZ8E/,(IW:[Y./WR3NM M!#E[W>0;+C]L';^!1/]D0^G(K)7PI O#4_0AU-@PC8MO'Q(+K"3]\>2QLFTC M]]B]9PF+&K:M#F&) M(3N3?/.2P.IAOO5 )+)225+KL=766DH84^0X3_.T*'^/91QX^$#[?D^)[*H? MN_EL-;E-6+QP6W/$Q#TB"^2/2Z:+6Q-7]?UNW>JRJUY;R\EG9R5>*0%=(_'* M-6<;$I9,W0YUR=:&56>V/S[63E 7,"$J6&P6[?,N*Q#LK66Q6]FU4?L(5G7K M[96/E=@6;,KL6J*"Z%V@$'O1';8N-J8BEQ-H]L!,G"$@(6M\;WV M<6NI,TKIQ4&;F9XGPL65?T(4>=Q0JM1A*L4 8]<*#[1.]+[.3B]\GQ M9/I>_:KJ!R-CFZF-3)]>\_GWU\T+OX[>B# M?K&&'L?',_'#OTR/_C4]E2!DLKVKR<$EX"(P2."U(&E*B8+ IUY8N!OW@CZS MR X&KWD/4O?![)I+4'2&KV5HNK8OD8""X@MG+]%1[6!&8^B#(*;A&NR-V;O4 M<9,WA2P^27> $("6^Q"[+IBAAX*57!]'T4"T,-ZT8N\K""U7'.I0O)N\Z=RN@RD<3W7BX M$,=! WMD_;W L//9?>RH[C)*N03YOXX,T37+3 (2DS,:FB]I-K=F'(YS-T$/ MH'S="B'K6L^B>;KYF#VPR3K=R_08!=B,HP6?H0->?R@;4O[;;/+N:'I2)Z\F MLYE.QYMC"[&ASR_?3&;7$_2V/@P!.L$5 ;[%9 R>)?AH 5-C"8"KX,71J=G@ MALS(/2C=!Z_K[&7OO8'$4Z5[+)8D-O% T?:8 3HL@A(D7,@%T7#68'':$D7TO :'VFY)/'[J#9UL8&?8D[@C*XJLD$U"AA""F+>G5@\3 W.I\2NFA8:TB3U2)W%>MK[KLA\V7 MV\_NL<3!ZZS]BFQ;3-@%:0=L.50.MB>3QSSJ4OY6DK1#+IY8%UA,B8VV-'TV MZ363Q1R+F&9NN;HQT?%06=W^FK_-1"4>B#^26$&.W3G7JP22Q"'I3FH;<^I= M\->P+XZ9XO"FN E=N^!DE:?TJ0736]6W1+'U7A0X55\X2K304ACR@R$&;\VN M.?EU7*DE&<^LV8H4(5OFF[9>EAAX@ M]I; S*T[V>Y]HPS8JF[K63;U'-WBN)_EQ#R$X$TG-_G5"H#^>BMF 6G&;&4L8TTV M(QAQC<63P.^L XO5AWB3):JW9)8T)CVSWM*0.]X]P7L^)\$"V!!LTKWPOENR ME(L&^4G1XUC/]RALKTR[F"A66Y.-27-OG+DEGR,[TWJP2ZHNY4AIV/:P>X+W M?$ZE-32^/3J?_>\=>NY7O M&:D9:SI'CA:]@62:C:5'N5_B7O-PG9:0N4#"O:A<]^J2;!'P$GH*@EW :S. M 4=R!\C4$8\Y#(MO+EO0.G\6NXZ<+K=$P,TE(N-C;@$!Q>ME"]90!TZZ+&EX MK/3&X?)+>IN,^Q"Z,A7DNMA+X"RP%G5KG$L"W ,#"-;*BY-B!.#"N)QB/9W7 MKUH?="78Q9O)B>*LZ^)'#9!F[Q>?W]9)U^@<:C2LC?GHC*,LUL54$@A86ZSC M9EP,-*PJ64O3@UE8)7<)?!O5X"Q+K ]B#ENR+13VQDJ$M#BU:[ZK#W@W+ PV M<6TZV0<.WG2/(F[-@XHB4Q)31LQ5T-H N]F"7U22+__XYD2M%"#5WN5^=3%0 M8CC%KSB7HY@%%ZR S<&^>B^!PHZ(^IY'#-P&(YU=H9AS!,+F'(O%"_/DE6B M_'5)I:I9+%5]Z!D2P1'0EF.*:KBQ+14P4QQ2U>]+' ?%XL)86W=0Z ML0@6V=0QW>R!R4:N2IBW.Q("B!]UCFJ%TN5.NR4UTG'8/3^2L#6%BQ?[)H41 M;!,7)%J4#(IYUVGZQJ>6M$0TE<$CV25-.IM1^/O1'Y_ W4.\D4"/XF/W$LQF MS,FGVFL22Y1S[ZF/E2#6@;BCY13?2=)#&5B95A&"HM/M5&+<@V[^TD$!D5J) ML92Q0]M:#NX.4[H= _]Q/OOOS\G2!QQ!Z-F))W#.](P%,9M0K!'(I6.5;1@W MWQJYEG=P<#=-#V9AU2$T;M[V"E DG$-J L/$YX*R$;5(<=BFZ4.X0XDVX^"7 MR>NCTSZYHVAK5>1MBA$(6\B5(O>3$Q<=""_:4ZT6I8VI NO\PCZAS__XYA2M M;NHJ9*W.,NL)>S>9;=8X1IN\33=+[P;8>E#]=)U#0Z<;PII$5% 'N^G$PO)"G\M(P[84KFP9:%W\?Z5L=8&B M!/PEZA VX_0!.J7A9CMMZ%W8*+6Y-\GBB $JF\G6+1> M5VH73,6I'N>:"R2)2R1@$848^S'8 -RI!ZOHVA4K-]-A&IJ(E#0Q-CWYV*R8 M/[S\\&YRH^-:WQ*O\?3ODSE^ON,;?SD_>_UR,GN[;A6",56\N \;H@V9!]]Y!L6&+J?@A_"^'[=0MAJ5>&7KRM&:, -P&TF$+522P] ME=%U?[OFY\6;\]GE!A8;>\G>E(:=!;MJ)V<$WQ6RH4W)/:;% M=B!PK(KGC(T0HOP.&(/U8DM"6[+O\H?T=VJR/42F".(U#68G@-0F"?LA_7W:[-2MII,=4-%\6LG-:^V$A#?AE3675B)*%)TAGJ7<%*"C6S)2:C6!'6!UBM^FU)9=Y$8 MN?M(*(I!V,$2^>:"19MU%T(=//D31ZLK"S8Q^YJ0DT X%'O,,;;6(7<3V'-< M\JYZ71SS=*P\=>!-Q8NKTG?HH@]WD3A5:TT&5UQ--/@P"N[N#- W)+#'--;) M%!W;4C3-B6 ]Z9Z.7A-S(0]]2/[_$/X.?8+K%#N*]>.*2 ZROF@;7ZP$@$6T M_8?P]^AZ0"!*\Q2Z)8/-)/)>!W@ETEK[3D/9V;=K?38-NVL.(AWQ:]RUB:\2 MY1J\SQUU_LPXZ@>S1-P^,;J&F8WK(94J,42I M;7BI.1P#] B&0?BDW&PJF V:'#FD%EP+U70P'E3YJS*;G$POA0S][@^_3]X>3<_D"_/Y;';^A_RA'+V3S]U1 /'%JMWZ*;<$ M\OOD_?GI>_U)M[YFS8CN2"&Y4H%-U31J)QOT)<97WSJ%<Q38+;95/ +'+]_,)I,MV-8O7SOL!9S88NHF9HQLN(>:.;LYQBE]<-H1 MAO&I^V-\/CU,/[G.QUH*!8NN-Y!0T);L@C>IQM:C;=X/IO/13FY^5M=']\?Y M<$F_W,ZM]57K4+$XBUP[YN*3RPR=Q*Y*4.!P7$TG)QOAL;B>_CGG^?]-9N<; M,KR!ID9KP,O=-%&"_00V]V"M8"M*%+C:)1-TK0<(C\2S?OX*Q9A>V=]73 G)#':3E=$Q^=<36 M]Y:'0"[,&SYW0M6>G+R.@O/1 T-E9#!4B9.5H Y:A!"7%-R26$5^ M))[V[^2#K91"\K5:.5Q(!#J0(14H42QI&O@7)\_NL8YT+T[>-*QB-8E([(;1 M<9>AV.1[LFA2@\%H!M$*W-'5>EHGGW(-F:U-V#$YH 9H8ZM&7 A%&LN5!,O2 M8S&^J9,W'KL!\&![1E=:JCJME0.H\W=I9>9K;\3OS<%K[Y2SCM!\'#]H@V%)G4J>1 .VYO)>31':?=CEER[J MAN((.8&+M>B ]01B,L?V36?N/H!E'0>;4+@*B13JNALF1I<1V2H4D6BU8XTI MD*51?& 7FXLVI_!S7FF]%.GF$6=M=D),7H@LXE,E##$:9^DRZ9J&UI+K]J>[ MJ?Q,QCWH7)0EW;IP3?0OUB;!4Z22L@3Q$@+*T3:\=R6THN+SX\CQQ_FRR..3M-E.9K-/L@'[];9SV;N ME^GE]/7\.:4<7=QXA?GWH]?3LZ/3OT\NWN@G+A;>6&[_RU-=6_CKT:6@T.>O M;A+T^7U6$O006Q01\RDBZ[!QBAPQ0=Q#4.<(=R)'3LLI53RM0%QEDH>LM3:66<,\XA M!'\ #-U3Z>^T=-5G2"XT\7DD( )SYN9%! Y,#VX<64'.#*]6^Y+#?>$&D:T4 MV$.@AMDWII 36HDUJ&8[6F\QW3" S"VHVR%;*^==>0PM1J,SC3!Q9/&L"I*< MKCP1/1Z@,SXF5]>3:Q97BVPT?."F"_(.Y;B()(Z,6 WDYB6JJIHU+L6,TZ3= MIBYH V+7<_QQ-<+Z4=P/N)TW$7[W+D$'"+4D%&R5T2!#*C5!Z77<,>0W]LB? M.-F YP6W-Y\!O-PVG4RF_SD?M=#FZU]O9'C?BL"/C\[^/CF1WTY??+CX,H9P MUQ:-4T^U(WG C)P;0PG)2B17)83#//2BJM_=3&3+!+&1_-Y/+X2K?2K-K=LK%%>^#]4>88^UHD1C8QLZ"5#IF=!!(FSZ>.1AQSF$L&).V']4<8 M#5RCC1T<8PQ8;$DZE"]D0^)D2^5QPMTXBNE>K%^;@^>O=$/=V E M>'0Z+?$F-CWY1*>( .YD?N3J82*@_VO[Y%\B OG5T5H1Y.ED]OZG=G9R/A^$ M>S;_DJ/3=Z?'D\NCTY\6G,;+J=AEW;)Y,GT_/=$\Q.[->M9Z_FYY/3SX6P7]4L 5AOKCZU\7D?ZY$ M:$TGWWVNI+_C\^N$ER)09'#0(*,CGQRG)%XIER;RM&GPQ%8"B3LEMT08CR6Z MEY.+RW.!++/SL\DR^+=CN66GWJJ)ZPIBR0-D0H*6=-5WJ19O0N5CY6^^??S> M@OO[T>R_)_-U>_/*CWGI\WUS')B]C299GZ/#32[JCI@)[' M34?/[&(R9BOZ=L[8'N= !TN+M_92/J,_Y,7QY.Q(7/U"N?W%I\]_(69MF9V3 M6XK1=C%DNM'.Y@*&DM88)ACG>A^>W%?+Y-,'?YM-WD_/KRY./_P^>7<^4W^R MIL52(M=6P41?'5ITKAD":G6!7^%8!'JB5I20]9AK M\CEWC&[5?+==<]0E2#Y3\)B.+P4+7=YG>W@-H8::P#9;$()X:SD<9XUH=0OB M@9;L0D&_4,RV.7F[9>HKMQW-R7]JD(@]"XQ/.GLG.=;^L']?0')+$]V0U M7,G0JS$QA:N,:BY'(4' %JJ:#"^O('-8'68JIBGT< MM_<$)]^Q/YYTR/7%Y0/-!K6&E3II>CMP3$Q1L'XO)%Z0VCAS@ -LPM$2VG;+ MT5=N,X+&]YU#,57P1H#D4LJ-K8@7B,:52)%B"('S1K+$<36PAI)B)!%M@;1Q[A= L R3TL"2YZ0/M MD:>/Z.1!EH,Y-_*Q1<_B]2H*T-!^;^T_R9S&\FMPSH:->%I"W6YY^LIMAV^" M,#R [:U(J.BU",&S%>AJ4JL+2,^H"+W2^LOQ9=R&6 MU&VIX[)=<&">7"?7[0P,$HCFYI)/&4/-NNRP!R,0/W1@'GN/.3#OB*?K97O+ M=X6O68R1=)$KUY1"<=@(D]BSDG62<\A%4."@I!Q"'+3T"P';4;82\NB#0R?? M:P5T+-;*87%&8G_0=05#RNB95L'.(B1B-*40>\HQ0\N5 MY8]+HFVMV,$=DK9'V_AU[?,JHJ80(W)+*#ZZD01Y%L#99$*G,2'Z; Z,=W\. MA[?3*S60&VU[C=Y+S%#8NHZ0M"@.V(T=*Z*D#L/.E'3U@M7N!9<408MR:JA; M<:LURBI""N='#I=PA'5.N37[^U*W=K M#\[&B]G=]7=%_41_=+I!Z9A M#I&T7=Z@-HBEUL;!2MJ"Y?=*\+J]6#:G$LG&(E%AB8X$NMH8-E9X58/QGD_F\&P:J<>D;K74GA?8U[2=>L6(X"] M$/SC\GTZ(!NTW2DYB U[DAM8)&BC1%U?6>J2#J'%',=^S^?PKF!OK ^8SE), M*('V?,N!$.X$/;1&XZI==S^5_E@&=9V2N2Z<>#TV,7RLH*N38V_OKI>)HI1) MX@@.)+:68Y9X7"*)7*O0GV^51W_Y]_XS7UU,SR87%__YZ5\69FYP<2>!]V#C M#EMRFPOK3 ^ZFI1L0/9=7[EL(0GCJ12)Z#?F K;EXOGMX[I7IL;K9KG<6P*) MA5#,HA8@5^!6.EE*PQ/0,^<7.FR74'$?(E?9ZU(:1LN"0H.N:^[4$MN4R4B, M[L4UC]$X!EA8)+T+,M?E;V*38[>NI1S1,K,05S09&4TD7KH.5G#?/JA; 0X %!@CP :H\,2V"/ "JLC*?7"H7"?Y(E-0G[[,- %W@Y O/0G,< M(A@C9OV6/A MYRQI(,$T(V_,WKEXV<>A')^1)H/"/CI>98=7578+S!)F<0#6Q9]3\-9]#1^U+O&9:$FQZ>UZ\&-8G^W.T/$<[= MN \&RJ=X@UV39W2K!ZA_Z/Z^LXT17# XH]WTT= PVWIA^I3, $"D)R;,]#P,Y08%5(!@9S!(][0[DVE5\=$1\PT*(& MN]8RYC)XD:!)C,P&Q% R!4*X85@%6)=?)0VW!EIC2N",X^P\(C.UGF%).:$9 M:,L3;]#PK29W.ET<"1'KC_BMVQ^@>P7?_6MWM0K@5J,_'?9"<)R!L9)$D)PG M;/@#WKCA68%W0AJN%9C9CZ+3K@L_&#&VL4WMLTFM7'1)FCH?"ESER&FVE K6 ML!#X(YGF.(GQ$ Y1[KP-&L.@,F"GV>PP@0S/I*?WSIC_] M@E\S&FYR"6;6:75^!PYOEPZ+&MQ@9=C/HW&-CM/IN/_QI@X3?1BA60A+&8\& M=14NEF)6DX>2RB+P'77 >H82B>-:N,?*7!R[#CZ>V#!MXI$6VF-(=[Q'4-^S M8HHEOFFA=O9 ?FP_[(0C5%HA<[3&IFP-^-TJT90%;[I/CS-+7ISZ&[/^CE$ M,K%2@<7LJ<:.NM8'*148AM2)G EI!,4>;UZ?]AD<2@)2! %( F=).&F,\#XK ML#/Q%LA1W71O)-O@%Q\=]/8^,-KS;-@RAEDS1_1W H92 B 3P1N+U&5B>S!H-BB!; M@1/+65#-'*X='.87I/W)X(^1'G5N!MB1@#\)7@M,_1,A)DJ:,^=:,8*._@0. MQ?T&Q^:"]<,H%]C+'AN,"JVPU3[%<8?/B9"\%.U/R@#2F:F8&'-12F&8X08K MVER.5%#>3,ALPP Z^@,X&/1;'SF+T3HMI37.NX2E+Y%0S'[FC3JGXR?[R:"^ M5903(9/-*4J:G-'$*Z=P@J=)233S0=JP.H_^! [%^$0F8ERVR1B&$[6\T-$$ MS;WR-JEFUL51D/WDS7RO%+?<^D ,@#TX5SF!GJ4LV02^5F[P_/.H?J0$/YAA M@].JN$C8X%5:AZ-C)7'*B>APTD7#L*%WDL./BN(G!.O$LR@]S8I(&97)@5A' MDHC!!-:\ZWZ5!#\4BP=CE+4Z>A6TY$8ZP;@(SG*>*-6J.3WR;G+JT5#\E"SV MD#.Q,5-J698Y&VLX-@EA-B:N73.=ZE@)?C*88HC3&*@W5 2I"?49C!4JI+$V M>R-R;H8J&Z.&6Q6##]J7:UMY#08)6 + M69D=Q1[E+@FGK?)!N8P3FFVSH2*W3&U(?3X!JA[LBEA0'S-X!YKA%,QL=$Y9 M"XGEN8[$9D'USE?$K=%S6\8'8Y)@>R-*I9$L!X.5$M('SR/%:&,C U:R39G" M!]O(:8@;P+"-Q%&E Y-:8U(C-Y%IM+K!TVDFQ0M]IUW%J5#U4.)& _CD'"PW M(JWD0CJG#-Y.6,L33\W.]+O?1[=#SP<2S5C@SFGF131>XGQDJC(/":!8!@MF M4@LQS3;W<1K2)HGWV3&C.2?2>&(R=Z#F3#8$S'K9R.M\2:)NQ6(1?;0F).$) M.(C9.WB33AK8(XTW MYO'HROT4WO]2=0?]_ZW._P9Z 1/ ?QK_T/_GS7QZT9/QS8 9:$ 27<2BNG\@!J&V55S-PZ&<%&#LP%'3F8F\&Z!.[44R_8RFD\23,X@"GP9R,+ MU$H3J0.5&@5VL1+$:_?4[(HC/8TG WSR";-/F/01; C@54Y=C-J'R#.SS2H8 M;H7^D<""2FD-#GOFT=%F.Y0=96]P?K0!D![R>9NCLH=I&G M(H-UQ55L9GLI2?3C+=6VMW$:@F:D3 2<;2\5L 2 5TQ 30<.I;?@D3>B4KNY ME,=#TX-%@*.BRAN0+U0*W#FF"0Y6DKKN;]*HR=LE';<]:C[49%11%T"P-/<< MVYP;[NIZ]"PH(UPT4F]V2LPX=AA6(%% 5I T:G/"L2*.B:1HI TQ>PE";ATD)WC"#K&,""93)E91 M:A%8K0[:IN8XCIV"+FUOXS1$S 6A2?8^)(W]@KB)(5N1'&*6R^Z9@:SCH>G! MDNN-9][C)!&M9<["$&X#MA-B'"PQ]=1V$[L2\F$W<-ZOX:>+E6FL3[Z-P+XB M@D:? L7;K;JCI?4T,".,;$;K'KGI9VWBY2BU=9:3BD;R($#@N#0V6QN%RR)& M;Y(Q39?B%5/JH;XM(M/$K;5X%P&@8TG0B3F-!'2JF83SNBFUO6,K^*DY$&FP MHDU*$YRT68JH21",-M3B,5'J26@#3H$@DB9P;&40PFL%_)&2CT'(]5;&.^>X MM[/TTU#]FH._DI6#?QQ.C;).2$W!X([*$?WDK/67)N&A-'UT6GJ?@^1$22^R M4\DK&[![KS%,O30;;D4,FBVXU*NHM2^![B*05 MCU)N /(#LN$#UHDGX#F'C.$^)D'1&HM(JNNL$J?"4\W\=E9]&L+#LL!XNK!* M*(T)M,(J"H8H#MW3*5"L3!+4D/34,]4@2_FTXGE^ _L=H@!M; -Q/ MPY7>A2UV9*:91T[ 3A!,2Y5#;5OI8(4C@=%FU.VQMTC/W?+T GG$V'//%O?0A@8\H0&4[L#A<#KKA(!NR@R\+?\ \"@Z[J,&"HQ'2J.R8 MPQE(5@ ,9M6<$&CX!M]H7PO?1G&<&" !:P1670)W@V-,.>.1<)R[9AHWNU*; M#1D4.ZU\C/@S?BR3WXY,& TGH\$\;><]:/MUW?Y7T.KC?G?P2P4?U.O7ZAD? M>B@FX/"6+;'(P#.T$I.7B#(6W!K07IYMX+B-N]^\IV?N_N][WST7>"$F3,H> M3C\J"ZI:2 Q;8-DS=PM@.,-'LE>]F\.4M70\NF1)I#BGA[D8R(:L8\/%9EWQ, 5^ M[GZI@ZDCL%?JP33P K?5/Z^18S1]SX XBN+!A8/"H7DY5PG@YL<,9E)C& M,<4:9\J,4F*O&\=\L@43;#79M(Y6*1FTP$^ M!*BUI\-H,G7#<_A=-?ZMJI&J&IY?_W>ZNAZ,OE35K]5O MLW%1W>%YO2I?#:L+W%3MG./;)W26 M ^NX$ BP-AA)/F$PY*IIQ'G_S4+FZD1W-Y'Y[4O/G6"_NW7/\/;Q_W>SY?= M\56W5]U,^ST@X-I;4#P?'-T+KFWD1DG!9701?2G0LRYKPMV&?%+&)+V7DP]/ MX<5S-4$W<-8>>1,I))3E8)0HJ60RG( 3EQ6UWN:4F^-=K#@BUFR#<&WQH%<8 M=M"9I0#F/:8LNCK<"KZ]\]EM:!!F)7TA4K;".DKX2(,36G-@'QH]#X3*3+DD MH$A$ ]88X>:EA&X_1ZY82K A,/O FO7=J[KG0_NWW@ MU R/$NQ_:3AX!=1JX^!E(ISZE'SP#:-2$K/1&VIEMQ]&KO?/F_ZX NOTNAI/ MOR .H!+!VYOKJT:<]C%"E%2RV!,JT2S!:G8Z"9I- .P';\@T9!Y;ZV_>X,.+ M:VM+#Z4Y*6MH J]5D"0]=BH.7F9KE<"$,-UL$P.:;J,CM^N6QM5UMW\^]^#= MW*"$T)T-#8DS#BS%%"!N49 71+TPE]@!V5H\*T!K;.)5KBD)7@=3@2; M%7C3I#OX\'MU?G]1EU!_AA@]$$]C'Q7]:^]#;%:/,7WEK&/X"B[?Y'U1U,+WN@9.MW M_]"_ZL-I;SA#N7J&6GJ"T]31"P^2>P_&IE$IIZ ==8UF,%:@5EP_PPSP-OJX)MX0)U'D8S$.^^<8=6! M6?!*T:OQC'5B M.CA(>Q@-!E7=G."GB_IMOU2]JO_;DZ@=)<"H].";:\LW^"_+'_^C M#ZI[W+O\\@-87X,U:V/YS/OA]\M M^!I4!Z; .G,9L-YZ$,88G #3H'E#^]IHSU^0]L)$GC.CD2A1YSMID26A/C'/ M20K;JNQ:I_V/U8Z!%*69T318;7T$VS!8[(,>C59499LW1(08M[H!B_&)LD(,,\#)B0ZYWRFRM/LP'\RHMDIMMFYKE5JGM Q'6PZ M5X;3$0Q;.P 4Q> E2C&HY>BL3LT\C]=Q-"=3M0&N+G,\V\# X(_@H5 ;51(& MW# -GGLC@>QU2=!)U--QSC7Q7DFPG*1/PBIGN',A."V#-=N*TD[U:$ZIX$T9 MKD3R@65O)2,,42VEF%RV.LKF;+9R/(>;*68SI\QDQ8V4.M3MG",W8%5:+/'< MUI;CA(_F9'1/<-@95!-PR9T,40"\22I3\@PG>.I7"FPGH7.L8TDXL-%,3)(: M"E9;B#$*+9FC633"LZ=R-*^C(VQ*P9&8#>6R%AD?D_!9<)4#4=PW*O;V9+1M MJJ(\[D,ZE/@D%;U105HCG63"&2/P9@_<'Z644-MJH4_V8$Y'[4AO6 33+!(E M208M1"+>S3C-N37--BFO27I.0OD$J1D&B0VC48+5YJUGGD:,'ZL =MNKDYY3 M8LU:;0*0 8\ 98I2$LTI$,9TPU%D.YX6D!@NRO75!>8GM][7S0@K*I'3$ M<3BUUW@P)Z-SI$T!3&D;>5)26VJ(B,KS &Z.4S2\/H/@5!P=;/+%C28Q^2A% M\%Y3K+34PHC$(]V6YW_0@QGU^FMO/'D?QA"=&,/B91YE#,%1X:/57&%D[;BSL&N?1+T9'";T)0(U\XE MXB7':4Q4I\P,MD&QQC5R=$Z6J(?B4D,C80DX-7 G<^ ^4 L<:Y,)*EH6CX:@ MIV23!T:(Q4D*27LI)+<$RR+3K(:&[QZM.UJB'LPJ,%('R:*F 0QHAJD%B6(Y MC%0*0."HN/1DL#0F!7Z(3$J##9R$!/>>9XNY8> Z,KFMC\5I$?507*IBB,1R M#[XW!\94CM*<=').9\%\;E_C7R\K6V/U)9IB(R;:*2TDBO>?*,:1DU M"X0T&\W9.[UJ[JY@M]4]D(X+[C)EU&@N-94!V-(&E@/FSA$J]:;1=8P^:76S M9GFCX:;!:VS2'+3OW85O6<_S%KY5ZK(W$;8"2@U M> 5(;NXR^=X6OG4KA70V:,UX%IQ@\8K1/B?)@>K.*^)HLQB2LYK) M[ZQ\ZX*>M_B[.;BKBQ>&YAB,,QKXA3)G5,99I%$![VON&Z%I3MG=JJ*G+_Y) M->,F@N,CDF4!5DK!K[1@#QFE@HU.Z= $%4:$;+!X=94\GY/K>_.=?JBLPJ. 1NCV! M?\>^4M?=\7S.[A36A16M[;;LT@_TMGG_8UZO8*(2]$<600+5F:=2)LV)28)H MJK:'\GX M])\N?A[-*N0G:="_Z@_QL0V%XQ0HP%2[[$K6*CFC,EID'[@'$R,:"0J;"*&# MYRRL57)>SQ?\S9_L;N3:LN-[:1 MR3>=7-.37912+_9T^TE^# NJSN_TIGJ@_)XZ;W4]V!6<*)Z)-3$*8YRFU"9. MM^?X-X_LV4?ZJ#,!A[T:X-E68&%=CV%G]<$.-%Z+H$]WM:-][O'TFB/9<"]L%EDM[!'CG)PJ>LA94-@YW2?6VWM;;9 M[5H&:]0B)F@"_KNQWDN3O+4^1,Q&8=ZA$]$,^!T!M8K"?UCA<^DRC=H93AA. M2/,6S&MJP306&--M-FZ5QR '.YWL4=&;:8.]@3BC7DN7LK-4924,_%IXIAH7 M?.KD!&E?Y-ZLYAX@MZ.1,1H=N-M*9N4,<81S&115#-1;0ZMQ?@ARGY95*W$" M9>9>,1$2CG-E3H%EP'#TKP[-&.@>K=IG]!L_;JL6<$#[Z 27ECD9K>$UC3D8 M(C[FU!SXN3^K=F<:XPWI<#H:?_FO<7]:_71Q\9!0$B?0XL(8+Y,D1(^S.T@F M5+*4!&O,>M M/EEZB-$V:K"/3'9@U..5:P83R0<;J;:YT261[@REFZL"@3,(Z;'XNI.>9 MX&?^>HTNP&#Z!7N[J?B4#_^GZM4)?P\1'*P33SEC5K(LHV0. ML,&"G0\'D<$1;;"]V)C'\#52_$F8#&"B &E8!%]"2N6<=\8SQKU1@K/8'!!) MC@&4CX+>=:KJL#MK KX;U;5AC$5K6?)6&JX 52)E5FNGN#.IV7!Y;T;BZ499 MDN8\.Q4ME59RSZW)@EDFN11$D&:B.C^,@GP<$;%!_A%XP)1(R8VP4ADIK06; M/1,&4*M48%'+1A2%J:,AX;$F,#F2DA=,!29N*DUV/V?ZZ$C:%@2$X*VS"C>X]%&(LHS9Y+A710"3BB&4Y)DTBPWF:#-EA@.H=L81]A[CNA!TY=] (NG]IZM&BWU3AK! K5@+_#$ M4B"!$$J9YI(TRND?2# Y:BJW8[3M1%XFK>35DK4_-^Q$1O!4Q MUUG:$ '\C/,RIV2!!9D@P24P[,D&/^:AM,:GT67.-1N[ AQ#>/*);K4@.06P MCSS%OF-4.:T3(1*LT0C^XP,S3YKD.5GRM>5[JN "Q:'M06F9 3V]L%9E%S(G M7&SHBL.LWA+1.@A97S#^IU,0SD@C,?L;F \<3YLH,A7L^)$:;HZ>9D&8?,/*, M)B#'H-P8S@8&?58/3>7&!*68,HX$EAFGC3@ 5W6.[BLE8FNHXT)4)FIJDI4Y M*A>\ST9S%U,@SC0KQ0GCZH7)^H(J3J4H*&=&XE LKT').8 S'()A Y>^D9$@ MR&L@5EO,!J8I$RKZ&(%Z,5F;;9T[+B*G.J3M_5OW2KA6F(,92CB.Z20A2!T, M=OT.G$6O,9FR.2%9$-EH17BX3;:FW8CGVO'D@E0R@_FG)4^,8VLWY;)K.!WM M(,@]J9Z/ZA^Y%HUSX)%ZID24CN.ZC5)@;X&];XE238/D@7K8[:MK=P4 0"+C>"#(EN#:0?:U(;NC>OI)T;!1D2BP4E# MHR74:X<-CIA.UC?X[(&\D"7EWNWMDZ,:;<_K,Y3=XP]TB8K_94C6#.]_HZM%A.A"70H MX4J!0T"M,6 B [<:X%^?22,N^=80J["5^OHV'EK4<[>PK0VCY1'@S@C'0:UY M1HQ3U,+_9VJ$Y;F1"?K6&,XQZG7P+2QY\?9P)WDT_K'Z#!\PNAEBU<+/X]$0 M?NQ5MU?/RW]AT'_CH^GHP[V8]:U\= M9BOM_U:EBXNJ-_TP[@YG[>/6OBSVX:^UO>RKZ>>J&OX"]O/PIOKS3?^\"[]] M/YR]?3:3$D. %]-J_&%TW>\IHAZ<'^&<-SP'0'\)_H.1-GMCE0>[CE'?[.W% MR-U\R$,>US-)&;J#WNS;_C8\1R-P"R$?24 C0TK83(XQ*:URE@DJE764Y42\ M:F@8Y'G#&LUT=R-BO>Q[,PCN[R!.P&:7DC'AG&3>6J:EUB(D$D1,HB&?VBC3 M2'^=??'?0OUNATG()VQK>YBRY2X)E MIX#S'?8PM=Z!6<"3S+F!MTQR?C<6L1=:I/&T>PT&Z14 TFP[SCLH;OA@0.4FZZK:LFCEL)3K27- MV$4LB\RY$CC],36J'_%*JY&*M1=2_73='79?ECC&47#Y>/ "QQ0$9AEX?5$( M"VZMI,WD:"JTO.L%[8,@%H\N4PU:*[%9T%RHJ"(5F!=A3?,:2A#%[UJ7>R36/5![$-1. M >](+&<&? B!@S8=$0&K5L'$D\W<,&+87==A+Y3Y.?T2?@KIP\LRCE8^",*# M"-S(S*E/TG-!,SI;6;F&4N.4BX.0Y]>__?SS+^F']S_^X%Z60AE\22"$MX%; MF9(S8,I&S3+XT$"B9OB;@6C=O578"X4^C*;=P9'AD%,LJYSJBTH9E'8D<^)R M3"$)93>TEZ1<-R9_[(5:_]F=C";U((/#88\G+J644[8Q2B6R(39DF84&<]KP MT#2'B-2-:HW]4&,TF';!L_AS-7AAQ04FH]"&.66-)#HZ%H5R.AHE(S5-SXM: M2NZ6>>R%0O]_OWLQJ'Y_8>RQ)$K-B#!@"P9JG'"$6 MS'XN\0I!VDAR\WZ?U)GLA]S:HPM'UGP:SI**!&>469FI,X;1H$TB.&7+-WN% M,BMTF_9#^WU.UHPC&QQ7,H-!R*4DQF"B'/PB96I8DDWQ4X(_TYO=.N=.>@W@ M1Q,-1'HKK%$01$7DG@NO8;'Q GQM9>!QYCB=2Q348A4G!OP _$6]?P(42D5N=/6TFERDN MU$&LPV.,5(&3&2BUH9X*S*@R61D+QGVD*BI/&X79G&&Y]B&H]1*1*D(2XF^F M,EM)DO%@\BA@'BUQP*EJ9D[#GY_KQSV2&D<3J:+!YP#8PW"4*B' ,"Y@OPT< M*;UA&K/D2AS$+CJ*2)6BQHJ@54@1NXI''QEE2:N8%!B-I#G0 F3NN==U?W^Y M4)5W'MPJ,&8RP0G1SD4#WE44AF!SOV89G6:6-NI4#K/=7:$ 3DV#PDC VTY& MX[VA-AG'::(&$]<:?"X%5\\,5>VXM2>%JB0 N]016ZS"OACUA@L.;G& [0&3 M-CF4,2U-BQ&#/<>JP*X&7:8C2T8&9WP,SDD;*?49F+)A'H&\@OI[QNX>& 'O M:*#.1LS=]])J[3W1.& TAVPLX\W.X^ LJ>?@Y9W^ U][_J)3C&H7B(Z$R(1S MAL!B-H22H)@TO!$L?,OHLP+.=\A_?/F(PF=01-@=-&KTL:SGULJH1 ;[3],F M9 LM]7,N4\P1Y_@!=UCG;<9N.3)E@(O,L$TC88X2+YISTF1MR^R?%B\!#+%G74:85.F9%91+# *:@M M9"YLF0HLQG-*X(,V##S!I6[1GCKBR"GW7EFB'+CG2H*46>*E,%F"L\Y52LU: M-B[E\RW?DPF)@\P$^&^.(,2+*I"B7K)G%0 0YB-8_QL IUK 9H0(0+,M$L\LV$9&42LPD MWTRHI:#Y#F,CO43@5#%FE.?9!9:EB\YQ PYX( S<71K(AK'RC//GQ+T>3XUC M"9P:+W1*QG-*M8S (8Y1$+?H N@GMR'%3Q+YG"N_1U/H. *GR1*>C5'6!LER MM 1T$PB8<2J$U,P15>"&/"),">V"-( 7CD2=5 J8SBCCAG99 MI#D3Y3#;W=FE%LJ&Z)+7 F?6M/BIL&[2*. M@TTT!BFC\UPZ)I2!+;(DF^77Z!*K%LVK_89-LP64II$"B#L)OKYA @MY#0[G MXHQON/ABXIG@M#7%3RF5K?$>>_*!7K%X21D$H8H(SD-C.0S^ $[4LQ=4PJ:+ M V Q10[>IPU:J*IIU%&L!.PIQ6/4AOI M$55HMLP:A@D[S1QN9E6+$'/<<5.PH&02CC)E)77**(< M9=S4QYP)X@Q TMJ:):2$,M_?8J9 -6UM)>MH6)P6AW7E(M- 4GAG&+D2@0 M&50,SL5&F%@HH^Z,'3G<7AY(%(83"8:YA.U0)G M[>7VLNU<+#@ 3MMH+)526VD%%=E[FJB"TV(-DT9HH^CSS^4W>'38J^KY /=V M&;Y_>F)P0'T? 4^IU%XXG)N((3SBF(ZQ 5*TT=_ZS@IV7=RVEL[ M5HZJ:7F M68*EZ&SR5G FN''9-1L8B[JHI*W%;6#=M8EITDI*O([P#Z@MX3E-@BC0RS9C M ^H-[G.K:]M&N C&LM4E2!+ V4E)0Y!@Y["4A-H R7>[4V]>R!.7NDVR,WPU MJ+4L@0$E%<* "I=">N-Q^)-O9M^1N\6Y>UWJ6K]ZZ9C2@>M 0=LF@'X:<0Z* M,CK%O&D 14-D6EOJ P($KK E(J!J=C)$ZJESV)/!*; %?6A4K-+&J+=6E[J5 M = M#:"DX/@!B#C&6E7()EC%HVRVHQ0]"?]:35W M+&?7G/>"W.T],[[YPY?K%4_TA]'P$UBP5Z$[N7P/8#5$+;DP7&^S;)PEQB3% M1>+!92, %&G0/"GB693DFS_]S/[._TI-?(@(S]SB4=+PQ]'P/ZO)M#JOF_WW M>U-TX4:]?S3(:&G4.(U19& L;!'BB/&9!V)I4D+FFHQ?-05KNOUTC:@_ZKZG^ZA'\=6E^?JC_#1T\CN/&YVQ_C9/4'QOELH##LXV($?CT0MV;/ MOP'ZWQL)_Q5.H O[7LLL6?P29Y)L" JL3;45,FD VT0-V.XI6!Y5M#GR9(/6 MZ8Y-!TNKZ;5VEWL,1&[ET'^\05+]=.'.S_NS $O]W,3=3"]'X_[_5N>/L9C> M_YA7PQ@J)ZJM<6#=2\6=]Q9SCTW6)F/CBA7Z3NHOP\YG]7_OVB#QPUM:HQRR MV^5H<%Z-)XO#Z0UNSE&X1N/Z*Z>@<#[>U%'"#R,X'R3(>%3[P'5H"HYKMW$Q M.0'?@>-:QQ' ,O?$*TUC8CR3#+9NP_HQHA'G:679AR#$MJ$S7 !.1LX45\ I M6F%:A;1*4O"@+54-O_XM6(KB3F',L5)BEJ98G?ON &&-[L8B)A$=@2N(RQ14 MK[$!\ F<(ZE-9$YN8!%M[_0XV\\VMA.J1K.='1?"J921QIP]D2%1)R)XKEE& MBWEKI'%+\E8]M--Z':M+O8.F"XR(_<$-FD0U0/QT,YU@;BCL?N?0;334R^S! M[ON0&'PCRII2MT^C=NR@S3Y[[I)0&8YA@KSRV<8/B M;B;I"V]PVPD&"[:H(-EK#JY1 'X%;$E"<\D4MH39?()W1PVTO\'&>T"C]WN[ M7YXH;8R5SG#M)'89PV'%F1"*Q:?"Y6=)X.8UMKNYK=+'LV;.YB!UED8$0Y*S MD02'?>;46A/CW:5O[YM[0/)BT%$ .\H8.&!HL#@7A !NE]YQ,^C M0;_WY0-LQ@] ?]Z_L]L0E767$3AZW]=_FX Y_ATEU]/O MO_GW3]/O[[P=[)#J[66]]>\H(__V_77W''?Y=CJZ_LY<_W[O9^#O-ZVA/P2S MH#^]^[[ZY>?9]WP$,V+V03/J=6[)UUFG'W[1'_"MBV_] RS]I7=1/_Y=?]J% ML]VZK\&7SOO)Y ;\NWLWV/EQ-.W\O0(2G(^N@?DZW4EG=-%I['M/Z_RU@B]% M/O_W[M7U]_]"%?F>D[,.,F9KI$>&?PMK^#3\;E!=3&>O^\-SV/YW7+5W-O7[ MW@\[N?HXQB&IN MUU@$KM9/[0S"L^]W!ZD$L:Y0Z?@3_=-YD]ZO_MM.?G]BO M?X.S>5=_R%O"SO9P)+.-UH0WC)'O?ZC S9YTWM1%.1TCV+?+/]+OG_OU]9=U MWN"VYEOZMC,==?K#WAB_MC/%8J)K3'?K?>D 80"JKN!E]V-_ +9^IWLU I*- MQI^ZP_[_UE&"2>?CE\ZXZHT^P6^0GH/Z<[J3205LC9\P^\6@/_N,/FQM-*R/ MX^/,S^E,+BO@?'STO#_I#483_)A_5%]@576DJK[VZ'XIWF)TQD\#:N [X/MP!+!6QG#B<)N%\N%9=Y9W9>SSN?+?N\2 M'KD&N*]%$S\7%X8, ^\??00>GJT)/NJJ^X^JS^(D MD[-Z9UT@Y!@^\7HTLRC'*"AO1Q=O;Q;$VDP5($#G:C29[;R"O0)G_^5F4'.U MF7,U\.L&=C5O*3D$NX;1>?]B7J#6>7]U/1[]-L&ROC=K]= MG!XNHG\.)S\$1AE]!K8%);U<5&_0'?5[V*%2+3)9$! MW\)!3Q3[V\5>WK+2LZWLSW#"A8%MPNRC:ZK>L,+ M6("O7AE["Z;P;!QPO+/3!IW&U@ 7\ M*T+R]',U^ U)-YQ>@L"-:[S&3T<>^+U>\7GG8CRZ:N+B^@'V9[F/_>%-?1RC M3O5;=W #]*G?"-S9[4T7&X)G5Y7$[% NN[ .Y-QI_4D3,-?/:_)>+"V&R>)* M9+*Z;7S#7&F!!D!XGN)JD!2]FO<75+P>@\<"QLA\,3?7J-+.9T>P9'Q\<,X? M^/LS7%)W5?=\!.T'WS_'IOGV%]).]?>3I0X"M0W4GQ'\IE:/P]&PASL>8 @2 MV0I3R!;Z>H(&9ZV3\,-OUA7XK<9;JNXU(JV=S&3.>W-FG]P,:N;L=B9@^=6* M8CB]-3=JP+VU%)HVPJ8];OURT(^@N=%DJ4F[0) EK6O:K%\?;550'#-^/^\ D^$B%D]N6NI@OLL5.P;>.&?/Q1MW9-#YBJK)W#ZK MX\B3=Z_"4'_(I#F,!0YNVP#8\M:L@<,/<_O@0_?WSJQT?C+#IE4TGL7DD1'& MU64UG* *>#\$6:Q:4<.K>OU6)8,)_ZZS\JK3'0Q&GR1[5:#U_'/W8W:"+\6LQ/Q=3_SA2H5G6$>'CG#;>F2!<;2G0BN/JU9J5R MYCC7'SFY'-T,SA';:SL$R=>OR3TW*V8?ASN^!:CQN@T!-@QJ-#0BYD_#>V<6 M&'["W'"8JX3>);I%BT__V[M?WW4NJG/,'4;_XWHT1J4X/UP\F_GKV6$ M9%0 M2PL%S(@TLZ$6:X._WF-#(7#>@(-31SLVXQM:+BM'\EB G['-9&:Q5..Y'D+B MWBKGZ]&L <;I@N!C?3IB7]2GVZ/[1NR:J-O:M9[,.7IFGH/&'?>KZ9>:V]$+ M6G7GSF8>-C!:!3[?>()LCYAGL?:BOR"I:,N[JSV$^S2@(4TC4\O+X!(Z_7^3BO#.J@I5/;88 R8RN&W>Z!C6V0,T:U+B;3^!C/BJ Q %L;E%A3[@3E\S;R>/N5?5Y-/[' M\HS8]^$6 '"Q*T__,C,#9E* ?(KY6IU95MQ?P?"^F?UMCZ87Y:N81?DB#' ; M-)PO=;RZ5#3"<*6_U2N]NEUIC5E[HO(\:L3(V3[)M$Z-AM5U 10!&?H"-N1C M8&3]\8= Q-Y"]4H0;W4]\U- I%A&:*;@B-9^,[RZ?V9 M1K#.+7BUBO1? P+)0R!0@-6 13Q>H_2*98"L^WX]QEE70:%OAR=[/HMPA,'H MYKP^M9OZ;2L)E, 0X-R_QP#] MKFE27^+CVZMWVUW8+$CJ]3^2Y[\UW.0K+/_6+0 >=@5 U& MUVCUC#[6PMZ?U2P/ZJN4R>AB^AD-G3>W0;H-*P6@ 6*B];5\ W!#7>4)RS_' M4&7];=7O_% M([>)NHB7R_N*VO?#U/[2,&UW4SCM(^0" ZWP19H/W-U95+P/VN$SB MQ=#NZH[K=\+G32]OK]%6@*A>V/)[4;LUS=3.W2@$K&Y.*H#V7G=RV;FHHQ;X M6?.8WMH5PD;2+;4%''P/3+9U()7KY[95&SVL77;45^O?C<'S9A#@KI^/=OA= MQQ].XP&AF*VW-CC0FU^-)=3!QGWI*?D\N_IL@U&]>@E\VBKN1W0TD7T>H^3, M093G&B==-RM.T-VYIU3%[>U9!:[FKU21.WS.M%\.V-"=.+N\^"H65Q@ M?0>P_NW"X9_M!!3.(@I8YR[,MH3R/-M3;S08=#^.9O7R:W!ZW1U/^[T^L"ZP MYDJ@KK>X;:E=7P2ANBL%:HS%Y<:H;^\-T'.JX6TSD:K?YI]8TWT M-WW8X#4&;6>Z:W8%46HC-[F\>W/]BT]5#5CUE\WI\6[]@%X,7,WB[&Y#&RM(NR&4NHJ4_5F/W;5;8OCU MDO4[;_[2'=:7$W0>U;US)?WM?C'6G!+&ODARW9:($-?D+=6V. &35S"QRI-[G-,_AN M*XO4146@!0>#.4/\\1OR3?UZ HBR>/V(/.'.?__ ?5KYXPQ* :G7>RISG00P>7,DV M<;JS^X5TH;WXG4#Y>I:P+/E.-?EN]337:77O3A\F^K:MWC6'VT2%%<&7;Q$9 M]F_;/DKP%YESH-:__0Y,D(MJC$(W=[AO]0)6_IZUCQ)S6.ROAK_D$B_.Z^74 M&4.K-TH+.V4%8A P1L.J-H3.9LY\;=>M/5+U &_N6&1I>#Y:O(MRMSV>LADTX_FXA4A_D,-506W"FX=-VZIM\0=(_G]O]G3>_+.5Y\15_'F,BS_P]/U;3;]OWZF\1[J_=,< 2 M$O+;/1'Q^:=3?\P,?&XN(@"=-&MO[Y["%T\A(*(!1%?+R(> MIIKD"8CX?B4M=Z6Y3>>GE;1EM'5^J"]XX*F]VG8 #8/7@'RKR<[7*U0=W:%J M=_V:% W* 58)U/D_8PQ%3;\L[M8FW^-;"DH6E'R]*'F@!/5=4;(=H-O3SGZL MJ_3>_EI?X:Z5$"+"_+PL3TK+\J36(?Q.39]ZRPZB[CY4O=17U2M=1@9FA=98Y+JX;KFM%9Q'/Q=7=8NZS-L\K>7^ MMM]'/$8_'.V]\(1LE$'4 $_^5V/?NXF$!:8) 1*;E,65KF=J^5PJ]=<\^KRE P 8:N^D#(SJ<1 MQ@6QNF>6VS7!V\SZ+OKV0'I+Y8,WS4/L%W"SR N#@QO4TKXH(+R-5\ [9SBQ M7-JL@G)1#(J_'Y-](/% MQU<5T&>>QE 78]8'_':&.M-%7ZM:E%=K6J]64*8^+/C4T=GL##]7\^P!+!<; MU(7GR\_HS$M=[V8AK?9GV+K2L^4E]FWP><.^N^-E2@1\T*RX=4ZF10[OC,.N M9E6@O]75MYA;-2N?6GS)O-"SFC/9YH^46'.+=\BS:_@5;V>RA.71N _+K7$< M&716D%67P=TLB[8P96%2E^/5%;%+\F":Z&+MJX6H*)?C^KZP,ZRFV/%H5C#; MPHUUS6O_RM_1#CPU0.!I!6TP1P^98$-)(##&G4,\NVVPL6#BVV+XE4R(NT1Z MP#C8+.7;7,#[Y'=GD-C_';O>>L>N\=YG_WIKK17]VT[=#K*S^LN]7:_KM0JQ M>KO+-A_+P,6L2\P\MK%>.(+9M;66Z&$+ENDBRZS;J7N!O9V)^;QI2Z>+W6V7 M-0#8W !5T)?;]-M5D%Q!A44# R#S I@4<6>W\#2/H[ 6'I#O^T :X&"Q$^K M4]YJYZ::)7^Q;^ODSF7CG4'U.SY7J^0[@9;'[>[>O4W6*7GX^EB]GABUT'>+ M3B$+=-VH (:SYU:ZNM3+@$WYM,N\SF MPD]\'.[\GS_LW@MNV4'NU]XE,,J@^NFB3E9Z/P0*?.J#6^/JS.T/=>?8'3K( MY>@$U]G)0*,D2=H8LDF61:54--(2H 0']$.&[^M4VRO)]5WBQ\:OL'FZ/$R M4,G$6@1S]^CO;$V,_]NN\>>U]]-GOIV\[->7S9?-E\V7S;_6S>]V P@^Q71T MM7YSQT"%KNK4U=>SY]=^-5-Z[#&WFBN*_J[N6UL!57OU[IZZ\Z/S+;)C*/DY@.]4;-IEY&DG- MO12=3Z&8ETDLW3<^\\+T#E0^,M[%>ENL-?WNLG\.[-FJ&W);W%&XL!4N=+W9 MR#(,:!26*RQW )9[ORRF+QQ7..X0'#=K&_F&-E,&"[\5?FN?W]*R9V2HBY%[ M7SH?\!Y_,+O!*4Q8F/#0_L4CXN4/IX$]WF/^V.W]X]-X=#,\Q\#N:/S=O_1Z M575Q\76YTO,+9KRF'_:GU;Q3T.U=R9Y\Z?W2?BY*]75"0XX>DH"C0Y!3X>*C M(UQAQ\*.1T2XPHZ%'8^(<(4="SL>$>$*.Q9V/"+"%79LG:K/O]>F+^*-M^MI MOUU,D\+4][I'1MV,;];2>&,3]J=*]Q[B2<="QG\]-)':ITG-FZT2A0M]Q@@Y M%&F.A1?P?1_'G=X I.F/WPQ'P^J;/RRW6V+8^[]J\5V"R MP.2)L&J!R5.]_WR0H#O=2)P$L[9V75$ M !H ="C ] #7]T6!"T(6A#TQ7FR M(&CQU(NG7F"RP&2!R==X87[:;/=<+N-"3%RVYN_<\CH60[06YGA'$.IHXE9#Z3!"V=YH%+PI>%/PIN!-P9N"-P5O"MX4 MO"EX<^S<5O"FQ(I?,B_Q]*^M/HR[@%W=JYU:]2R7R_9P2[K#R-/V14B! -FV M!.A8SGC?.KFHWEW9A?0G)*?4Z#.M1%NR M^F32'0L?[EOME:NN(J O?-M<1+2(:!'1UNCXAC)[IK1ZJD49UKR%Q?>8Y'#HER+>!Z1>+[19T+H%Y?.HEJ+[!;9W3FXQ(@\X[8$ MEXXGMY&1$PX4SU[BXQL&%MXWK+#E('+[Z=BGT"RTM93L%R+(/L!-27HFM6P9 MW(Z;#_;M'11#H@!, 9@]1_Z/FQ,*Q!2(*1!SDC<73XJ2G 3OO*B'4-#G%7!0 M09_#W+P<-Q<4XZ; 2X&7$[PY*J9-P9Z"/05['AT<5A9OOXIQLX-QL\?ZB!$;">EIU7<++@Y$G>"Q:D+$A9D+(@Y6M!RC>,ZC.YK\*L MIY"T1 \+B!80+2!Z2B!*R9G:5P5.P=""H05#CY(I"X8>ZU5T@= "H05"3X I M"X2V>3ND%3^CK=^HEYCGWBI-7P(C+^M2S^]DRS?KSZL(YWOH[OD V4Z,5(6K M"E<5KBI<=0JD*EQ5N*IP5>&J4R!5X:K"52V3ZD0S=7-H%OW(;H: 97^MSOMCX;?[8-''VJ4=1@>7CF#'E"Y&J]0RCR-P.9> M^OKNH#OL59WN!#L[Q:I777VLQAU.SSJ,T-;KP+[B,'#APONYT*U(=F&YPG(' M8+GW5]?=_O@*OJ>U2I_"<87CMG#<3W6%V1M:*H<+OQV"W]+%1=6;HED7;L;C M:MC[TODP[@XG@Z)F"Q.^C'_Q:W4]G3L8I'8PS%[]YR/*2GGI(N=\3YO?_?C1 M!Z3[*0#$T1#K]2)KX;C"<87C"L<5CBL<5SBN<%SAN&,B7.&XIQ#N^7?&+S/? M_-"^[0_]7C6QZRF\=BP)[(=L*G@T50YON"9GC-&V]_YUCZTK>JO Q.N" M"4;/F&(%)0I*%)0H*'&X1G''"=/:$+:O(Y2PQQR^K^.BX\.X"Y_/N8LW$><8Y&E?=O/1<2*B!41*R)61*R( M6!&Q(F)%Q(J(%1$K(E;B(,<>O?P*@Y2Q^JT:C*ZK\\ZTZET.@5,^?=F+F.ZA MF/YEI96=<2+.A&HMC_FQ)'K=@EMN)XO0W2]T0A)0DJ2(7!&Y(G(GZ_@]0*-C M$:!]^W]%KKYBN=KGQ,DB4D6DOD*1XF>LO1[(1:**1'WU$O6&G6E!SJP]F%A] M'1Y7Z8_XS-3*T;0[Z(SJ%KTK[1'WPZ1ES.>G,N:S9515AIX1NZ?0<9F6W&KX MZXAP]^A,HP*C!49?[C) TS/57H>0 J(%1 N(G@!3%A ]H>N=,G2^(&5!RH*4 M)X^4^[RP*R!90+* 9 ')DP?)/5[!%HPL&%DPLF#DR6/D&WY&N3DSIKU:GQ*Y M?,E*H:_BROW':GIB%^['PHF'P\[]$:5]%!1GG.HS9<3!J',L_+!ONZ^8=X^? M8+0'6IT"?0K_%/XI_%/XI_#/<=*G\$_AG],*;QV+<5V<7$&:.J.%L[ M.ELKT:$_3+NPPXW/K_R\LJ]!?UB]O:QJ2*&$_-OW]V_4/&V?R[?]]_*_K1NK M=]#I58/!G%O_^ WYIGX-Q]-;O-[PU1_Z5]6D\V/UN?/+Z*H[_+YS'ZTWA= ^ M]\^GE]^)1TG$.@\^_N'=HG@@L[LPZ-I!,CC(]1-8#\49W.8SCO(-?7[2)>QO M)PE\8(//V_X_-Y/I536<3CKC:M"=5IWIJ#49_#]_J(;GU]_]VKNL MSF\&U4\7]9>^7\8IW61232NWH'U?G[86]T5?TPFDQ\=3$:5[/7'[J_?QBM/C[[ M]=U'UE8 9S)$1/BENOCC-SDR0LW_Q__^(7[3Z9_#+[J]Z=LDE#%$MC M!=95YWH\^JU_7B$'K1U49W31&=V,D9Y+^G<:S/64%> Q=R[&HZOZK/K#&Z!% M9W1=C>=?_+$^WTZ_/F!8Z^^M?.M9Y_-EOW?9Z4\ZY]6T&E_!J9S#EW2ZO1[H MW>ZP5W4^]Z>7G;^]^_5=YU,UA/4,!E_PS]4U[AV?N\'U?@*:P>+ZUP.@VIOZ M\3\[]_.W9R!]-^TKL:;5)]0ON>B7B^XILK!R0>Z:=P! &AI=(1Q#YPH>N9QT #E@A[\BN:\^ KYQCFXFL+;)M]]MA>YM@+("(#W@EFK\&%A:4[#DSE47OE[]FN%H?-4=K"$7 M):LZN34CZ,[*K[KC3_WA;)'=F^EH\8N93UG_9F8)U;;@W((&O3SH7D^J[Q8_ M-"!VLVEUJ\_51N_]\:;1W#JS_[:K<;;V?OK,MY.7_?JR^;+YU[_Y$TEU.+IP MVG*Y^K@;@#0TZC.875]L)JK556%%8KK%90K;#:4;#: MHU'MM77-:_6NI([!K]V #)Y]>7% D2_E48_CUM.O?J*"GQ'5FGXII4U[I-U7 MK+0+PA6$>RK",7VF;7NY=@7A"L(5A"L(=SP(IS0]D_)(9U6>!+<5A"L(5Q#N M>!&.GA%I6FWX5C!NCS>S+S.LMTUBO<=(:S69=JK?KZOAI#KK#*OI4X+,#PVI MV7,ZP!X:+W)Z9MH3Q&,Y<'Q?:0-QF(N7UR<33)])UMK\D"(3129.7B:XD6>F MO;!;D8DB$Z,55LIS8AFD:Y5=<;/")=%NHIT%>G: M0U!!B#-E>1&O(EY%O/8@7A3$2Q;MM5[W3K MID8ERH&2A5$.W9ID'9EH>6!XD8DB$R3*9"Q<]W],ANG,1W!S^/IL!J7RZ ZR'>F>2F,*"&^$N);QA_*U6B1AR(/ MMQJ"GQ%6:B**2!216 ;2SJPL]Z)M.!]?RQW0KQ5X';.\M(_5L+KH@RN"'LJH MGO>'U4*=<75^TZN?Z _[4QS6]AN.(6.EA.@!!X:0$B$HP;O1[@,*24. M1;J*=.U)NM@9%45W%>DJTK6GIC]6E^+RO?IOK\Q-"[#);G_8&8 #]JEVU][. MYJ^?KWEK];#H:MCK5Y.Z\5SG#=^+EW9R,O>&GFG96G9LDT]VW?\IM',LD<2O M6F#8&6\OEE@DIDC,*Y<8*L^X+@48122*2-PJ$7%&:&O)W5^'$BG75=L:*6"W MA$[_ZKK;'V/>7*=WV1U_PNLH4:ZC'N@*Q,Y8>Z-G7WW4H03U2E!O!SI9<6:9 M*-)5I*M(USZJV_F9(*TY5T6\BG@5\5JQ#<\(XV>6%P';JY/VVGRQWC]O^I-^ MXS*J/YQ6G^8YA?UI=07.F2RW4#,Y8Z:UB=G'P@8E0G@\*NGT)$*=J?8RC8I( M%)$X?9'@H"5:BR04D2@BF9ID5+M.&#?"T713^,)I,.."#P%;! \%,N MZ^NBT47GO/JXEX&LKR<<,$,?PRC;?\#I6/BE1-Q.0'$5$2LB5D2LB%@1L2)B M1<1>7L0D^&6\)#WLU6%[97Y9'HTK^.!.[V8\KH:]+W4N7P^;3,PND*:CSO2R M@I=757=R@__,O#:\5!KW1O#P\$OMPL%O)M/Q3=T\KP1),&YX)EFY7"IAPQ(V M7(8-SP@I+?.*1!2)6"F#E:J4P>+[2E%?$9A'" P[LZQ4P>XD,.5>:@L5?\). M#?/>#&H_)4NC\7DU7E"#7O_>F8P&_?/.OY#ZOU<4?GA#V^N(_&RJO6Z9+H'! M0P0&OQK);3'3_*DT.Q81W+<_5R2S2.9.!J\YXZ*U.&)1JT5XB_ >[@I &_OB MHGLL4OA9:<[Z>#O M>OCFNF/7!?#GH#_]TJE^OZZ&DVHV G3Q:;/A,O-0+OYA\=2[9PMZD9D3D)F= M!KV>C,QBDLEZJNK@>C+_#]D]M1OK6T8]E4&]_UK^P=[CCA>/#E;-E<'J@,\#>NNI,*P*]731!R?ZN& MT]'X"[ZE&N-$Y+;(3=ZQXR0W>V?V2>V5069SNK=%4=HNF[1'44K?B7V2M.J" MN@W8SQ3=/Q36]Z,\9KW)4IW^\Z;C 9+>P+ MO/BM,;-;8VBK$'HPX.R#<=,#"P.OJN%;SJOK<=7KSV"S+7[CLET1/KMS@/,B MV6=^].P5/OW=<#2^Z@YFO_D\4[OS7]7?#\37G;^]^_5=Y\_5$#ZIU_D9)/2J MVZMN:BT_Z?RRQD'OEQS4QN[?=>+L8U]$73?CED\ZP.[<[+B5O4-J<&K;A>[V M$%#0=[Q=4=F[=,NC):9JV70XVYL^/E*#DIIWP0;:(C>3R1P?T1B\ EJ,^]W!%JNPQ'V^AKC/3J.C3R;NLXB5SI)9Z_8QM2#\ ML.-D[2Z\[69<__6\FO3&_8^U?_0,P51+P6P--BC@1AA=7?7G&\4=A=6]M(*I M!0Z^!CC8:<#BR<#!)G]LU4*K)TUV/HU&YY_!>EK,-^D./_619;LXCG*R!RPP M[6.!!2MF=1MU)3JXZHO-M((%K2RWBW89KG*R>A2?X>FJ3%V/L>1@ M"H;U]: [O\NJ_GG3OYZ5*YS"J>AWG8P<]I_=P4W5^>MMT[,"S06:'PO-.XU7 M.AEH;MG%?(%+NBXXEW<53!V];>/39]#8QB*;XAH.P_S7R P_5_VWK2I M<21K%/[\/+]"47?ZOA"AHKT -E4S$^$":II^:F$*NOO._7(C+:=M=$6,"VU#KP#G^F84C6>S58-QK0]UJ M[8;C1[97:,_;!(1OQ+NBC2N'WW5H=-!LL*_!P&YW[W"M" [*G#"D51@$.>,H M3.$2FS&*L >HU0EZ[>&[ZS"?>JR<-+@P89"/P7K/:WQ2C:AU3EUZ@>K2O?IN M.77IR=2E.EM\ G8>#?+)6"3"(<,B@P5E*DM1\A4RQ/UE-E^#'C4PV+X:"9'D M#-P,4^TV=#-3\9%^*%LZA,.,\W?=0_AB&;M9?2?V?.\J!@6P]<$9 Q^%.'ZC#@/A\R7Y<)N;E MXNOJ)0BL2]CXAR@)OO_]O__KK]8*DG'I"QD@.IV1[P=M\6/AA3@C[0; J/PH M]A-)@X /W_CX;V\^GB!9_+/[K\N3-UXX@B]8D+\][G[H')^:6PU(E<-MN2^G;)%>9=+.]NY5R M;\,KH_HBX-BJ?Q7LM,1ZJX*-^-E\C<;?J3\6ZE/J%;I2BSBL[22TND(F=<*CG^ZK M$EKWMQ]Y>^MY7^\V[S;_\C>_)8VJ-JY 6"^W]\@.([ M3**1>,XE:5:?A4)UNJA0/=I>=DCGD*Z*=%]0B7\\SCGN]TA$[#X#(MX!R^=& MS5K[T?$\AVIK0;7&6N,X5'.HYKB:0[6-0+65N=J](XN;U!9]G?UU=+KFHJ?V M.+1<=O'+]Q_,;Q&\=O'+]Y"G[3 M/6K[8$4Y7N-XC>,UCM>LE==T^GV_M]_<.(9-/_W'\IK[NW9>E@?GZZJ9=\_) M@S8%6(VQFFWB*.W]EG_8:FQHWZ:+.#[PHOA K^]WFS-B-N4H'1MP M;,"Q@?L8&.V>?] [='S \0''!UXQ'SCL[?OM7F.)89MRE@WZ$U:;&+2DVO31 MM9Y8/5ID;R>,S=\- IJDDIVS&[QF$(_@F[3@HT\A&^)C)H']ZT#XZ[7:.VP8/CXZ^_?;F\\,X'_QI\^'3J#;Z'.!+52@R02^Z,$Z"UMYR)MT,Q:[,I3ES=2SZES]4EHU7WE[ MP@-9#]#V-ZP,U]NA+C))D<%"LUU7.KLQI;/]1BIG>P>OJ81PPVYW]9/;8'*X M!.CE"=#W$8_.Z'48V#P&*MW)0,#VDE9_+C'_?KAZF3+L(%]1Y9^3KI<"?BL& M"6]$DLF6C*)N'?K=3G.#J+<:;];M5MX@=K9QHM>Q,,?"'@:J_H'?W6],"]YN MM&G0(?XJ$^R^\;Q(8]$)E*&+D\7!O;+I]-([=U@0CPZA/369=0Y:_F'7A9"< M5?U@J_KET036BG3W'4TX0W]%\3)D^7KD2:,0?%:B:A]T_,Y18X+FQ1=%.*OS M"433"R*OP[[?[78=>3F3:"7XB00F/&9G!Y'.Y[&E MT(2SD^Z0-6ERPR(L^C.&[XW"+$_#84$CB^FY;T4 MDG#&UFV=59UF=WLOL8Y_U&JLE]B+5^V0,IWNEO1[YAWUG.3V1Y=3>>I%U MF>0L:@Q=K(8&W?D/;Y04V,7G,1T-MJ)DKKE*RU5!N/45EVV_U3[R6\WE?-T) MNJW I)=GKZYWL->Z]2O'TAQ+NP=+.SKT^YWF9K$XEF8K:?=ML/K(=JAF1]4/ M11;&/,N.D]DPC,F7_+ &JH>]5N?X^+AUU.KV#SH?6Q\^GI[LMTX/NJWVQX.C MHY/7T$#U /NG_O.WLXNSR[.O7[:D3>K7V!O,TS#R.H>B:9I/;4P!(8"N;CQJ MGB52DA./>9^IT54V#>?>F4Q2IM@[M?;USHLTF+*,>X-)RCE-W=G!AUTD,[BI M]H)=[SK,I_#<>#1E,^\7@"AL/?.]3Y^.Y'R% 2R77R2WN0EK(W->0&L3^U#_5;917F3#N#TWF=B=!'<&JK.R/1R MV&N0%RSRYFDRAR?<^/C7J AR;S "-8:>:-DY0.XK>] MBSUY\QZ"L5R)>7BP*B,.5LR3F&Y&IH6PDH=:.6[\ZBP>A2Q^.P0$''E_X*RH MP!M*!NCML PV,88/F*\8)=>[>]M!P$!36<'@/B!0W"6&_C*UY5LHSZ9SFGY. M,$MY,_U_L=-L(P]2>[%(SJ(X1*H:5":\8K'')K#G"5"'%[!LZLT5*(#M!9QX MP1PHZ4^=\W2%)!6Y6X%"? DAIO 3W :5R&LC7:$:Y[% MX5CR,H\T7(W@!M.'%\P1/O +J#)!4*0LP)_@&< >63#E=)=:W,I+LB"OY85D MK @*6"7(F!4@N!T,Y3;&BWW3 Q0SB(3 <+G:]CA,017X=P'' 2(9P-Q!1X@) MN0P@EHU9H#ARB1R*

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�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�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Ũ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end